Company Stories D-E

Stories that earlier appeared in Nelson's News
Note: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed.

Looking for other old stories? Visit the archives

Dabble .... Dairyvative Technologies ..... Daktari Diagnostics .... Dance Biopharm .... Dara BioSciences ... Daré Bioscience Operations ..... Dark Wolf Solutions... Dart Therapeutics ... DaStrong .... Datafiniti .... Data Physics .... DataRobot ..... Dato (formerly GraphLab) .... Datuit ... Daxor ..... Daylight Solutions ..... Day One Pharmaceuticals .... DayStar ... DayZero Diagnostics ..... DBS Energy ... DCL Medical Laboratories ... Deca-Medics ... deciBel Research .... Decibel Therapeutics .... DecImmune Therapeutics .... Deciphera Pharmaceuticals .....Decision Biomarkers ... Deepwater Wind ... Defense Engineering .... Defense Research Associates .... Defibtech ... Dekkun .... Delcath Systems ... Deltanoid Pharmaceuticals ... Denali Medical ... Denali Therapeutics ..... Dendreon ... DeNovo Sciences ... Deposition Sciences ... DermAvance Pharmaceuticals ... DermBiont .... Dermira ... Desalitech .... Descartes Labs .... Design Knowledge .... DesignMedix .... Design Therapeutics .... Detcon .... DE Technologies ... Devicix ..... Dew & Ken Group ... Dewey Electronics .... Dewpoint Therapeutics ..... ... Dexcom ... Dharmacon ..... Diagnostic Biochips ... Diagnostic Hybrids ... DiaMedica .... Diamond Foundry ..... Dianomi Therapeutics ..... Diatomix ..... Dicerna Pharmaceuticals ... Diffusion Pharma ..... DiFusion Technologies ... Digene .... Digirad ... DigiSight Technologies .... Digital Fusion ... Digital Lumens .... Digital Optics ... Dignify Therapeutics .... Dimien (Amherst, NY) .... Dimension Inx .... Dimension Technologies ..... Dimension Therapeutics .... DioGenix ... Dipexium Pharmaceuticals ..... Directed Manufacturing ... Directed Perception ... Disarm Therapeutics .... Disc Dynamics ... Disc Medicine .... Discovery Genomics ..... Discovery Labs ... DisperSol Technologies ..... Displaytech ... Distributed Energy Systems ... DivergenceDiversified Energy ... D. Light ... DMC Biotechnologies .... DNAnexus .... DNAPrint Genomics ... DNAtrix ... DNV GL .... Dova Pharma ..... DoX Systems ... Dracen Pharma ..... Dragon Systems .... Dragoon ITCN .... Drilling Info ... DrillMap ... Dronewerx ... DropWise .... DR Technologies ... DrugCendR ..... DSM ... DT Solar ... DTx Pharma .... DuBay Ingredients ... Dune Medical Devices ..... duPont Aerospace ... Dura Biotech ... Durata Therapeutics ... Durin Technologies .... DVS Sciences .... DxUpClose .... Dyadic International ....Dyax ... ... DynaBil Industries ..... Dynasil ... Dynavax Technologies ... Dyne Thrapeutics ... Dynetics ..... Dynogen Pharmaceuticals .... Dyno Therapeutics ... E25 Bio ... E3 Clean ... Eagle Optoelectronics ... Earl Energy .... EarLens .... Earth Networks .... Earthrise Nutritionals ... eASIC .... Eboo Pharmaceuticals .... EBR Systems .... Ebullient .... Eccrine Systems ...... Echelon ... Echodyne ..... Echogen Power Systems .... Echometrix ... EchoPixel ..... Echo Therapeutics ... ECI Biotech ... ECM Technologies .... Ecocurrent ... EcoPesticides .... EcoPro Polymers .... Ecovative Design ... Edaptive Computing ... Eden Bioscience ... Edenspace Systems ... Edge Therapeutics ..... Edgybees .... Edico Genome .... Edison Agrosciences ..... Editas Medicine .... EEStor ... Effector Therapeutics ... Egalet .... eGenesis .... Eidos Therapeutics ..... Eiger BioPharmaceuticals ..... Eikos ... E-Ink ... EIS ... Eko Devices .... Ekos .... EKRTherapeutics ..... Ekso ... Elcelyx Therapeutics ... Electrical Geodesics ...... Electric Power Systems .... ElectroChemical Systems ... ElectroCell Technologies ... Electro Energy ... Electromed ... Electro Scientific ...Electrozyme .... Elementary Robotics .... Elemetric Instruments ... ElevateBio .... Elevation Pharmaceuticals ... Eleven Biotherapeutics .... Elevian ..... Elicio Therapeutics .... Elira Therapeutics ..... Elixir Pharmaceuticals ... Elixir Biopharm ... Elixirgen Therapeutics ..... Ellipse Technologies ..... Elon ..... Eloxx Pharma ... Elroy Air, Sentient .... <Elstar Therapeutics ..... ... Eltron ... Elucid Bioimaging .... EMagin ... Electro Optical Sciences ... Embera NeuroTherapeutics ... ... Embodied .... EmboMedics ..... Embrex ... EMCORE ... >Emendo Biotherapeutics .... Emerald BioStructures .... Emergent BioSolutions ...Emergent Technologies ... Emmaus Life Sciences .... EM Photonics ..... Empire Genomics ....Empire Robotics ... EMRes Technologies ... Emtora Biosciences (formerly Rapamycin Holdings .... Emulate .... Enable Injections ... Enanta Pharmaceuticals ..... EnChroma ..... Encite .... Encoded Genomics .... Encoded Therapeutics .... Encompass Bioscience .... Encore Vision ... Encysive Pharmaceuticals ... Endeavor Robotics ..... Endece ..... Endgame Technologies ... EndoChoice .... Endocyte ... EndoGastric Solutions ... Endo International ..... Endoscopic Technologies ... Endosee .... EndoStim ... Endotherapeutics ..... Ener1 ... EnerG2 ... Energen ... Energesis Pharmaceuticals ... Energetiq Technology ...Energid Technologies ... Energous ..... Ener-G-Rotors ... Energy Control ... Energy Conversion Devices ... Energy Focus ..... Energy Materials .... Energy Recovery ... Energy Solutions ... Energy Storage Systems .... EnerMat Technologies ..... EnerMed ..... Enertech Environmental ... EnerVault ... Engage Therapeutics ..... Engineered BioPharmaceuticals ... Engineered Propulsion .... Engineous Software ... Engrail Therapeutics .... Enlibrium ..... Enlight Bioscience ... EnSync Energy Systems (formerly ZBB Energy) ..... Ensysce Biosciences ... Entasis Therapeutics .... EntechEntegrion ... Entellus Medical .... Entera Biotech ..... Entergem Ventures ... Enterin ..... EnteroMedics ... Entia Biosciences ..... Entira Bio ..... Entopica Therapeutics ... Entrada Therapeutics ..... Entra Pharmaceuticals ... EntreMed ... ENTrigue Surgical ... Entrotech Life Sciences ... Entvantage Diagnostics ..... Envia Systems ... EnviroFlight ...... Envisia Therapeutics ....Envistacom ..... EnVivo Pharma ... Enzenia ... Enzium ... Enzo Biochem ... Enzymatics .... EnzyMed .... Enzyvant ..... EO2 Concepts ..... EOIR Technologies ... Eonix .... EpiBiome .... EpiBone ... Epicentre Biotechnologies .. . Epic Sciences ..... EpiCypher ... Epic Systems ..... Epicypher ... EpiEP ... Epigen Bioscience..... Epion ... Epiphany Solar Water Systems ... Epirus .... Epitomics ... Epiva Biosciences ..... EpiVax ... EpiWorks ..... Epix Pharmaceuticals ... Epizyme ... Eppin Pharma .... EQRx ..... EqualLogic ... Equex ... Equillium .... Equipment Concepts ... EraGen Biosciences ... Erallo Technologies ... Erasca .... Ercole Biotech ... ERT ..... Escalier Biosciences BV ..... Escalon Medical ... E-Scape Bio ..... Escient Pharmaceuticals .... Escoublac ... eScription ... eSolar ... Eso-Technologies ... Esperance Pharmaceuticals ..... Esperion Therapeutics .... ESS .... Essential Biotechnology ..... Essential Medical ..... Essentient .... Essex ... ESS Tech ... Eta Devices ..... EtaGen ... Etegent Technologies ... E-TekDynamics ... EternoGen Aesthetics ..... Eton Pharma .... Euclid Labs ... Euclises Pharmaceuticals .... Eureka Therapeutics .... Euthymics Bioscience ... EVapt ... Evena Medical .... Ever Cat Fuels ... Evergen Biotechnologies ... Evergreen Solar ... Everspin Technologies .... Evestra ..... Evident Technologies ... Evofem Biosciences .... Evoke Pharma ..... Evolution Robotics .... Evolv ... Evolve BioSystems ..... Evolved By Nature ... Evozyne ... EWI ....Exact Sciences ... Exagen Diagnostics ... Excelimmune ... Excision BioTherapeutics ..... Excivity ... Exelixis ... Excel Technology ... Exelixis Plant Sciences ... Exemplar Genetics .... ExicureExo ..... Exogenesis ... Exone .... Exonics Therapeutics .... Exosome Diagnostics .... Exovita Biosciences .... ExploraMed NC4 .... Expression Analysis .... Exquadrum ... Exsulin ... Extreme Molding ... Extremity Innovations ...EyeGate Pharmaceuticals ... EyeNetra .... EyeTel


Dabble (St Louis, MO)

Dabble  (St Louis, MO; no SBIR) , a California-based startup brought to St. Louis last year after it won a $50,000 Arch Grant, has moved to Chicago and raised $1 million from a group of [Chicago] investors ... [CEO] said he’d tried for months to raise money in St. Louis   [Brian Feldt, St. Louis Business Journal, Dec 9, 15]

Dairyvative Technologies (Markesan, WI)

Dairyvative Technologies LLC (Markesan, WI; no SBIR, founded 2012, seven employees) with a technology for concentrating milk to give it a longer shelf life and make it lactose free, has raised $2.5 million from four investors, according to [SEC] filing [Milwaukee Journal Senitnal, Nov 30, 15] a super-concentrate, only requires one truck where before we needed seven.  We can now ship product across the country to where it is needed at a fraction of the price and with huge sustainability benefits.  [company website]

Daktari Diagnostics (Arlington, MA)

biotech startup Daktari Diagnostics (Cambridge, MA; no SBIR) has raised $5 million of a planned $10 million financing round made up of equity placement and debt, federal documents show. ... working on a low-cost HIV point-of-care test that can perform critical CD4 white blood cell counts, to be used to monitor the effectiveness of AIDS treatments in developing countries.  [Rodney Brown, Mass High Tech, Dec 28, 11]

Daktari Diagnostics (Cambridge, MA; no SBIR)  biotech developing blood-based diagnostic tools for the developing world, has reported a $1.25 million debt funding  ... founded in 2008, reported that it has sold $1,178,530 so far in the offering. The company had raised at least $5 million in total during three previous equity rounds  [James Connolly, Mass HIgh Tech, Aug 17, 11]

Daktari Diagnostics (Arlington, MA; no SBIR) raised $2.5M of a planned $2.9M equity financing. [Mass High Tech, Aug 27, 09]

Dance Biopharm (Brisbane, CA)

Drug maker Dance Biopharm (Brisbane, CA; no SBIR) called off its [IPO], amid investors' concern over potential fallout for U.S. markets from signs of weakness in the global economy. [Jason McCormick, Silicon Valley Business Journal, Oct 17, 14]

Dara BioSciences (Raleigh, NC)

In its attempt to raise $11.3 million Dara Biosciences (Raleigh, NC; no SBIR) shifted strategy again and now plans to sell preferred shares instead of common stock. ...   to license other products to add to its portfolio of drugs it can market.  [Jason deBruyn, Triangle Business Journal,  May 21, 14]  

specialty pharmaceutical company Dara Biosciences (Raleigh, NC; no SBIR) filed notice to sell additional shares, with a proposed maximum sale of $32.5 million. ....  Dara has some specialty drugs on the market, specifically Soltamox to treat breast cancer, and is developing a new treatment targeted for cancer patients.  [Jason deBruyn, Triangle Business Journal, Apr 21, 14]

Dara BioSciences (Raleigh, NC; no SBIR) is seeking to raise as much as $32.5 million through a sale of stock and warrants.  ...  to fund “commercial activities related to our product portfolio” and other uses.  .... has two products on the market: Soltamox, an oral liquid formulation used in the treatment and prevention of breast cancer, and Bionect, a topical treatment for skin irritation and burns caused by radiation. Dara also has exclusive U.S. commercial rights to market and sell Gelclair for the treatment of oral mucositis, or swelling and bleeding of the mouth and gums. [David Bracken, Raleigh News & Observer, Apr 21, 14]

Dara Biosciences (Raleigh, NC; no SBIR) sold $2.5M in converrtible stiock and warrants to further finance the commercialization of its approved cancer support products.  [Lauren Ohnesorge, Triangle Business Journal, Dec 31, 12]

Early drug safety results for Dara BioSciences' (Raleigh, NC; no SBIR) experimental diabetes medicine boosted the stock of the small drug development company about 12%. ... Dara's strategy is to license drugs that are discovered by others, develop them through the second phase of human tests and then sell the marketing rights. The company employs 10.   [Raleigh News & Observer, Jul 11, 08]

Daré Bioscience Operations

DARE Bioscience up 10% [Sep 5, 17] Cerulean Pharma and Daré Bioscience Operations, (formerly Daré Bioscience, Inc.) announced the closing of the transactions contemplated by the stock purchase agreement entered into by the companies on March 19, 2017. As a result of these transactions, (i) the former holders of Daré equity securities now hold approximately 51% of Cerulean capital stock (calculated based on the stock purchase agreement), (ii) Daré Bioscience Operations, Inc. has become a wholly-owned subsidiary of Cerulean, (iii) Cerulean is changing its name to "Daré Bioscience, Inc.," effective as of Thursday, July 20, 2017, and (iv) a one-for-ten reverse stock split of the combined company's common stock will be effected on Thursday, July 20, 2017.   [company press release, Sep 5, 17]

Dark Wolf Solutions (San Diego, CA)

US Navy awarded a $100,000,000 indefinite-delivery/indefinite-quantity multiple award contract for the development and integration of new software solutions. Companies are Dark Wolf Solutions (San Diego, CA; $2.9M SBIR); Geo4S Technologies (Catonsville, MD; $750K SBIR); ISPA Technology (Lithia, FLlorida; no SBIR); Moebius Solutions (San Diego, CA; one SBIR); Objective Function Systems (Canoga Park, CA; no SBIR); ODME Solutions (Del Mar, CA; no SBIR); Opal Soft (Sunnyvale, CA; no SBIR); Raft (Reston, VA; SBIR); TapHere! Technology (Manassas, VA; no SBIR); TDI Technologies (Coronado, CA; $1.3M SBIR); and The Marlin Alliance (San Diego, CA; no SBIR). [Naomi Cooper, govconwire, Jul 28, 2023]

Dart Therapeutics (Great Barington, MA)

Dart Therapeutics (Great Barington, MA; no SBIR), a company the Wall Street Journal profiled in its health blog this week as a “do-it-yourself drug development” company focused on developing treatment for Duchenne muscular dystrophy and funded by patient organizations....  the DIY company model that Dart has adopted has led to the formation of a new company, Halo Therapeutics  (no SBIR), after Dart bought the drug halofuginone as a potential treatment for DMD. And the model could potentially serve other rare disease drug programs.  [Michelle Lang, Mass High Tech, Dec 30, 11]

DaStrong (Buffalo,NY)

DaStrong (Buffalo, NY;  SBIR) is in the process of closing a $300,000 angel investment round from venture capitalists in China ...  has developed a product that cools electronic devices without the use of fans. The product uses electromagnetic force and is significantly less expensive, more reliable and longer-lasting than competitors, company leaders say. ...  first publicly acknowledged private capital raise from a winner of the 43North business competition ... founded by Hayden Ren and Oscar Xu when they were attending Rice University    [Dan Miner, Buffalo Business First, Aug 25, 15]  43North gives out $5 million in cash prizes each year [as] is part of New York Governor Cuomo’s Buffalo Billion initiative [43North website]

Datafiniti (Houston, TX)

Datafiniti (Houston, TX; no SBIR) is moving to Austin after having difficulty recruiting technology workers in Houston. [Christopher Calnan, Austin Business Journal, May 10, 13]

DataRobot (Boston,MA)

artificial intelligence company (Boston, MA; no SBIR) Leader in Automated Machine Learning,announced the first close in its Series C financing. ... an additional $54 million, bringing total funding to $111 million. ... “The number of AI and machine learning (ML) solutions being generated by all the data scientists in the the world is not even making a dent in the massive demand for these solutions, and this deficit is growing rapidly as executives across the globe–in all verticals–realize that an AI-driven organization is now a necessity.   It is now obvious that the only way to meet this demand is to automate the development of AI and ML solutions by teaching machines to do most of the work. This is exactly what we’ve been doing for the last 4.5 years.[company press release, Mar 23, 17]  Software is not usually a subect for this blog because it is usually only a business risk, not a techncal risk.  Software people can almost always do what they propose.  AI, though, is a risk-laden software where "correct" coding and logic are necessary but not usually also a sufficient criterion for success. But the global surplus of capital is now more willing to accept such risk in decent amounts. 

Dato (formerly GraphLab) Fremont, WA)

machine learning company GraphLab (Fremont, WA; no SBIR, founded 2013, 27 employees) announced an $18.5 million funding round led by Paul Allen's Vulcan Capital. ...  also renaming the company "Dato."   The series B funding brings the company's total funding to date up to $25.25 million   [Rachel Lerman, Puget Sound Business Journal, Jan 8, 15]

Datuit (Roseville, MN)

LifeScience Alley, the regional trade association that represents life science and health technology companies, announced that 10 organizations will be exhibiting cutting-edge products as part of the association’s New Technology Showcase at the 2013 LifeScience Alley Conference, Nov. 20 at the Minneapolis Convention Center.   Featured will be:  (Rochester, MN;  no SBIR), developing a cancer-selective virus particularly suited to destroy relapsed or metastatic cancer cells; Omnis PharmaRebiotix (Roseville, MN; no SBIR), which will present something called Microbiota Restoration Therapy, which delivers live, human-derived microbes to patients’ intestinal tracts to restore balance and treat certain diseases; and (Naperville, IL; no SBIR) will demonstrate its remote patient monitoring and predictive analytics system, which converts patient vital signs into information to aid in care.    VGBioCogCubed (Minneapolis, MN;  no SBIR) will exhibit an approach to diagnosing and treating cognitive health by analyzing game play data; Datuit (Roseville, MN; no SBIR) will display a platform allowing patients, family and clinicians to confidentially share medical information; Imanis Life Sciences   (Rochester, MN; no SBIR) will show a gene-based platform for promoting non-invasive, long-term imaging technologies in living beings; Mednology Solutions (Excelsior, MN;  no SBIR) will exhibit a system designed to improve efficiency in the management of medical emergencies; NanoVault Medical (St. Paul, MN; no SBIR) will show a cellular and biotherapeutic delivery technology to treat autoimmune diseases. ReMind Technologies of Houston, Tex., will exhibit a smartphone-based medication dispensing device and Skyline Medical, Inc. of Eagan will show an automated surgical fluid disposal device with unlimited capacity and real-time fluid volume data. For more information.  [James Walsh, Minneapolis Star Tribune, Sep 25]

Data Physics (San Jose, CA)

Battery Ventures has bought a controlling stake in -based Data Physics (San Jose, CA;  no SBIR)  ... Financial terms of the deal were not disclosed.  Data Physics designs and manufactures test and measurement tools for noise and vibration analysis and sells into sectors that range from aerospace to electronics.  ...  founded in 1984 by former Hewlett-Packard Co. employees Dave Snyder and Sri Welaratna, who will remain involved with the company. [Sarah Drake, Silicon Valley Business Journal, Feb 19, 14]

Daxor Oak Ridge, TN)

Daxor (Oak Ridge, TN; $700K SBIR) up 38% [Jun 4, 21]

Daxor down 16% [Mar 3, 20]

Daxor (Oak Ridge, TN; one SBIR) up 66% [Mar 2, 20] announces active engagement with both hospitals and government agencies in the military and civilian sectors regarding the use of its technology to help guide fluid management of critically ill patients with COVID-19. [company press release, Mar 2, 20] (Troy, NY)

The two [founders of (Troy, NY; founded 2015)] met in the 1990s as employees of the Silicon Alley startup that meshed social with video. Bush's connection to RPI led them to build in Troy. ...  [co-founder Dennis] Adamo worked in marketing and business development for LG and Yahoo in Russia. [co-founder V Owen Bush] was a producer for the MTV show Amp and developed a show for the Hayden Planetarium. He came to Troy in 2003 to work at the Rensselaer Polytechnic Institute where he was part of The Molecularium Project, a planetarium show and 3D IMAX movie about atoms. ... Using Google Cardboard, will be able to sell its device for the price of a selfie stick, about $20.  It's an industry that Forbes estimates will be worth $4 billion by 2018.   [Chelsea Diana, Albany Business Review, Sep 18, 15]

Daylight Solutions (San Diego, CA)

Leonardo (Italy)  has signed a definitive agreement to purchase Daylight Solutions (San Diego, CA; $1.8M SBIR founded 2005, 110 workers) a leading developer and supplier of quantum cascade laser products and technology. ... Daylight Solutions is expected  to grow significantly in the coming years, thanks to the rollout of new U.S. military aircraft survivability systems, where Daylight Solutions has secured significant roles.   [Leonardo press release, Mar 7, 17]

Day One Pharmaceuticals (Menlo Park, CA)

Biotech Day One Pharmaceuticals (Menlo Park, CA; no SBIR) debuts with $60M to change cancer care—starting with children. The drug has been tested in more than 250 patients, adults and children, and it’s in an investigator-sponsored trial testing it in children with relapsed gliomas. [Amirah Al Idrus, Fierce Biotech, May 21, 20]

DayStar   (Halfmoon NY)

Daystar got its share price back above a buck with a 1 for seven reverse split.

DayStar  up 20% [Jul 28, 10]

DayStar down 14% [Jul 26, 10]

DayStar Technologies up 96% [Jul 22, 10] announced it is pursuing a strategy for offshore manufacturing of its CIGS solar modules.  [Tech Trader Daily, Jul 22, 10] After $1M SBIR, economics takes over any nationalistic idea of American manufacturing.

DayStar Technologies has backed out of a deal to purchase a Canadian solar photovoltaic company.... said it will not buy EPOD Solar, based in Kelowna, British Columbia. DayStar in September said it planned to pay $300 million in preferred stock for EPOD [The Business Review (Albany), Oct 20, 09]

For all of 2008, DayStar reported a net loss of $26M [compared] to a net loss of $36M in 2007. [The Business Review (Albany), Mar 17, 09]

DayStar Technologies reported a deeper net loss for the third quarter than it had a year ago. .... a net loss of $6.7 million,   [Business Review (Albany), Nov 14, 08]

DayStar down 14% broke the buck. [Nov 21, 08] Sic transit gloria energii.

DayStar up 11% [Oct 20, 08]

DayStar up 19% [Oct 13, 08]

Daystar up 10% [Aug 28, 08]

DayStar Technologies up 11%  [May 13, 08]

DayStar up 12%  [May 8, 08]

DayStar down 15% [Mar 7, 08]

DayStar up 11% [Feb 11, 08]

DayStar down 10% [Jan 23, 08]

DayStar down 11% [Jan 17, 08]

DayStar up 25%. [Dec 31, 07]

DayStar up 24% [Dec 26, 07]

DayStar down 15% [Nov 12, 07] on decline of solar stocks with oil prices.

DayStar up 11%  [Nov 6, 07]

DayStar Technologies priced its public offering for $64M  to repay in full $9.2M in debt and to engineer and manufacture a deposition tool. [AP, Oct 26, 07]

DayStar down 13% [Oct 24, 07]

Day Star up 10%[Oct 19, 07]

DayStar up 15% [Oct 15, 07]

DayStar up 12% [Sep 26, 07]

DayStar Technologies that a former research manager stole trade secrets in that right after being notified of his intended layoff as the company moved to California, the employee began sending "the first of over 1,000 e-mails to his personal e-mail accounts," which had sensitive company information, including confidential memos, summaries of experiments, research findings, copies of patent applications and studies. [Larry Rulison, Albany Times-Union, Sep 22]

DayStar up 28% [Sep 19,07]

DayStar said it will start planning in 20008 for a 100-megawatt solar-cell factory to be built in 2009. [Albany Times Union, Aug 12,07]

DayStar Technologies up 10%.  [Aug 8, 07]

DayStar up 11% on announcement of new issue of shares. [Aug 6, 07]

DayStar down 10% [Jul 27, 07]

DayStar up 14% [Jul 13, 07]

DayStar up 31% [Jun 25, 07]

DayStar Technologies is scrambling for $25M in equity financing by the end of July as it abandons New York's $11M incentive to return to California and build a manufacturing site for thin-film solar cells. [Albany Times-Union, Jun 22] Gearing up for serious business and going public are not recreational diversions from doing SBIR for the government money.  It takes serious money, serious adults, and serious attitudes.

DayStar shot up 24% [May 18, 07]

DayStar down 10% [May 15, 07] as it will move its headquarters back to [Santa Clara] California and cut 20 jobs locally [in Halfmoon NY] in a bid to survive. [Eric Anderson, Albany Times Union, May 16] New York State wants its incentive money back.

DayStar shot up 24% [Mar 14, 07]

DayStar Tech down 14% [Mar 5, 07]

DayStar up another 20%  [Feb 26, 07]

DayStar Technologies up 11% [Feb 23, 07].

A local VC put up 10% of a $5M VC investment in DayStar by New York investors. Michael Dura is also on the board of Evident Tech, a Troy NY nanofirm. [Albany Times-Union, Jan 26, 07]

DayStar up another 16% [Jan 18, 07]. It announced a financial restructuring of a $15 M investment by a hedge fund and agreeing to sell $5 M in additional stock. [Larry Rulison, Albany Times-Union, Jan 20]

DayStar up 25% [Jan 17, 07]

Daystar exploded, up 52% [Jan 11, 07] without company news. The local paper reports only speculation, .Are there brighter days ahead for DayStar?

Rough Start.  DayStar dropped 18% atop a 14% drop on the year's first trading day. [Jan 07]

A potential financing deal between DayStar Technologies and a New York investment firm appears to have fallen through. [Albany Times-Union, Dec 8] No $15M and a new CEO.

DayStar jumped 13% on news that its solar cell production is exceeding expectations.  DayStar had one Phase 2 SBIR for $1M from MDA four years before it went public in 2004. From three employees for the SBIR, it has expanded to 50 employees although revenue is still tiny as it builds  production capacity and loses a few million a year from private sector capital and $11M state handout to move to Halfmoon NY from California. Halfmoon is on the edge of the Capital District which has seen several other successful small high-tech firms some of whom benefitted from a relationship with Rensselaer Polytechnic. I'll confidently guess that the competition for SBIR in MDA induced DayStar into getting third party financing for commercialization as a condition of most of the Phase II million since there had been many life-style companies wanting to dabble risk-free in the photovoltaic chemistry that DayStar exploits. [Sep 06]

DayStar aims to manufacture a [CIGS solar] cell that is competitive on performance, cost and durability. [Albany Times Union, Aug 5]  ... CIGS technology has an extensive 20+ year history and became commercially viable in part due to the leadership of [founder] Dr. Tuttle and his associates during his 11- year tenure at the DOE’s National Renewable Energy Laboratory.  One DOD (MDA at the end of its decade of SBIR innovation) Phase 2 SBIR for $1M in 2000, three years after founding and with only three employees, in a technology that had been advancing incrementally for years.  Now it has 79 employees as a public company since 2004, having accepted an $11.2M relocation package from NY State and moved the Company’s operations from California. MDA would do well to advertise its ROI for the early investment, but MDA is no longer inclined to look for, or even at, economic ROI.

DayZero Diagnostics(Boston, MA)

Day Zero Diagnostics (Boston, MA; $200K SBIR, founded 2016) an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced it was awarded up to $6.2 million in non-dilutive funding [to]support the development of Day Zero’s diagnostic system that is intended to help physicians quickly and accurately diagnose and treat life-threatening bacterial infections. [company press release, May 11, 20]

DayZero Diagnostics (Boston, MA; no SBIR,  founded 2016) an infectious disease diagnostic company using genome sequencing and machine learning to enable rapid and precise treatment in an era of growing antibiotic resistance, announced the completion of a $8.6M Series A round. .... developing a sequencing-based rapid diagnostic that identifies, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. [company press release, Jan 23 19] prior funding $12M []

DBS Energy

Grab Your Politician for Plus-Up. Smaller and more transparent earmarks of federal funds for favored domestic projects are returning after a one-year moratorium on the controversial practice. ... a bit less than 1% of total R&D appropriations (3% for DOD) ... The Senate Top 10, are mostly smaller states with senators in key committee chairmanships—Mississippi, New Mexico and Tennessee are at the top. ... search AAAS's new database of 2008 earmarks [AAAS Newsletter, Sep 07] But for small business, even 1% is a big honey pot. In the list (August version): Electro Energy  (CT; SBIR), Ocean Power Technologies (OR, SBIR in NJ),  DBS Energy CT, Eikos (MA; $8M+ SBIR), Cellular Bioengineering HI, Cerematec  (UT; SBIR), Ramgen WA, Advanced Radar Technologies WY, Compact Membrane Systems (DE; $20M SBIR), SD Catalyst Group SD.  Your story is that high-tech small business will create jobs, and they don't know whether your claim is valid or just wishful thinking. Like the federal mission agencies who then have to award and supervise the contract, they don't seem much to care.

DecImmune Therapeutics (Cambridge, MA)

DecImmune Therapeutics (Cambridge, MA; $4.3M SBIR) said that it has completed a $2.25 million equity financing. .. is looking to develop an antibody therapeutic that reduces tissue damage after a heart attack. [Boston Globe, Feb 26, 13]

&DCL Medical Laboratories ((Indianapolis, IN)

DCL Medical Laboratories (Indianapolis, IN; no SBIR) plans to hire an additional 125 workers at its Northwestside complex, nearly doubling its local work force, to help it keep up with a brisk demand from doctors' offices, pharmaceutical companies and other customers. ... also plans to add 20,000 square feet of commercial lab space as part of a $4.7 million investment. [Indianapolis Star, May 8]

Deca-Medics (Columbus,OH)

SolidWorks (Concord, MA; no SBIR; a unit of (French) Dassault Systèmes) focused on computer aided design, said that one of its customers used SolidWorks software in developing a belt that helps emergency responders administer more effective CPR chest compressions to cardiac arrest victims.  What's more, the life belt from Deca-Medics (Columbus, OH; $1.1M SBIR) was deemed the winning design in the annual NASA Tech Briefs "Create the Future Design Contest," SolidWorks said. [Boston Globe, May 4, 09]  Solid Works founded 1993, bought by Dassault 1997 for stock valued at $310 million. [company website]

deciBel Research (Huntsville, AL)

deciBel Research (Huntsville, AL; $10M SBIR) won a potential 60-month, $172.6M contract to help the Missile Defense Agency develop software and model applications to support ballistic missile defense system operations. [Brenda Marie Rivers, GovConWire, Jun 17, 19] Military software makes useful R&D and sometimes build government confidence in a contractor, especially one near the flagpole. Which gets the gov R&D done with little chance of technical failure, but opens few windows for innovation with long range consequences. It all comes from Congress's wish to help small biz without annual appropriations wrestling.   

Decibel Therapeutics (Boston, MA)

Decibel Therapeutics (Boston, MA; no SBIR) startup is launching a $52 million investment in an often overlooked area of drug development: Drugs to prevent, slow or even fix hearing loss.  ... says it’s already identified one potential drug, and Starr told Xconomy that it’s an antibody (a biologic drug) meant to help grow axons or dendrites from a neuron, and would likely be injected into the ear.    [Don Seiffert, Boston Business Journal, Oct 15, 15]  If $50M is needed for an innovation, SBIR just cannot do it.

Deciphera Pharmaceuticals (Waltham, MA)

Deciphera Pharmaceuticals (Waltham, MA; no SBIR) down 75% [Nov 5, 21] announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care sunitinib. [company press release, Nov 5, 21]

FDA approved Deciphera Pharmaceuticals (Walham, MA; no SBIR) drug ripretinib (Qinlock), a new treatment intended for patients with a gastrointestinal stromal tumor (GIST) who have failed at least three previous treatments. [Sarah de Crescenzo,, May 15, 20]

Deciphera Pharma up 16% Apr 28, 20]

Deciphera Pharmaceuticals has been handed a priority review from the FDA for its cancer drug ripretinib. [Ben Adams, Fierce Biotech, Feb 13, 20]

Deciphera Pharma down 16% [Feb 13, 20]

Deciphera Pharma up 80% [Aug 13, 19] Announces Second Quarter 2019 Financial Results "In recent months, we've made substantial progress across our pipeline of novel candidates from our two Phase 3 GIST trials with ripretinib to the addition of DCC-3116, a potential first-in-class autophagy inhibitor aimed at treating mutant RAS cancers," said [CEO]Hoerter. [company press release, Aug 13, 19]

Deciphera Pharma down 18% [Oct 19, 18]

Deciphera Pharmadown 11% [Oct 4, 18]

Deciphera Pharma down 12% [Jun 22, 18]

DeecipheraThera down 17% [Jun 21, 18]

Deciphera Pharma down 14%  [Jun 7, 18]

Deciphera Pharmaceuticals (Waltham, MA; no SBIR, founded 2003, market cap $845M) up 48%  [Jun 4, 18], focused on addressing key mechanisms of tumor drug resistance, announced the presentation of updated data from its ongoing Phase 1 clinical trial of DCC-2618, the company’s broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) and provided additional clinical and regulatory updates on DCC-2618. ....  very encouraging and supports the planned initiation later this year of our Phase 3 trial  [company press release, Jun 2, 18]  announced that it has commenced a proposed public offering of 3,750,000 in shares of its common stock  [company press release, Jun 4, 18] total funding $142M, IPO Sep 2017 []

Deciphera Pharmaceuticals (Waltham, MA; SBIR) raised $128 million in an upsized IPO.  Deciphera develops drugs that block kinases, enzymes that play a key role in the growth and spread of cancers. Its lead drug, called DCC-2618, blocks a full range of kinases that drive gastrointestinal stromal tumors, or GIST. The compound is in a Phase 1 clinical trial.  [Frank Vinluan,, Sep 29, 17]

Deciphera Pharmaceuticals LLC (Waltham, MA; no SBIR, founded 2002) is getting a money infusion.  The clinical-stage biotech company has increased the size of its Series B financing deal to over $90 million ... originally closed a $75 million deal. nearly doubling its previous investments to date.  ... specializes in developing advanced kinase inhibitor treatment drugs targeting the tumor cell and the tumor microenvironment [ Dora Grote Kansas City Business Journal, Jan 14, 16]

Deciphera Pharmaceuticals LLC (Waltham, MA; no SBIR founded 2002) clinical-stage biotech company closed a $75 million Series B financing ... to advance its pipeline of a kinase-inhibiting cancer drug ...  previously received $30 million from Eli Lilly in April 2014.   [Dora Grote, Kansas City Business Journal, Oct 20, 15]

Decision Biomarkers (Waltham, MA)

Decision Biomarkers (Waltham, MA; one SBIR) announced today the launch of the Avantra biomarker workstation, along with its Max Biochip 8-plex cytokine immunoassay. ... the first multiplexed immunoassay system that enables nonspecialized technicians to perform complex protein biomarker analyses in both the lab and directly at clinical trial sites. [Chris Reidy, Boston Globe, Jan 18]

Deepwater Wind

Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M;  A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.

Defense Engineering (Beavercreek, OH)

Defense Engineering (Beavercreek, OH; $1M SBIR, 13 employees) landed a $4 million Air Force Research Laboratory contract.  .....   for work on electromagnetic scattering and antenna technology, or EMSAT.  [Joe Cogliano, Dayton Business Journal, Nov 20]

Defense Research Associates (Beavercreek, OH)

Defense Research Associates (Beavercreek, OH; $45M SBIR) landed a $45.6 million contract with the Air Force Research Laboratory.  [John Bush, Dayton Business Journal, Jun 25, 18] Innovation or just good engineering? all in the eye of the contracting parties and the re-election campaigns of Ohio politicians.

Defense Research Associates (Beavercreek, OH; $1.8M previous SBIR, 45 employees) is getting $3.5 million for unmanned aircraft sensor work from the U.S. Air Force. ...   recently awarded $1.5 million SBIR as well as $2 million from the Airborne Sense and Avoid program, managed by the Air Force Life Cycle Management Center. The $1.5 million is a new award and the other is funding under a $23.5 million contract the company won at Wright-Patterson Air Force Base last fall.  ... centers on developing sense-and-avoid capabilities to improve the agility of [drones] and allow them to make collision avoidance maneuvers on their own. [Joe Cogliano, Dayton Business Journal, Mar 20, 15] Sounds like what the AF prefers: sound and safe engineering by firms in the Dayton area around the flagpole.

Defense Research Associates (Beavercreek, OH; $1.8M SBIR, 45 employees) won a $23.5 million [six-year] contract to continue work on a U.S. Air Force sensors project.  ...  includes commercializing technology it previously developed by incorporating collision warning capability into sensors without having to modify aircraft. ....   specializes in electronics and communications equipment research and development,     [Joe Cogliano, Dayton Business Journal, Oct 21, 14]

Defibtech (Guilford, CT)

Defibtech (Guilford, CT; no SBIR), manufacturer of automatic external defibrillators, said that it signed an agreement to be acquired by Tokyo's Nihon Kohden Corporation.  ....  [from 30 employees in 2006] one of the state's 40 fastest-growing technology companies each of the last six years, according to the the Marcum Tech Top 40  [Brian Dowling, Hartford Courant, Nov 13, 12]

Dekkun (Cambridge, MA)

Stealthy, early-stage pharmaceuticals company Dekkun (Cambridge, MA; no SBIR) has raised $9.93 million of a planned $30.5 million equity offering, according to a regulatory filing.  The company was incorporated on Jan. 3 this year, posting its location in Cambridge, and operating out of the office of HealthCare Ventures LLC, a life sciences-focused venture capital firm. It does not yet have a working website.  [Michelle Lang, Mass High Tech, Jan 10, 11]

Delcath Systems

Delcath Systems (NYC and Queensbury, NY; no SBIR) medical device manufacturer,  .... raised $21 million from investors during the first two months of 2013, and wants $50 million more.  [Barbara Pinckney, The Business Review (Albany), Mar 14, 13]

Also IPOing this week is DELCATH SYSTEMS with zero revenue and a $57M loss last year by five employees. It makes a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

Delinia (Cambridge, MA)

Delinia 9Cambridge, MA, and San Francisco, CA; no SBIR) raised a $35 million Series A round ...  plans to treat “serious and life-threatening autoimmune diseases,” according to a company statement, though it hasn’t said which ones as of yet.  There are many autoimmune disorders, from rheumatoid arthritis to inflammatory bowel disease and lupus. The common theme is a haywire inflammatory response that causes damage to one part of the body or another—in RA, our joints, and in IBD, our guts  [Ben Fidler,, Sep 14, 16]

Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals (Madison, WI, no SBIR) raised $12M in a second financing round led by the Wisconsin Alumni Research Foundation.  ... to continue developing for clinical trials two compounds with the potential to treat side effects of renal failure ... brings to $16 million the total raised by Deltanoid, which was started in 2001. The company has fewer than 12 employees  [Milwaukee Journal-Sentinel, Dec 18]

Denali Medical (Blaine, MN)

Takeda Pharmaceuticals  (Japan) and Denali Therapeutics (South San Francisco, CA; no SBIR, founded 2015)  announced that they have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases. Each program is directed to a genetically validated target for neurodegenerative disorders, including Alzheimer’s disease and other indications, and incorporates Denali’s ATV platform for increased exposure of biotherapeutic products in the brain.   $150 million up front in cash and stock to co-develop up to three drugs for neurodegenerative diseases. [joint companies press release, Jan 5, 18]

Med-tech startup Rotation Medical (Plymouth, MN; no SBIR) which has developed an implant for treating rotator cuff disease, has raised about $5.5 million through the sale of debt, according to a regulatory filing.  ... spun out of venture-backed med-tech incubator Denali Medical (Blaine, MN; no SBIR). ... founded in 2009, raised $10 million in 2011 and received regulatory approval to market its technology in January.[Katherine Grayson, Minneapolis / St Paul Business Journal, Jun 5, 13]  

Denali Therapeutics (South San Francisco, CA)

Denali Therapeutics (South San Francisco, CA; no SBIR), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, announced the [IPO] pricing of near $300M.[company press release, Dec 7, 17]

Denali Therapeutics (South San Francisco, CA; no SBIR, founded 2015) startup focused on Alzheimer’s and other neurodegenerative diseases. Backed by $217 million and led by a trio of former Genentech scientific and business development stars,   [Ron Leuty, San Francisco Business Times, Oct 16, 15]

Denali Therapeutics (South San Francisco, CA; no  SBIR), a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that it has launched with an initial investment commitment of $217 million. ...  Dr. Ryan Watts, Denali Co-Founder, Acting CEO and CSO, said, “Our team will place an emphasis on rigorous translational medicine for targeted drug development, seeking evidence of drug activity in the brain and identifying biomarker-defined patient populations to increase the probability of clinical success. We are committed to collaborating with leading academic groups, companies and advocacy groups.”  [company website, Jun 2, 15]


Mitch Gold, the former CEO of Dendreon, has just gotten some big backing for his latest cancer drug startup.  Alpine Immune Sciences,(Seattle, WA; neither time nor need for SBIR) touting a next-gen method of harnessing our body’s defenses against cancer, has raised a whopping $48 million Series A round. [Ben Fidler,, Jun 13, 16]

Dendreon (Seattle, WA; no SBIR) biotech that developed the prostate cancer drug Provenge, has filed for Chapter 11 bankruptcy protection.  .... was looking at $620 million in debt that was coming due in January 2016. 

Dendreon , the region’s most valuable biotech company of the past couple years, started last week worth more than $5 billion, and ended up yesterday worth about $1.5 billion. Some of this is because there’s panic selling in the overall market, but mostly ,investors ran for the exits after Dendreon said it is fallign short of its sales forecasts of $350 million to $400 million this year because it has had trouble convincing doctors that they can get Medicare reimbursement in a consistent and timely manner.  [Luke Timmerman,, Aug 11, 11]

Dendreon dropped 6.8% after the U.S. government said it would begin a coverage analysis on whether the company's immunotherapy treatment for prostate cancer is "reasonable and necessary."  [Wall Street Journal, Jul 2, 10]

Dendreon CEO sold more than $28 million of company stock in the hours after the U.S. Food and Drug Administration approved the cancer treatment Provenge late last week. ...   Other company officials also sold shares   [Wall Street Journal, May 4]

FDA approved [Dendreon's] Provenge, sometimes called a "cancer vaccine" because it stimulates the immune systems of men with advanced prostate cancer to attack their malignancies [Washington Post, Apr 30, 10]

A decision is due this week on Dendreon's application to bring the country's first cancer-treatment vaccine to market. ... Analysts estimate a course of Provenge will cost between $50,000 and $75,000. As many as 100,000 men a year develop the advanced form of prostate cancer the treatment would initially be prescribed for.[Sandi Doughton, Seattle Times, Apr 25, 10]

Dendreon expects to spend up to $50 million to expand its therapeutic biotechnology processing facility in Morris Plains, New Jersey, the company said Monday in a regulatory filing  [Seattle Times, Jun 22, 09]

Dendreon down 45%.[Apr 28, 09]  Shares of the company hit a 52-week high of 25 earlier in the session, but tumbled shortly before being halted prior to the announcement and never resumed trading.[Wall Street Journal, Apr 29]   Dendreon's experimental immune therapy extended prostate cancer patients' lives by 4.1 months and improved three-year survival by 38 percent, the firm announced today. [Seattle Times, Apr 28]

An experimental treatment that takes an entirely new approach to fighting prostate cancer proved it extends survival in a late-stage study, Dendreon said Tuesday, sparking a leap in its stock price.  [Seattle Times, Apr 15, 09]

Dendreon shares rose from a months-long slumber today after three members of Congress called for an investigation of the FDA's decision not to approve the Seattle company's lead therapy for prostate cancer, Provenge. ... However, it's unlikely that a Congressional investigation will propel Provenge forward, because the interim clinical trial results sought by the FDA might be available before the inquiry reaches any resolution, Latta said. [Seattle Times, Dec 13,07]

Dendreon jumped nearly 14% early [Jul 3, 07] boosted by a scientific articlethat cast positive light on its flagship anti-prostate cancer therapy, Provenge. [Angel Gonzalez, Seattle Times, Jul 3] It ended the day up 7%.

Dendreon plunged 64% after the FDA requested more clinical data to support the effectiveness of the Seattle biotechnology company's prostate-cancer drug, Provenge.  The news was a setback for Dendreon and other companies with treatments that use the body's immune system. Among those stocks, Cell Genesys declined 6.1%; Antigenics lost 12%; and Favrille fell 18%. [Wall Street Journal, May 10]

DeNovo Sciences (Ypsilanti, MI)

  in this year’s Accelerate Michigan business plan competition  DeNovo Sciences (Ypsilanti, MI; no SBIR) won the grand prize of $500,000. [over] nine other finalists on the last day of the competition with its microfluidic-based platform technology that can detect circulating tumor cells earlier and with greater sensitivity than standard biopsy approaches. Winning a runner-up prize of $150,000 was Fusion Coolant Systems, (Ann Arbor, MI; one SBIR), a University of Michigan spin-out that makes an advanced coolant and lubria­tion sys­tem for use in man­u­fac­tur­ing. [Sarah Schmid,, Nov 18, 11]

Deposition Sciences (Santa Rosa, CA)

Defense giant Lockheed Martin has acquired  Deposition Sciences  (Santa Rosa, CA; $500K SBIR, 85 employees, a subsidiary of Advanced Lighting Technologies (Solon, OH;  no SBIR)) that provides thin film coatings   [Emily Mekinc, Washington Business Journal, Jun 19, 14]

DermAvance Pharmaceuticals (Berwyn, PA)

Ben Franklin Technology Partners of Southeastern Pennsylvania invested $2.3 M in 10 companies in its latest round of funding. DermAvance Pharmaceuticals (Berwyn, PA; no SBIR). received the largest investment -- $500,000. ...acquires and commercializes anti-aging products. [Philadelphia Business Journal, Jun 6, 08]

DermBiont (Boston, MA)

Skin microbiome therapeutics company DermBiont (Boston, MA; no SBIR), raised $8.8M in a funding round, according to an SEC filing. [Rowan Walrath, Boston Inno, Jun 11, 19]

Dermira (Redwood City, CA)

Eli Lillyannounced a definitive agreement for Lilly to acquire Dermira (Menlo Park, CA;  no SBIR) for approximately $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions. [joint companies press release, Jan 10, 20]

Dermira up 17% [Dec 11, 19] announced that [FDA] has granted Fast Track designation for lebrikizumab, its novel, investigational treatment being evaluated for patients with moderate-to-severe atopic dermatitis. [company press release, Dec 10, 19]

Dermira up 15% [Dec 9, 19]

Dermira up 18%  [Nov 8, 19]

Dermira up 26% [Oct 18, 19] announced that detailed primary results from its Phase 2b dose-ranging study of lebrikizumab are being presented during the 39(th) Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderate-to-severe atopic dermatitis. [company press release, Oct 17, 19]

Dermira (Menlo Park, CA; no SBIR, founded 2010) up 84% [Mar 15, 19] generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Dupixent. [Fierce Biotech, Mar 18, 19] total funding $130M []

Dermira up 10% [Oct 3, 18]

Dermira down 23%  [May 24, 18]

Dermira up 10% [Mar 12, 18]

Dermira up 11% [Mar 6, 18]

Dermira (Menlo Park CA; no SBIR, market cap $1B) down 66% [Mar 5, 18] In a major surprise for Dermira and Wall Street alike, Dermira’s acne drug failed to meet the co-primary endpoints of two important, late-stage clinical trials. .... shares have dropped nearly 63% over the last three months [Emma Court, Market Watch, Mar 5, 18]

Skin treatment developer Dermira (Redwood City, CA; no SBIR) raised its IPO fundraising targets and hit them, raising $125 million.  ...  Despite $68 million in accumulated deficits and no revenue   [Cromwell Schubarth, Valley Business Journal, Oct 3, 14]

Dermira (Redwood City, CA; no SBIR), a biotech company working on treatments for psoriasis and other skin problems, plans to seek up to $75 million in an IPO. ...  has raised about $128 million since it was founded in 2010  [Cromwell Schubarth, Silicon Valley Business Journal, Aug 28, 14]  

Dermira (Redwood City, CA; no SBIR), a development stage biotechnology firm focused on dermatology therapies, raised $35 million in Series B financing [Chris Rauber, San Francisco Business Times, Jun 11, 13]

Dermira (Redwood City, CA; no SBIR). said it has raised $42 million in Series A funding..... for acquisition, development and commercializing dermatology-related therapeutics. ... development stage biotechnology company developing and commercializing new therapies in dermatology, with a lead product in clinical trials for acne. [Silicon Valley / San Jose Business Journal, Oct 20, 11]

Desalitech (Newton, MA)

Desalitech (Newton, MA; ineligible for SBIR) clean water technology company, has landed $11 million in equity funding from a private investment group  ...  brings total funding to date to about $24M ... moved from Israel to Newton last year, recently sold one of its water purification systems to one of the world's largest Coca-Cola bottlers and plans to double its workforce in Newton   [Sara Castellanos, Boston Business Journal, Dec 2, 14]

Descartes Labs (Los Alamos, NM)

Descartes Labs (spinout from Los Alamos NL, Santa Fe, NM; $1.5M SBIR, founded 2014) announcing that it has closed a $20 million round of funding [Ingrid Lunden,, Oct 11, 19] prior funding $38M []

Descartes Labs (Los Alamos, NM; too soon for SBIR) startup that specializes in using detailed satellite imagery of the Earth's surface to track climatic trends, agricultural production and geologic changes has landed $5 million in venture capital, according to a report in the Santa Fe New Mexican.  ... formed by a team of former scientists at Los Alamos National Laboratory  [Mike English, Albuquerque Business First, Dec 1, 15]

Design Knowledge (Fairborn, OH)

Design Knowledge (Fairborn, OH, a stone's throw to WPAFB [company website]; at least 31 SBIR awards for something like $25M typically in management technology, founded 2002) won a seven-year R&D contract with the U.S. Air Force. [John Bush, Dayton Business Journal, Jun 7, 18]

DesignMedix (Portland,OR )

DesignMedix (Portland, OR, housed in the Portland State Business Accelerator; $5M SBIR/STTR, founded 2008) entered into an agreement with [NIH] that will pave the way for first-in-human clinical trials of DesignMedix’s malaria drug DM1157. The agreement  builds on the strong package of preclinical data DesignMedix has developed to prepare its malaria drug for clinical trials. Under the agreement, NIH will sponsor a Phase I clinical trial of DM1157.   [company press release, Apr 10, 17]  received a $350,000 phase I grant award from NIH SBIR [company press release, Apr 4, 16] received a major Phase II STTR [NIH STTR] grant to continue development and manufacture of a new anti-malarial drug.  [company press release, Apr 15, 14]

(Oregon) Gov. Kate Brown announced that five companies would receive a combined $300,000 to fund innovation from Business Oregon, the state's economic development arm, and act as follow-on funding for awards from [SBIR]: DesignMedix (Portland, OR; $1.4M prior SBIR): makers of a drug to improve malaria treatment, $75,000;  Energy Storage Systems (Portland, OR; no SBIR): makers of a new kind of battery for utility-scale energy storage, $75,000;   SupraSensor  (Eugene, OR; no SBIR, founded 2012): makers of a testing device that helps farmers use fertilizer more efficiently, $61,875; NemaMetrix  (Eugene OR; $200K SBIR, founded 2011): makers of an advanced drug screen for cheaper, faster testing, $49,100HM3 Energy (Gresham, OR; one SBIR): developers of a technology that converts forest debris into briquettes that can replace coal in power plants, $40,171.  [Mason Walker, Portland Business Journal, Apr 17, 15]

The Portland Seed Fund has emerged as one of the most active early-stage investors in Oregon and with its latest class, the fund has sunk its teeth into companies that are further along in the business lifecycle.The 10 companies completing the PSF accelerator are:
    ActionSprout, which makes tools to help nonprofits better use social media.
    Amplion, which makes biomarker business intelligence software for pharmaceuticals and diagnostic companies.
    Bigleaf Networks, which provides cloud-based networking infrastructure software.
    Crowd Supply, which is a platform for crowdfunding product development.
    CrowdStreet, which is a marketplace and investment platform for real estate development.
    DesignMedix, which develops drugs to fight drug-resistant diseases.
    Elli, which is an online marketplace aimed at wedding planning.
    Lumen Learning, which is a platform for colleges and universities to use courseware based on open education resources.
    Poached Jobs, which provides online tools and a jobs portal for the restaurant and hospitality industry.
    Scratch-it, which is developing audience engagement tools for email marketing.
[Malia Spencer, Portland Business Journal, Apr 9, 15] Nine of the ten are low tech risk projects whose only risk is how well the product will sell, which is just fine for  a quick return (if any) for not much investment.  But no big downstream job and industry creation potential. Which is just fine for private investors, but not for public "market failure" investment.

DesignMedix (Portland, OR;  $1.4M SBIR) a biotech startup with ties to Portland State University, has received nearly $3 million from [NIH] to work on the new [anti-malaria] drug over the next three years.  ...  will share the three-year grant with the chemistry lab of PSU professor David Peyton, who invented the technology and co-founded the company.  [Dennis Thompson, Portland Business Journal, Apr 15, 14]

Design Therapeutics (San Diego,CA)

Design Therapeutics (Carlsbad, CA; $700K SBIR) down 33% [Dec 8, 2022] Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress [company press release, Dec 7, 2022]

Design Therapeutics (San Diego,CA; $300K SBIR) announced that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions. The company has closed a $45 million Series A financing [company press release, Mar 20, 20] with ties to the University of Wisconsin-Madison [WiscInno, Mar 31, 20] no prior funding []

Detcon (Woodlands, TX)

Detcon (Woodlands, TX; no SBIR) was officially founded in a Houston-area garage in 1983. After years of product development, the Woodlands-based gas-detection technology manufacturer has finally hit a nice stride and is quickly expanding its local operations.  .... was acquired in 2011 by Industrial Safety Technologies, a conglomerate of technology safety companies, Detcon has been able to focus more on its technologies while getting exposure to more international markets. [Molly Ryan, Houston Business Journal, Sep 11, 13]  began commercial activity with its first products in early 1985  [company website] 

DE Technologies (King of Prussia,PA)

DE Technologies (King of Prussia, PA; $7M SBIR) has won a contract worth a little more than $6.9 million from the Office of Naval Research to develop technologies for a small-diameter, shaped-charge warhead, the Defense Department said  [Philadelphia Business Journal, Dec 31, 08]

Devicix (Eden Prairie, MN)

Contract electronics manufacturer Nortech Systems (Wayzata, MN; no  SBIR)  is hoping to capitalize on high demand for health care gadgets by acquiring [Devicix (Eden Prairie, MN; one SBIR, 30 employees, founded 2004)]  that does outsourced design work for large and small medical-device makers. ...    $5.3 million plus sales milestones  [Joe Carlson, Minneapolis Star Tribune, Jun 18, 15]

Dewey Electronics (Oakland NJ)

Low Dollar, More Sales. John Dewey rarely sells his signature line of electronic generators abroad.  But two months ago, the CEO of Dewey Electronics (Oakland NJ; no SBIR) started getting calls from overseas. He asked a Greek government official what had changed.  "I said, 'You guys would generally never talk to us,' " Dewey said. "And he responded, 'With the dollar doing what it is, it's changed the assumptions.' "  [Hugh Morey,, Nov 4, 07]  Now if DOD and NASA would use SBIR for more firms like Dewey and less on modeling turbulence and rocket plumes, US export sales could do more to re-balance the national accounts.

Dewpoint Therapeutics (Cambridge, MA and Dresden, Germany)

Dewpoint Therapeutics, a Boston-based molecular condensates company, raised $77.1M in equity, according to an SEC filing.

Dewpoint Therapeutics (Boston,MA; no SBIR), the biomolecular condensates company, announced it has raised $77 million in a Series B financing [to] further develop its platform and identify additional compounds that modulate these condensates. [company press release, Sep 29, 20]

Dewpoint Therapeutics (Cambridge, MA and Dresden, Germany; no SBIR, founded 2018), translating the emerging area of biomolecular condensates into drug discovery, launched with a $60 million Series A. ... is harnessing recent insights into biomolecular condensates elucidated by founders Anthony Hyman of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden and Richard Young of the Whitehead Institute with the goal to uncover treatments for the toughest diseases. Biomolecular condensates have long been known but historically understudied because they are difficult to analyze with traditional drug discovery methods like protein crystallography and biochemical activity assays. [company press release, Jan 30, 19]

Dexcom (San Diego, CA)

Dexcom ($3M SBIR) bests its 'best year ever' with 27% surge to $2.5B revenue in 2021 [Fierce Biotech, Andrea Park, Feb 11, 2022]

Dexcom down 17% [Mar 16, 20]

DexCom (one SBIR, market cap $14B) up 27%  [Nov 7, 19]

Dexcom, a maker of continuous glucose monitors for people with diabetes, said it will cut 350 full-time jobs in San Diego and Arizona as its shifts some customer support and other functions overseas. [Mike Freeman, San Diego Union Tribune, Feb 22, 19]

medical device maker Dexcom has acquired a University of Virginia software spin-off that develops algorithms for regulating and adjusting insulin delivery for people with diabetes.The purchase price for TypeZero Technologies (CHARLOTTESVILLE, VA; $200K SBIR, 15 employees) was not disclosed. But the deal is not expected to have an impact on Dexcom’s financial results in the short term.  [Mike Freeman, San Diego Union Tribune, Aug 24, 18]

DexCom up 31% [Aug 2, 18] "Q2 was a fantastic quarter for DexCom and demonstrates that CGM adoption is increasing significantly," said Kevin Sayer, DexCom's President and CEO. [company press release, Aug 1, 18]

Dexcom up 13%  [May 3, 18]

Dexcom posted a 30 percent jump in revenue for the March quarter as it prepares for a major launch of its next generation continuous glucose monitors that no longer requires finger pricks for calibration.  [Bradley Fikes, San Diego Union Tribune, May 2, 18]

Dexcom  won [FDA]regulatory approval for its latest continuous glucose monitoring system that eliminates the need for finger pricks and is nearly one-third smaller than its current wearable sensor for diabetes patients.  [Bradley Fikes, San Diego Union Tribune, Mar 29, 18]

DexCom down 10% [Jan4, 18]

DexCom inks a development agreement with Eli Lilly  to include Dexcom Continuous Glucose Monitoring (CGM) into Lilly's diabetes ecosystem. The companies plan to combine Lilly's smart insulin delivery devices and Dexcom CGM as a comprehensive solution to improve diabetes management. Clinical studies will begin next month. Financial terms are not disclosed.  [Douglas W. House,, Nov 21, 17]

DexCom down33% [Sep28, 17]

Dexcom (San Diego, CA; $100K SBIR in 2001 in Wisconsin, founded 1999, market cap $6.3B, 1900 employees), manufacturer of continuous glucose monitoring for patients with diabetes, has expanded into a new manufacturing facility in Mesa. The 180,000-square-foot facility will support the company's global manufacturing operations and is projected to create more than 500 jobs over the next several years. [Angela Gonzales, Phoenix Business Journal, April 14, 17] ...  IPO 2005  ...  based on the groundbreaking research of Dr. Stuart J. Updike and George P. Hicks in 1967—implantable, long-performing glucose sensors that the body would not reject.   [company website]

Medical-device maker DexCom is designing an app that will display readings from its diabetes glucose monitor on Apple’s smartwatch, giving the watch an early foothold in the health-care market.  ... Apple declined to comment. The company hasn’t accepted any apps for the coming watch yet but has provided guidelines and code to developers for creating apps for it.   [Kate Linebaugh, Wall Street Journal, Feb 8, 15] 

DexCom  up 14% [Nov 7, 14]

DexCom up 14% [Aug 7, 14]

Dexcom up 45% [Nov 7, 13]

Dexcom up 21% [Aug 8, 13] revenues up 65% []

DexCom,which makes continuous glucosemonitoringdevices for patients with diabetes, acquired SweetSpot Diabetes Care (Portland,OR; no SBIR) health IT company. DexComsaid it will pay as much as $8.5 million in payments over time for SweetSpot, which developed a cloud-based service that helps process data from monitoring devices. [Bruce Bigelow,, Mar 2, 12]

Dexcom  down 20% [Nov 3, 11] after the company reported quarterly earnings

DexComdown18% [Aug4, 11]

Dexcomdown 22%[Nov5,


Dexcom up 10%[Jun16,10]

Blood-sugar-monitor maker DexCom (San Diego, CA; one SBIR in Wisconsin)  said it plans to sell 3.5 million shares of common stock to raise money for working capital. [San Diego Union Tribune, Jan 14, 10]

Dexcom up 10% [May29,09]

Dexcom   up12%[May18,09]

Dexcom up12%[Mar23,09]

Dexcom up 10%[Mar10,09]

Dexcom down 11%[Mar2,09]

Dexcom up 12%[Feb11,09]

Dexcom  up 11% [Feb 6,09]

Dexcom down 13% [Jan20,09]

Dexcom up 12% [Jan16,09]

Dexcom up 19%[Jan5,09]

Dexcom down 16%[Dec18,08]

Dexcom down 11%[Dec15,08]

Dexcom up 11%[Dec12,08]

Dexcom up 10%[Dec8,08]

Dexcom up 10%[Dec5,08]

Dexcom up 50%[Dec4,08]

Dexcon up 12%[Oct28,08]

Dexcom down 10%[Oct15,08]

Dexcom  up 25%[Oct 13, 08]

Dexcom down 18%[Oct9,08]

Dexcom down 10%[Oct7,08]

Dexcom up 10%[Jul22,08]

Dexcom up 10%[Jul11,08]

Dexcom up 11%[Jun13,08]

Dexcom up 13%[May12,08]

Dexcom up 21%[Apr18,08]

Dexcom up 16%[Apr7,08]

Dexcom down 10%[Mar28,08]

Dexcom down 13%[Mar10,08]

Dew & Ken Group (Madison, WI)

A Wisconsin company that has opened two new subsidiaries in China is hoping to play a big role in LED development. James Sun, company founder, worked on developing the technology for high-power LEDs while working at Lumileds, a Silicon Valley spinoff of HP ... Sun's company, Dew & Ken Group (Madison, WI), employs 20 people worldwide and has installed more than 260 LED streetlights in China, with orders for another 2,800.   [Thomas Content, Milwaukee Journal Sentinel, Jun 7, 08]

Dharmacon (Lafayette, CO)

The Scientist strives annually to identify the latest and greatest tools, technologies, and techniques to hit the life-science landscape. This year’s selection includes Quanterix (Lexington, MA; $200K SBIR) brought its Simoa biomarker detection technology to the lab bench, launching the compact SR-X system; Promega (Madison, WI; $5M SBIR) new protein detection system excels at measuring protein levels across the cell; and Dharmacon (Lafayette, CO; $1.6M SBIR) launched on the market in June 2017, instead provides users with an arrayed library of synthetic crRNA guides with a “one-well-per-gene” format, allowing for a much subtler assay. [The Scientist, Nov 30, 17] .

Diagnostic Biochips (Columbia, MD)

[A] sensor, being developed by Diagnostic Biochips  (Columbia, MD, no SBIR, founded 2011), sends real-time data about brain activity to researchers using a wireless signal. ... more accurate than MRI scans and less invasive than blood tests  ... plans to soon launch an angel investing round to raise $1.5 million.  ....among the 41 startups moving forward in the state’s InvestMaryland Challenge. ....  work has been primarily funded through a stream of National Institutes of Health grants (a total of $1.6 million over two years).  Diagnostic is not yet profitable. The company’s total funding so far includes $150,000 from angel investors, a $100,000 Maryland Technology Development Corp. award and investments from its founders.   [Sarah Gantz,  Baltimore Business Journal, Feb 19, 14]

 The Maryland Technology Development (Tedco) has invested $1.1 million in 14 state startups.The grants were made through the organization's Technology Commercialization Fund. ... toward advancing the each company's technology and product commercialization efforts. Common Curriculum LLC, Diagnostic Biochips Inc. and Firejack Inc. were each awarded $100,000.  • Authentik Solutions LLC; Brain Sentry LLC; Clear Guide Medical LLC; ConverGene LLC; Cordex Systems LLC; Pregmama LLC; SameGrain, Inc; TimberRock Energy Solutions, Inc. and Vasoptic Medical, Inc. each received $75,000. • Magpie Sensing LLC was awarded $74,990  • Weinberg Medical Physics LLC received $60,000  [Baltimore Business Journal, Jul 19, 13]

Diagnostic Hybrids (Athens, OH)

Quidel (San Diego, CA; no SBIR, founded 1979)  said it has received regulatory clearance to sell a test to detect respiratory viruses.   .....In early 2010,  acquired Diagnostic Hybrids (Athens, OH, $500K SBIR) as part of a continued focus on increasing its research and development efforts to accelerate the rate of new product introductions.  [Bradley Fikes,, Mar 12, 13]

diagnostic test maker Quidel (San Diego, CA; one SBIR) announced plans to buy the privately held Ohio diagnostics company Diagnostic Hybrids (Athens, OH; $500K SBIR) for about $130 million. [Thomas Kupper, San Diego Union Tribune, Jan 12, 10]

DiaMedica (Plymouth, MN)

Diamedica Thera up 22% [Jun 19, 20]

Diamedica Thera up 19% [Jun 17, 20]

Diamedica Thera up 16% [Feb 18, 20]

Diamedica Thera up 30% [Jun 20, 19] announced that DM199 (recombinant KLK1) was observed to be safe and well tolerated with no drug-related serious adverse events (SAEs), consistent with earlier DM199 studies in healthy volunteers. [company press release, Jun 19, 19]

Diamedica Therapeutics (Minneapolis, MN; no SBIR) up 19% [Jun 17, 19]

DiaMedica Therapeutics (Plymouth, MN; no SBIR) announced the [IPO] pricing tp raise$16M. [company press release, Dec 7, 18]

Diamedica Thera down 23% [Dec 7, 18]

DiaMedica (Minneapolis, MN; no SBIR, founded Y2K) files to raise $15M through public offering toward further development of its drug candidate, DM199 [Katharine Grayson, Minneapolis/St Paul Business Journal, Nov 12, 18] total prior funding $4M []

DiaMedica Therapeutics (Plymouth MN; no SBIR), a biopharmaceutical company focused on the development of DM199 (recombinant human KLK1),  announce it has completed a private placement for gross proceeds of approximately $2M [company press release, Apr 21, 17]

Asian investors have entered into a two-part, $4 million investment deal with DiaMedica  (Plymouth, MN; no SBIR) over an experimental drug it produces to treat acute ischemic strokes.  ...  According to DiaMedica’s chief scientific officer Todd Verdoorn, DM199 will be placed in competition with a similar drug manufactured and sold in China. Both products use a protein known as killikrein to improve blood flow within the area of the brain that is experiencing a stroke.   ...  the Chinese version [backed by Takeda Pharmaceuticals] is extracted from urine  while DiaMedica’s is a synthetic product made in a lab. To that effect, [CEO] Pauls believes DiaMedica’s drug is comparatively less expensive and safer than the urine-based formula.  [Sam Schaust, Twin Cities Business,  Jul 18, 16]

Diamond Foundry (San Carlos, CA)

CVD diamond revives.  Diamond Foundry (San Carlos, CA; no SBIR) is not the first company to try to use chemical vapor deposition, to grow diamonds by depositing layers of carbon atoms in a high-energy plasma field.  ....  spent years developing a new manufacturing technique based on a plasma source with a new “shape” that is 10 times as powerful as what has previously been used by manufacturers of synthetic diamonds, R. Martin Roscheisen, a founder of Nanosolar  (San Jose, CA; $1.7M SBIR) said.   By modifying the shape of the plasma field to what he described as a pancake, the group was able to make the reaction that formed the diamond structure more efficient  ...  the founders of Nanosolar, a large start-up that raised about half a billion dollars in its first six years, began exploring ways to build that would apply their expertise to new technologies. ...   A group of engineers and scientists, led by , announced that they had developed an advanced approach to making diamonds, using technology derived in part from making silicon chips and solar cells, to be used by a new company.   [JOHN MARKOFF, New York Times, Nov 11, 2015]  SDIO/BMDO/MDA SBIR funded several CVD diamond projects starting in the late 1980s.

Dianomi Therapeutics (Madison, WI)

startup Dianomi Therapeutics (Madison, WI; no SBIR) draws a $3M investment .... says it has a new way to make prescription medications pack a bigger punch — to help not only humans but injured pets or technology combines drug candidates with mineral-coated microparticles. It is based on the concept that minerals in bones and teeth stabilize proteins and extend their staying power. [JUDY NEWMAN,, Feb 24, 19]

Ligand Pharmaceuticals (San Diego, CA; SBIR) announces closing a [$3M] investment in Dianomi Therapeutics (Madison, WI; no SBIR, founded 2017) focused on improving the delivery and efficacy of large and small molecules in the treatment of a variety of diseases and on therapies for inflammatory diseases, such as osteoarthritis and pain. [Ligand press release, Feb 5, 19] Dianomi's proprietary Mineral Coated Microparticle (MCM) technology [was] developed at the University of Wisconsin-Madison, that is uniquely designed to provide stability and controlled release delivery of biologics and small molecule drugs. [Dianomi press release]

Diatomix (Beaverton, OR)

With assistance from the SBIR/STTR Support Center operated by Oregon BEST, two Oregon start-up companies [won] $450,000 in [NSF SBIR] [Oregon Best website]    Gadusol Laboratories (aka Seaceuticals, Corvallis, OR; no prior SBIR, founded 2017) $225K to advance a technology for producing UV blocking compounds found in marine life that can be used in environmentally friendly, all natural sunscreens, from gadusol that's been found in fish and their eggs at Oregon State U.  Diatomix (Beaverton, OR; no prior SBIR, founded 2015) $225K has developed a patent-pending, bio-engineered smart material that improves indoor air quality by adsorbing and then breaking down hazardous, airborne volatile organic compounds (VOCs) [with] patent pending photo-catalytic product actively and continuously degrades VOCs in the air by turning them into harmless carbon dioxide and water. [company website] $130K raised 2017 []

Dicerna Pharmaceuticals (Cambridge, MA)

Dicerna Pharmaceuticals (Lexington, MA; $5.7M SBIR) up 79% [Nov 18, 21] announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk (Denmark) will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion [company press release, Nov 18, 21]

Dicerna Pharmaceuticals (Lexington, MA; $5.7M SBIR) down 28% [Aug 6, 21] announced positive top-line results from the Company's PHYOX(TM)2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. [company press release, Aug 5, 21]

Dicerna Pharma up 17% [May 11, 20]

Dicerna™ Pharmaceuticals (Lexington, MA; $3M SBIR) and Novo Nordisk A/S [Denmark] announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. ... Dicerna will receive: An upfront payment of $175 million, $50 million equity investment in Dicerna at a premium, $25 million annually during each of the first three years of the collaboration, contingent on Dicerna delivering RNAi molecules for a defined number of targets, up to $357.5 million per target in development, regulatory, and commercialization milestone payments, plus tiered royalties on product sales ranging from the mid-single-digits to mid-teens. [joint companies press release, Nov 18, 19]

Dicerna Pharmaceuticals (Cambridge, MA; $3M SBIR) announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to develop novel therapies for the treatment of chronic hepatitis B virus (HBV) infection using Dicerna’s proprietary GalXC™ RNAi platform technology. will receive $200 million in an initial upfront payment and may be eligible to receive up to an additional $1.47 billion over time for the achievement of specified development, regulatory and commercial milestones. [company press release, Oct 31,19]

Eli Lilly teamed with  Dicerna (Cambridge,MA; $2.2M SBIR, founded 2007) in a wide-ranging deal to co-develop RNAi medicines for pain, and cardiometabolic and neurodegenerative diseases. Lilly will pay Dicerna $100 million up front and make a $100 million equity investment in the company at an unspecified premium. The agreement includes another $350 million in downstream payments, plus royalties, but those will only materialize if the programs in the collaboration progress. [Ben Fidler, Oct 29, 18]

Alexion Pharmaceuticals and Dicerna Pharmaceuticals (Cambridge, MA; $2.2M SBIR, founded 2007, total funding $295M [] announced a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases. Dicerna will receive an immediate upfront payment of $22 million, with Alexion making a concurrent $15 million equity investment in Dicerna at a premium to market as of the collaboration effective date. [joint companies press release, Oct 24, 18]

Dicerna Pharma up 14% [Sep 7, 18]

Dicerna Pharma (Cambridge, MA; $2.2M SBIR) down 18% [Sep 6, 18]

Dicerna Pharma (Cambridge, MA; no SBIR, founded 2007, IPO 2014) up 18% [Apr 20, 18] announced [it] resolved all litigation with Alnylam Pharmaceuticals. ... allows Dicerna to advance all of its key and planned pipeline programs while maintaining a strong balance sheet. [company press release, Apr 19, 18] total funding $295M; develops therapeutic agents in various disease areas based on dicer substrate technology platform. []

Boehringer Ingelheim (Germany) and Dicerna Pharmaceuticals (Cambridge, MA; no SBIR, founded 2007), a leading developer of investigational RNA interference (RNAi) therapeutics, announced a research collaboration and license agreement to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases. The partnership will initially focus on nonalcoholic steatohepatitis (NASH), a devastating, chronic liver disease for which there is no approved treatment option.  [joint companies press release, Nov 2, 17]

In 2006 Merck paid $1.1 billion for Sirna Therapeutics (no SBIR), a biotechnology firm reckoned to be a leader in the field. Roche and Novartis also made big investments around the same time. RNAi, it seemed, was going to take the pharmaceutical world by storm.  But siRNAs, so attractive in theory, proved impossible to tame in practice. Roche ended its work in 2010. Novartis and Merck followed suit in 2014. Nevertheless, a clutch of biotechnology companies are still working on the idea, and some of them now think they have cracked it. Chief among them are Alnylam and Dicerna (Cambridge, MA; no SBIR). These firms have, they believe, overcome one of the problems that caused RNAi to fall so deep into the trough of disillusionment—getting siRNA molecules across cell membranes to where they are needed. [The Economist, Oct 17, 15]

Dicerna Pharmaceuticals  (Watertown, MA; no SBIR), which has its own proprietary approach to silencing disease-related genes through RNAi, is announcing today it has raised $60 million in a Series C round of venture financing. ... now gives Dicerna $110 million in raised venture funds  ... Rather than engineering small RNAi molecules in the way that, say, Alnylam does, Dicerna makes them a little bit longer, which enables them to act a step earlier in the gene-silencing process, and thus potentially be more potent and last longer in the body. This, in turn, could mean that Dicerna could give its drugs in lower doses, produce them for less money, and administer them with fewer shots.  [Ben Fidler,, Aug 2, 13]

Dicerna Pharmaceuticals (Watertown,MA; no SBIR) said that Kyowa Hakko Kirin Co. Ltd., or KHK, has elected to advance its first collaborative oncology candidate from the research stage into formal development studies, a move that triggers a $5 million milestone payment for Dicerna. [Chris Reidy, Boston Globe, Dec 19, 11]    venture-backed RNA interference (RNAi) company developing novel therapeutic agents and related drug delivery systems in multiple disease areas based on its proprietary Dicer Substrate Technology™ platform and Dicer Substrate siRNA (DsiRNA) molecules. Dicer Substrate Technology is a next generation RNAi approach that results in greater potency, longer duration of action and enhanced delivery potential, differentiating it from other RNAi approaches [company website]

Dicerna Pharmaceuticals (Watertown, MA; no SBIR) has added $4 million in a second close of its Series B financing, bringing the round to $29 million. ...  drug delivery systems are built around the enzyme Dicer, which is used for gene silencing in generating drug candidates with greater potency and longer action duration than earlier RNAi approaches. [Mass High Tech, Oct 21, 10]

Dicerna Pharmaceuticals (Watertown, MA; no SBIR) RNA interference platform development company, has closed a $25 million Series B funding round ...  support the company’s oncology-focused program and its drug delivery systems [that are]  built around the enzyme Dicer, which is used for gene silencing in generating drug candidates with greater potency and longer action duration than earlier RNAi approaches ... in January it announced it had entered into a research collaboration and licensing deal with Japanese biopharmaceutical firm Kyowa Hakko Kirin Co. Ltd. for up to $124 million.   [Michelle Lang, Mass High Tech, Aug 11, 10]

teaming up to collaborate on some research-and-development work ... are Archemix (Cambridge, MA; $2M SBIR) focused on commercializing aptamer therapeutics, and Dicerna Pharmaceuticals (Watertown, MA; no SBIR) seeking to use RNAi gene-silencing technologies to develop novel drug treatments  [Boston Globe, Jul 21, 09]

Diffusion Pharma

Diffusion Pharma down 27% [Mar 29, 17]

Diffusion Pharma (Charlottesville, VA; no SBIR) up 81% [Mar 28, 17]

Diffusion Pharma up 176% [Jan 9,17]

Difusion Technologies (Austin TX)

DiFusion Technologies (Austin, TX, no SBIR) a start-up medical device company, is gearing up to launch a flagship product that will target the orthopaedic market at the same time it's raising additional capital.  Dr. Matthew Geck, founder and board member of DiFusion, said the company will release a medical device this year capable of killing 650 types of bacteria, including antibiotic-resistant bacteria such as MRSA (also known as “Superbugs”), in local surgical wounds for up to four weeks following surgery.  .... plans to seek between $2 to $3 million in its Series A round of funding in early 2009, [Austin Business Journal, Jan 6, 09]


OpGen (Gaithersburg, MD; no SBIR) filed to go public in hopes of raising as much as $37.4 million. ...  working to develop diagnostics to address the threat of antibiotic resistance.  ...  describes itself as an "early commercial-stage company using molecular testing and bioinformatics to assist health care providers to combat multidrug-resistant bacterial infections."  ...  led by CEO Evan Jones, who co-founded Digene  ($1.3M SBIR), a genomics company well known to local biotech watchers during Montgomery County's "DNA Alley" heyday of the late 1990s and early aughts. Digene was acquired by Qiagen NV in 2007 for $1.6 billion.   [Jeff Clabaugh, Washington Business Journal, Mar 3, 15]  

Digirad (Poway, CA)

Digirad down 26% [Mar 10, 20]

Digirad (San Diego, CA; $1M SBIR) up 114% [Mar 6, 20] announcd quarterly and year-end financial results

Digirad (Suwanee, GA; $900K SBIR in 1990s California) won a potential 10-year, $100 million contract from the Defense Logistics Agency to supply computed tomography imaging equipment devices to U.S. service branches and federal civilian agencies.  [Ramona Adams,, Jul 11, 17]

Digirad  (Suwanee GA; $1M SBIR two decades ago in CA) down 10%  [Nov 16, 15]

Digirad  down 15% [Nov 25, 13]

Digirad up 15% [Nov 11, 13]

Digirad (Poway, CA; $1M SBIR) said the FDA gave the company approval to market Ergo, a nuclear imaging camera system for hospitals that’s smaller and more portable than existing hospital systems. [Bruce Bigelow, signonsandiego, May 13, 10]

Digirad down 18% [Apr 24, 08]

Digirad down 13% [Mar 17, 08]

Digirad down 10% [Jan 23, 08]

Digirad down 18% [Jan 8, 08]

Digirad up 16% [Nov 26, 07]

DigiSight Technologies (Portola Valley, CA)

DigiSight Technologies (Portola Valley, CA; no SBIR) said it has raised a $7.8 million B round to pour into mobile technology that lets eye doctors monitor their patients’ sight between visits.  [Alex Lash,, Feb 12, 15]

Digital Fusion (Huntsville, AL)

Kratos Defense & Security Solutions (San Diego, CA; no SBIR) will Digital Fusion (Huntsville, AL; $600K SBIR)in an all-stock $38M deal. [San Diego Union Tribune, Nov 25]

Dialing for Dollars.  [Stewart Hall] decided to create a government contractor nearly from scratch. He assembled a group of investors, many of them fellow lobbyists. Together they bought a 25% stake in Huntsville, Ala.-based Digital Fusion Inc., a small technology-consulting company on the verge of bankruptcy. It did little business with the government, so Mr. Hall set out to beef up its defense-contracting business. Today, it mainly helps government agencies use computer technology for tasks ranging from budget analysis to missile engineering. That happens to be a growing part of the government's large defense operations in Huntsville, the home terrain of Sen. Shelby.... It has snagged more than $85 M in federal software contracts. In the two years since Mr. Hall invested in the company, revenue tripled to $20.9 M. The stock shot up as high as $3.75 earlier this year from a low of 15 cents before Mr. Hall showed up. [Brody Mullins, Wall Street Journal, Oct 7] Digital Fusion now has a Phase 1 STTR from the Army, but the public record will never show whether any political influence was used to win it.  And why does a company with $85M in federal software contracts and an in with an influential Senator need nursery funding?  For the same reason that other SBIR firms with $200M in past SBIRs, it's easy money once you learn how.

Digital Lumens (Boston, MA)

Digital Lumens (Boston, MA; no SBIR) said it has raised a $10 million round of funding from existing investors amid growth in installations for its Intelligent LED Lighting System. ....  brings Digital Lumens to at least $35 million since its founding in 2008. [Kyle Alspach, Boston Business Journal, Jan 9, 13]

Digital optics

Light Stopped. Two physicists slowed light by trapping it in a really cold crystal of praseodymium-doped yttrium-silica crystal. Phil. Hemmer at the AFRL and Selim Shahriar at MIT sent the news to Physical Review Letters while the try stretch the hold time to tenths of a second. [facts from Business Week, Nov 19]. Sharhiar also has commercial dreams, although not with halted light. from an SBIR Phase 2 from BMDO in his company Digital Optics.

Dignify Therapeutics (Research Triangle Park, NC)

Real seed investment. On average, every dollar N.C. Biotech loans to young life science companies is met with $118 in additional funding to those firms from disease philanthropy and government grants, angel and venture investment and other financial support, according to the center. Every grant dollar is met with an average $28 in additional funding.  ...  loans and grant made by the Biotech Center in the second fiscal quarter:      $50,000 in a Company Inception Loan to Spyrix (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, developing a treatment for cystic fibrosis. The loan is intended to help position the company for outside investor and foundation funding and to help with preclinical development of its product.       $75,000 to Eppin Pharma (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, to help in its development of a reversible, oral, non-hormonal male contraceptive pill. This money will help support toxicology and other testing of the company's lead drug candidate and help position Eppin to seek additional funding from investors, federal grants and foundations.       $250,000 to Dignify Therapeutics (Research Triangle Park, NC; one SBIR, eight employees), developing a novel drug to help people with spinal injuries clear their bladders and bowels when they choose to do so. The loan will support studies of the drug's safety and help Dignify develop a final formulation of the remedy, for use in clinical trials.      $458,000 to Bioptigen  (Morrisville, NC; $2.9M SBIR), to support late-stage development and clinical testing needed for FDA approval of its intrasurgical optical coherence tomography device for real-time guidance of ophthalmic surgery.       $500,000 to Baebies (Durham, NC; no SBIR),  to help it develop its products to diagnose health risks in infants from a single dried blood spot, using a technology called digital microfluidics. This loan supports the company's newborn screening tests for three devastating disorders (Pompe, biotinidase deficiency and galactosemia).  [Jason deBruyn,Triangle Business Journal, Feb 4, 15]   SBIR has no chance of such rewarding results because about three-fourths of the money is spent by agencies that just want what they can use for their own purposes with no regard for whether there is any widespread economic payoff, nor any payoff to society. SBIR can hide these facts behind privacy of private business whihc is OK with Congress as long as the small biz get the prescribed handouts.

Dignify Therapeutics (Research Triangle Park, NC; one SBIR, eight employees) drug developer took a big step forward by raising more than $3 million in venture capital, the first venture financing in the company's history. ...  is developing a drug to help people with spinal injuries clear their bladders and bowels when they choose to. [Jason deBruyn,Triangle Business Journal, Feb 4, 15]

Dimension Inx (Chicago, IL)

Dimension Inx (Chicago, IL; no SBIR, founded 2017) a next-generation biofabricationcompany developing regenerative medical implants that repair tissues and organs, announced that it has raised $3.175M to close its Series Seed financing round, [to] support the commercial development and FDA approval of the company’s first therapeutic implants for facial reconstruction in patients followingtrauma as well as those with dentalma lformations due to congenital defects or aging. [company press release, Nov 10, 20]

Dimension Technologies (Rochester, NY)

PTC Thera down 11% [Oct 3, 17]

RegenxBio  has opted to back away from a deal to buy Dimension Therapeutics after the biotech received a better buyout offer. RegenxBio said it doesn't plan to match, or best, the unsolicited $6-per-share price that Ultragenyx Pharmaceutical is now offering to Dimension Therapeutics that's struggled with its pipeline in the last year. (Washington Business Journal, Oct 2, 17)

Dimension Technologies (Rochester, NY; $6M SBIR) has been featured in a NASA technical publication on Aviation and Air Transportation.  ... features DTI’s DTI ROC3D technology that allows users to view full-resolution 3-D images without the need for glasses or headsets, the company said. The firm, part of the Rochester Institute of Technology’s Venture Creations, manufactures and licenses product for computer and video displays.    [KERRY FELTNER, Rochester Business Journal, Feb 2, 17]

Dimension Therapeutics (Cambridge, MA)

Dimension Therapeutics (Cambridge, MA; no SBIR) up 40% [Sep 18, 17]  a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-binding, unsolicited proposal from Ultragenyx Pharmaceutical  (no SBIR) to acquire Dimension for $5.50 per share in cash. But As announced on August 25, 2017, Dimension entered into a definitive merger agreement with REGENXBIO under which REGENXBIO will acquire Dimension in an all-stock transaction.  [company press release, Sep 18, 17]

Dimension Therapeutics (Cambridge, MA; no SBIR) agreed to be acquired by RegenxBio (Rockville, MD; no SBIR), the gene therapy developer that originally helped form the company four years ago. RegenxBio will pay approximately $86 million. By comparison, Dimension went public at $13 per share in 2015. Dimension’s closing stock price on [Aug 24] was $1.20. [, Aug 25, 17]

Dimension Therapeutics (Cambridge MA; no SBIR) down 17% first day from its IPO that raised  $72M  [Wall Street Journal, Oct 22, 15]

Fidelity Biosciences, a venture capital firm that is a subsidiary of the parent company of Fidelity Investments, and REGENX Biosciences announced the formation of Dimension Therapeutics (Cambridge, MA) gene therapy company focused on developing novel treatments for rare diseases such as hemophilia. [Chris Reidy, Boston Globe, Oct 31, 13]

Dimien (Amherst, NY)

Dimien (Amherst, NY; $900K SBIR) clean tech manufacturer of ceramics and inorganics that are used as additives in laminates, inks, coatings, plastics, and other ceramics [company website] was a Finalist in the 43North startup competion for $1M. The winner was SparkCharge (Syracuse, NY; no SBIR) a Syracuse University spinoff that offers a portable electric-vehicle (EV) charging unit   [Eric Reinhardt, Central NY Business Journal, Oct 5, 18].

DioGenix (Gaithersburg, MD)

Montgomery County [MD, a competitor for America's richest county] will dole out $500,000 to investors in 10 life sciences companies through its coveted biotech tax credit, a fifth of which will go to backers of diagnostics company DioGenix (Gaithersburg, MD; no SBIR)  ... piggybacks on the $3.5 million in tax credits from the state to those same 46 investors. The incentives are tied to a total $7 million in private biotech investments in the county last year. Also receiving the credits are backers of 20/20 GeneSystems (Rockville, MD; $4.6M SBIR, incl one of $3.3M),  Alper Biotech LLC, American Gene Technologies International Inc., BeneVir Biopharm Inc., ConverGene LLC, Creatv MicroTech (Potomac, MD; $11.6M SBIR)., Rafagen Inc., Sequella (Rockville, MD; $10.3M SBIR). and SynAm Vaccine. [Bill Flook,Washington Business Journal, Feb 28, 14]

Dipexium Pharmaceuticals (New York, NY)

PLx Pharma (Houston, TX; $3.4M SBIR) down 19% [Apr 20, 17]   announced completion of merger with Dipexium Pharmaceuticals [company press release, Apr 20, 17]

Dipexium Pharmaceuticals (New York, NY; no SBIR) and PLx Pharma (Houston, TX; $4M SBIR) late-stage specialty pharmaceutical company, announced  that they have entered into a definitive agreement under which PLx Pharma will merge with a wholly-owned subsidiary of Dipexium in an all-stock transaction. ...  Dipexium will be renamed PLx Pharma Inc., and will operate under the leadership of the PLx management team.  .... focused on completion of manufacturing scale-up and label finalization for the previously conditionally approved AspertecTM 325 mg aspirin dosage form thereby satisfying the open conditional items, and filing of a supplemental new drug application (sNDA) for Aspertec 81 mg maintenance dose form.   [joint companies press release, Dec 21, 16]

Directed Manufacturing (Austin, TX(

Directed Manufacturing (Austin, TX; no SBIR, founded 2007) has developed the largest 3-D printed rocket engine component NASA has tested. ...  the rocket engine injector that was tested during an engine firing that generated a record 20,000 pounds of thrust [Christopher Calnan, Austin Business Journal, Aug 28, 13]

Directed Perception (Burlingame, CA)

Flir Systems said it has acquired Directed Perception (Burlingame, CA; no SBIR) for $20 million in an all-stock deal. ... Directed Perception makes pan-tilt motion control systems for commercial and military markets. [Portland Business Journal, Dec 27, 09]

Disarm Therapeutics (Cambridge, MA)

BioGenerator (St Louis, MO) supported startup company  Disarm Therapeutics  (Cambridge, MA; no SBIR, founded 2016)   ...   Prior to the company being formed, BioGenerator supported the academic inventors, Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University.  [BioGenerator press release, Sep 19, 17]      a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing.   [Disarm company press release, Sep 19, 17]   BioGenerator wins slice of $17 million federal grant to invest in startups ...  estimates it will support 60 jobs and $110 million in additional investment attracted during the project and a total of 160 jobs and $411 million in additional investment after the project closes.   [Brian Feldt, St. Louis Business Journal, Sep 21, 17]

Disc Dynamics (Eden Prairie, MN)

Disc Dynamics  (Eden Prairie, MN; no SBIR), a once-promising medical device start-up that raised about $65 million from investors, has shut down and is selling off its assets.  ...  developed a minimally invasive technique to treat low back pain, failed to win a go-ahead from the FDA to conduct a pivotal clinical trial.  [Minneapolis Star Tribune, Feb 5, 10]

Disc Dynamics (Eden Prairie, MN; no SBIR) was founded in 2000 to develop the Dascor technology and has received $65 M from private and venture capital investors.   Disc says  The potential market for devices and related biologics treating back maladies is estimated to be $4.1B in the United States this year, and is expected to grow 20% annually.$10M of the VC money came from Steve Stassen who sold his previous company SpineTech to a Swiss company in 1998 for $600M, and Stassen went on to help found the venture capital firm Split Rock Partners. But he never forgot the promise of the Dascor technology.   [Janet Moore,Minneapolis Star-Tribune,Jun 11] with that scale knowledgeable financing, a companydoes not need, cannot afford, the slow nickels and dimes of sbir.

Disc Medicine (Cambridge, MA)

Disc Medicine (Cambridge, MA; no SBIR), a new biotech that aims to treat anemia caused by a variety of blood disorders, launched out of Cambridge, MA venture firm Atlas Venture on Tuesday with $50 million. The company is developing drugs to impact hepcidin, a liver hormone that helps the body regulate iron absorption. [Sarah de Crescenzo,, Oct 29, 19]

Discovery Genomics (Minneapolis, MN)

gene therapy biotech startup Immusoft (Seattle, WA; one SBIR, founded 2009) has acquired Discovery Genomics  (Minneapolis, MN; $5.5M SBIIR).  With the acquisition, Immusoft gets a license to use Discovery Genomics’ Sleeping Beauty Transposon System, which can deliver genes into cells without using a virus, which is less expensive and more scalable than using a virus, said Matthew Scholz, CEO and founder  [Greg Lamm, Puget Sound Business Journal, Mar 9, 16]

Discovery Labs (Warrington, PA)

 Discovery Laboratories (Warrington, PA; one SBIR) changed its name to Windtree Therapeutics. [John George,  Philadelphia Business Journal , April, 18, 16]

Discovery Laboratories (Warrington, PA; one SBIR), closed a $40M stock offering to fund late-stage testing of its aerosolized surfactant replacement therapy for respiratory distress syndrome in infants born prematurely.   [John George, Philadelphia Business Journal, Jul 22, 15]

Discovery Laboratories (Warrington, PA; one SBIR in Y2K) was awarded [NIH SBIR] valued at up to $3 million to support the company’s development of a potential new treatment for radiation-induced lung injuries.  ...    was awarded $1 million and is eligible to receive an addition $2 million over the next three years ... The company’s lead product, Surfaxin, is a synthetic surfactant product used to prevent respiratory distress syndrome in infants born prematurely. The drug was approved by the Food and Drug Administration in 2012, and launched last year.   [John George, Philadelphia Business Journal, Oct 1, 14] 

Discovery Laboratories (Warrington, PA; one SBIR in Y2K) is planning to raise $50 million in a public stock offering.  .... to support its commercial introduction of Surfaxin, a therapy to prevent respiratory distress syndrome in premature infants.  [John George, Philadelphia Business Journal, Oct 31, 13]

Discovery Laboratories (Doylestown, PA; one SBIR in Y2K) stock soared more than 47 percent Friday morning after the FDA agreed to the company’s updated product specification for Surfaxin. .... has initiated manufacturing of Surfaxin for its planned commercial introduction of the product before the end of the year.   [John George, Philadephia Business Journal, Oct 4, 13]

Discovery Labs  up 11% [Feb 27, 12]

Discovery Laboratories (Warrington, PA; one Y2K SBIR) entered into definitive agreements Friday with institutional investors that will provide the company with gross proceeds of about $11.3 million.  The deal will give the biopharmaceutical company a needed cash infusion following a setback last month when the FDA for the fourth time, delayed making a final decision on the company’s new drug application for its flagship new drug candidate Surfaxin. [Philadelphia Business Journal, May 11, 09]

Discovery Labs up 18% [Apr 29, 08] while still awaiting FDA approval.

Discovery Labs down 16% [Apr 29, 08] awaiting FDA approval.

DisperSol Technologies (Georgetown, TX)

DisperSol Technologies, LLC, (Georgetown, TX; no SBIR, founded 2007) secured financing [over $10 million] to expand its drug formulation and GMP manufacturing capabilities for its partnerships with the pharmaceutical industry. ... to develop its own portfolio of proprietary drug products with significantly improved bioavailability profiles [company press release, Feb 3, 16]

Displaytech (Boulder,CO)

Onspan Million Micros(Dec 24) Displaytech (Longmont, CO) shipped its one millionth microdisplay, after 12 months of volume production. The millionth microdisplay shipped was a LightView NTSC Monochrome FLC Video Display, produced specifically for use in electronic viewfinders of digital camcorders.Displaytech specializes in ferroelectric liquid crystal (FLC) displays after about $13M of SBIR over a dozen years.

Displaytech develops second sourceFerroelectric liquid-crystal microdisplay maker Displaytech (Longmont, CO) announced that new primary manufacturing facilities in Nagano, Japan, are now producing its displays. The facility, Miyota Company, is executing all phases of microdisplay production. Rather than working with retrofitted semiconductor machines, Miyota has put together its own microdisplay-specific production machines that include packaging, assembly, thin-film, and vacuum tools. The swing into production will open the door to a difficult-to-reach Japanese customer base, according to Displaytech.

Displaytech HP Alliance(Nov 10) With Enough Money, and Time, and Patience... Hewlett-Packard (not a small firm) says it has an alliance with Displaytech (Boulder, CO) for ferro-electric liquid crystal wherein Displaytech makes the reflective silicon chips and HP does everything else, especially selling them. [Wall Street Journal, Nov 9] The government (SBIR) has pumped $12M or so into Displaytech since 1985 for the FLC stuff as the company's employee count steadily rose from one in 1985 to 45 last year. Is that a good enough return for 13 years of investment, and should government be doing that with a start-up nurturing program? No matter, it's being done with lots of other companies because government doesn't know what else to do with its SBIR money since SBIR has far too much money and far too fragmented a management for any efficient start-up program.

Keep Priming, Please (Feb 19) Displaytech (Boulder, CO) has pursued the application of Ferroelectric Liquid Crystal technology, which offers substantial advantages over other approaches. [Handschy & Locke, Advanced Imaging, Jan97] For a decade SBIR has invested something like $10M in Displaytech's FLC with exhortations to get commercial. Now it promotes yet another potential use - high performance virtual displays. But Hanschy's article mentions no business success, only a bright theoretical future. It sounds like so many SBIR Phase 2 proposals with a bright future if only government will prime the pump, and prime, and prime.

Distributed Energy Systems (Wallingford, CT)

Distributed Energy Systems (Wallingford, CT; $2M SBIR) says that it has filed for Chapter 11 bankruptcy protection. [Mass High Tech, Jun 13]

Divergence (St. Louis, MO)

Last month leading ag-biotech company Monsanto purchased former Larta NSF-CAP1, USDA-CAP, and Ag Innovation Showcase company participant Divergence  (St Louis, MO; $4.4M SBIR) focuses on developing technologies to fight against parasitic nematodes, a pest that costs farmers billions of dollars each year. The company has worked closely with Monsanto since 2004 [LARTA, Mar 9, 11]

Divergence (St. Louis, MO; $2.5M SBIR) said it raised $11.8 million in Series C funding to continue development of its technology to prevent or control parasitic nematode infestations [CleanTech Group release, Feb 16, 09]

Diversified Energy (Gilbert AZ)

BioFuel from Pork.  Two companies, Diversified Energy (Gilbert AZ; formed in 2005) and Velocys (Plain City, OH) , are working together on a portable system that converts coal, natural gas, and biomass into diesel and jet fuel. The military could use the system to convert waste created at military bases--food scraps, paper, wood--into a fuel for military jets and vehicles.  .... Velocys, a subsidiary of Battelle Memorial Institute, was launched in 2001 and has developed a portfolio of 70 patents and received $100 million of investment from industry leading partners, [Pachi Partel-Predd, MIT Tech Review, Dec 21]  In June 2005 Congresswoman Deborah Pryce (R-Upper Arlington) today announced that $21.8M for Defense Department projects in Ohio is included in the FY 2006 Department of Defense Appropriations Bill, pursuant to her requests. In Oct 96  A Congressional appropriation for Velocys’ synthetic fuels project was approved for fiscal year 2007. The latest contract to Diversified Energy is a Phase 1 SBIR.


In 2007 Stanford MBAs Sam Goldman and Ned Tozun figured out a safer, cleaner way to provide power to low-resource areas. They started D. Light, (no SBIR) a company that makes portable, rechargeable, solar-powered lights. D. Light manufactures the lights in China and sells them in over 30 countries. It offers three models, which range in price from $10 to $40, depending on the model and the country where it’s sold. The most high-end product, called the S250, provides up to 12 hours of light per day, and includes a cell phone charger. ... has raised $12 million in funding, won’t disclose sales. Tice says that companies like General Electric (which today announced plans to build the largest solar power factory in the United States) have approached D. Light about strategic partnerships.  [Helen Coster, Forbes, Apr 7, 11]

DMC Biotechnologies (Boulder, CO)

Bill Gates's Breakthrough Energy Ventures (BEV) aims to invest $1 billion into radical energy startups capable of drastically cutting global emissions. The investees: QuantumScape (San Jose, CA; no SBIR, founded 2010, total funding $100M) building an all-solid-state battery; Commonwealth Fusion Systems (Cambridge, MA; no SBIR, founded 2017, total funding $65M) nuclear-fusion reactor that uses high-temperature superconductors and aims to be the first fusion system to produce net-positive energy ; Pivot Bio (Emeryville, CA; one SBIR, founded 2010, total funding $17M) microbial solution that can replace nitrogen fertilizers; CarbonCure (Canada, founded 2007, total funding $9M) trapping carbon dioxide in concrete blocks, while endowing them with greater strength than conventional concrete; Fervo Energy (San Francisco, CA; no SBIR) rethinking geothermal power with the help of modern computational models and horizontal-drilling; DMC Biotechnologies (Boulder, CO; $900K SBIR, founded 2017, total funding $2M) tailoring microbes to produce high-value chemicals, including biofuels; Zero Mass Water (Scottsdale, AZ; founded 2014, no SBIR) specialized panels that use solar power and batteries to pull water from the air. [Akshat Rathi, Quartz, Sep 26, 18]


Among the Technology Review fifty smartest companies: Illumina ($5M SBIR plus acquired firms), Alnylam ($600K SBIR), DNAnexus (one SBIR).  The other quadrillion SBIR winners haven't been as smart as the best. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 12 months. [, Jun 29]

DNAPrint Genomics (Sarasota, FL)

DNAPrint Genomics (Sarasota, FL),which trades for less than a penny a share and lost $12.3 million last year, has been told by its auditors that it is in danger of going out of business, ... "It's a long shot. That's the game we're in. They're all long shots," said Mark Chalek, chief of business ventures at [its deal partner] Beth Israel Deaconess. ... another frustrating chapter in the development of the drug, a form of erythropoietin invented in the mid- 1990s by Dr. Arthur J. Sytkowski of Beth Israel Deaconess, and known officially as PT-401. His work was financed through grants from the National Institutes of Health and the US Navy. [Christopher Rowland, Boston Globe, Apr 9]

DNAtrix (Houston, TX)

Add another player to the field of developing checkpoint inhibitor drugs: biotech DNAtrix  (Houston, TX; no SBIR) . ... announced a partnership with pharma giant Merck to develop a therapy to treat glioblastoma, an especially deadly form of brain cancer. [Angela Shah,, Oct 6, 15]

DNAtrix (San Diego, CA and Houston, TX; no SBIR) that is modifying viruses to treat the most aggressive forms of cancer, said it has raised $20 million in a Series B round  [Alex Lash,, Oct 17, 14]

DNAtrix  (Houston, TX; no SBIR) biotech company that researches the use of viruses to target and destroy cancer cells, announced that it was awarded a $10.8 million grant to further its program for treating an aggressive form of brain cancer.  The Cancer Prevention and Research Institute of Texas (CPRIT) gave DNAtrix the grant to help the company usher its product, DNX-2401, a genetically modified adenovirus that attacks brain tumors, through the second stage of its first phase of development.  ...  In 2012,  DNAtrix merged with Vectorlogics (Birmingham, AL;  $2.8M SBIR)   [Josh Cain, Houston Business Journal, Feb 24, 14]

DNAtrix (Houston, TX; no SBIR)  Using a virus to attack cancer cells. ... conducting clinical trials on nine brain cancer patients at the University of Texas M.D. Anderson Cancer Center  ... received $500,000 from the state’s Emerging Technology Fund and is eligible to receive $500,000 more if it meets certain milestones. DFJ Mercury has invested about $480,000 in venture capital and the Marcus Foundation has given $2 million. ...  also received $4.5 million in federal grants for clinical production and testing. [Purva Patel, Houston Chronicle, Aug 28, 10]

DNV GL (Rochester, NY)

New York State Energy Research and Development Authority awarded $250K to  DNV GL (Rochester, NY; no SBIR) –  will develop a novel separator for lithium-ion batteries. ... to decrease the risk of fires due to Lithium-ion batteries, which – while rare – have occurred in the past. Ultralife (Newark, N.Y.) and Oak-Mitsui (Hoosick Falls, N.Y.) will participate in project reviews. The company will also investigate methods for automatically extinguishing a Lithium-ion fire should it occur. [NYSERDA, Oct 27, 14]

Dova Pharma (Durham, NC)

Dova Pharmaceuticals (Durham, NC; no SBIR) up 38% [Sep 30, 19] announced it has entered into merger with Swedish Orphan Biovitrum AB (Sobi) ... [for] total potential consideration of up to $915M ... to further accelerate growth in our haematology franchise. There is a large unmet medical need within thrombocytopenia and for us this is a great opportunity to be able to give patients access to new and improved treatments. [company press release, Sep 30, 19]

Dova Pharma up 22% [Aug 15, 17]

Dova Pharma up 20% [Aug 14, 17]

Dova Pharmaceuticals (Durham, NC; no SBIR) focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, announced the pricing of its [IPO] for total gross proceeds of  $75M  [company press release, Jun 28, 17]

Dova Pharmaceuticals (Durham, NC; no SBIR)  set terms of its [IPO] which the developer of drug candidates for diseases treated by specialist physicians expects to raise up to $69.1 million   [Tomi Kilgore, MarketWatch, Jun 20, 17]

Dova Pharmaceuticals (Durham, NC; no SBIR, founded 2016, four employees), focused on developing drugs to treat low blood platelet counts, is attempting to raise as much as $75 million through an IPO.  .... one promising drug candidate called avatrombopag, which it acquired from the Japanese pharmaceutical company Eisai in March 2016  [Zachery Eanes, Raleigh News & Observer, Jun 7, 17]

DoX Systems (Toledo, OH)

Rocket Ventures, a pre-seed, early-stage venture fund for technology-based [Ohio] companies, has awarded Ignite! grants to three Toledo firms - ADS Biotechnology, TechTol Imaging, and DoX Systems. These grants are given to help the companies develop and use technology to create new products or improve processes that have an impact on jobs and revenues in Northwest Ohio.   [Toledo Free Press, Jun 13, 08]  No SBIR.

Dracen Pharma (Balimore, MD)

Deerfield Management will put up $36 million of Dracen Pharma (Balimore, MD; no SBIR, founded 2017)’s $40 million series A round [to] propel the startup’s cancer programs into clinical trials. ...  working on drugs targeting immuno-metabolism, an approach that combines immuno-oncology and cancer metabolism. [Amirah Al Idrus, Fierce Biotech, Mar 22, 18]

Dragon Systems

Another buyout has much less basis for any paternity claim by SBIR. Dragon Systems a big research house (but still under 500 employees) in speech recongition was bought by a Belgian company Lernout & Hauspie for something like $600M. Dragon's SBIR experience is $400K ten years after its founding and in the middle of its growth to over 300 employees. Talk big and fast to convince anyone that $400K wasn't just another nickel in the piggy bank. Inknowvation, a persistent SBIR advocate, has tried to make the case by crediting a 1993 DARPA $250K Phase 2 with the key that opened the door. It sounds more taking credit for United Airlines success by buying one round-the-world ticket. Outside finance came from Seagate Technology 1994-1997 in the form of a seeming 35% equity stake after which a planned 1999 $100M IPO busted when earnings started to falter.Ah well, if you are an SBIR advocate justifying SBIR's economics, you need all the imagination you can muster for every success no matter how small.

Dragoon ITCN (Centerville, OH)

Dragoon ITCN (Centerville, OH; no SBIR, 13 employees, founded early 1990s) landed a $1.4 million [AF SBIR] contract ...  to upgrade a cable networks tester. ... Developed by the company years ago, Dragoon ITCN will work to add extra capabilities to the tester under the new contract   [Joe Cogliano, Dayton Business Journal, Nov 24, 14]   Downstream economic impact?  Where's the innovation that would open any new market?  What would have happened if the AF had opened the product improvement to open competition?  Who knows? This way the AF can use SBIR for ordinary product improvement that would probably fail any test of competitive innovation. The AF shows no sign of considering economic impact in awarding its SBIRs. The company's proximity to the AF flagpole also gave it some advantage in the occasions to schmooze AF officials and engineers. The Ohio Congresscritter for the district will surely rejoice in public.

Drilling Info (Austin, TX)

Drilling Info (Austin, TX; no SBIR) that provides data and intelligence to the oil and gas industry, has landed a $165 million equity investment that will help continue Drilling Info's swift growth, company officials said [Barry Harrell, Austin American Statesman, Mar 5, 12] 

DrillMap (Austin,TX)

DrillMap (Austin, TX;  SBIR) cleantech startup, said today it has raised $6.5 million in [Round A] venture capital.   [Angela Shah,, Aug 8, 13]

Dronewerx (Elyria, OH)

Dronewerx (Elyria, OH; no SBIR) has designed a new drone with shielded rotors that it hopes will make flying safer.  
....  an unmanned systems company has developed a multi-rotor drone, the DWX PG-Y6 Guardian — a craft with six motors and a prop guard that protects the aircraft rotors. ...  Multicopters are an especially popular form of UAS, common with hobbyists for their inexpensive price thanks to models like the DJI Phantom quadcopter   [Tristan Navera, Dayton Business Journal, Sep 8, 14]

DropWise (Cambridge, MA)

The [water-repellent] coating improves the efficiency of a key part of a power plant, the steam condenser.  ... is being commercialized by a startup called DropWise  (Cambridge, MA; no SBIR).   ...  To get the right thickness, MIT researchers invented a new process that involves flowing two gases past heated filaments. The gases react and form a polymer coating that is “just thin enough to still be much more efficient, but thick enough to be durable,” Boreyko [Virginia Tech professor and expert on heat transfer] says.  So far the coating technology has been tested only in the lab.   [Rachel Becker,, Nov 20, 14]

DR Technologies (San Diego, CA)

DR Technologies (San Diego; $4M SBIR) has raised $4.5 million from private equity firm Nogales Investors of Los Angeles. The company makes composites for commercial, military, and scientific satellites and other space systems.  .... customers include Lockheed Martin Space Systems, Boeing, and Orbital Sciences. Nogales acquired a controlling stake in the company in 2009. [Mike Freeman, signonsandiego,com, Jun 10, 10]

DrugCendR(La Jolla, CA)

DrugCendR (La Jolla, CA; no SBIR) developing tumor-penetrating peptides that enhance delivery of anticancer drugs announced it has entered into a collaboration with Xiamen Tobefar Technology Co. Ltd  (China), partially owned by Peking University and Beijing Institute of Collaborative Innovation (BICI). [company press release, May 3, 17]

DSM (Exton, PA)

BiO2 Medical (San Antonio, TX; no SBIR, founded 2010) will use biosciences firm DSM’s (Exton, PA; no SBIR) lubricous coating on the Angel Catheter, its flagship product.  Placed at a patient’s bedside, the Angel is designed to protect intensive care patients from pulmonary embolism, or the blockage of an artery by a blood clot.  [Sanford Nowlin, San Antonio Business Journal, Nov 12, 13]

DT Solar

Last year, [Ted] Turner invested several million dollars in DT Solar (no SBIR), a New Jersey company .... He also created a holding company, Turner Renewable Energy, and said that he's looking to expand his holdings. ...According the Solar Energy Industries Association, the photovoltaic industry grew by nearly 80% last year, and the solar water heating business more than doubled. [Austin American Statesman, Sep 26]

DTx Pharma (San Diego, CA)

DTx Pharma (San Diego, CA; no SBIR)  announced the final closing of a Series A financing totaling $10.6 million dollars [to] speed development and deployment of their proprietary platform for delivery of RNA medicines. [company press release, Jan 6, 20]

DTx Pharma (San Diego, CA; no  SBIR, founed 2017) announced the final closing of a Series A financing totaling $10.6 million dollars [company press release, Jan 6, 20] prior funding $13M []

DuBay Ingredients (Stratford, WI)

Two Wisconsin companies raised nearly $4.5 million of angel funding in the third quarter, according to the Wisconsin Angel Network. span style="font-weight: bold;">DuBay Ingredients (Stratford, WI; no SBIR) with a technology for producing ethanol from whey, raised $4.25 million from LA Investment Capital. The other company is span style="font-weight: bold;">, Onalaska, which provides customers with competitive pricing from contractors and other building industry professionals.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 30, 09]

Dune Medical Devices (Atlanta, GA)

The scientists, leaders and investors of Dune Medical Devices (Atlanta, GA; no SBIR, founded 2002 ) [are] working towards eradicating the need for more than one operation to remove cancer from the body—a feat more than 20 companies have been unable to accomplish in the past two decades. The startup, which was founded in Israel in 2004 and later moved its operations to Atlanta, was founded by Dan Hashimshony, who discovered how to differentiate healthy tissue from cancerous tissue using physics and an algorithm. Using the algorithm, Hashimshony developed a pen-like probe that could determine if tissue was cancerous during surgery. [Madison Hogan, AtlInno, Jul 17, 19] total funding $50M []

duPont Aerospace (LaJolla, CA)

executives at duPont Aerospace (LaJolla, CA; one SBIR) continue to declare the discontinued experimental military plane – and, more specifically, its engines – theirs. ... refuses to turn over two costly engines nearly a year after NASA demanded their return. The engines were purchased with a 2002 government grant to the company, and are valued together at $1.5 million.  The parties appear poised to go to court to settle the issue. ... the congressman continued to push earmarked funding for nearly 20 years, finally totaling $63 million in 2007, the aircraft never passed a major technical review.   [San Diego Union Tribune, Nov 4]

Dura Biotech (Mansfield, CT)

Dura Biotech (Mansfield, CT; no SBIR), a startup, is expecting a $400,368 loan that Connecticut Inovations could choose to convert into an equity stake.... to work on early research for an aortic valve concept, and to fund an animal study of the valve, which is designed to be compressible to a smaller diameter as it is threaded through the body to reach the heart.     [Mara Lee, Hartford Courant, Aug 6, 14]

Durata Therapeutics (Morristown, NJ)

Durata Therapeutics  (Morristown, NJ; no SBIR) wants to raise $81 million [in an IPO]. The company, which has never been profitable, hasn't yet received approval for any of its drugs. Early-stage drug developers can have a difficult time pricing and trading even in perfect market conditions, although the last one that came public, Tesaro (no SBIR), priced within its expected range and traded up slightly during its debut last month.  [Lynn Cowan, Wall Street Journal, Jul 16, 12]

Durin Technologies (New Brunswick, NJ)

Durin Technologies (New Brunswick, NJ; no SBIR) has landed a $351,200 grant from the Michael J. Fox Foundation to expand the development of the company’s experimental blood test that can detect the presence of Parkinson’s disease earlier than the clinical observation of symptoms.  [John George, Philadephia Business Journal, Aug 29, 13]

DVS Sciences (Sunnyvale, CA)

Fluidigm (South San Francisco, CA: $1.1M SBIR) will buy DVS Sciences (Sunnyvale, CA; no SBIR)  in a cash and stock deal worth about $207.5 million. ...makes similar laboratory research equipment that Fluidigm said is "directly in-line with our strategy."  [Steven E.F. Brown, San Francisco Business Times, Jan 29, 14] 

DxUpClose (Frisco, TX)

Telemedicine Up Close (Frisco, TX; no SBIR) which operates as DxUpClose, was awarded $280,000 [from Texas Emerging Technology Fund] of up to $1.5 million for the commercialization of a diagnostic kit designed to identify bacterial infections and determine antibiotic treatment, Gov. Rick Perry’s office announced [Christopher Calnan Austin Business Journal, Jul 25, 13]

Dyadic International (Jupiter, FL)

Dyadic International  (Jupiter, FL; no SBIR) announced that it has entered into a definitive agreement to sell substantially all the assets of its Industrial Technology business to DuPont’s Industrial Biosciences business for $75 million in cash ....  Dyadic intends to focus exclusively on its biopharmaceutical business.  ...  intends to use a minimum of $15 million of the transaction proceeds to initiate a  stock repurchase program. [company press release, Nov 10,15]


Dyax up 12% [Dec 3, 15]

Dyax (Cambridge, MA; $300K SBIR in 1999) up 28%, [Nov 2, 15]   Shire Plc (Ireland) has agreed to buy U.S. rare disease specialist Dyax for about $5.9 billion - and potentially up to $6.5 billion  ...  amid a record wave of deal-making in the broader healthcare sector so far this year, which amounted to $477 billion as of last week, according to Thomson Reuters data.    [Ben Hirschler, Reuters, Nov 2, 15]

Dyax up 19% [Oct 15,15]

Dyax up 54% [Apr 1,15] after the biopharmaceutical company reported favorable safety and efficacy results from an early-stage study of its treatment for hereditary angioedema attacks, which causes severe and painful swelling.  Dyax said the drug candidate, DX-2930, also received fast-track designation from the  [FDA]  [Josh Beckerman, Dow Jones Newswire,  Apr 1, 15]

In about two months, Dyax will report trial results on an injectable drug that could enable patients with a rare swelling disease called hereditary angioedema to live without fear of attacks.  [Don Seiffert, Boston Business Journal, Feb 12, 15]

Dyax down 10% [Dec 23, 14]

Dyax up 11% [Jul 30, 14]

Dyax up 13% [Jun 27, 14]

Dyax up 27% [May 27, 14]

Dyax down 10% [Apr 11, 14]

Dyax  down 10% [Apr 10, 14]

Dyax up 11% [Sep 26, 13]

Dyax said it has priced a registered direct offering for gross proceeds of approximately $30 million. ....  intends to use the net proceeds from this offering to fund research and development activities, including the development of DX-2930, a drug candidate for the treatment of hereditary angioedema, or HAE, and for general corporate purposes. [Boston Globe, May 13, 13]

Dyax  down 35% [Apr 26, 13]

Dyax up 20% [Mar 5, 13]

Dyax is partnering with CVie Therapeutics as part of plan to make Dyax’s hereditary angioedema drug available in China, Hong Kong, and Macau. The drug, Kalbitor, is currently marketed in United States for the treatment of acute attacks of hereditary angioedema  [Chris Reidy, Boston Globe, Feb 7, 13]

Dyax said it is partnering with a Colombian company that will develop and commercialize its hereditary angiodema treatment in such Latin American countries as Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The strategic partnership is with Novellus Biopharma AG of Bogota. Hereditary angioedema, or HAE, is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. [Chris Reidy, Boston Globe, Jan 31, 13]

Dyax said it signed a deal with CMIC Co. to develop and sell the genetic disorder drug DX-88 in Japan.  ... Dyax will receive $4 million upfront and $102 million in future development and sales milestones for DX-88 in hereditary angioedema and other angioedema uses. [Boston Globe, Sep 30, 10]

Dyax said that it has launched a newly enhanced product website, that features the company's financial assistance program. KALBITOR is approved for the treatment of acute attacks of hereditary angioedema, or HAE, in patients 16 years of age and older. [Boston Globe, Jul 19, 10]

Dyax has partnered with Sigma-Tau SpA subsidiary Defiante Farmaceutica S.A. of Portugal on the development and commercialization of DX-88, an under-the-skin treatment for hereditary angioedema (HAE), in Europe, North Africa, Middle East and Russia. The deal will bring a total of $5 million to Dyax in upfront payments, with the potential to earn more than $100 million in milestone payments.  [Mass High Tech, Jun 21, 10]

Dyax stands to receive up to $12 million after selling certain rights to royalties to an investment fund [Mass High Tech, Apr 20, 10]

Cubist Pharmaceuticals announced that it will no longer develop its drug ecallantide, a potential therapy to control bleeding in high-risk cardiac surgery patients. ...  will end a licensing agreement with Dyax  which discovered ecallantide and licensed it to Cubist.  [Mass High Tech, Apr 2, 10]

Dyax announced a public stock offering. ..  for net proceeds of just about $3.4 million. [Mass High Tech, Mar 25, 10]

Dyaxsaid that KALBITOR, its treatment for acute attacks of hereditary angioedema in patients 16 and older, is now commercially available in the United States. [Boston Globe, Feb 2, 10]

Dyax jumped 21% [Dec 2, 09] after the FDA approved its ecallantide drug to treat acute attacks of rare swelling disorder known as hereditary angioedema in patients 16 years old and up. [Wall Street Journal, Dec 3]

Dyax said that it received a $1.5 million payment as Eli Lilly & Co. moved a potential leukemia treatment into early-stage clinical trials.  ... reported $43.4 million in revenue in 2008 [Boston Globe, Aug 26, 09]

Dyax says it is raising $15 million through a follow-on offering of 7.4 million shares of its common stock at a price of $2.02 per share.  ... development and commercialization of DX-88, the company’s treatment for the rare and often fatal condition hereditary angioedema [Mass High Tech, Jun 25, 09]

The FDA wants more information about Dyax's drug candidate DX-88 but won't require the company to conduct more tests, Dyax said late yesterday.  ... Shares fell 13% in aftermarket electronic trading [Boston Globe, Mar 27, 09]

Dyax and Fovea Pharmaceuticals SA said that they have entered into an exclusive license agreement for the development and commercialization of a Dyax drug candidate for the treatment of retinal diseases. [Boston Globe, Feb 9, 09]

Dyax said  that it has entered into a committed equity financing facility under which it may sell up to $50 million of its common stock to Azimuth Opportunity Ltd. over an 18-month period.  [Boston Globe, Oct 30,08]

Dyax  jumped 15% after the company reported positive results from a second late-stage study of its treatment for hereditary angioedema, a rare blood disorder. Dyax plans to apply for regulatory approval in the fourth quarter, which, if granted, would result in a mid-2009 launch.  [Wall Street Journal, Aug 19, 08]

Dyax said it is negotiating with an Italian pharmaceutical company over the European licensing of one of its drug candidates. [Boston Globe, Jul 15, 08]

Euro Too Dear. Dyax has begun talks about closing the research facility of its Belgian subsidiary in Liege, Belgium, officials report. ... enable Dyax to consolidate its discovery and preclinical programs at its headquarters in Cambridge, company officials said. The weakening U.S. dollar has contributed to a rise in operating costs in Europe.  [Mass High Tech, Apr 28]

Dyax entered into a license agreement with Paris-based sanofi-aventis that gives an exclusive worldwide license to the French pharmaceutical company for the tumor-fighting monoclonal antibody DX-2240  [Mass High Tech, Feb 12,08]

Dyax filed to raise up to $100M. [Dec 26, 07]

Dyax and German company MorphoSys AG announced the signing of a licensing agreement covering a broad patent portfolio relating to antibodies and protein. The agreement grants MorphoSys a fully paid up license to a variety of phage display-related patents from Dyax as well as other patents. [Chris Reidy, Boston Globe, Nov 20]

Dyax signed a third extension of the antibody library collaboration with New York-based ImClone Systems Inc. for the discovery of therapeutic antibodies, officials report. [Mass High Tech, Nov 8]

Dyax (Cambridge, MA: 3 Phase 1 SBIRs) signed a deal to discover therapeutic antibodies for a German pharmaceutical company. [Mass High Tech, Sep 6]

Dyax reports positive results from a Phase 3 clinical trail of the Cambridge firm's lead drug for the treatment of hereditary angioedema (HAE). [Mass High Tech, Apr 13]

Dyax (Cambridge MA) granted a non-exclusive license to its antibody phage display libraries to ZymoGenetics Inc. for the discovery of therapeutic antibodies. ...  The pact adds to Dyax's more than 75 revenue-generating licensing agreements for therapeutic discovery. [Mass High Tech, Oct 31]  Three Phase 1 SBIRs.

DynaBil Industries(Greene County, NY

DynaBil Industries (Greene County, NY; no SBIR)  plans to expand its business, investing almost $10M ...  will increase the size of the aeronautics parts manufacturer by well over 50%   ... manufactures precision aircraft sheet metal parts and assemblies from titanium, stainless steel, aluminum and exotic metals ...  such parts as titanium door and window frames and parts for the 787's floor. ... employs 200 people ... still a tiny piece of the aviation industry, worth about $205B last year.  [Alan Wechsler, Albany Times-Union, Apr 13]

Dynasil (Watertown, MA)

Med-tech firm Xcede Technologies (sub of Dynasil (Watertown, MA), Rochester, MN; no SBIR) closed on nearly $3 million for development of a patch that stops bleeding and seals tissue. [Minneapolis/ St Paul Business Journal, Dec 1, 15] Mayo Clinic has a financial interest in the technology ....  Revenue Mayo receives is used to support the clinic's not-for-profit mission in clinical practice, education and research.   [Dynasil press release, 2013]

Dynasil(Watertown, MA; no SBIR) announced that its RMD Research subsidiary has been awarded contracts totaling $3.65 million from the Department of Homeland Security... will foster Dynasil’s continued research and development of gamma and neutron radiation detectors capable of identifying illicit nuclear materials. [company press release, Dec 8]

Dynavax Technologies (Berkeley,CA)

Dynavax Tech (Berkeley, CA; $6.3M SBIR) up 16% [May 19, 22]

Dynavax Technologies down 20% [Nov 5, 21] reported third quarter finncial results

Dynavax Tech down 19% [May 10, 21]

Dynavax Technologies (Berkeley, CA; $6.5M SBIR) down 18% [Apr, 20, 21]

Dynavax up 63% [Feb 1, 21] Clover Biopharmaceuticals (China), and Dynavax Technologies announced the plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021 [joint companies press release, Feb 1, 21]

Dynavax (Emeryville, CA; $6M SBIR) up 25% [Jan 25, 21] Medigen Vaccine Biologics (Taiwan), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies, a biopharma focused on developing and commercializing vaccines, announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901. [joint companies press release, Jan 25, 21]

Dynavax Technologies up 20% [Jul 17, 20]

Dynavax Tech up 29% [Jun 1, 20]

Dynavax Tech up 26% [May 29, 20]

Dynavax Tech (Berkeley, CA; $6.5M SBIR) up 34% [May 19, 20] in anticipation of the company's COVID-19 vaccine program update, which is scheduled for later today. One of the main reasons for all the excitement is that Dynavax has already announced that one or more of its collaboration partners should initiate an early stage COVID-19 vaccine trial by July. [Motley Fool, May 19, 20]

Dynavax (Emeryville, CA; $6.5M SBIR) focused on developing and commercializing novel vaccines, and Sinovac (China) a leading provider of biopharmaceutical products in China, announced that they have entered into a collaboration to develop a vaccine to prevent COVID-19. The collaboration will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018 ™. [Dynavax press release, Apr 16, 20]

Dynavax (Berkeley, CA; $6.5M SBIR) up 15% [Dec 9, 19]

Dynavax Tech (Berkeley, CA; $6.3M SBIR, founded 1996) is pulling out of immuno-oncology R&D, laying off 82 staff and parting company with its CEO. The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B. [Nick Paul Taylor, Fierce Biotech, May 24, 19] total funding $175M []

Dynavax Tech up 18% [May 9, 19]

Dynavax Tech down 14%  [May 17, 18]

Dynavax Tech up 17%  [May 10, 18]

Dynavax Tech up 11% [Aug 7, 17]

Dynavax Tech up 71% [Jul 31, 17]  after [FDA] advisory committee said the safety data for its hepatitis B vaccination supported its approval.  [Dow Jones Newswire, Jul 31, 17]

Dynavax Tech down 11% [Jul 27, 17]

Dynavax up 11% [Jul 24, 17]

Dynavax Tech up 10% [Jun 12,17]

Dynavax up 17% [Jun 5,17]

Dynavax Tech (Berkeley, CA; $3.5M SBIR) up 53% [Mar 1,17] top percentage gainer ...  announced that [FDA]accepted for review Dynavax's responses to the Complete Response Letter (CRL) issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the company's vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older.  [compant press release, Feb 28, 17]

Dynavax up 10% [Dec 5, 16]

Dynavax Tech up 16% [Nov 15, 16] announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for HEPLISAV-B(TM) [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for immunization of adults 18 years and older against hepatitis B infection.  [company press release]

[FDA] rejected Dynavax Technologies, down 65%, marketing application for its hepatitis B vaccine, Heplisav-B, for the second time in three years, sending the company's shares tumbling 71 percent in premarket trade. [Reuters, Nov 14, 16]

Dynavax Tech up 19% [Oct 3, 16]

Dynavax Tech (Berkeley, CA; $3.5M SBIR) down 32% [Sep 2, 16] FDA announced that it had cancelled Dynavax's November 16, 2016 meeting with the Vaccines and Related Biological Products Advisory Committee "to allow time for the FDA to review and resolve several outstanding issues" with Dynavax's Biologics License Application for HEPLISAV-B(TM). [company press release, Sep 2, 16]  lawyers pounced for securities violations.

Dynavax Tech (Berkeley, CA; $3.6M SBIR)  down  12% {Apr 27, 16]

Sarepta Thera  down 26% [Apr 26, 16]

Dynavax up 11% [Jan 22, 16]

Dynavax down 10% [Jan 8, 16]

Dynavax Tech (Berkeley, CA; $3.6M SBIR) up 11% [Mar 23,15]

Dynavax Tech (Berkeley CA; $2.6M SBIR) down 10% [Dec 15, 14]

Dynavax Technologies (Berkeley, CA; $3.5M SBIR) said partner GlaxoSmithKline dumped a failed lupus drug. ...  The drug, called DV-1179, is part of a family of compounds designed to inhibit proteins known as toll-like receptors. ...  Dynavax said Friday that DV-1179 could be used in "a range" of other diseases, possibly including autoimmune pancreatitis and nonalcoholic steatohepatitis.    [Ron Leuty, San Francisco Business Times, Dec 1, 14] 

Dynavax Technologies (Berkeley, CA; $3.6M SBIR) started its first human trial of a potential asthma treatment.  ..... will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo.   ... treatment is being developed together with AstraZeneca   [Stephen EF Brown, San Francisco Business Times, Oct 9, 13]

Dynavax Tech  down 47% [Nov 16, 12]  following an unfavorable [FDA]panel safety view of its experimental hepatitis-B vaccine, Hepislav.  [Motley Fool] 

Dynavax down 23% [May 9, 12]   priced a stock offering at a 17% discount to Tuesday's closing price []

Dynavax Tech  up 11% [Feb 2, 12]

Dynavax Tech  up 10% [Dec 20, 10]

Dynavax Technologies (Berkeley, CA; $2.2M SBIR) will start a 2,000-patient trial of its investigational adult hepatitis B vaccine, aiming for data in the first half of 2011. .. has a Phase III trial under way in chronic kidney disease patients using the same vaccine [Ron Leuty, San Francisco Business Times, Feb 8, 10]

The Nasdaq warned Dynavax Technologies (Berkeley, CA; $400K SBIR) it doesn’t meet a minimum shareholders’ equity rule for listing on the exchange.  [San Francisco Business Times, Nov 16, 08]

Dynavax down 59% after the FDA put a clinical hold on a late-stage trial for its Hepatitis B vaccine Heplisav. Dynavax and co-developer Merck said that one patient in a study outside of the U.S. was diagnosed with an uncommon disease causing blood vessel inflammation. All patients in that study have completed dosing with the vaccine. [, Mar 18,08]

Dynavax down 12% [Mar 17, 08]

Dynavax Technologies  up 12% [Feb 25, 08]

Merck has agreed to pay biotechnology company Dynavax Technologies (Berkeley, CA; two SBIRs)  up to $136M for the rights to co-develop and eventually sell Dynavax's experimental hepatitis B vaccine, [San Jose Mercury News, Nov 1, 07]

Dynavax Technologies fell 30% on poor results in its a clinical trial of its ragweed-allergy treatment Tolamba.  Two Phase 1 SBIRs.

Do-It-All Flu Shot. On the hunt for a vaccine against bird flu, biotech companies are coming up with leads on something even better: a universal vaccine that works against all kinds of flu. ... Dynavax Technologies in Berkeley believe they have found a possible solution. They have developed a vaccine that targets two other common flu proteins, the nucleoprotein and matrix protein, which tend to remain stable. [>Steve Johnson, San Jose Mercury News, Oct 30]  At least two Phase 1 SBIRs

Dyne Therapeutics (Cambridge, MA)

Dyne Therapeutics (Waltham.MA; no SBIR) focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing [company press release, Aug 10, 20]

Dyne Therapeutics (Cambridge, MA) new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched today with a $50 million Series A ... eveloping breakthrough medicines based on its proprietary product platform, which delivers nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision. [company press release, Apr 2, 19]

Dynetics (Huntsville, AL and Arlington, VA)

Dynetics (Huntsville, AL; $5M SBIR), a Leidos company, has received a potential $124.7 million contract from the U.S. Army to provide cyber electromagnetic activities support for the service branch’s missile and space program executive office. [Jane Edwards,, September 13, 2023]

A Leidos Dynetics (Huntsville, AL ; $4.6M SBIR) subsidiary has received a potential four-year, $428.3 million contract modification from the U.S. Army to build prototypes of the Common-Hypersonic Glide Body system. [govconwire, Jul 25, 2023]

Leidos' Dynetics [Huntsville, AL; $5M SBIR) subsidiary has won a $478.6 million contract from the U.S. Army to develop a thermal protection system intended to protect surface-to-surface hypersonic missiles from intense heat during flight. Dynetics will build the Hypersonic Thermal Protection System prototype and help the military branch conduct materials research, inspection and acceptance efforts under the cost-plus-fixed-fee contract, the Department of Defense said [Angeline Leishman, govconwire, Nov 22, 21]

Dynetics (lots of SBIR), a wholly owned subsidiary of Leidos , has secured a potential $90 million contract to build a laser-based technology to measure the temperature, pressure, carbon dioxide and oxygen within the Orion spacecraft during NASA's planned human missions to the moon. [, Jun 1, 21]

Leidos'Dynetics (many SBIRs near the Huntsville AL flagpole) subsidiary has secured a potential 10-year, $356M contract to produce and maintain a suite of foreign radar simulators for use by the U.S. Air Force and the Department of Defense in enterprise-wide test efforts [Mary-Louise Hoffman,, Jun 22, 20]

Leidos agreed to acquire technology services contractor Dynetics (Huntsville AL; lots of SBIR) for $1.65B cash to further build up its position in the intelligence, civil and defense markets. [Jane Edwards,, Dec 18, 19]

Dynetics (Arlington, VA and Huntsville, AL; at least 30 SBIRs) has secured a potential 10-year, $737.9M contract for support services to a facility where the Defense Intelligence Agency assesses data on foreign weapons systems. DoD noted the contract includes a five-year option period that could extend the performance of work through Oct. 31, 2029 [Matthew Nelson,, Nov 4, 19]

A team led by Dynetics (Arlington, VA and Huntsville, AL; at least 30 SBIRs) technical solutions business will develop prototypes of the Common-Hypersonic Glide Body system under a potential three-year, $351.6M other transaction agreement with the U.S. Army. Dynetics said it will work with Lockheed Martin, Raytheon, and General Atomics’ electromagnetic systems business on the C-HGB prototype development project. [Jane Edwards, GovConWire, Aug 30, 19]

Dynetics was one of eleven companies picked by NASA to produce prototypes of a human [lunar] landing platform with descent, ascent, transfer and refueling elements and shoulder at least 20 percent of the total development cost under the Next Space Technologies for Exploration Partnerships Appendix E contracts. [Jane Edwards, GovConWire, May 17, 19]

The U.S. Army selected Dynetics (at least 30 SBIRs) to be the prime contractor on a potential $130M contract to build and demonstrate a 100-kilowatt-class laser weapons system. Dynetics said Wednesday its partners for the High Energy Laser Tactical Vehicle Demonstrator program are Lockheed Martin, Rolls-Royce and MZA Associates. [Mary-Louise Hoffman, GovConWire, May 16, 19]

[John] Ismay writes [New York Times] that "In June 2018, [manufacturer] Dynetics {at least 30 SBIRs) received a $470 million 'indefinite quantity' contract to supply Special Operations Command with GBU-69s." A spokeswoman told the Times USSOCOM has ordered more than 2,000 of the GBU-69s already. Read on, here . [, Mar 28, 19]

DARPA has awarded Exquadrum (Adelanto, CA; 48 SBIRs) and Dynetics (Huntsville, AL; 32 SBIRs) a contract to develop technology for hypersonic weapons. Called the Operational Fires (OpFires) Propulsion System program, "the program aims to develop and demonstrate a novel ground-launched system for hypersonic boost glide weapons to penetrate modern enemy air defenses and rapidly and precisely engage critical time sensitive targets," the companies said in a joint statement. [DefenseOne, Jan 17, 19]

Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]

Dynetics (Arlington, VA and Huntsville, AL, $6M SBIR, founded 1974) landed a potential $470 million sole-source contract to manufacture GBU-69/B Small Glide Munitions for the U.S. Special Operations Command  [Nichols Martin, GovConWire, Jun 11, 18]

DARPA's "Gremlin" swarm drone attack and recovery program is picking up speed with a late-April "21-month, $38.6 million contract to Dynetics (Huntsville, AL; $6M SBIR)" the Washington Post reported this weekend. Dynetics will be working with " Kratos (San Diego, CA; no SBIR), a venture-funded tech company that specializes in cheap drones used for target practice." [DefOne, May 7, 18]

Dynogen Pharmaceuticals

At least five Massachusetts biotechs — Dynogen Pharmaceuticals Inc., Epix Pharmaceuticals, Oscient Pharmaceuticals, Biopure Corp. and span style="font-weight: bold;">Altus — have more or less ceased operations since the stock market meltdown in September 2008.  [Julie Donnelly, Mass High Tech, Mar 5, 10]

Dynogen Pharmaceuticals (Waltham, MA; no SBIR) filed for Chapter 7 bankruptcy protection this week, meaning the company will likely be liquidated.... burned through at least $67 million in venture capital and other funding... trying to develop drugs for irritable bowel syndrome, overactive bladder disorder, and nocturnal gastroesophageal reflux disease (often associated with heartburn).  [Boston Globe, Feb 24, 09]

Apex Bioventures Acquisition Corp. said it agreed to acquire for $98M in stock span style="font-weight: bold;">Dynogen Pharmaceuticals (Waltham, MA; no SBIR) focused on gastrointestinal and genitourinary disorders. [Boston Globe, Feb 7, 08]

Dyno Therapeutics (Cambridge, MA)

Dyno Therapeutics (Cambidge, MA; no SBIR) emerged from stealth with Novartis and Sarepta Therapeutics as partners. The biotech’s technology designs superior versions of the viruses commonly used in gene therapies. Financial terms weren’t disclosed. [Sarah de Crescenzo,, May 11, 20]


E25 Bio (Cmbridge, MA)

E25Bio (Cambridge,MA; one SBIR) rapid diagnostic innovators, announces award funding of $4.14M from the Bill & Melinda Gates Foundation and $1.68M [NIH SBIR]. [company press release, Aug 13, 20]

E3 Clean (Athens, OH)

Start-up Silicon Valley.   SVForum names [as Most Likely to Succeed], Bugcrowd, FLASHiZ (Luxembourg), WHILL (from Japan), E3 Clean (Athens, OH), OnFarm (Fresno, CA) as the winners of honor that draws attention of venture capitalists and angel investors.  [San Jose Mercury News, Jun 5, 13]  None has SBIR.

Eagle Optoelectronics (Boulder, CO)

A Business Week story says Eagle Optoelectronics Inc. (Boulder, CO) is in the van on WDM plug-in optical cards. Eagle got its only Phase 2 SBIR from BMDO in 1995 for a new type of an "intelligent" DWDM transceiver able to tolerate millisec-scale time-varying wavelengths.

Earl Energy (Virginia Beach, VA)

Earl Energy  (Virginia Beach, VA; no SBIR, 10 employees) said it has won a $1.2 million U.S. Army a multi-year contract to develop large power converters for the military. ...  developing a Silicon Carbide power converter that the company says is 80 percent lighter and 350 percent more powerful than existing converters. ... has developed a laboratory model and is now working on a prototype for the Army. [Lauren Ohnesorge, Raleigh News & Observer, Sep 6, 13]  owned and led by veterans [company website]

EarLens (Redwood City, CA)

Lightstone Ventures closed its first fund at $172 million, aimed at biotech and medical device companies.  ....  will make about five investments per year, Carusi told Dow Jones, with three-quarters of the investments in early-stage biotech and medical device companies  ....   has invested in  hearing aid company EarLens (Redwood City, CA;  $900K SBIR)  as well as Catabasis Pharmaceuticals (Cambridge, MA; one SBIR), a clinical stage biotech company targeting cardiovascular, metabolic and inflammatory diseases, and FIRE1, a therapeutic device company in Ireland.  [Ron Leuty, San Francisco Business Times, May 1, 14]

Earth Networks (Germantown, MD)

Fifteen university research teams from Maryland will receive a total of $4.1 million to work with local companies to turn their research into products that could one day be sold on the commercial market.  .... MIPS will contribute $1.8 million and private companies will contribute $2.8 million. The companies:  A&G Pharmaceutical (Columbia, MD; no SBIR),  Rehabtics LLC (Baltimore, MD; no SBIR)  High Impact Environmental (Church Hill, MD; no SBIR),  Birich Technologies (Towson, MD; no SBIR), Earth Networks (Germantown, MD; no SBIR), Fiberight (Halethorpe, MD; no SBIR), CoolCAD Electronics (College Park,MD $1.6M SBIR), XChanger Companies (Annapolis, MD; no SBIR), Remedium Technologies (College Park, MD; no SBIR), Pothole Pros LLC (Waldorf, MD; no SBIR), Hoopers Island Oyster Aquaculture (Fishers Creek, MD; no SBIR),  Metompkin Seafood (Crisfield, MD; no SBIR) GreatGrow Maryland LLC (Rock Hall, MD; no  SBIR), vCalc (Hagerstown, MD;  SBIR), Shore Thing Shellfish (Tall Timbers, MD; no SBIR). ($114,094)  [Sarah Gantz,  Baltimore Business Journal, Feb 26, 14] 

Earthrise Nutritionals (Irvine,CA)

Sapphire Energy (San Diego, CA; $200K SBIR) startup developing algal biofuel, said it successfully modified certain cyanobacteria, also known as blue-green algae, to produce significantly higher yields of “green” crude oil. Sapphire said it also has tapped into the deep expertise in producing blue-green algae through a licensing agreement with Earthrise Nutritionals (Irvine, CA; no SBIR), which produces food colors and nutritional supplements from a type of blue-green algae known as Spirulina.  [Bruce Bigelow,, Mar 2, 12]

eASIC (Santa Clara, CA)

Custom chip designer eASIC (Santa Clara, CA; no SBIR, founded 1999) disclosed  that it plans to raise $75 million in an upcoming IPO. ... raised more than $139 million  [since founding]  [Cromwell Schubarth, Silicon Valley Business Journal, Feb 20, 15]

Eboo Pharmaceuticals (Durham, NC)

A 2-year-old pharmaceutical startup Eboo Pharmaceuticals (Durham, NC; no SBIR) specializing in Parkinson's disease treatment has won grant support up to $1.5 million from the high-profile Michael J. Fox Foundation for Parkinson's Research.  ....   "virtual" company with no employees, no office and a post office box address ..... expected to provide an efficacious and well-tolerated initial monotherapy without the debilitating side effects of current therapy.  [John Murawski, Raleigh News & Observer, Jun 20, 13]

EBR Systems (Sunnyvale, CA)

EBR Systems  (Sunnyvale, CA; no SBIR) developer of a wireless cardiac pacing system, raised $20 million in venture funding ... has raised $81 million to date. ...  eliminates the need for leads and lets the physician place the endocardial technology at the most optimal site (inside the left ventricle) where it can be most effective.     [Gina Hall, Silicon Valley Business Journal, Apr 8, 15]

Ebullient (Madison, WI)

Ebullient (Madison, WI; no SBIR) start-up that is developing a computer cooling technology, has raised $535,000 of a proposed $646,000 funding round, another SEC filing said. Ebullient's technology, which uses liquid rather than air to cool computers, was developed by Timothy Shedd, a mechanical engineering professor at the University of Wisconsin-Madison. [Milwaukee Journal Sentinel, Jan 19, 15]   dramatically decreases the iconic noise for which data centers are known ... can cool any data center computer load on the hottest day ever recorded in Death Valley without a compressor, air conditioner or cooling tower ... many state incentive programs reward Ebullient system installations and can subsidize your purchase   [Company website]

Eccrine Systems (Cincinnati , OH)

Sweat technology startup Eccrine Systems (Cincinnati , OH; no prior SBIR, founded 2013)  awarded a $750,000 [USAF] SBIR Phase II contract focused on real-time measurement of specific biomarkers in human sweat as an index of cognitive performance. [company press release, Feb 1, 18]


Echelon (Santa Clara, CA; one SBIR, 74 employees) up 98% [Jun 29, 18] Adesto Technologies (Sunnyvale, CA; $800K SBIR), a leading provider of innovative application-specific semiconductors for the IoT era, and Echelon Corporation announced a definitive agreement under which Adesto will acquire Echelon for [a total equity value of approximately $45 million] Echelon is a pioneer in the development of open-standard networking platforms for connecting, monitoring and controlling devices in commercial and industrial applications. [Echelon press release, Jun 29, 18]

Echelon up 11% [Oct 13, 17]

Echelon down 10% [May 6,16]

Echelon down 16% [Feb 7,14] 

Echelon up 17% [Jan 31,14] 

Echelon up 19% [Jan 28,14]

Echelon up 10% [Sep21, 12]

Echelon down 11%[May7,10]

Echelon up 10%[Apr21,10]

Echelon up 11%[Sep28,09]

Echelon up 21%[Aug28,09]

Echelon up 21%[Aug10,09]

Echelon down 10%[Apr7,09]

Echelon up 13% [Mar 10, 09]

Echelon up 11% [Feb 13, 09]

Echelon   up 10% [Feb 6, 09]

Echelon down 11% [Jan 20, 09]

Echelon up 13% [Dec 17, 08]

Echeoln up 11% [Dec 16, 08]

Echelon up 11% [Dec 12, 08]

Echelon up 15% [Dec 8, 08]

Echelon  down 16% [Dec 1, 08]  On a stock bloodbath day

Echelon up 13% [Nov 26, 08]

Echelon up 11% [Nov 24, 08]

Echelon down 10% [Nov 14, 08]

Echelon down 10% [Nov 6, 08]

Echelon down 24% [Sep 29, 08]

Echelon down 11% [Sep 26, 08]

Echelon up 15% [Sep 18, 08]

Echelon up 10% [Sep 16, 08]

Echelon up 11% [Aug 13, 08]

Echelon down 14% [Jul 30, 08]

Echelon up 13% [Jul 14, 08] on news of a Danish deal to service 390,000 homes.

Echelon up 11% [May 27, 08]

Echelon up 12% [May 15, 08]

Echelon down 11% [Apr 29,08] on accounting problems.

Echelon down 10% [Mar 27, 08]

Echelon up 12% [Mar 5, 08]

Echelon up 18% [Feb 7, 08] on good earnings.

Echelon down 10%. [Dec 31, 07]

Echodyne (Bellevue, WA)

radar company Echodyne (Kirkland, WA; one SBIR) raised $135 million. Bill Gates and Baillie Gifford led the funding. [Rick Morgan, Seattle Inno, June 13, 2022]

Tom Driscoll's Echodyne (Bellevue, WA; no SBIR) may be the only [company] whose quadcopter packs the kind of sophisticated radar used on fighter jets ...  Driscoll’s drone carries an electronically scanning radar instrument that doesn’t have a conventional phase shifter. The outgoing radio waves are steered with a much simpler device, built using techniques borrowed from a relatively new area of research on what are known as metamaterials.  ... Metamaterials are made from repeating structures that are smaller than the wavelength of the electromagnetic radiation being manipulated.  ...  hopes to mass produce compact radar systems that cost only hundreds or thousands of dollars. ...  also received investment funding from Microsoft cofounder Bill Gates  [Tom Simonite,, April 6, 2015]

Echodyne (Bellevue, WA;  Bill Gates is better than SBIR), the secretive  company that spun off of Intellectual Ventures, said it's raised $15 million in an initial funding round led by Bill Gates ...  noting that it "will bring to market radar products based on metamaterials technology invented by Intellectual Ventures in collaboration with Duke University and the University of California at San Diego." ... Metamaterials, Echodyne said, are "artificially structured materials used to control and manipulate a range of physical phenomena, including electromagnetic radiation."   [Ben Miller, Puget Sound Business Journal, Dec 19, 14]

Echogen Power Systems (Akron, OH)

The Department of Energy will award $128M to support 75 research projects that seek to advance the development of solar technologies. Most money went to academic and large businessses. Several awards went to former SBIR winners: Energy Materials (Norcross GA one SBIR) won a $4M Solar project award to create new methods to deposit layers of material to make the cell, develop a high-speed process ; Leading Edge Crystal Technologies (Gloucester, MA; one SBIR) won $2.5M to develop a floating-silicon method for producing high-quality single crystalline wafers ; Sunvapor (Livermore, CA ; one SBIR) won $2.5M to show how using enormous tanks that normally store liquefied petroleum gas can be used to accumulate and store solar-generated steam ; Brayton Energy (Hampton,NH; $3M SBIR) won $700K to partner w Oak Ridge Lab to examine examine creep behavior—the tendency to deform under mechanical stress—in thin-sheet nickel alloys; Ceramic Tubular Products (Lynchburg, VA; $3.2M SBIR) won $1.9M to develop silicon carbide composite receiver tubes for molten chloride salt and liquid sodium receivers; Echogen Power Systems, (Akron, OH; $300K SBIR) won $4.4M to develop a large-scale, low-cost, single-shaft compressor for supercritical carbon dioxide (sCO2) power cycles; Osazda Energy (Albuquerque, NM; one SBIR) won $1M to develop a cost-effective metal paste that strengthens the metal connections in solar cells; Scion Plasma (East Lansing, MI; $200K SBIR) won $1M to develop a tool that rapidly deposits transparent conductive oxide onto heterojunction silicon with intrinsic thin layer (HIT) solar cells; Swift Coat (Peoria, AZ; one SBIR) won $1M to make and scale multilayer, anti-reflective and anti-soiling coatings for solar glass [Jane Edwards, govconwire, Nov 7, 19]

Echometrix (Madison,WI)

Six start-ups will be recognized for making strides to commercialization at a biotech industry summit in October. ... part of a one-day Biotechnology Vision Summit 2009 that is being run by BioForward, an organization that represents Wisconsin's biotech industry. AquaMost LLC (Madison, WI; one SBIR) , Echometrix  (Madison, WI; no SBIR), Flex Biomedical Inc(Madison, WI; one SBIR), Semba Biosciences (Madison, WI; no SBIR),  Invivosciences LLC (Wauwatosa, WI; no SBIR), and Rapid Diagnostek Inc  (Hudson, WI; no SBIR).  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 22, 09]

EchoPixel (Mountain View, CA)

Two Silicon Valley companies have developed a 3-D virtual reality kit that lets medical students and doctors practice surgeries and organ dissections without the messiness of working on real cadavers.  Three-dimensional holographic imaging display maker zSpace (Sunnyvale, CA; no SBIR) provides the hardware, including stereoscopic VR displays and transparent glasses. EchoPixel (Mountain View, CA; no SBIR) which makes medical imaging technology, provides the software. ... They plan to submit a proposal next week to [FDA] that, if approved, would allow them to start selling the kits for $75,000 — for use in clinical settings with real patient data.   [Jose Fermoso, Silicon Valley Business Journal, Dec  9, 14]

EcoPro Polymers (Corvallis, OR)

EcoPro Polymers (Corvallis, OR; no SBIR) startup is working on what could be the first non-toxic adhesive for the wood products industry.   Oregon BEST has invested $124,000 of early-stage funding to speed commercialization of the adhesive [the first to not contain urea-formaldehyde] which is collaborating with Oregon State University researchers on the product.  [Portland Business Journal, Dec 1, 15]

Echo Therapeutics (Franklin, MA)

Echo Therapeutics' (no SBIR) largest investor has agreed to invest another $4 million in the Philadelphia medical device company under a deal that will result in the departure of three Echo board members. ... attempting to commercialize a wireless and needle-free continuous glucose monitoring system. It suspended its product development, research, manufacturing and clinical programs and operations in late September to conserve its remaining cash.    [John George,Philadelphia  Business Journal, Dec 22, 14]

Platinum Management said this week it has informed the board of Echo Therapeutics (Philadelphia, PA; no SBIR) that it intends to seek the return of its $5 million investment .. developing a wireless and continuous glucose monitoring system for use initially with patients in critical-care settings ...  Platinum said when it made its investment, it was given assurances Echo would focus it efforts on the commercialization of its experimental products. Platinum arranged for Echo to work with, and potentially get additional funding support from, Medical Technologies Innovation Asia (MTIA) Ltd.  ....  The letter alleges the company’s board reneged on its obligations to Platinum, and has not spent its investment funds on “developing products that will raise the stock price and benefit all stockholders.”      [John George, Philadelphia Business Journal, Sep 18, 14]   

Capital demands its say.   Echo Therapeutics’s (Philadelphia, PA; no SBIR) largest shareholder sent a letter to the  company's stock holders urging them not to re-elect current director and interim-CEO Robert F. Doman to Echo’s board of directors.  ...  Platinum Management — which has invested $18.6 million in Echo — said it “can no longer sit idly by while stockholders continue to suffer under the direction of the current board.” Platinum Management, which owns about 20 percent of Echo’s common stock   .... is developing the Symphony CGM System, a wireless continuous glucose monitoring system for use initially in post-surgical patients at critical-care units in hospitals [John George, Philadelphia Business Journal, Apr 23, 14]  If you can't grow your own capital, you'll have to invite new owners with new opinions, or convince a gullible government to give you something for nothing. Fortunately, US politicians love to give something for nothing for non-economic reasons. And as you can inagine, there is a long queue at government's door.

Echo Therapeutics (no SBIR) said it has reduced its workforce by 33 percent, or about a dozen people. The move is part of a cost-reduction initiative designed to conserve cash while the company works toward getting its lead product approved in Europe and the United States. [John George, Philadephia Business Journal, Oct 3, 13]

Echo Therapeutics (Philadelphia, PA; no SBIR) raised $12.5 million in a public stock sale ... developing a non-invasive and wireless continuous glucose monitoring system called Symphony.  [John George, Philadelphia Business Journal,  Jun 19, 13] did a 1-for-10 reverse split of its common stock Jun 5

Echo Therapeutics (Franklin, MA: no SBIR), a medical technology company making a needle-free monitoring and drug delivery system, has taken in $5.5 million in a set of new financing deals  [Rodney Brown, Mass High Tech, Jan 6, 11]

Echometrix (Madison, WI; no SBIR) said it named a former GE Healthcare executive to chief executive officer following a $250,000 funding round. ... developer of ultrasound technology ...  based on technologies developed at the University of Wisconsin-Madison and licensed from the Wisconsin Alumni Research Foundation. The company's proprietary ultrasound technology extracts additional information from ultrasound data to help surgeons, trainers and therapists diagnose injuries; determine proper tensioning of tendons and ligaments during surgery; and monitor tissue healing and functional recovery during rehab. [Kathleen Gallagher, Milwaukee Journal Sentinel, Apr 21, 10] Echo Therapeutics brought in $3 million in new funding from a private stock and warrants sale to unnamed accredited and institutional investors.  [Mass High Tech, Nov 13]

Echo Therapeutics (Franklin, MA; one SBIR as span style="font-weight: bold;">Sontra Medical) got its wish, landing a $2 million equity financing round ... In June, Echo licensed its needleless glucose-monitoring technology to South Korea-based Handok Pharmaceuticals Co. Ltd. for $600,000 and royalties and other payments. [Mass High Tech, Jul 29, 09]

Sontra Medical (Franklin MA; one SBIR) a developer of transdermal treatments and diagnostics, reports it has officially changed its name to Echo Therapeutics[Mass High Tech, Oct 8, 07]

ECI Biotech (Worcester, MA)

The Massachusetts Life Sciences Center, a quasi-public agency, awarded $3.75 million in loans to five early-stage life sciences companies. AesRX (Newton, MA; no SBIR)  biopharmaceutical company focused on the development of sickle cell disease and other orphan drugs; MoMelan Technologies (MA; no SBIR) medical device company; Myomo (Cambridge,MA; one SBIR) focused on helping people move again after a neuro-muscular impairment; ECI Biotech (Worcester, MA $1.6M SBIR) developer and manufacturer of affordable diagnostic sensors that can be incorporated into any consumer product or medical device; and Grove Instruments (Worcester, MA; $400K SBIR)developing a painless, noninvasive technology that accurately measures blood sugar.  [Boston Globe, Mar 23, 11]

ECM Technologies ((Houston,TX)

ECM Technologies LLC (Houston, TX; no SBIR)  raised the first portion of a seed round to help develop the company as it moves closer to manufacturing [of]. ollagens for biomedical needs  ... was a part of the Texas Medical Center's first TMCx accelerator class.  [Joe Martin, Houston Business Journal. Apr 11, 16]


Thirteen NC companies will split $1 M from a new state fund intended to help businesses create environmentally friendly technologies. In the Triangle area: Ecocurrent of Raleigh received $100,000 to convert hog manure into electric power; Kyma Technologies of Raleigh received $60,000 to work with N.C. State University on a more efficient, cheaper electric switch.; 3F LLC of Raleigh received $100,000 to develop a natural fiber-reinforced concrete formula.; Piedmont Biofuels of Pittsboro received $75,000 to work on a reactor that more efficiently creates biodiesel.; Nextreme Thermal Solutions of Durham received $57,319 to manufacture a generator that converts waste heat into electricity.; Rain Water Solutions of Raleigh received $18,000 to develop a new rain barrel manufacturing process. [Raleigh News & Observer, Jul 1]

EcoPesticides (Albuquerque, NM)

EcoPesticides (Albuquerque, NM; no SBIR) closed out a $400,000 [Series A] round of funding. ...  a part of the New Mexico Angels' Startup Factory and is using technology developed at UNM. It makes microbial pesticides, which is a new class of pesticides that use microbes to target certain pests without harming water, plants or other animals. EcoPesticides developed a new capsule for the fragile microbes that shields them from the elements but not from the insects that eat them. ...  [CEO] Stewart said he expects to raise another $3 million to $5 million later to bring a product to market.   [Dan Mayfield, Albuquerque Business First, Jan 20, 15]

Ecovative Design (Green Island, NY)

Ecovative Design (Green Island, NY: $4.5M SBIR) raised $60M in Series D financing (Albany Business Review, Mar 30, 21]

Ecovative Design (Green Island, NY; $600K SBIR) awarded a contract valued at up to $9.1 million from the [DARPA] to develop next generation building materials: living materials that are more versatile, more efficient, and more cost effective in rapidly creating structures, by literally growing those structures in places where they are needed.  ...  founded on the fundamental breakthrough idea that the mycelium of a mushroom can work as “nature’s glue” to bind agriculture salvage and/or wood products together.  [company press release, Jun 28, 17]

Ecovocative (Green Island, NY; $600K SBIR, founded 2006) is ringing NASDAQ's closing bell Feb 12 with the head of SBA  [Chelsea Diana, Albany Business Review, Feb 12, 16]  in 2006 Eben and Gavin team up in a class called Inventor’s Studio at RPI to invent a new insulation material using agricultural waste and mycelium.  in 2007 Eben and Gavin graduate RPI and are convinced by their professor, Burt Swersey, to pursue the technology into a company.   ...  commercialized custom molded protective packaging called Mushroom® Packaging, an engineered wood alternative called Myco Board   [company website]

Ecovative Design  (Green Island, NY; $600K SBIR, founded 2007, 60 employees), the startup whose innovative mushroom technology is serving as packaging material for such big players as Dell Inc. and Steelcase Inc., has raised more than $14 million in private equity ... uses mushroom roots and vegetative waste to make a natural, biodegradable replacement for Styrofoam and other foams and plastics.  ....  plans to build its first out-of-state manufacturing plant in Cedar Rapids, Iowa to be closer to Sealed Air, an $8 billion company, [and the sole licensee of Ecovative's mushroom packaging. .... In 2011, the company received a multi-million-dollar investment from 3M, Rensselaer (Poly Inst) and the Dutch-based DOEN Foundation.  ....  won $100,000 through the Buckminster Fuller Institute in Oct 13.    [Pam Allen, Albany Business Review, Nov 7, 13]

Ecovative Design  (Green Island, NY;  $600K SBIR, 70 employees), was awarded $350,000 [from the state’s Energy Research and Development Authority] to improve the energy efficiency of the manufacturing processes used to produce its product, a packaging foam synthesized from farm by-products. .... has been making a natural alternative to standard packaging foam by bonding farm by-products through adhesives found in mushrooms.    [Troy Record, Feb 15, 13]

Edaptive Computing (Centerville, OH)

Edaptive Computing (Centerville, OH; $12.5M SBIR, founded 1997, 60 employees) won Air Force deal that could be worth as much as $20 million during the next five years. .... to help the Large Aircraft Infrared Countermeasures Program office improve its operations   [Joe Cogliano, Dayton Business Journal, Jul 29, 14] Thirteen years of software SBIR for a firm near the AF flagpole. 

Edaptive Computing (Centerville, OH; $13M SBIR, founded 1997) won a U.S. Air Force deal that could be worth as much as $4 million during the next few years.   ...  to support rapid technology transition  ....  may help the military predict how flying more missions would affect its overall supply chain performance and weapon system availability.   [Joe Cogliano,     Dayton Business Journal, Jun 27, 14] How nice and warm.

Eden Bioscience

Eden Bioscience (Woodinville, WA; one small SBIR years ago) which went public in 2000 and raised $133 million over the years, said it will delist and deregister its stock at the end of the month as it winds down the business.  [Seattle Times, Jun 19, 09]

After more than a year of limping along, Eden Bioscience (Woodinville, WA; one SBIR a decade ago) said that it will liquidate its assets.  [Seattle Times, Dec 6, 08] Eden Bioscience up 77% to $1.40 a share but down more than 99% from $400 in 2001 ...  sells harpin protein-based products to the home and garden markets in the United States. [Yahoo Finance]

Eden Bioscience  up 23% [Apr 18, 08]

Edge Therapeutics (Berkeley Heights, NJ)

An experimental head injury drug took Edge Therapeutics (Berkeley Heights, NJ; no SBIR) all the way to [2015 IPO]. But one failed clinical trial later and the company announced plans to merge with PDS Biotechnology (North Brunswick, NJ; $1.9M SBIR in various places), that is developing a group of cancer immunotherapies. [Ben Fidler,, Nov 26, 18]

Edge Therapeutics (Berkeley Heights, NJ; no SBIR, IPO 2015) stopped a Phase 3 study of its lead drug early because the drug, EG-1962, developed to treat severe head injuries, was deemed likely to fail. Shares plunged 85 percent, and Edge announced plans to restructure.  [Frank Vinluan,, Mar 30, 18] total funding $101M []


The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20]  almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics,, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release , Mar 13, 20]

Edico Genome (San Diego,CA)

Illumina announced that it acquired Edico Genome (San Diego, CA; no SBIR, founded 2013), the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. [company press release, May 15, 18] the deal is reportedly worth $100 million [Chris Jennewein., May 16, 18]

Illumina announced that it acquired Edico Genome (San Diego, CA; no SBIR, founded 2013), the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. [Illumina press release, May 15, 18] for $100M ;total Edico funding $32M []

Edico Genome (San Diego, CA; SBIR), which makes a fast processing platform for next generation gene sequencing, said Tuesday that it has raised $22 million in a second round of venture capital fundingled by Dell Technologies Capital.  
Though it has been quietly investing in startups for a couple of years, Dell Technologies Capital revealed its $100 million start-up fund on Monday after previously operating in stealth mode. [Mike Freeman, San Diego Union Tribune, May 9, 17]

Edico Genome (San Diego, CA; no SBIR, 28 employees) a startup that makes a high-speed DNA sequence analyzer, said it has collaborated with Intel to help its Xeon chips analyze DNA sequence data. ... said it has been granted its first patent, for the technology in its Dragen bio-IT microprocessor ... Products from the Edico/Intel alliance should hit the market starting next year, said [CEO Pieter van Rooyen].    [Bradley Fikes,, Apr 21, 15]

Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive.  ....  Genome sequencers from Illumina took second and third place   [Bradley Fikes,, Dec 1, 14]  Other winners: BioNano Genomics, RainDance Technologies  (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo  (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape.    [The Scientist, Dec 1, 14]

Edico Genome (San Diego, CA; no SBIR) raised $10 million in Series A financing to commercialize the specialized processor technology it has been developing to slash the time and cost of genome mapping. ...says its technology reduces the computational time required for analyzing a whole human genome from 24 hours to 18 minutes.  [Alex Lash,, Jul 17, 14]

Edico Genome (San Diego, CA; no SBIR) has developed the Dragen Wavefront Processor system that can take data that might require 20 hours to process today and do it in less than 30 minutes, said [CEO] Pieter van Rooyen.  [Mike Freeman,, Apr 11, 14]

Edison Agrosciences (Durham, NC)

Edison Agrosciences, a biotech company originally from Durham, North Carolina, announced it plans to relocate its headquarters to St. Louis. [with the sweetener of $800K from Missouri Technology Corp]  [Brian Feldt, St. Louis Business Journal, Jan 25, 16]   is developing a sunflower rubber crop that will serve to diversify global rubber production and provide the US with an alternative source for this strategically important commodity.  [company website]

A state-funded biotech startup Edison Agrosciences  (Durham, NC; no SBIR, five employees) developing new ways to turn sunflower into rubber has kicked off a debut $830,000 funder. ... measuring the amount of rubber in plant tissues – the ultimate goal being to create a sunflower plant to be grown for rubber production.  [Lauren K. Ohnesorge Triangle Business Journal, Nov 10, 15]

Editas Medicine (Cambridge, MA)

Editas Medicine up 23% [Jun 30, 21]

Editas Medicine up 30% [Dec 21, 20]

Editas Medicine up 32% [Dec 10, 20] announced it submitted an Investigational New Drug (IND) application with [FDA] for the initiation of a Phase 1/2 clinical trial of EDIT-301, an experimental CRISPR/Cas12a gene editing medicine in development for the treatment of sickle cell disease. [company press release, Dec 9, 20]

Editas Medicine (Cambridge, MA; one SBIR), a leading genome editing company, announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10, which were previously shared within a strategic research and development alliance with Allergan, which has since been acquired by AbbVie. Editas Medicine and AbbVie have terminated the original agreement and entered into a new agreement. [company press release, Aug 6, 20]

Editas Medicine began a collaboration with Asklepios Biopharmaceutical (RTP, NC; $3.2M SBIR) to explore gene-editing medicines for neurological diseases. No financial terms were disclosed. [Frank Vinluan,, Oct 18, 19]

Editas Medicine up 15% [Mar 1, 19]

The stock price of Editas Medicine sank nearly 20 percent after CEO Katrine Bosley announced without warning she will leave in March. The news comes as Editas prepares to start its first clinical test: An experimental gene-editing therapy for an inherited form of blindness. [Alex Lash,, Jan 25, 19]

Editas Medicine down 20% [Jan 22, 19]

Editas Medicine up 10% [Mar 7, 18]

Editas Medicine up 13% [Jan 29,18]

Editas Medicine up 14% [Jan 22,18]

Editas Medicine down 11% [Jan 8, 18]

Editas Medicine up 12% [Jan 2, 18]

Editas Medecine down 11% [Aug 15,17]

Editas Medicine up 11% [Aug 11,17]

Editas Medicine up 10% [Aug 10, 17]

Homology (Bedford, MA; no SBIR) wrapped up an $83.5 million Series B round ... making the bold claim that its underlying science, technology it calls AMEnDR, is a better version of existing gene editing methods, among them the CRISPR-Cas9 technology that has taken the scientific research world by storm and has led to the formation of three now publicly traded companies, Editas Medicine (Cambridge, MA; no SBIR), Intellia Therapeutics (Cambridge, MA; no SBIR), and CRISPR Therapeutics (Switzerland). [Ben Fidler,, Aug 1, 17]

Editas Medicine up 10% [Jun 7,17]

Stock prices of Editas MedicineCRISPR Therapeutics (Switzerland), and Intellia Therapeutics (Cambridge, MA; no SBIR) dropped sharply after the publication of a Nature Methods article that described unintended effects stemming from the use of CRISPR-Cas9 gene-editing technology. But as Xconomy noted two years ago, the possibility of “off-target effects” from use of these tools have long been a concern. [Ben Fidler,, Jun 2, 17]

Editas Medicine down 10% [May 29,17]

Editas Medicine down 10% Mar 17, 17]

 Allergan will pay Editas Medicine (Cambridge, MA; no SBIR) $90 million in cash up front to get an option to license up to five experimental gene editing treatments for eye diseases—including Editas’s lead program, a drug for a rare form of genetic blindness called Leber Congenital Amourosis type 10. ... Editas got a boost in February when founders at the Broad Institute of MIT and Harvard won a patent fight against a group led by the University of California, Berkeley, over ownership of CRISPR-Cas9  [Ben Fidler,, Mar 13, 17]

Editas Medicine down 13% [Feb 22,17]

Editas Medicine up 29% [Feb 15, 17] announced that the U.S. Patent and Trademark Office (USPTO) issued a favorable decision in the CRISPR interference between the University of California, the University of Vienna, Emmanuelle Charpentier and the Broad Institute, Inc. (Broad) regarding certain CRISPR-Cas9 patents the Company exclusively licenses from Broad. [company press release, Feb 15, 17]

Editas Medicine down 10% [Dec 22, 16]

Editas Medicine up 11% [Dec 2, 16]

Editas Medicine down 10% [Oct 25, 16]

Editas Medicine up 11% [Oct 4, 16]

Adverum Biotechnologies (Menlo Park, CA; no SBIR) and Editas Medicine (Cambridge, MA; no SBIR) announced a collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.  This collaboration brings together Adverum’s next-generation adeno-associated viral (AAV) vectors for use with Editas’ leading genome editing technologies to create a series of novel therapies for debilitating eye diseases that have poor therapeutic options. [joint companies press release, Aug 9, 16]

Editas Medicine has licensed CRISPR-Cas9 gene editing work from Massachusetts General Hospital that aims to make more precise cuts in the targeted DNA. Published in January, the technology comes from the lab of Keith Joung, who is an Editas cofounder.  [Ben Fidler,, Aug 5. 16]

Editas Medicine, a leading genome editing company, announced a three-year agreement with Cystic Fibrosis Foundation Therapeutics, , the nonprofit affiliate of the Cystic Fibrosis Foundation, in which CFFT will pay up to $5 million to Editas Medicine to support the discovery and development of CRISPR/Cas9-based medicines for the treatment of cystic fibrosis (CF). In addition, Editas will access CFFT’s extensive network of CF scientific advisors and clinical researchers.  [company press release, May 16, 16]

Editas Medicine up 13% [May 16, 16]

Intellia Therapeutics (Cambridge, MA; no SBIR)  up 23% [May 6, 16], which owns rights to an important but disputed piece of the CRISPR-Cas9 gene editing technology, .... raised $108 million by IPO.  ....  joins Editas Medicine, Cellectis (France), and Sangamo Biosciences as publicly traded biotechs using gene editing to develop their main products.  [Alex Lash,, May 5, 16]

Editas Medical up 11% [Mar 31, 16]

Editas Medicine up 17% [Mar 11,16]

Editas Medicine down 14% [Mar 10,16]

Editas Medicine down 26% [Mar 9,16]

Editas Medicine up 18% [Mar 3,16]

Editas Medicine up 15% [Feb 26,16]

Editas Medicine up 17% [Feb 22, 16]

Editas Medicine up 10% [Feb 19, 16]

Editas Medicine up 20% [Feb 11, 16]

Editas Medicine  up 14% [Feb 3, 16]  faces a numberof hurdles ... no such therapy has been approved for clinical use in either the U.S. or Europe.  More importantly, Editas doesn’t even know for sure whether it even has the right to use CRISPR. ... already faces competition from two other startups, Intellia Therapeutics (Cambridge, MA; no SBIR) and CRISPR Therapeutics  (Swiss) [which] recently announced a $300-million joint venture with Bayer AG to develop new drugs for a range of illnesses.  [Michael Reilly,, Feb 3, 16]

Editas Medicine (Cambridge, MA; no SBIR) in the early stage of developing a treatment to correct disease-causing genes in patients, raised $94.4 million in its [IPO]  [Corrie Driebusch, Wall Street Journal, Feb 2, 16]

This biotech company has burned through $75m in the past few years and has not yet started clinical work on a drug candidate. It says it will be many years, “if ever”, before it has something ready to commercialise. If this were not enough, not only is there a thorny patent thicket to manage but the firm must fight and win a case seeking to overturn its own intellectual-property claims on the ground that it was not the first to invent them.  Despite all this, shares in Editas Medicine  (Cambridge, MA; no SBIR), which filed [an IPO], look set to draw great interest from investors. It will be an opportunity to buy into a revolutionary new technology called CRISPR-Cas9, which allows DNA to be cut and edited almost as easily as one might rewrite a document on a computer. Editas, spun out of the work of geneticists at the Broad Institute in Cambridge, Massachusetts, has already raised $163m from private investors and is seeking a further $100m from the markets. Its initial aim is to begin trials by 2017 on a possible treatment for a rare form of blindness.  [The Economist, Jan 9, 16]

Editas Medicine  (Cambridge, MA; no SBIR)  co-founded by Dr Zhang. In early August, Editas raised $120m from a group of investors that includes Bill Gates. This comes on top of $43m the company raised in 2013. [Economist, Aug 22,15] its mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.  [Company website]

UC Berkeley professor Jennifer Doudna won the 2015 Breakthrough Prize in Life Sciences for her research into the CRISPR/Cas9 bacterial defense system, which has become a new method to edit genomes, with potential use in therapeutics. Doudna and her co-winner, French researcher Emmanuelle Charpentier, published a paper in 2012 that is often cited as the key that unlocked the potential of the system. Doudna is a cofounder of Editas Medicine (Cambridge, MA; no SBIR), which is pursuing CRISPR/Cas9-related therapeutics, and of Caribou Biosciences (Berkeley, CA; no SBIR). The prize is part of the series created last year by several Silicon Valley moguls. [Alex Lash,, Nov 13, 14]

[molecular system being used to make genetically engineered laboratory animals more easily than could be done before, with changes in multiple genes] Crispr is moving toward commercial use. Five academic experts recently raised $43 million to start Editas Medicine  (Cambridge, MA)  that aims to treat inherited disease. Other start-ups include Crispr Therapeutics, which is being formed in London, and Caribou Biosciences (Berkeley, CA).  [Andrew Pollack, Nerw York Times, Mar 3, 14]  Serious tech advances can raise serious money.


EEStor says that it has taken a big step toward high-volume production of an ultracapacitor-based energy-storage system that, if claims hold true, would far outperform the best lithium-ion batteries on the market. ... But skepticism in the research community is high  [Tyler Hamilton, MIT Tech Review, Aug 5, 08]

EEStor (Cedar Park, TX; no SBIR) has made bold claims about its technology but has so far failed to deliver a working commercial product. However, an agreement announced this month with Lockheed Martin, based in Bethesda, MD, suggests that the company could be making progress--at least enough to convince a major defense contractor that the technology has merit. The agreement gives Lockheed an exclusive international license to use EEStor's power system for military and homeland-security applications  [Tyler Hamilton, MIT Tech Review, Jan 22]

EEStor's secret ingredient is a material sandwiched between thousands of wafer-thin metal sheets, like foil-and-paper gum wrappers stacked on top of each other.  Charged particles stick to the metal sheets and move quickly across EEStor's proprietary material. The result is an ultracapacitor, a batterylike device that stores and releases energy quickly.  "The idea of getting rid of the batteries and putting in capacitors is to get more power back and get it back faster," Hebner said. But he said nothing close to EEStor's claim exists today. [Grant Slater, AP, Sep 4]

Barium-titanate Silver Bullet.  EEStor (a secretive Texas startup) boldly claims that its system, a kind of battery-ultracapacitor hybrid based on barium-titanate powders, will dramatically outperform the best lithium-ion batteries on the market in terms of energy density, price, charge time, and safety. Pound for pound, it will also pack 10 times the punch of lead-acid batteries at half the cost and without the need for toxic materials or chemicals, according to the company. ... Where they're weak, however, is with energy storage. Compared with lithium-ion batteries, high-end ultracapacitors on the market today store 25 times less energy per pound. [Tyler Hamilton, MIT Tech Review, Jan 22]

Effector Therapeutics (San Diego, CA)

eFFECTOR Therapeutics  (San Diego, CA; no SBIR),  leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing  ...  to advance a broad Phase 2 development program for eFT508, eFFECTOR’s investigational small molecule MNK1/2 inhibitor, including a combination study in colorectal cancer with avelumab* (BAVENCIO), conducted under a clinical collaboration agreement between eFFECTOR, Pfizer and Merck KGaA  [company press release, Jul 24, 17]

San Diego County companies that raised the largest amount of venture capital in the fourth quarter of 2015
Sapphire Energy ($200K SBIR) $91 million;  Effector Therapeutics: $40 million;  MD Revolution: $22.45 million;  AltheaDX: $20.1 million;  Elcelyx Therapeutics: $20 million;  Amplyx Pharmaceuticals: $20 million;  Astute Medical: $20 million;   Glysens  ($6.8M SBIR): $20 million;  Crinetics Pharmaceuticals  ($200K SBIR): $18 million;   Enlibrium: $15 million   Source: MoneyTree Survey by PricewaterhouseCoopers and the NVCA with data from Thomson Reuters  []

Effector Therapeutics (San Diego, CA; no SBIR, founded 2012) raised $40 million in venture financing, the biotech said.  .... will support testing of Effector's orally administered cancer drug eFT508 in a Phase 1/2 clinical trial, which looks for evidence of safety and early signs of efficacy. In another trial, the drug will be tested in lymphoma...... derived from the research of UC San Francisco researchers Davide Ruggero and Kevan Shokat. They found that certain proteins involved in disease can be controlled to inhibit the disease while preserving normal cell functions.  [Bradely Fikes, San Diego Union Tribune, Dec 21, 15]

After Switzerland’s Roche paid $230 million in cash to buy Anadys Pharmaceuticals (San Diego, CA; $1.4M SBIR)  in 2011, Anadys CEO Steve Worland ...  began talking prominent academic researchers about hot areas of research and development. ...  led him to UC San Francisco and scientists Kevan Shokat and Davide Ruggero. Together they founded Effector Therapeutics (San Diego, CA;  no SBIR) to develop new small molecule drugs that target translation, a process in the cell for synthesizing proteins. ...   raised $45 million in Series A financing, which should be enough to fund the lead candidate through proof-of-concept studies. [Bruce Bigelow,, May 21, 13]  Successful entrepreneurs attract VC like a magnet.

Egalet (Wayne,PA)

Egalet  (Wayne, PA; no SBIR) a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions,  announced the closing of its previously announced underwritten public offering .. expected to be approximately $30.0 million [company press release, Jul 11, 17]

Egalet (Wayne, PA; no SBIR), specialty pharmaceutical company developing tamper-resistant pain medication, has resolved a patent dispute with Purdue Pharma (Stamford, CT; no SBIR)and Purdue Pharmaceuticals. [John George, Philadelphia Business Journal, May 24, 16]

Egalet (Wayne,PA; no SBIR),  focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the termination of its collaboration with Shionogi Limited around its abuse-deterrent, extended-release hydrocodone product candidate. ... Egalet gains worldwide rights to the Phase 1 product candidate, S-718632.  ... Through the collaboration Egalet received upfront and milestone payments totaling $20 million, as well as an investment of $15 million in Egalet's common stock in connection with Egalet's initial public offering in 2014. All development to date for S-718632 has been funded by Shionogi.  ... In the third quarter Egalet expanded the base of SPRIX prescribers, began commercial promotion of its second product, OXAYDO, and raised $86.3 million through an equity financing   [company press release, Dec 3, 15]

For the third time in the past two weeks, Egalet (Wayne, PA; no SBIR) announced plans to raise cash through a follow-on public stock offering. ...  said it priced a $75 million stock offering.   ... for [R&D] and for sales and marketing efforts of its two approved pain treatments: Oxaydo tablets and Sprix nasal spray.  [John George, Philadelphia Business Journal, Jul 28, 15]

eGenesis (Cambridge,MA)

Biotech startup eGenesis (spun out of Harvard in 2014), which is applying gene editing to animal organs in order to make them suitable for human transplant, has raised $100 million to ramp up work on its kidney program and bring it into human testing. [, Nov 8, 19]

eGenesis (Cambridge, MA; no SBIR) focused on  utilizing  genome  editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a  $38 million Series A financing  ....  Xenotransplantation is the process of grafting or transplanting organs or tissues to humans from other species , and it holds vast potential for filling the tremendous medical need for  healthy organs for transplantation.  [company press release, Mar 16, 17]

Eidos Therapeutics

Eidos Therapeutics (a subsidiary of BridgeBio (Palo Alto, CA. San Francisco, CA; no SBIR, founded 2017)  which develops treatments for a family of rare diseases linked to the buildup of a certain protein in the body, set an initial IPO goal of $115 million. [Frank Vinluan,, May 25, 18]   total funding $64M []

Eiger BioPharmaceuticals (Palo Alto, CA)

Eiger Biopharmadown 12% [Apr 6, 18]

Eiger BioPharmaceuticals (Palo Alto, CA; no SBIR, founded Y2K, market cap $89M) is ready to stop development of ubenimex in pulmonary arterial hypertension (PAH). ...  after a phase 2 trial in the indication failed to find a hint of efficacy.   [Nick Paul Taylor, Fierce Biotech, Jan 16, 18]


Grab Your Politician for Plus-Up. Smaller and more transparent earmarks of federal funds for favored domestic projects are returning after a one-year moratorium on the controversial practice. ... a bit less than 1% of total R&D appropriations (3% for DOD) ... The Senate Top 10, are mostly smaller states with senators in key committee chairmanships—Mississippi, New Mexico and Tennessee are at the top ... search AAAS's new database of 2008 earmarks [AAAS Newsletter, Sep 07] But for small business, even 1% is a big honey pot. In the list (August version): Electro Energy  (CT; SBIR), Ocean Power Technologies (OR, SBIR in NJ),  DBS Energy CT, Eikos (MA; $8M+ SBIR), Cellular Bioengineering HI,Cerematec  (UT; SBIR), Ramgen WA, Advanced Radar Technologies WY, Compact Membrane Systems (DE; $20M SBIR), SD Catalyst Group SD.  Your story is that high-tech small business will create jobs, and they don't know whether your claim is valid or just wishful thinking. Like the federal mission agencies who then have to award and supervise the contract, they don't seem much to care.

E-Ink (Cambridge, MA)

Yuan Tai Technologies the Taiwanese video display maker that bought E Ink (Cambridge, MA; no SBIR) last year, announced today that it has changed the international version of its name from Prime View International to E Ink Holdings Inc.  "With this change, Yuan Tai Technologies reaffirms its strong commitment to ePaper, an industry that it has pioneered for over a decade," the company said in a press release E Ink was founded in 1997 by Russell Wilcox and a group of researchers at the MIT Media Lab. The company makes thin black-and-white electronic display screens that simulate the look of ink on paper. The screens are used in most of the world’s electronic book readers, including's popular Kindle devices.  [Boston Globe, Jun 18, 10]

EIS (Vienna, VA)

A massive U.S. Air Force contract has been awarded to a group of five small businesses that will share in the $851 million worth of work, according to Washington Technology ...  sharing the contract:Abacus Technology (Chevy Chase, MD); EIS (Vienna, VA); Odyssey Systems Consulting Group(Wakefield, MA); P3I (Hopkinton, MA); and SpectrumS4 (Burlington, MA). [Dayton Business Journal, Nov 1, 12]  No SBIR to any.

Eko Devices (Berkeley, CA)

Eko Devices (Berkeley, CA; $300K SBIR) granted breakthrough device designation for an electrocardiogram (ECG)-based algorithm that could serve as an easily accessible screening tool for heart failure during routine physical exams. [Meg Bryant,, Dec 18, 19]

Ekos (Bothell, WA)

EKOS  (Bothell, WA; $4M SBIR) said the FDA cleared its ultrasound device for breaking up pulmonary embolisms, or blood clots in the lungs. The company claims the device, the EkoSonic Endovascular System, is the first FDA-cleared treatment for pulmonary embolism since the drug tPA in 1990. The device helps infuse clot-dissolving drugs into the lung arteries without invasive procedures. EKOS is part of the London-based healthcare firm BTG International [since July 2013]. [Alex Lash,, May 29, 14]

The 18-year-old Ekos (Bothell, WA; $3.6M SBIR) sells an ultrasound device that makes medicine more effective at dissolving blood clots. Since it was introduced in 2005, the EkoSonic Endovascular device has been adopted by more than 490 U.S. hospitals and 100 overseas.  The past couple of years have made Ekos especially attractive. It turned a profit of $2 million on sales. [Robert Celaschi, Puget Sound Business Journal, Jul 12, 13]

London-based health-care company BTG has agreed to buy medical-device maker Ekos (Bothell, WA; $3.5M SBIR, 150 employees)  for $180 million or more, the companies said.... developed an ultrasound-enhanced system for breaking up blood clots, marketed since 2006 and now used in 490 U.S. hospitals and another 100 elsewhere. [Seattle Times, May 24, 13]

Ekos (Bothell, WA; $3.5M SBIR) maker of an ultrasound-based technology for dissolving blood clots, has won approval to market its device against life threatening clots in the lungs among patients in Europe.  [Luke Timmerman,, Jan 17, 11]

EKR Therapeutics (Bedminster, NJ)

Cornerstone Therapeutics (Cary, NC; no SBIR) announced that it is being bought by an Italian pharmaceutical company, ending the Cary drug marketing firm’s five-year run as a publicly traded company. The acquisition values Cornerstone at nearly $300 million  ....  the culmination of Cornerstone’s 2-year-old business strategy of getting specialty drugs to patients by selling directly to hospitals rather than working through doctors. ... Cornerstone was created as a publicly traded company in 2008 when Cornerstone BioPharma (Cary, NC; no SBIR) acquired Critical Therapeutics (Boston, MA; no SBIR) .  ....  Chiesi is a privately held business founded in 1935 in Parma, Italy, with plants or facilities in France, Brazil, England and Rockville, Md. The company employs 3,800 people.  ..... Last year, Chiesi further extended its commitment, agreeing to lend Cornerstone up to $90 million to acquire EKR Therapeutics (Bedminster, NJ; no SBIR) [which] gave Cornerstone the rights to oral hypertension drug Cardene, Cornerstone’s best-selling product today.  [Raleigh News & Observer, Sep 16, 13]

Ekso (Berkeley, CA)

 Ekso Bionics (Richmond, CA; no SBIR) says it will now provide 80 of the rehabilitation suits for the SoldierSocks organization, according to a story on Yahoo finance. ...  announced an expansion of its program to manufacture robotic exoskeleton suits [over the next three years] for the nation's veterans.   [David Mills, San Francisco Business Times, Oct 1, 14]

Mr. Abicca, a 17-year-old from San Diego, is essentially wearing a robot. His bionic suit consists of a pair of mechanical braces wrapped around his legs and electric muscles that do much of the work of walking. It is controlled by a computer on his back and a pair of crutches held in his arms that look like futuristic ski poles....  Ekso (Berkeley, CA; no SBIR) [founded seven years ago by engineers] says it was the first company to introduce a self-contained robotic suit, without any tethers to, say, a power supply . [Brian Chen, New York Times, Sep 11, 12]

Elcelyx Therapeutics (San Diego, CA)

San Diego County companies that raised the largest amount of venture capital in the fourth quarter of 2015
Sapphire Energy ($200K SBIR) $91 million;  Effector Therapeutics: $40 million;  MD Revolution: $22.45 million;  AltheaDX: $20.1 million;  Elcelyx Therapeutics: $20 million;  Amplyx Pharmaceuticals: $20 million;  Astute Medical: $20 million;   Glysens  ($6.8M SBIR): $20 million;  Crinetics Pharmaceuticals  ($200K SBIR): $18 million;   Enlibrium: $15 million   Source: MoneyTree Survey by PricewaterhouseCoopers and the NVCA with data from Thomson Reuters  []

Elcelyx Therapeutics’ (San Diego, CA; no SBIR, founded 2010) diabetes drug NewMet has passed a mid-stage clinical study, the company said .... said the results support its plan to offer itself for sale to a larger drug company   ..... has raised $43 million in [VC] .....  a “virtual” biotech company. Such companies operate with a handful of core employees doing key tasks and outsource everything else. Virtual biotechs have become common as a more efficient way of advancing products from research into the clinic, without the bureaucracy and overhead of a big company.  [Bradley Fikes,, Sep 4, 13]

Elcelyx Therapeutics (San Diego, CA; no SBIR) raised $20 million in a Series C venture round led by the GSM Fund, a fund created by Eastbourne Capital portfolio manager Rick Barry solely to invest in Elcelyx.  Alain Baron, who was an entrepreneur in residence at Morgenthaler, founded Elcelyx in 2010 to develop compounds that boost the signal along the appetite-control pathway that tells your brain your gut is full.  [Bruce Bigelow,, Feb 15, 13]

Elcelyx Therapeutics  (San Diego, CA: no SBIR) a stealthy biotech developing new therapeutics for treating diabetes and other metabolic diseases ... has raised just over $6 million from investors in what appears to be the first closing of an early stage round. [signonsandiego,Jan 28, 11]

EectroCell Technologies

ElectroCell Technologies (Colchester, VT; no SBIR), an early graduate of the Vermont Center for Emerging Technologies, has taken in $300,000 of an equity, warrants and options financing, planned for slightly more than $815,000, according to a regulatory filing.  A profile of the company in 2006 noted that ElectroCell develops a technology to treat farm waste with low levels of electricity to reduce odor. The process is also said to improve the environmental impact from wastewater runoff.  [Michelle Lang, Mass High Tech, Mar 2, 11]

ElectroChemical Systems Corp (Ridgewood, NJ)

ElectroChemical Systems Corp (Ridgewood, NJ) started delivery of its advanced FibroMillingTM Etcher equipment which enables the users to produce PWBs, MCMs and other substrates with until now unthinkable advanced designs - all at highly competitive cost. Almost entire electronic manufacturing depends on some form of wet processing involving etching. The FibroMillingTM Etcher has found immediate use in both military and civilian applications. As an inexpensive alternative to traditional equipment it can be directly retrofitted in existing PWB processing lines and provide immediate payback with its superior quality production. CEO Dr. I. V. Kadija, said, " Our first customers are taking advantage of this unique technology and positioning themselves ahead of competition." The commercialization came from a BMDO SBIR with help from the New Jersey Commission on Science and Technology (NJCST).

Electrical Geodesics (Eugene, OR)

The health care arm of European-based technology firm Royal Philips is buying medical device maker Electrical Geodesics (Eugene, OR; $15M SBIR)  for roughly $36.7 million.  [Malia Spencer, Portland Business Journal, Jun 22, 17]

Electric Power Systems (Lombard, IL)

NASA has a nice piece by Mike DiCicco of Goddard Space Flight Center on commercialization from  four NASA SBIR/STTR awardees. Read the stories.. Companies: Serionix (Champaign, IL), Cambrian Innovation (Watertown, MA), Electric Power Systems (Lombard, IL), Zeus (Orangeburg, SC)

Electro Energy (Danbury, CT)

Grab Your Politician for Plus-Up. Smaller and more transparent earmarks of federal funds for favored domestic projects are returning after a one-year moratorium on the controversial practice. ... a bit less than 1% of total R&D appropriations (3% for DOD) ... The Senate Top 10, are mostly smaller states with senators in key committee chairmanships—Mississippi, New Mexico and Tennessee are at the top ... search AAAS's new database of 2008 earmarks [AAAS Newsletter, Sep 07] But for small business, even 1% is a big honey pot. In the list (August version): Electro Energy  (CT; SBIR), Ocean Power Technologies (OR, SBIR in NJ),  DBS Energy CT, Eikos (MA; $8M+ SBIR), Cellular Bioengineering HI, Cerematec  (UT; SBIR), Ramgen WA, Advanced Radar Technologies WY, Compact Membrane Systems (DE; $20M SBIR), SD Catalyst Group SD.  Your story is that high-tech small business will create jobs, and they don't know whether your claim is valid or just wishful thinking. Like the federal mission agencies who then have to award and supervise the contract, they don't seem much to care.

Electro-Energy rose 10% before its afternoon report of 26% higher revenue and gross loss cut 84%. [Nov 20, 06]

Plug-In Hybrid. "If you look at how people typically drive cars, about half of the driving that you use gasoline for you could be using the electricity that comes out of your wall," says Martin Klein, CEO of Electro Energy of Danbury, CT, which developed the battery pack and control system for one of the cars on display in Washington.  100mph and wall plug recharge (although not at instant as pumping gasoline).  Plug-in hybrids have a larger battery pack, which allows them to run on the electric motor much longer -- for 20-25 miles in the case of the Electro Energy car. [MIT Tech Review, May 24  ] [Thanks to Leslie Aitcheson of MDA's Tech App squad] Economics and convenience? Well, think of the benefit from avoiding $3 gasoline and don't ask questions about the total cost per mile for solely gasoline engines and plug-in hybrids. Electricity is NOT free and its cost will vary with the price of gasoline. Electro Energy got early Phase 2 help from BMDO SBIR and then at least four more from other agencies.  Electro Energy says it got a $1M, one year AF contract to keep developing a manufacturing process for its NiMH aircraft battery. The stock is trading at half its six month ago price.  [05]

Electro Energy got a $2M slice of pork to keep developing its bipolar nickel-metal hydride batteries with an Energy Dept earmark (Congressionally directed spending item).  You, too, can go for such pork if your need for money overrides your ideals of lawmaking. Washington lobby houses like Strategic Marketing Innovations do small firms for a living. 

ElectroEnergy suffered a power loss of 15% when it reported soggy earnings. And NVE lost 14% on a dismissive article by Motley Fool  on No Visible Earnings with regard to its supposed licenses that have the market drooling. [Nov 23, 04]

Bipolar lithium for the spooks. Electro Energy (Danbury, CT) got an investment from the CIA's VC (In-Q-Tel) for bipolar design to lithium battery chemistry. CEO Martin Klein made the usual noises We are very pleased with the confidence that In-Q-Tel has shown in our company. EE got its first of only a few SBIRs from SDIO (grandfather of MDA) in 1992, the year of its founding when SDIO believed in funding new companies with entrepreneurial sounding proposals. Since EE joined the CIA portfolio, it has gone back-door public by merger this year and had a $5M private placement. 

Earmark. Electro Energy said it will get $1M from the 2007 DOD budget for continued development of its bipolar wafer-cell Nickel Metal Hydride (NiMH) battery for advanced military aircraft applications.  When an appropriation specifies the vendor of a product or service, it's politics. When Congress specifies a particular recipient of $1M out of a $530,000M budget, its politics.

Electro Energy got an $800K equity investment from In-Q-Tel, CIA's VC arm for advanced rechargeable bipolar lithium ion batteries. [Mass High Tech, Oct 21, 06]

Divided Management.  Electro Energy (Danbury, CT) says it has received funding on two government contracts to continue the manufacturing technology development of its bipolar nickel metal hydride battery for military applications. The company received an additional scope of work and amendment to its contract with the U.S. Air Force that added approximately $1.7M. Electro Energy says it will direct the funds, which will be used over a 12-month period, at the continuation of the manufacturing technology development of bipolar nickel metal hydride batteries for aircraft applications. In addition, under a new contract with the U.S. Army for approximately $848K the company will direct manufacturing technology development at bipolar nickel metal hydride batteries for communication and other applications.  [Mass High Tech, Jun 25] Roughly, Electro Energy has an interesting technology that the military wants. But the US military is not just one entity; it is competing services spending separately appropriated money often for the same technology intended for similar equipment with different colors of paint.  Double management costs and extra costs for the company (reimbursed by the military) to manage two formally different customers. 

Commercial Battery Production Electro Energy (Danbury, CT) plans to enter full commercial production of a battery inspired by the design of fuel cells.... Martin Klein, who co-founded Fuel Cell Energy predecessor Energy Research Corp. in 1970, is ready to take Electro Energy off government contract work and into the commercial sector. To date, EE has subsisted on SBIR from the Department of Energy [and BMDO], and has been working with Ford in Partnership for a New Generation Vehicle. ... EE's patents lie in creating effective seals to prevent fluid leakage which is both a structural and materials problem and in eliminating separate terminals and current collectors, allowing it to make the battery lighter... Founded 10 years ago, Electro Energy was one of the older companies in this month’s Connecticut Venture Fair competition. It took home the Ignite prize for best business plan from a company that has raised $1M or less in venture financing.,, plus $10M in SBIR.[Mass High Tech, May 29]

Electromed (New Prague, MN)

Electromed (New Prague, MN; no SBIR) raised $5.5 million in only the third initial public offering for a Minnesota company since the start of 2008. ...  the manufacturer for the SmartVest System, a Food and Drug Administration-approved device to treat excess lung secretions. ... has reported strong business growth in recent years. [Wendy Lee, Minneapolis Star Tribune, Aug 13, 10]

Electro Optical Sciences  (now MELA Sciences)

Electro-Optical Sciences up 25% [May 26, 10]

Electro-Optical Sciences up 12% [May 10, 10]

Electro-Optical Sciences  down 21% [Mar 25, 10]

Electro-Optical Sciences  down 10% [Jan 22, 10]

Electro-Optical Sciences down 14% [Nov 9, 09]

Electro-Optical Sciences down 12% [Oct 28, 09]M

Electro-Optical Sciences  down 11% [Jul 17, 09]

Electro-Optical Sciences  up 13% [May 1, 09]

Electro-Optical Sciences  up 11% [Mar 26, 09]

Electro-Optical Sciences down 17% [Feb 26, 09]

Electro-Optical Sciences  down 12% [Feb 25, 09]

Electro-Optical Sciences  up 10% [Feb 23, 09]

Electro-Optical Sciences   down 14% [Feb 18, 09]

Electro-Optical Sciences   up 12% [Feb 17, 09]

Electro-Optical Sciences  up 80% [Feb 13, 09] said its experimental device proved effective in detecting melanoma, a type of skin cancer, sending its shares soaring   [Reuters]

Electro-Optical Sciences   up 28% [Feb 6, 09]

Electro-Optical Sciences down 26% [Feb 5, 09]

Electro-Optical Sciences down 13% [Feb 4, 09]

Electro-Optical Sciences  up 11% [Jan 28, 09]

Electro-Optical Sciences up 25% [Dec 30, 08]

Electric-Optical Sciences down 17% [Dec 15, 08]

Electro-Optical Sciences up 13% [Dec 8, 08]

Electro-Optical Sciences up 13% [Nov 26, 08]

Electric-Optic Science up 19% [Oct 31, 08]

ElectroOptical Science down 14% [Oct 24, 08]

Electro Optical Science down 11% [Oct 23, 08]

Electro-Optical Sciences up 10% [May 27, 08]

Electro-Optical Sciences up 13% [May 16, 08]

Electro-Optical Sciences up 18%  [May 2, 08]

Electro-Optical Sciences up 27% [Mar 24, 08]

Electro-Optical Sciences rose 14% after announcing the initiation of the pivotal clinical trial for MelaFind®, the company's non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma  [Feb 21, 07]

Electro-Optical Science up 11%. [Nov 15, 06]

Electro-Optical Sciences, a medical-device company, traded at $7.7 after its IPO at $5.  EOS got part of its start with three Phase 2 SBIRs in the mid 1990s. The $5 was a big come-down from its summer dream of $10-12, says the Wall Street Journal (Nov 1).

Electro Scientific

Electro Scientific Industries down 10% [Jan 29, 15]

Electro Scientific Industries up 13% [Aug 1, 14]

Zygo (one Phase 1 SBIR) is among the more successful Connecticut-bred tech firms, with 375 local employees and a solid market niche. Its merger [with Electro Scientific (no SBIR)] — which is being contested in court by a shareholder group — would leave Zygo under the control of another company. But that is the best plan for nurturing the business, Zygo officials said. ... The deal is typical of a market where tech companies are searching for growth and capital, said Matthew Nemerson, president and CEO of the Connecticut Technology Council. [Kenneth St Onge, Hartford Courant, Dec 19, 08]

Electrozyme (San Diego, CA

Biosensor startup Biolinq (formerly Electrozyme, San Diego, CA; $2.2M SBIR, founded 2012) said it has raised $4.75 million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device. .... seeking to commercialize a nickel-sized patch that’s designed to gauge blood-glucose level and take other measurements when the device is applied to the skin.  [Sarah de Crescenzo,, Mar 28, 19] prior funding $10M []

Elementary Robotics

Elementary Robotics (Los Angeles, CA; no SBIR, founded 2017) announced a $12.7M Series A funding round .... has built a hardware and software platform for applying machine learning and computer vision for intelligent automation of quality and traceability workflows in manufacturing and logistics. .... is working with a number of world class manufacturing and logistics companies [company press release, Jul 8, 20]

Elementary Robotics announced a $3.6 million seed raise ... With a team of experts culled from the Pasadena-based NASA Jet Propulsion Lab, Caltech and the ArtCenter College of Design, Elementary Robotics puts its talent to work building “robust, intelligent robot assistants that are affordable and human,” according to its website.  [Samson Amore, LA Business Journal, Dec 19, 18]  in stealth mode [company website]

Elemetric Instruments (Los Alamos, NM)

Los Alamos National Laboratory has approved $250,000 in new funding for four companies from its Venture Acceleration Fund [which] provides investments of up to $100,000 to regional entrepreneurs, companies, investors or strategic partners who use LANL technology or expertise to create or grow regional businesses. Award recipients are chosen based on potential for regional impact, team composition, technical feasibility, market opportunity, and the availability of matching funds or in-kind contributions. Retriever Technology (Santa Fe, NM; no SBIR) will receive $25,000 to upgrade a low-light imaging camera for advanced digital imaging into a more user-friendly and functional form for customer demonstration and evaluation.  Elemetric Instruments (Los Alamos, NM; no SBIR) will get $100,000 to further develop a prototype of an instrument that immediately detects elements in liquids and gases with continuous online, real-time processing. The device, called an element presence detector, is based on LANL technology with potential markets among food and pharmaceutical makers.  STAR Cryoelectronics (Santa Fe, NM; $2M SBIR) will get $75,000 to accelerate development of a high-resolution alpha particle spectrometer to be used in nuclear forensics and nuclear nonproliferation work.  Veezyon (somewhere, NM; no SBIR) will receive $50,000 to improve the technical capabilities of its Web site — a knowledge-based online video site focusing on shared interest user collaboration.  Since the venture fund was launched in fall 2006, LANL has awarded about $600,000 to six companies, not including the new grants, [New Mexico Business Weekly, Jan 7, 09]


ElevateBio (Cambridge, MA) biotechnology holding company, announced it has established and launched HighPassBio, a company dedicated to advancing novel targeted T cell immunotherapies. [Nick Paul Taylor, Fierce Biotech, Oct 1, 2019]

ElevateBio unveiled $150 million in Series A funding to back its plans to invest in cell and gene therapy startups, and build a shared facility in Waltham, MA, that will manufacture their experimental treatments. [Frank Vinluan,, May 17, 19]

Elevation Pharmaceuticals (San Diego, CA)

the Marlborough [MA]-based subsidiary of a big Japanese drug company, said it has agreed to buy Elevation Pharmaceuticals (San Diego, CA; no SBIR, founded 2008)  specializing in the development of aerosol therapies for patients with respiratory diseases. Sunovion said it will make an upfront payment of $100 million to the shareholders of California-based Elevation on the closing of the acquisition. The sales agreement also calls for more than $300 million in additional milestone payments if certain conditions are met. [Chris Reidy, Boston Globe, Aug 30]

Elevation Pharmaceuticals (San Diego, CA; no SBIR, founded 2008) startup developing aerosol-based treatments for respiratory diseases, said it has raised a tranched $30 million in Series A venture funding. It’s a sizable round for the [San Diego] life sciences community, but other recent fundings have come close. Last month, VentiRx(no SBIR) raised $25 million, Pfenex (no SBIR) got $24 million, and Zogenix (no SBIR)  got $20 million.  [Bruce Bigelow,, Mar 8, 10]

Elevation Pharmaceuticals  (San Diego, CA; no SBIR) a biotech startup developing aerosol-based treatments for respiratory diseases, said today it has raised a tranched $30 million in Series A venture funding [Bruce Bigelow, San Diego, Union Tribune, Feb 24, 10]

Eleven Biotherapeutics (Cambridge MA)

Eleven Biotherapeutics changed its name to Sesen Bio [, May 18, 18]

Eleven Biothera up 24%  [May 16, 18]

Eleven Biothera up 11%  [May 2, 18]

Eleven Biothera down 10% [Sep 22, 16]

Eleven Biotherapeutics (Cambridge, MA; no SBIR) became an eye-disease company several years ago, a move that allowed it to go public, raise a bunch of money, and get an eye drug all the way to a pair of late-stage clinical trials.  Both studies failed, however, which left the , company searching for a new direction—which today has been revealed as a plan to develop cancer drugs.  Eleven has acquired a Toronto biotech called Viventia Bio (Canada). The combined company will keep the Eleven name, but take Viventia’s strategy and management team. [Ben Fidler,, Sep 21, 16]

Eleven Biothera up 14% [Aug 15, 16]

Eleven Biothera up 17% [Aug 12, 16]

Eleven BioThera up 10% [Jul 28, 16]

Eleven BioThera up 14% [Jul 27, 16]

Eleven BioThera up 13% [Jul 26, 16]

Eleven BioThera up 15% [Jul 25, 16]

Eleven Biothera up 15% [Jun 16, 16]

Eleven Biotherapeutics (Cambridge, MA; no SBIR) may be in strategic limbo, but today it’s gotten some cash to help figure out its next steps  [as it] licensed EBI-031, an experimental, preclinical drug it’s been developing for eye diseases like diabetic macular edema and uveitis, to Swiss pharma giant Roche. Eleven got $7.5 million up front, with another $20 million to $22.5 million coming if EBI-031 is cleared to begin human clinical trials.  [Ben Fidler,, Jun 14, 16]

Eleven Biotherapeutics (no SBIR) also was bludgeoned by investors. ... after the company’s lead drug, isunakinra, failed its second Phase 3 trial in seven months. Eleven is now putting its cash behind a preclinical drug, EBI-031, for diabetic macular edema, and a spokesperson said this week the company is considering “various business development and financing approaches” going forward. [Ben Fidler,, Jan 22, 16]

Eleven BioThera down 69% [May 18, 15] after the company said its late-stage dry eye disease treatment failed to meet its two primary endpoints. [Wall Street Journal, May 18]

Eleven BioThera up 12% [Sep 8, 14]

Eleven Bio  up 11% [Jul 30, 14]

Eleven BioThera  down 12% [Jul 17,14]

Eleven Biothera up 12% [Feb 21, 14]

Eleven Biotherapeutics (Cambridge, MA; no SBIR) said it plans to raise up to $69 million with IPO.  {Boston Business Journal, Jan 2, 14]

Eleven Biotherapeutics (Cambridge, MA; no SBIR, founded 2010)   said it has secured $20 million dollars in Series A equity financing,  ....  to advance Eleven’s first drug candidate, known as EBI-005, into clinical development later this year. The drug is designed to treat dry-eye syndrome.  [Chris Reidy, Boston Globe, May 9, 12]

Eleven Biotherapeutics, (Cambridge, MA; no SBIR) said it has completed a $35 million Series A financing ...  based on recent breakthroughs in protein engineering and structural biology ...  initial focus includes developing products to treat inflammatory conditions and coagulation disorders. [Boston Globe, Feb 17, 10]

Elevian ((Allston, MA)

Early-stage biotech Elevian (Allston, MA; no SBIR) raised $15 million as it looks to target multiple age-related diseases. The company said the small raise would help its preclinical work toward the clinic to treat stroke and other age-related diseases. [Fierce Biotech, Nov 23, 20]

Elicio Therapeutics ((Cambridge, MA)

Elicio Therapeutics (Cambridge, MA; no SBIR, founded 2019), developing vaccines and immunotherapies to defeat an array of aggressive cancers, raised $6.1M in equity in a $30M funding round, according to an SEC filing [Rowan Walrath, BostInno, Jul 17, 20]

Elira Therapeutics (Frontenac, MO)

Elira Therapeutics (Frontenac, MO; no SBIR in stealth mode, founded 2015) medical device startup raised $1.9 million from a group of investors [St Louis Business Journal, Jan 2, 18]... developing a system to suppress appetite and assist with diet adherence. [, Aug 2016]

Elira Therapeutics (Frontenac, MO; no SBIR, founded 2015) health care startup raised $1.9 million of a planned $5 million offering, according to [SEC] documents [Brian Feldt, St. Louis Business Journal, Dec 21, 16] earlier Sep 2015 raised $1.1M

Cellular Dynamics International (Madison, WI) is following a split with a spinoff. .... earlier this month announced it divided the company into two business units, is now saying it has launched a new venture that will focus on developing medicines to treat diseases of the retina. The new company, Opsis Therapeutics, ... However, Cellular Dynamic was acquired by Tokyo-based Fujifilm last year—did not announce the creation of Opsis until earlier this week.[Ben Fidler  [Ben Fidler,, Sep 30, 16]  

Elixir Biopharm

Bioheartand ElixirBiopharm going public this week.  Neither used SBIR. [Jan 08]

Elixirgen Therapeutics (Baltimore, MD)

Elixirgen Therapeutics (Baltimore, MD; one SBIR) is gearing up to launch a pair of clinical trials this year — one for its new drug that targets bone marrow failure syndromes, and another for its version of a Covid-19 vaccine. [, Feb 25, 21]

Elixirgen Therapeutics (Baltimore, MD; no SBIR) raised $4 million in a Series A funding round from University of Tokyo Edge Capital (UTEC). .... a biotech focused on curing humanity’s ailments through innovations in stem cell biology. [company press release, Jul 9, 18]

Elixir Pharmaceuticals (Cambridge, MA)

Elixir Pharmaceuticals is calling off its IPO.  The 9 year-old biotech says it has raised a total of $87 million in three rounds of VC. [Mass High Tech, May 12, 08]

Elixir Pharmaceuticals that was expected to go public this week, has postponed its initial public
offering,. [Boston Globe, Jan 18]

Elixir Pharmaceuticals  (Cambridge MA; no SBIR)  plans fan IPO for $86 M. With 30 employees it most recently raised $10M VC from Swiss drug giant Novartis AG atop an already $100M from US VCs. [Mass High Tech, Sep 24, 07]

Ellipse Technologies (Aliso Viejo, CA)

Medical device maker NuVasive (no SBIR) paid $380 million in cash upfront to buy Ellipse Technologies  (Aliso Viejo, CA; no SBIR) which could get an additional $30 million in milestone payments. Ellipse has developed implantable rods that can be lengthened magnetically to help correct spinal and complex skeletal deformities. The technology would help extend NuVasive’s own line of spinal surgical tools. [Alex Lash,, Jan 8, 16]


Elon  down 10% [Feb 10, 12]

Elon down 19% [Nov 4, 11]

Elon up 10% [Oct 4, 11]

Elon up 15% [May 6, 11]

Eloxx Pharma (Waltham,MA)

Eloxx Pharma up 28% [Mar 4, 20]

Eloxx Pharma up 27% [Dec 10, 19]

Eloxx Pharma up 18% [Nov 20, 19]

Eloxx Pharma up 15% [Nov 1, 19]

Eloxx Pharma (Waltham,MA; no SBIR, founded 2013) up 80% [Oct 31, 19] a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, announced positive data demonstrating that ELX-02 results in a pronounced increase in both CFTR protein expression and mRNA stability further supporting its proposed mechanism of action, and that it was well tolerated with no serious adverse events in the Phase 1 program. [company press release, Oct 31, 19] The data ..., was so persuasive that [FDA] last week approved the three-drug combination, called Trikafta — five months ahead of the agency’s deadline. [Carolyn Y. Johnson, Washington Post, Oct 31, 19] total funding $38M []

Elroy Air, Sentient<

The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20]  almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics,, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release , Mar 13, 20]

Elstar Therapeutics (Cambridge, MA)

Elstar Therapeutics (Cambridge, MA; no SBIR, founded 2015) fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapies, announced the closing of a $39M Series A financing round [to] expand its growing pipeline and progress several early stage molecules towards the clinic immunotherapies.  [company press release, Jan 3, 18]

Eltron Research (Boulder, CO)

After two decades of SBIR support (at least 40 Phase 2s), Eltron Research (Boulder, CO) may have the way that America can return to what was common as late as about 1950 - making fuel gas from coal. A news item in MIT Tech Review (Oct 03) notes that Eltron has developed a candidate membrane that separate hydrogen from carbon dioxide with tenfold better efficiency than present membranes (which means that today's technology is grossly inefficient). The enviro trick is to create lots of hydrogen while preventing the scads of accompanying carbon dioxide from escaping into the ionosphere. Instead the CO2 would be pumped underground for long term storage or disappearance.   Chevron, BP, and Shell contributed and expect a piece of the pie from the jpoint R&D project. Eltron seems to have grown from a handful of employees in the mid-80s to 70-ish today.

Elucid Bioimaging (Boston, MA)

Elucid Bioimaging (Boston, MA; $4.6M SBIR) announced $80 million in Series C funding [company press release, Nov 9, 2023]

The cardiovascular imaging company Elucid Bioimaging (Boston, MA; $4.5M SBIR) has made it clear they mean to deliver on their promise of artificial intelligence-powered exams to chart the insides of blocked arteries. And now they’ve raised $80 million to do so. [Conor Hale, Fierce Bikotech, Nov 13, 2023]

EMagin (Hopewell Junction, NY)

eMagin up 29% [May 15, 15]

eMagin down 17% [Mar 13, 15]

eMagin  down 10% [Feb 27, 15]

eMagin up 10% [Feb 24, 15]

eMagin (Bellevue, WA; $700K SBIR) declared an intitial dividend.

[Nov 2012]

eMagin up 13% after being down 10% early. Bloggers were blogging, including one seeing smoke and mirrors in a neat technology too expensive for the consumer game market. And yet another lossy quarter. [Nov 10, 06]eMagin up 15% after its 1:10 reverse split. [Nov 7, 06]

eMagin got a cold -26% shower after reporting the same loss as last year's quarter even though revenue rose nicely. And it said it had "serious cash flow pressure." A for-profit entity can't keep taking in $2.3 while paying out $6.1. [Nov 3, 06]

eMagin announced a November 1-for-10 reverse split to get its stock price back up to AMEX standards. [Brier Dudley [Seattle Times, Jan 2] sees eMagin as a star of the Consumer Electronics Show in Vegas with its Z800 3DVisor. The company started life in early 90s [under a different name]with a half dozen SBIR Phase 1s and went public in 2000. It now has a market cap o $58 million despite selling a way under a dollar a share - down from $20+ in the opto-electronics boom. The company's website claims it continues to hold a leadership in OLED microdisplay technology and virtual imaging systems.

eMagin , which calls itself the leading developer of organic light emitting diode microdisplay technology lost $10M for the quarter. on revenues of $1.6M. The company press wriggled about pro-forma numbers that lost only $4.2M. One of the quarter's highlights was getting a 2001 U.S. Army SBIR Phase II Quality Award and 2000 Display of the Year Gold Award from The Society for Information Display and Information Display Magazine.

Read Screens in Daylight. EMagin got another $5M from the AF (Phase 3 SBIR) to keep developing microdisplays for way luminescent uses, to 30,000 cd/M2 which the company says is 200 times brighter than a laptop. [facts from Laser Focus World, May 01]

New Display, eMagin (East Fishkill, NY), formerly FED, unveiled a full-color active-matrix OLED-on-silicon microdisplay at the International Display Research conference with 1.3M 12-?m subpixels in a quadpixel arrangement (four subpixels per color group). The OLED material itself emits white light, with color provided by filters built directly onto the display. The full-color capability is built upon the company's military, medical, and industrial-oriented 1280 x 1024-pixel display demonstrated last year. eMagin plans to apply the technology to a consumer version available for sampling to systems manufacturers in early 2001. [press release]

Back Door IPO By merging with a shell company, FED Corp (Hopewell Junction, NY) became a public company eMagin in March without an IPO. It began life in 1993 to exploit semiconductors for display systems. It bought Virtual Vision in 1998 to evolve into an integrated provider of total systems solutions. It claims $35M in government contracts and research grants, and another $60M capitalization through 1999 including a recent $27M private placement led by Citigroup and Verus International Ltd. FED got its SBIR start with three Phase 1 awards in the 1993 TRP SBIR hawgrassle (150 winners from 2450 proposals) when it had seven employees, and then an 1999 Army Phase 2 with 76 employees. One of its technologies is OLED competing with UNIAX.After trading for a while in the low 20s it plunged in the tech slide to the mid-teens.

Embera NeuroTherapeutics (Sudbury, MA and Shreveport, LA)

Embera NeuroTherapeutics,(Sudbury, MA and Shreveport, LA; no SBIR)  developer of drugs for treating addictions, has added another $4.5 million in Series A financing, the company announced ... supporting the company’s drug, EMB-001, through a Phase 1 safety study  [Erin Kutz,, Aug 15, 11]

Embodied (Pasadena, CA)

Embodied (Pasadena, CA; no SBIR, founded 2016) socially assistive robotics and artificial intelligence company that develops companion care and wellness robots, has raised more than $12 million from investors, according to a securities filing. ... two seed rounds in 2016 and last year that netted nearly $6.8 million from Intel and Amazon [Dana Bartholomew, LA Business Journal, May 1, 18]

EmboMedics (Maple Grove, MN)

A new medical treatment developed at the University of Minnesota to kill cancer cells and uterine fibroids has been snapped up by a company interested in buying the full rights if the technology does well EmboMedics (Maple Grove, MN; no SBIR, 10 employees, founded 2012) developing the minimally invasive technique invented at [UMinn], signed an exclusive licensing deal with AngioDynamics (Latham, NY; no SBIR). The buyer is a $350 million device firm. [Joe Carlson, Minneapolis Star Tribune, Apr 10, 15]

Embrex (RTP, NC)

Three former Embrex executives, including Randall Marcuson, who led the company for 16 years before it was sold last year, claim in a lawsuit that the new owners reneged on compensation and benefits they were promised. ... A spokesman for Pfizer said the company is in compliance with the contracts.  [Raleigh News&Observer, Jan 22, 08]

Raleigh News and Observer notes that the execs of Embrex have collected multi-millions from the absorption by Pfizer without even losing their jobs.

Of the $155M that Pfizer will pay Embrex owners, Catherine Ricks, who recently retired as vice president of research and development, should get at least $1.3M. [Raleigh News and Observer, Nov 17] Catherine was the voice of Embrex in countless SBIR conferences.

Embrex, 1990s poster child for USDA's SBIR, rocketed 40% on news that it was being bought by Pfizer. [Nov 15, 06] Four small Phase 2s from USDA and one from NSF.

Embrex was one of the companies in which the head of FDA held stock options during his brief tenure. Crawford will plead guilty to two misdemeanors for failing to fully disclose holdings in firms regulated by the agency. [Wall Street Journal, Oct 16, 06]

Chickens Abandon Embrex (Jul 31) Traders knocked a third off Embrex on ten times average volume when it reported a huge dive in revenue from its egg inoculation technology. High PE multiples need high growth rates of profit.

Embrex stockholders had a good April as the price rose 50% despite a soggy general market and despite consensus estimates that its earnings will go up only about 5% next year.

Embrex reported another profitable quarter and year with growing revenue and profit. The stock price trend for the last year shows what steady profits do for stock prices, modestly upward.

And They'll All Taste Alike (Aug 17). Embrex says it got a research pile from NIST to clone chickens. Only the best eating chickens, of course, disease-resistant. Origen Therapeutics and Embrex got $4.7M for no early expected breakthrough. A Reuters report says The company aims to breed or genetically engineer a chicken with the required traits and then ``bulk-grow'' embryonic stem cells taken from fertilised eggs as soon as they are laid. Those cells will then be injected into the embryo of a fertilised recipient egg. Origen has a patent on the process still at the application stage. Embrex produces machines that can inject vaccines into up to 50,000 eggs an hour, the magazine said.

Is That A Boy Chick in There? Embrex made a funding deal that has Cobb-Vantress paying for lots of Embrex's development of a patented technology and device to determine the gender of poultry in the egg. For that money, Cobb-Vantress will receive favorable commercial terms upon adopting the gender sort device. The idea is that growers can have boy houses and girl for growing broilers. Embrex sees a $300M world market for the selctivity and has budgeted between $5-7M for the project. Cobb-Vantress is a poultry research and development company doing production, improvement, and sale of broiler breeding stock. Embrex is an international agricultural biotechnology company specializing in poultry In addition to Forbes's 200 Best Small Companies in America and BusinessWeek's Hot Growth 100, Embrex is also listed on the North Carolina Technology Fast 50. [Facts from company press release]

Embrex, the egg innoculator, said its quarterly profit went over $2M, a first, on revenues of $11M.

Embrexwon a small money ($270K) Phase II SBIR from Ag for development of an automated device for sorting poultry eggs by gender. Said Catherine Ricks, VP of R&D, Embrex has made substantial progress in developing a gender sorting device; and in laboratory trials, we have determined gender in a series of eggs with 100% accuracy. We plan to use this grant to further advance development of a novel device used to sort avian eggs by gender. Embrex says that Separation of chicks by gender at hatch is a valued aspect of the poultry industry - hens for eggs and roosters for broiling. It also says that gender sorting is an area that, to date has been underutilized by the poultry industry despite its potential advantages to the business. This is primarily because a cost-effective solution has yet to be found. Currently, a chicken's gender is determined manually and relatively expensively. [facts from company press release] So, why is the government putting a smidgeon of money into a public company for a cost-effective method when the company earned EBITDA of $12M last year? What is a free-market government for? Will Embrex's directors vote Republican to foster free-markets for business? Would W have the gumption that his father didn't show and shut down corporate welfare with his veto pen? Well, not if he keeps his election claim of making nice with everybody in Washington.

Cut Them Off From SBIR. When a company uses its cash to re-purchase shares to hold up the share trading price, it should be cut off from subsidy programs like SBIR. Embrex, poster child for the USDA, says it will extend its repurchases, and the stock rose last week in response. SBIR's whole raison d'etre is to fill and investment gap in high-tech companies. Any company that uses its cash to re-purchase its own stock has thereby declared it does not need R&D investment help. Some time ago, SatCon also announced such repurchase plans although it is not clear that any stock was ever actually repurchased.

Embrex (Research Triangle Park, NC) reported a 62% rise in profits to $1.8M for the quarter on a 16% rise in revenues. It also dsaid that it started a series of field trials for the in ovo coccidiosis vaccine with a major poultry producer. Jim Green, a VC said in a Wall Street Transcript interview that Embrex has developed and commercialized the first ''in ovo`` platform delivery system which inoculates chicken eggs several days prior to hatching and thus eliminates the need for individual manual vaccination of newly hatched chicks. Their machines can apply 20,000 to 50,000 inoculations per hour, which renders tremendous savings in labor costs, as well as ensuring that every bird gets its proper medication.'' The USDA rooster is still crowing over Embrex's success with one SBIR.

Embrex reported record revenue and earnings for 1999. Profit doubled to $5.7M, on 18% higher revenue of $34M. Embrex credited the gains to sales of its Inovoject systems, which vaccinate baby chicks through the eggshell before they hatch. USDA SBIR helped hatch the early development. (Mar00)

(Nov 9) Embrex reported doubled profits for the quarter on an 11% rise in revenues. It also entered into a multi-year collaborative R&D deal with Pfizer to develop a ovo coccidiosis vaccine for parasites in poultry. Embrex is the poster-child for USDA's SBIR after one small Phase 2 in 1987. The stock market has favored Embrex with a doubling of price over the last year. What is USDA's SBIR like? Judging only by the Phase 2 awards for 1999, a narrow base indeed, USDA likes to spread its small money around in little packets and has a lot of squishy projects that have practically no tech innovation. Even one to help find angel investors. Feels like some backroom political pressure.

(May 11) Embrex (Research Triangle Park, NC) reported quarterly profits of $527K, double last year's quarter. The company, a poster-child for USDA's SBIR, sells Inovojects to vaccinate broiler chickens before they hatch.

EMCORE (Somerset, NJ)

Emcore down 11% [Apr 10, 18]

Emcore down 11% [Feb 6,18]

Emcore down 16% [Dec 5,17]  completed an outstanding fiscal year 2017 with a 34% growth in revenue and 182% growth in profits over the last year.  [company press release, Dec 5, 17]

Emcore down 10% [Aug 3, 17]

Emcore up 14% [May 4, 17]  excellent growth in revenue and non-GAAP net income [company press release, May 4, 17]

Emcore (Somerset, NJ; $6M SBIR) up 31% [Dec 7, 16][CEO said] "A combination of strength in customer orders and improved manufacturing efficiency drove significant income generation in the fourth quarter and allowed us to finish the year strongly"   .... designs and manufactures Indium Phosphide (InP) optical chips, components, subsystems and systems for the broadband and specialty fiber optics market.  [company press release, Dec 7, 16]

SolAero Technologies (Albuquerque, NM; no SBIR) that bought Emcore’s solar space division last year, has acquired Vanguard Space Technologies  (San Diego, CA; no SBIR). [Joe Cardillo,  Albuquerque Business First, May 11, 16]  Solero earlier signed a definitive agreement to acquire Alliance Spacesystems, LLC, a leading provider of high-performance composite structures for spacecraft applications. [SolAero press release, Apr 15, 16]

Emcore up 20% [Apr 13, 16]

Emcore down 11% [Feb 5, 16]

Emcore up 12% [Dec 1, 15]

Emcore up 15% [Aug 5,15]

EMCORE announced today that it will no longer have a presence in New Mexico once the $150 million sale of its space solar photovoltaics division to Veritas Capital is complete.  ... The company has grown to more than 1,000 employees worldwide ...  Last month, it sold its space photovoltaics division to Veritas Capital. It recently announced that will sell its tunable laser division for $17.5 million to NeoPhotonics (no SBIR).       [Dan Mayfield, Albuquerque Business First, Oct  29, 14] On to high tax California, from which businesses are fleeing, according to the "cut my taxes" crowd.

EMCORE (Somerset, NJ; $6.5M SBIR) announced that it has sold its Space Photovoltaics (Albuquerque, NM) business [its most profitable division] to private equity firm Veritas Capital.  ...  for $150 million in cash, pending shareholder approval. The sale is expected to close in December of 2014 or in early 2015.  ... Revenue for the Space Photovoltaics business in 2013 was $70.5 million, the company said.  ... In 1984, a group of former Sandia National Labs engineers — including the city’s now head of economic development, Gary Oppedahl — formed MicroOptical Devices, or MODE, to develop new laser technology. EMCORE, at the time, was a New Jersey firm that had worked with Sandia since the early 1990s.  In 1997, however, EMCORE acquired MODE and the new firm became the first to move into the Sandia Science & Technology Park in 1998.  ....  In 2012, EMCORE sold its fiber optics business to Sumitomo for $17 million.  [Dan Mayfield, Albuquerque Business First, Sep 18, 14]

Emcore announced its first dividend $1.50.  [Jul 8, 16]

EMCORE up 25% [Sep 18, 14] 

EMCORE and Lockheed Martin Space Systems have signed a new long-term agreement for EMCORE to produce solar cells for Lockheed Martin’s satellite programs.  ....   EMCORE’s solar technology came out of research done at Sandia National Labs, and the company’s cells have been used to power most satellites launched in the U.S. over the last decade. Lockheed Martin has the contract to operate Sandia National Laboratories.   [Dan Mayfield, Albuquerque Business First, Jul 30, 14]

EMCORE has signed a long-term supply agreement with Space Systems/Loral to manufacture the company’s solar cells for satellite programs.  ...  SSL has used EMCORE’s panels for 15 years.  [Dan Mayfield, Albuquerque Business First, Jun 19, 14]

Emcore down 15% [May 8, 14]

Emcoredown 15% [May 10, 13]

Emcoreup 10% [Mar 7, 13]

Emcoreup 11%  [Jul 13, 12]

Emcore down 13% [May 4, 12]

Emcore up 10% [May 1, 12]

Emcore up 12% [Feb 6, 13]

Emcore up18% [Feb 16, 12]

Emcore down 22% [Mar 9, 11] in sympathy to a reaction to a gloomy forecast for optics slowdown in China  [Tiernan Ray, Barron's, Mar 9]

The Obama administration has forced [Emcore, based in New Mexico makes components for fibre optics and solar panels] to abandon a planned joint venture with China’s Tangshan Caofeidian Investment Corporation because it believes the tie-up would threaten national security.  ... the second time in less than a year that the administration has sought to block a transaction involving a Chinese company because of security concerns.  [Stephanie Kirchgaessner, Financial Times, Jun 29, 10]  If China can't use American money to buy American assets, why should they take it or keep it? Are we still the big dog that makes the rules?

Avago Technologies (Singapore) won a patent-infringement case against Emcore and can seek an order to block imports of Emcore’s opto-electronic devices used to connect computers in a local area network, the United States International Trade Commission said Friday. [Bloomberg News, May 14, 10]

Emcore down 16% [Nov 5, 08]

Emcore up 18% [Oct 20, 08]

Emcore up 19% [Oct 13, 08]

Emcore down 14% [Oct 7, 08]

Emcore up 10% [Sep 30, 08]

Emcore down 17% [Sep 29, 08]

Emcore up 26% [Sep 18, 08]

Emcore up 10% [Sep 17, 08]

Emcore down 11% [Sep 9, 08]<

Emcore received two new definitive supply agreements for solar cell receivers worth a total of $29 million. [New Mexico Business Journal, Jul 9, 08]

Emcore down 11% [Jul 1, 08]

Emcore down 13% [Jun 30, 08]

Emcore up 13% [May 1, 08]

Emcore up 16% [Apr 2, 08] received a follow-on order of $4.6 million for solar-cell-receiver assemblies from Concentration Solar la Mancha, a unit of Renovalia Energy. [Wall Street Journal, Apr 3, 08]

Emcore down 11% [Mar 25, 08]

Emcore down 23% [Mar 18, 08]

Emcore down 10% [Feb 15, 08]

Emcore up 14% [Feb 7, 08] on expected revenue increases.

Emcore up 10% [Feb 1, 08]

Emcore up 11% [Jan 31, 08]

Emcore down 10% [Jan 15, 08]

Emcore up 19%  on news that it would buy the telecom assets of Intel's optical platform division for $85 million, to expand its fiber optics product portfolio. [Reuters, Dec 18, 07]

Emcore up 22% [Dec 12, 07] agreed to supply solar-power systems with a combined 60 megawatts of annual generating capacity for a Pod Generating Group project in Ontario, Canada. [AP]

Emcore down 15% [Nov 12, 07]

Emcore up 10% on news that it has received a $24M solar cell order from Australia-based Green and Gold Energy. [Aug 29, 07]

Emcore up 11%.  [Aug 8, 07]

Emcore up 17% [Jul 19, 07] without benefit of news.

Emcore up 11% despite pending de-listing from NASDAQ. [Feb 23, 07]

Emcore fell 15% after declaring a profit. [Jan 9, 06] but a poorer than expected revenue to come.

Emcore down 10%, canceling its 8% rise the day before. [Nov 7, 06] Its involvement in options back dating didn't help.

In the fourth paragraph after the good news of higher revenue and gross profit margin was the bad news of yet more loss, $9M this time, for Emcore. [spring 05]

Emcore sank another 18% when Merrill Lynch poured ice water on capital growth estimates for the semiconductor industry.

When You're Cold, You're Cold. reported revenues up 76% to a record $53M. Profit? After paragraphs of various kinds of gross profit numbers, the press release comes to the net loss, Excluding non-recurring items and goodwill amortization, net loss for the quarter decreased 39% sequentially to $1.7M compared to a net loss of $2.8M. That's a lot of accountants dancing. The market, soggy overall anyway, responded by dumping more EMCORE to drive it 5% lower Friday to a new 52-week low.

Emcore Makes a Profit (May 1) Quarterly revenues doubled to $48M and net profit (after many accounting gyrations) was $3M. The market seemed to like the news as it bid Emcore up 20%.

Like laser light bouncing between mirrors, the shares of Emcore spent the year careening between 18 and 80. The small firm had a stock-market capitalization of $2.5B, and then $1.5B, as its shares fell back to a recent 49. That 's still a handsome price for a company with about $100M in annual sales and a decade-long deficit cumulating at $96M. A year ago, shares in the Somerset, New Jersey, outfit fetched eight bucks (adjusted for a recent stock split). Dazzling investors is Emcore's deal to supply a new kind of laser to optical networking giant JDS Uniphase. ... Clearly, this is a market that is expected to grow rapidly. It's also worth noting, however, that despite their importance to the still white-hot optical networking industry, these will be commodity products. And at this early stage, it's impossible to predict whether any VCSEL supplier will dominate. Indeed, even if Emcore garners half of the most optimistic forecasts for the VCSEL market, its shares, at 15 times revenues, are no bargain. What's more, Emcore has yet to prove that it can run a profitable business. Over the past decade, the company has delivered a nearly unbroken stream of losses. AXT, in contrast, has produced a nearly unbroken stream of profits.... In the mid-'Nineties, control of the company passed into the hands of the merchant banking division of Jesup & Lamont -- a broker and investment banker for such disappointing small-cap stocks as Hearx, Fonix and Hungarian Broadcasting. Richards was president of the merchant banking unit before he stepped in as Emcore's CEO in 1996. He says he and Emcore's two other controlling shareholders no longer have ties to Jesup & Lamont. [Bill Alpert, Barron's, Jan 1] How cozy that Jesup & Lamont published a "must have" recommendation on the stock summer 1999. Even if this pump turned out well for those who believed it when the stock was at $8, investors should treat a "must have" from a broker with caution.

Number 20 in Bloomberg's 100 list for 2000 is Emcore which had risen 534% in its year in the Bloomberg sun. Sales were 79% above 1999 which themselves were three times 1995. Even with VCSELs in the 10 Gb range, it still hasn't made a profit.Bloomberg says The company is adroitly managed, its products are at the cutting edge, and it operates in some lucrative niches of the massiver semiconductor industry.

Emcore reported big revenue gains, 79%, and a 15% rise in R&D spending. No word on when it will become profitable. Embrex reported big increases in profit (20%) and revenue (18%). SDL was up 15% although its stock price dances to the tune of JDS-Uniphase whose stock the SDL holders would get in the merger. AstroPower reported aquarterly revenue increase of 43% but a shrunken profit caused by legal expanses of defeding government charges of illegal overhead allocations. For the nine months, profit doubled.

GELcore buys Ecolux. GELcore (a joint venture of giant General Electric and growing EMCORE) will buy Ecolux, a leading global Cnadain LED Signal manufacturer. Ecolux is recognized as a world leader in the LED industry, offering the largest range of high-performance LED traffic control signal modules. It has built a reputation as an innovator with advanced technology solutions including Diolux LED modules. These LED signal products offer tremendous return on investment to end users through energy savings and reduced maintenance costs. [SPIE's OPTICS.ORG NewsAlert, Aug 4]. GELcore's main thrust until now has been to develop and sell white lights based on EMCORE's white LEDs.

The termites are nibbling at the pilings under Emcore. In a steady downslope for July, losing half its value, it is now only five times its lowest price for 12 months. Still, all that mutual fund money ($73B billion in net new cash, the strongest ever) has to be invested somewhere and Emcore has a good story of future profits (for an SBIR company).

Emcore has made a nice move up, doubling in June. The only notable news was the announcement of a 26% efficient solar cell to feed the alternative energy frenzy that isn't hurt by recurring bouts of politicized retail gasoline prices. It also said it would expand its Albuquerque plant.

Photonic Snapback (Apr 3) Emcore snapped back 44% Friday to close a wild week. It started the week worth $1.8B and ended it at $1.8B after passing through a trough at $1.2B. Said said Christopher Ely, manager of the Loomis Sayles Aggressive Growth Fund. This is a nice, solid correction..But with the economy rocketing along at 7.3%, an unheard of growth rate, the Old Economy will have the cash to buy Emcore's photonics niceties in the next decade. It is not a company.

Using EMCORE to compete with Cree. EMCORE says that UCSB Professors Shuji Nakamura and Steven DenBaars have ordered an EMCORE SpectraBlue gallium nitride (GaN) production platform for their pioneering development of GaN-based laser diodes and electronic materials and devices. Professor Nakamura, noted for his outstanding contributions to the semiconductor industry in blue lasers and blue spectrum High Brightness Light Emitting Diodes (HB-LEDs) based on GaN epitaxy, recently moved from Nichia Chemical in Japan to become a professor at UCSB. Nichia and Cree have been going head-to-head in the world market for blue lasers that last long enough to be ecoonomic.

Emcore raised $136M with a secondary offering at $136.

Optical Skywriting (Feb 18) Emcore rocketed 59% on no news but an apparent delayed realization that deals, if finalized, with JDS and Agilent (a sub of HP) for product sales willl have huge benefits. Emcore is now ten times its price of three months ago.

Why Is EMCORE Sinking? Who knows? Its stock price is down a third in a few weeks. Insiders have been noted selling (the chat boards in places like Yahoo don't let such news go untouted). But the chatters also have good opinions, OLED's Are a great idea- in theory; but, as the company(Universal Display) itself points out, they are no where near the point of SELLING a product "for the forseeable future" . This is in obvious contrast to Emcore which has paid its dues and over the past 14 or so years steadily converted its basic science strengths into marketable products, which it sells to leading customers throughout the world. Really, Universal has 6- count em'- six- employees. They make less than a few hundred thousand in revenue and have accumulated debt over 15 million. Emcore makes HBLEDs- NOW. They have joint ventures with huge corporations with powerful marketing capabilities and exposures(not to mention Compound Semi machines, sensors, vcsels, satellite panels,wireless apps etc.). No thanks, I will just stick with my Emcore holdings and let the GE lightwaves carry me home! Says one optimist, I believe that Emcore is somewhat similar to Microsoft in 1980's. Emcore products, all of them, help change this world. That is why Jessop and Lemont rates this stock a "must own" opto-electronics stock. I believe we see sometime soon stock price in triple digits. Triple digits??? Why not? SDL did it.

The Big and The Growing (Jan 22) GE Lighting and EMCORE (Somerset, NJ) formed a new joint venture for white LEDs with dreams of a $1B market within the next decade. The new company, GELcore LLC, will develop white LEDs as replacements for miniature automotive, compact fluorescent, halogen and traditional incandescent lighting. They call it the greatest revolution in lighting since the development of the Edison bulb. Bold talk! They also talk of a lifespan of over 100,000 hours and a lot less energy use.

Emcore Loses Money (Dec 14) Emcore (Somerset, NJ) says it expects to be profitable in 1999 after a disappointing $6.7M loss in the latest quarter (Blame the GM strike and the semiconductor industry overcapacity.) Meanwhile Uniroyal Technology Corp, a plastic products and specialty chemicals maker bought 6.4% of Emcore through a $9M purchase of convertible preferred stock.

Emcore Building (Apr 8) Emcore (Somerset, NJ). is seeking $55M in industrial revenue bonds to build a solar-cell plant in Albuquerque. .. The bond issue would be among the largest in city history. According to its proposal, the new plant would nearly double Emcore's existing operations. Emcore West designs, develops and builds advanced solar cells for the satellite industry. Emcore, which had sales of $47.75 million in fiscal 1997, established its presence in New Mexico late last year through the $30 million acquisition of Micro Optical Devices, a spinoff of Sandia Labs. [Albuquerque Journal, Apr 7]

(Oct 6) Emcore (Somerset, NJ) said its MOCVD was as good as MBE for pHEMTs. The AF SBIR made a 35 GHz half-watt power device. Maybe that's why EMCORE's stock is doing so well. If you don't know, don't worry. MBE has always been thought the best, albeit expensive route. But now that everybody has MOCVD anyway, it's a big advance to get the same quality. SBIR programs get zillions of proposals to use an existing MOCVD to do some material. It's gets government to amortize the investment.

(Jul 30) Emcore (Somerset, NJ) made $900K profit on $14M sales for the quarter but still shows a loss for the nine months. Emcore, which went public this year after several years of SBIR, makes semiconductor production systems.

(Mar17) EMCORE (Somerset, NJ) raised $22.5M in a Mar 6 IPO. The $9 share price was at the bottom of the expected range but the subsequent weeks' trading, ending at $12 gave the underwriters the profits they were seeking (on top of the 10% service charge). BMDO had given EMCORE two Phase 2 SBIRs and claim some paternity for the sales and employee growth from 60 employees in 1988 to 200 today with sales of $28M.

Emcore Files for IPO Emcore (Somerset, NJ) filed Dec 23 to go public. The filing claims: With 38% of the market, Emcore is the leading supplier of metal organic chemical vapor deposition (MOCVD) compound semiconductor production systems with prices from $350,000 to $2.5 million. Emcore also designs and makes semiconductor wafers and package-ready devices, with customers including some of the world's largest electronics makers who use the stuff for cellular telephones, pagers, direct broadcast satellite systems, CD-ROMs, and flat-panel displays.[Source: IPO Central] BMDO supplied two SBIR awards, one by Peter Norris, now CEO of his own firm NZ Applied Technologies (Woburn, MA), and the other with a little matching private investment. A year ago Emcore ranked about #140 in lifetime SBIR with $3.5M.

>Emendo Biotherapeutics (New York, NY)

Emendo Biotherapeutics (New York, NY; no SBIR, founded 2015), aiming to apply CRISPR gene editing to a wider range of genetic diseases, has raised $61 million ... on its website, it contends that CRISPR is limited in its ability to treat dominant genetic diseases, which are diseases caused by a mutation to one copy of a gene. [Frank Vinluan,, Jan 15, 20]

Emerald BioStructures (Bainbridge, WA)

Emerald BioStructures (Bainbridge, WA; $2M SBIR) and FORMA Therapeutics, (Cambridge, MA; no SBIR) drug discovery company, announced the signing of a strategic partnership for the structure-based design of cancer drug candidates for FORMA's pipeline.[Boston Globe, Jun 28, 10]

Emergent BioSolutions

Emergent BioSolutions announced it has entered into an agreement to acquire PaxVax (Redwood City, CA; $7M SBIR, founded 2009), focused on specialty vaccines that protect against existing and emerging infectious diseases, for a $270 million [cash]. [Emergent press release, Aug 13, 18] total fundung $200+M []

Protein Sciences facing possible bankruptcy and liquidation has been awarded a $35 million federal [HHS] contract to develop a faster way to make vaccines for pandemic influenza. ...  But only a day earlier, creditors filed a petition in federal bankruptcy court seeking to force Protein Sciences into bankruptcy and liquidation, saying they were owed $11.7 million. Almost all of that money is owed to Emergent BioSolutions, a vaccine company in Rockville, Md., that lent Protein Sciences $10 million last year in advance of the pending acquisition of virtually all the assets of Protein Sciences by Emergent. The acquisition deal fell apart, and Emergent sued Protein Sciences and its top executives, accusing them of fraud and breach of agreements. [Andrew Pollack, New York Times, Jun 23]

Emergent BioSolutions, in a push to diversify beyond its biodefense business, plans to announce today that it is buying Protein Sciences (Meriden, CT; $900K SBIR), a maker of a next-generation flu vaccine that federal regulators have put on a fast track to approval. for $75M [Kendra Marr, Washington Post, May 27]

Emergent Technologies (Austin, TX)

Austin-based Emergent Technologies will announce today that it has raised a $27.1 million venture capital fund to create biotechnology startups in Texas.  A number of high-profile Austin business executives invested in the fund, which will be used to commercialize technology developed in the University of Texas System. [Austin American-Statesman, May 7]

Emmaus Life Sciences (Torrance,CA)

Emmaus Life Sciences (Torrance,CA; no SBIR) raised $12 million in debt securities, according to securities filing. The developer of a breakthrough medicine for sickle cell disease raised $12 million from sales of convertible debt securities. Emmaus’ Endari drug, developed at LA BioMed on the campus of Harbor-UCLA Medical Center, is the first new treatment for sickle cell disease released in 20 years for adults and the first-ever treatment for children. It went on sale in January. [Dana Bartholomew, Los Angeles Business Journal, Nov 6, 18]

EM Photonics (Newark, DE)

EM Photonics (Newark, DE; $29M SBIR) agreed to pay $2.75 million to resolve claims that it defrauded the Navy, Air Force, NASA, and other federal agencies, according to a statement from the U.S. Department of Justice. received about $18 million in contracts for the U.S. Army, Navy and Air Force, among other federal agencies.  .... develops complex algorithms for modeling various physical conditions in fluid dynamics, structural mechanics, and electromagnetic fields  [Josephine Peterson and Karl Baker, Delaware News Journal, Jan 30, 19]

Empire Genomics (Buffalo, NY)

Empire Genomics (Buffalo, NY; no SBIR) closed on $1.75M VC [Buffalo Business First, May 20, 16] announced that it has received approval from New York State to offer molecular and cellular tumor marker testing through the state's Clinical Laboratory Evaluation Program (CLEP).  [company press release, May 10, 16]

Empire Genomics (Buffalo, NY; one SBIR) pulled in $300,000 in convertible debt financing from a previous investor [Dan Miner, Buffalo Business First, Mar 15, 16]    a strong track record in the development of high throughput technologies to enable genome-wide analyses aimed at determining the underlying mechanisms for diseases. Having played a fundamental role in the Human Genome Project and created the foundational Bacterial Artificial Chromosomes which served as the basis for sequencing the genome  [company website]

Empire Genomics  (Buffalo, NY; no SBIR, founded 2006, 27 employees), the growing [VC backed] biomedical firm, has signed a "strategic collaboration" with one of the world's top cancer hospitals.  ....  diagnostic tests will support Memorial Sloan Kettering Cancer Center, in Manhattan, specifically a [DOD] program aimed at earlier detection and more effective treatment of prostate cancer. ... will be the exclusive manufacturer of molecular diagnostic tests to support the award ...  raised $1 million in venture capital last year  [Dan Miner,Buffalo Business First, Dec 4, 15]

Empire Genomics (Buffalo, NY; no SBIR) is raising a $15 million round of venture capital ... now offers a variety of diagnostic tests that detect cancer – leading to earlier and more effective diagnoses, Johnson said. Its customers include a global network of major hospital systems.   [Dan Miner, Buffalo Business First, Jul 1, 15]

A top executive at Kinex Pharmaceuticals (Buffalo, NY; $1,.1M SBIR, 30 employees) said company officials have been eager to add a manufacturing segment in recent years.  And Kinex followed through with the announcement it has acquired QuaDPharma LLC (Clarence, NY; no SBIR, 13 employees, founded 2011), a pharmaceutical manufacturer.  ...  Earlier this year, Kinex expanded its Asian research efforts when it entered into a new licensing agreement with Taiwan-based PharmaEssentia Corp. The agreement grants PharmaEssentia exclusive development and commercial rights in Taiwan and Singapore to Kinex drugs Oraxol and Oratecan.    [David Bertola, Buffalo Business First Reporter, Sep 9, 14]   To meet growing manufacturing demand for clinical testing products with an FDA seal of approval, Empire Genomics LLC (Buffalo, NY; no SBIR) has partnered with commercial contract manufacturer QuaDPharma.    The companies recently completed a first batch of products for Empire Genomics customers that meet an FDA standard called “Current Good Manufacturing Practice.” [David Bertola, Buffalo Business First Reporter, Aug 29, 14]

Empire Robotics (Boston, MA)

A Cornell-spawned startup is releasing its first product this month. Empire Robotics (Boston, MA; some SBIR) says its "jammable gripper," priced at about $4000, is one of the first of its kind to be sold commercially. .... has so far raised slightly less than $1 million in seed funding and [NSF] SBIR grants  [Scott Kirsner,,  Jan 7, 14]

EMRes Technologies (Austin, TX)

Stealth-mode company EMRes Technologies (Austin, TX; no SBIR) reported receiving $2.9 million Series A round of funding.  ....  founded earlier this year and collected the capital from four investors ....  It’s unclear what type of technology EMRes Technologies is marketing. CEO Brett Butler said he planned to operate it in stealth mode until October or November.  "We're developing products we think are important to the audio space," he said.   [Christopher Calnan, Austin Business Journal, Aug 22, 14]

Emtora Biosciences (formerly Rapamycin Holdings (San Antonio, TX)

Emtora Biosciences (formerly Rapamycin Holdings, San Antonio, TX; no SBIR) received FDA orphan drug designation for its novel therapeutic [San Antonio Business Journal, May 8, 19]

Emtora Biosciences (formerly known as Rapamycin Holdings, San Antonio, TX; no SBIR, founded 2012) announced that [FDA] has granted orphan drug designation to eRapaTM for the treatment of patients with Familial Adenomatous Polyposis (FAP). ... plans to begin a Phase 2a trial in patients with FAP in late 2019. This trial will follow a Phase 1b safety and dose escalation study in early stage prostate cancer patients that will conclude this summer and will inform trial design for the FAP study. [company press release, Apr 30, 19] total funding $4M []

Emulate (Cambridge, MA)

The organ-on-a-chip developer Emulate (Boston, MA; one SBIR), a leading provider of next generation in vitro models, announced the close of an $82 million Series E financing round [company press release, Sep 7, 21]

Emulate (Boston, MA; no SBIR, founded 2013) announced that it has secured a $36 million Series C financing to expand the functionality of Emulate’s automated, lab-ready Human Emulation System — which is comprised of Organ-Chips, instrumentation, and software applications [company pres release, Jun 18, 18] total funding $95M []

Emulate (Cambridge, MA; no SBIR) is officially ramping up with a $12 million Series A round that it’ll partly use to move out of Harvard University’s Wyss Institute for Biologically Inspired Engineering—where it’s been incubating (where scientists and an assembled in-house executive team have raised more than $40 million in grant money from the FDA and DARPA)...It’ll try to prove that pharmaceutical companies and biotechs can reliably use its thumbnail-sized microchips in preclinical drug tests, rather than relying on in vitro or animal studies.   ...  CEO Coon and scientist Hamilton were executives of CellzDirect (Research Triangle Park, NC; no SBIR), which Invitrogen bought for $57 million in 2008. [Ben Fidler,, Jul 28, 14]

Enable Injections (Warren, OH)

startup Enable Injections (Evendale, OH; no SBIR, founded 2010) has developed a device (with multiple sizes to accommodate different doses) that’s disposable, hurts less than a typical syringe and is wearable on different locations on the user’s body. The company now boasts about 75 employees and more than $30 million in funding. While Enable Injections is beginning to test the device in two clinical studies in the coming year (the product is expected to hit the market in 2020), the enterprise already has agreements with a handful of pharmaceutical companies, such as the Bradley, Ill.-based CSL Barring.  [Courtney Gabrielson, CincyInno, Dec 28, 17

Enable Injections (Cincinnati, OH; SBIR, founded 2010) has developed a device (with multiple sizes to accommodate different doses) that's disposable, hurts less than a typical syringe and is wearable on different locations on the user's body. ... has raised $30M [CincyInno, Dec 5, 17]

Enable Injections (Cincinnati, OH; no SBIR, founded 2010) the developer of advanced wearable large volume injectors for subcutaneous delivery of biologics and high volume drugs, announced the closing of $30M Series A financing.... to commercialize the company’s patient-focused drug delivery product, the Enable Injector. [Business Wire, Oct 5, 16]

Enable Injections (Warren, OH; no SBIR, founded 2010) which will be seeking [FDA] approval to market a disposable mobile device that would let a patient painlessly self-inject – with the push of a button – a large dose of a prescription drug to combat anything from cancer to hemophilia. .... By comparison, a major Switzerland-based company is trying to get U.S. approval for a high-volume, subcutaneous injector that is the size of a deck of cards but can handle only 5 cc of medication, [CEO] Hooven said.   .... Hooven’s previous two startups were Enable Medical Corp. and AtriCure (West Chester, OH; no SBIR), medical device maker that specializes in treating atrial fibrillation. Enable was acquired by AtriCure in 2005 for $7 million. On Jan. 2, AtriCure announced that it had completed the $34 million acquisition of the California company Estech, which develops and markets devices that enable heart surgeons to perform a variety of traditional and minimally invasive medical procedures.  [Barrett J. Brunsman, Cincinnati Business Courier, Jan 7, 14]

Enanta Pharmaceuticals

Massachusetts Gov. Charlie Baker announced $20 million in tax incentives for 28 life sciences companies in the Bay State through a series of awards that are expected to create 1,325 new jobs this year. Some of the recipients are Alnylam Pharmaceuticalswhich just opened a new facility in Norton, MAEnanta Pharmaceuticals (no SBIR), and Moderna Therapeutics (no SBIR).  [Ben Fidler,, Apr 28, 16] That's a subsidy of $15K per speculative job, and don't expect any post analysis of actual return since government is good ony at input numbers in the present.

EnChroma (Berkeley,CA )

EnChroma  (Berkeley, CA; no SBIR) developed sunglasses to help people with color vision deficiencies based on about 10 years of R&D by EnChroma founders Andy Schmeder and Don McPherson ... so far, EnChroma’s rollout of its products to optometry centers has been slow and deliberate as the company figures out how to manage the supply and demand. The glasses, between $260 and $350, are in 30 optometry offices around the world.   [Annie Sciacca, San Jose Mercury News, May 14, 16]

Encite (Burlington, MA)

Encite LLC (Burlington, MA; no SBIR)  has raised $650,000 out of a planned $1 million equity round, according to a regulatory filing. The company has no website, and a man who answered the phone Tuesday declined to discuss what the company is working on. [Mass High Tech, Mar 15, 11]

Encoded Genomics (San Francisco, CA)

Illumina revealed the first three companies admitted to its six-month accelerator program in San Francisco for genomics-related startups. The three companiesEncoded Genomics  (San Francisco, CA; no SBIR), Xcell Biosciences (San Francisco, CA; no SBIR), and EpiBiome  (Union City, CA; no SBIR) —get full access to Illumina’s next-generation gene sequencing systems.  [Alex Lash,, Oct 17, 14]

Encoded Therapeutics (South San Francisco, CA)

Startup Encoded Therapeutics (South San Francisco, CA; no SBIR) raised $104 million to join the race to expand gene therapy’s reach. .... has emerged from the startup accelerator of Illumina. ... brings its total funding to $158 million and will back human tests of a gene therapy for a rare form of epilepsy called Dravet syndrome. [Ben Fidler,, Jun 26, 19]

Encompass Bioscience)

Genomics startups are increasing in number and quality, so much so that three-year-old Illumina Accelerator has expanded with its latest class to accommodate five of them.  ... provides genomics-focused startups with capital, lab space at Illumina Accelerator’s offices in San Francisco, access to Illumina’s sequencing equipment and expertise, and advice on developing a business from legal experts, recruiting professionals, and Illumina executives and scientists, says Amanda Cashin, co-founder and head of the accelerator.  ..... takes an 8 percent equity stake ..   Checkerspot: designing advanced physical materials that can be used in industrial applications; Chimera Bioengineering:  aims to improve the efficacy and reduce the side effects of engineered cell therapies for oncology;  Encompass Bioscience:  wants to integrate genetic information into the healthcare system; Mantra Bio: studies exosomes, small lipid vesicles that are excreted from cells and deliver information, aiming to discover new drug targets and therapies;  Solarea Bio: The only company not from the Bay Area, Boston-based Solarea is developing probiotic treatments that are derived from natural sources   ....   Of the previous 13 startups that have completed the program since 2014, a few have already made some funding splashes.  Xcell Biosciences (San Francisco, CA; no SBIR) develops a type of cell culture that can be used in certain types of cell propagation and gene editing, raised a $12 million Series A round of funding in February.  EpiBiome (South San Francisco, Ca) raised a $6 million seed Series A round of funding for its process of engineering microbiomes that might be used against drug-resistant bacteria in early 2016.  Trace Genomics (New York) raised a $4 million seed round in mid-2016 for its work sequencing and analyzing the genomes of soil.     [David Holley,, Jul 26, 17]  

Encore Vision (Fort Worth, TX)

A $1.7 million round of funding will help Encore Vision (Fort Worth, TX; no SBIR, founded 2000) develop products to the fight eye condition presbyopia. ... The  company is working on a solution that aims to restore eye lenses by reducing stiffness, allowing for thickness and flexibility. The liquid can be stored in an eye drop bottle and used directly on the eye.  ... an affiliate of Encore Health LLC. Founders Drs. Jon Till and Ronald Blum received a patent for their prebyopia treatment in 2005 and are currently working to commercialize the product, according to the company’s website.  [Korri Kezar, Dallas Business Journal, Sep 18, 14]

Encysive Pharmaceuticals(Houston, TX)

Encysive Pharmaceuticals doubled on news that Pfizer was buying it for $195M. [Feb 20, 08]

Encysive Pharmaceuticals announced it, along with partner companies, have filed a patent infringement lawsuit against Barr Laboratories of Woodcliff Lake, N.J., relating to Argatroban injections.  According to the suit, Barr is seeking approval to market a generic version of Argatroban. Houston-based Encysive said the patent covering the drug does not expire until June 2014. [Houston Chronicle, Dec 29]

Encysive Pharmaceuticals (Bellaire, TX; 2 Phase 1 SBIRs) the developer of a drug for a fatal lung disease, failed to overturn a decision by U.S. regulators that delayed its therapy from reaching the market.  [Houston Chronicle, Sep 6]

Encysive Pharmaceuticals formerly Texas Biotechnology, Houston, TX; three small SBIRs), the maker of a treatment for a fatal lung disease, said its chief financial officer had resigned, the second executive departure since the company's drug was delayed by regulators. ... The company also laid off 150 employees and retained 65. [Houston Chronicle, Jul 10] The stock price is down 80% from its range two years ago.

Endeavor Robotics

QinetiQ North America has won a $152M initial contract to manufacture small unmanned ground robots for the U.S. Army’s Common Robotic System – Individual program, Defense News reported Thursday. QinteiQ NA and Endeavor Robotics separately developed robotic systems under the CRS-I program’s engineering and manufacturing development phase through a $429.1M contract awarded in April 2018. [Brenda Marie Rivers, GovConWire, Mar 14, 19] some of the robotics came from former SBIR champ, now Qinetic subsidiary, Foster-Miller.

FLIR Systems agreed to purchase Endeavor Robotics (spinout from iRobot, Chelmsford, MA, founded 2016) from Arlington Capital Partners for about $385M in cash to make its entry into the market for unmanned ground vehicles for military, critical infrastructure and public safety applications. ... The transaction came weeks after FLIR acquired Canada-based unmanned aerial systems manufacturer Aeryon Labs for approximately $200M. [Jane Edwards, GovConWire, Feb 11, 19]

Endeavor Robotics (Chelmsford, MA; no SBIR) which split from iRobot, the startup that designed the ‘Scorpion Robot,’ for the U.S. Army’s Common Robotic System-Individual (CRS-I) program, has filed a lawsuit against QinetiQ North America and Foster-Miller Inc. over patent infringements. [Srividya (Sri) Kalyanaraman, BostInno, Jan 2, 19]

Endeavor Robotics (Boston, MA; no SBIR), the world’s leading provider of unmanned ground vehicles (UGVs), revealed design details and images of its closely guarded Scorpion™ robot, developed for the U.S. Army’s Common Robotic System-Individual (CRS-I) program. Endeavor is one of two finalists now in a run-off to provide the Army with a new multi-mission, ‘back-packable’ UGV weighing less than 25 lbs. Potentially worth more than $400 million, the contract to build up to 3,000 robots is scheduled to be awarded early next year. [company press release, Dec 3, 18]

The US Marine Corps just awarded $10 million for a ruggedized "throwable" robot useful in situational assessment in tactical situations. The platform is made by Endeavor Robotics, which was previously known as iRobot's Defense & Security Business Unit. [Greg Nichols., Jun 15, 18]

The U.S. Army has awarded Endeavor Robotics and QinetiQ North America spots on a potential nine-year, $429.1 million contract to engineer, manufacture and develop robotic systems.   [GovConWire, Apr 3, 18] The Waltham division of QNA was once called Foster-Miller, a top SBIR user.

Endeavor Robotics  (spinoff from iRobot, Chelmsford, MA; no SBIR), the global leader in tactical ground robotics, wins $159M Army contract  [Boston Business Journal, Oct 3, 17]  has been awarded a contract for 75 FirstLook robots from the United States Government for immediate operational use. This marks the company’s third major contract win in the past six weeks.    [company press release, September 19, 17]   recent order for the US Government valued in excess of $15 million for upgrades and accessories to support fielded robot systems.  [company press release, Aug 30, 17]

At iRobot , the wars are overThe company first made a name for itself by building remote-controlled military machines that picked through the rubble of the World Trade Center after 9/11 and disarmed Taliban booby traps in Afghanistan.  But in 2002, iRobot began selling a robotic home vacuum cleaner called Roomba, and today those home robots generate nearly all the company’s revenues. Shareholders noticed, and so did management.   And so in February, peace broke out at iRobot. In a deal worth up to $45 million, the company sold its defense and security division to the private equity firm Arlington Capital Partners as a new company, Endeavor Robotics.  [Hiawatha Bray, Boston Globe, Aug 18, 16]

Endece (Mequon, WI)

Endece Neural (Mequan,WI; no SBIR, founded 2006) said it has received a $225,000 grant from the National Multiple Sclerosis Society to continue development of its lead compound, which it says could improve the lives of patients with multiple sclerosis. [Kathleen Gallagher,Milwaukee Journal Sentinel, Sep 27, 13]  [in 2010] ENDECE announced that it has been awarded a $244,479 grant for its cancer research as part of the U.S. government’s Therapeutic Discovery Project. [company website]

Endece (Mequon, WI; no SBIR) said it has raised $1.2 million from private investors that it will use to further develop a compound it says could potentially turn off any kind of cancer cell. ...  Endece's funding, all from previous investors based in Wisconsin, brings to $15 million the company has raised, said James Yarger, its president and chief executive officer. Endece is developing a lipid-based nanoparticle formulation for animal tests in collaboration with Particle Sciences Inc. of Bethlehem, Pa., Yarger said.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 19, 11]

Endece (Mequon, WI; no SBIR) is prepared to begin clinical trials next year on a compound he says could potentially turn off any kind of cancer cell.  ... James Yarger with his wife, Jean, started Endece four years ago. The company has a staff of five. ... With help from $12 million of investor funding and a $250,000 loan from the state's Technology Venture Fund  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 1,10]

start-ups in the drug field within the Milwaukee 7 economic development region suggests another strategic direction for the regional economy. Those new ventures come as Concordia University of Wisconsin mounts an impressive campaign to build a new pharmacy school in southeastern Wisconsin, possibly in downtown Milwaukee. ... New ventures  in the emerging drug-making concentration:  MPP Group  (no SBIR),a venture headed by serial entrepreneur Frank Langley that is building drugs aimed at alcoholism. James Cook, a University of Wisconsin-Milwaukee researcher, developed the compounds.  Neuro Amp (no SBIR),a spin-off from PhysioGenix (Wauwatosa, WI; $3M SBIR) that is aiming at diseases of the central nervous system and Alzheimer's.  Promentis (no SBIR)a collaboration between Marquette University's David Baker and UWM researchers and former Schwarz Pharma managers who are targeting schizophrenia and central nervous system disorders.  Cytometix (no SBIR)a 2004 start-up headed by Lane Brostrom that is developing drugs for the treatment of pain and asthma. Endece  (no SBIR), a 2006 Mequon start-up headed by James Yarger that is developing compounds for treating cancer, sepsis, learning and memory. [John Torinus, Milwaukee Journal Sentinel, Jan 31, 09]

Endgame Technologies

It's September, do you know where your football is? A startup venture, EndGame Technologies, has designed novel computer modeling software to assist NFL coaches with critical play-calling decisions ... Already, their statistics on past NFL games have revealed that teams consistently lose approximately one game per season by making the wrong play calls in critical situations. ... But, it's too good: still illegal under NFL guidelines.

EndoChoice (Atlanta GA)

EndoChoice (NYSE: GI) raised $94.9 million in its [Jun 10 IPO] ...  to fund the commercialization and continued development of its “Fuse” endoscopy technology. EndoChoice says Fuse allows doctors to see more than twice the anatomy at any one time compared to standard colonoscopes and has been demonstrated to detect more pre-cancerous polyps than standard colonoscopes. EndoChoice began limited commercialization of Fuse in December 2013. [Atlanta Business Chronicle, Jun 11, 15]

EndoChoice (Atlanta, GA; no SBIR, founded 2007) medical technology company, filed [IPO] to raise up to $115 million  ... to fund the commercialization and continued development of its "Fuse" endoscopy technology. EndoChoice says Fuse allows doctors to see more than twice the anatomy at any one time compared to standard colonoscopes and has been demonstrated to detect more pre-cancerous polyps than standard colonoscopes ... began limited commercialization of Fuse in December 2013   [David Allison, Atlanta Business Chronicle, May 6, 15]  

EndoChoice (Atlanta, GA;' no SBIR) raised $57 million in preferred equity financing from three new institutional investors. ... toward continued expansion of sales and marketing efforts of the Fuse Full Spectrum Endoscopy platform, the company said.   The Fuse colonoscope uses three cameras to provide GI specialists with a 330 degree field of view as compared to the 140 to 170 degree field of view provided by standard colonoscopes, while the Fuse gastroscope uses two cameras to provide a 245 degree field of view as compared to the 150 degree field of view provided by standard gastroscopes.  [Phil W. Hudson, Atlanta Business Chronicle, Mar 5, 15]

Endoscopy system maker EndoChoice (Atlanta GA; no SBIR, founded 2008) plans to go public next year. ...  an IPO on Nasdaq to raise $100 million to $150 million, according to ...  makes and commercializes platform technologies including devices, diagnostics, infection control and endoscopic imaging for a wide range of gastrointestinal diseases.     [Ellie Hensley,  Atlanta Business Chronicle, Oct 31, 14]   last year acquired  RMS  Endoskopie-­‐Technik   [German]  endoscope  manufacturer    [company website]

Endocyte (West Lafayette, IN)

Endocyte up 50% [Oct 18, 18]

Novartis (Swiss) said it would buy cancer-drug maker Endocyte (Purdue startup, West Lafayette, IN; $3.6M SBIR, 44 employees, market cap $1.2B) for $2.1 billion, to refocus on higher-value medicines. [Denise Roland and Donato Paolo Mancini, Wall Street Journal, Oct 18, 18]

Endocyte up 11% [Sep 10, 18]

Endocyte up 15% [Jul 5, 18]

Endocyte down 10% [Mar 27, 18]

Endocyte up 23% [Mar 13, 18] 

Endocyte up 15% [Mar 8, 18]

Endocyte up 11% [Mar 6, 18]

Endocyte up 10% [Mar 2, 18]

Endocyte (West Lafayette, IN; $3.5M SBIR by 2003, market cap $200M) up 41% [Feb 28, 18] a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced the pricing of a public offering [to] raise $70M [company press release, Feb 28, 18]

Endocyte up 12% [Feb 20, 18]

Endocyte down 14% [Jan 24,18]

Endocyte down 14%[Nov 13, 17]

Endocyte up 13%[Oct 18, 17]

Endocyte down 11% [Oct13, 17]

Endocyte down 10% [Oct9, 17]

Endocyte a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,  today announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. Endocyte intends to move quickly into Phase 3 development of 177Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer (mCRPC). [company press release, Oct 2, 17]

Endocyte up 62% [Oct 3, 17]

Endocyte (West Lafayette, IN; $3.5M SBIR) says it paid $12 million up front to German biochemicals company ABX in exchange for exclusive global rights to develop and commercialize the drug PSMA-617. ABX stands to gain milestone payments up to $160 million, plus royalties from sales if Endocyte can bring the drug to the market. The deal also gives ABX 2 million shares of Endocyte stock, as well as a warrant allowing ABX to purchase up to 4 million more Endocyte shares.  [Frank Vinluan,, Oct 2, 17]

Endocyte (West Lafayette, IN; $3.5M SBIR) is halting a clinical trial for one of its cancer drugs and narrowing the focus of another following a review of the two early-stage drug programs, the company announced.  The changes are sparking a corporate restructuring that will shift the company’s focus to compounds in its drug pipeline that have yet to enter clinical trials. Endocyte said in a securities filing that the shakeup will cut 47 jobs companywide, which represents approximately 40 percent of the workforce.  [Frank Vinluan,, Jun 2, 17]

Endocyte up 12% [Mar 7,16]

Endocyte up 17% [Jan 21, 16]

Endocyte (West Lafayette, IN; $3.6M SBIR) up 12%  [Nov 4, 15]

Endocyte  up 10% [Mar 4, 15]

Endocyte up 18% [Nov 6, 14]

Endocyte down 13% [Sep 30, 14]

EndoCyte up 13% [Sep 10, 14]

Endocyte up 17% [Sep 9, 14]

Endocyte up 16% [Jul 30, 14] 

Endocyte up 10% [Jun 17, 14]

Endocyte down 62% [May 2, 14] Merck and Endocyte said they stopped a late-stage study of an ovarian-cancer treatment because results fell short of its goals. [Wall Street Journal, May 2, 14]

Endocyte up 10% [Apr 22, 14]

Endocyte up 29% [Jan 10, 14]

Endocyte up 12% [Nov 8, 13]

Endocyte up 29% [Nov 6, 13]  after reporting its third-quarter earnings results and providing a pipeline update.  [Motley Fool, Nov 6] Merck is working with Endocyte on a drug conjugate for a type of ovarian cancer that uses a small molecule, rather than the kind of large antibody used in Kadcyla and Adcetris, says Ron Ellis, Endocyte's chief executive. Endocyte's drug conjugate for a type of ovarian cancer is in phase 3 testing, the most advanced stage of clinical testing  [WSJ Apr 5, 13]

Endocyte down 10% [Nov 1, 13]

Endocyte up 12% [Oct 15, 13]

Endocyte dowm 24% [Oct 11, 13]

Endocyte  up 11% [Jul 5, 13]

Endocyte ($1.6M SBIR) up 11% {Mar 27, 13]

Endocyte (West Lafayette, IN; $3.5M SBIR) down 14% [Nov 2, 12]

Endocyte (West Lafayette, IN; $3.5M SBIR) up 12%  [Aug 3, 12]

Merck entered into an agreement with Endocyte (West Lafayette, IN; $3.6M SBIR)  to develop and commercialize Endocyte’s experimental cancer therapy in a deal potentially worth $1 billion.  [John George, Philadelphia Business Journal Apr 16, 12]

If all goes well, this is the year Endocyte (West Lafayette, IN; $3.5M SBIR) will apply in Europe to launch its first drug, a novel treatment for ovarian cancer.  It would be a huge step for the small, 65-employee biotech firm. It has put up an unusually tenacious, 16-year struggle to turn an idea from its scientist-founder, which debunked textbook teaching, into a drug that promises hope for cancer victims and profits for itself and shareholders. The long road Endocyte has taken has been costly -- over $150 million -- and lined with obstacles.  [Jeff Swiatek, Indianapolis Star, Jan 7, 12]

Endocyte (West Lafayette, IN; $3.5M SBIR) developing targeted small molecule drug conjugates, announced Friday it will price its initial public offering of 12.5 million shares at $6 per share. [Indianapolis Star, Feb 5, 11]

Endocyte (West Lafayette, IN; $3.7M SBIR) filed for IPO. ... develops therapies to treat cancer and inflammatory diseases.  [Indianapolis Star, Aug 19, 10]

Endocyte (W Lafayette, IN; $3.5M SBIR) is about to see if it has the right stuff to get a drug to market. ....   In a brutal fundraising environment, the company needs to continue raising tens of millions of dollars to get its wide portfolio of cancer-killing drugs through expensive, late-stage clinical trials.  And in the coming weeks, Endocyte needs to enroll about 120 female cancer patients at more than 50 sites in North America and Eastern Europe to test one of its drugs in a Phase II trial for ovarian cancer. Traditionally, fewer than 10 percent of cancer patients consent to try an experimental drug. ...  "We have good research, good technology, but the fundraising climate is awful," said Ron Ellis, Endocyte's president. ....  It has raised more than $80 million in venture capital, grants and licensing agreements. It has kept its original investors through four rounds of fundraising, a sign they are pleased with the progress the company is making.  [John Russell, Indianapolis Star, Mar 9, 09]  If SBIR were a venture capital fund, it would steer its money into the agencies that produce these kind of results and away from agencies grinding out sweet technology with no investment future. Instead, SBIR is a social "fair-share" program administered by agencies that may or may not care about investment success. If Congress wants SBIR to be an investment engine for new small companies, it has to drastically re-make its structure and incentives.  For example, it might consider shrinking the SBIR tax on agencies and sending the money to some investment entity with management rewards for investment success.

Endocyte (West Lafayette, IN; $3+M SBIR) secured $15M in venture credit through Oxford Finance Corp. and GE Healthcare Financial Services acting as agent. ... to pursue targeted therapies and diagnostic imaging agents to fight ovarian, nonsmall cell lung and kidney cancers. ... also has announced an exclusive licensing agreement with R&D Biopharmaceuticals to use its tubulysin anticancer agents in conjunction with Endocyte's proprietary drug- conjugate platform.  [Indianapolis Star, Feb 5, 08]

EndoGastric Solutions (Redwood City, CA)

EndoGastric Solutions (San Mateo, CA; no SBIR, founded 2003) announced the closing of its Series I financing at a total of $45 million. [company press release, May 28, 19]

Endogastric Solutions (San Mateo, CA; no SBIR) raised $30 million to help further its 12-year development of minimally invasive treatments for gastro-intestinal diseases  ....   to support publishing data from three randomized trials, bring new products to market and establish clear reimbursement for its technology.   [Cromwell Schubarth, Silicon Valley Business Journal, May 9, 14] 

EndoGastric Solutions (Redwood City, CA; no SBIR) said it raised $30 million in a new funding round. ... focuses on procedures to treat upper gastrointestinal diseases.  [Silicon Valley / San Jose Business Journal, Aug 30, 10]

EndoGastric Solutions  (Redwood City, CA; no SBIR), which is developing procedures for the treatment of upper gastrointestinal diseases, has completed a $30 million round of financing [San Francisco Business Times, Aug 30, 10]

Endo International

Endo International up 19% [Sep 23, 16]

Endoscopic Technologies (Ramon, CA)

Cardiac catheter maker Endoscopic Technologies (Ramon, CA; no SBIR), or Estech, raised $8.5 million in equity financing. ....  makes a minimally invasive catheter used in heart surgery. It has been cleared by regulators for treating atrial fibrillation in Europe and for cardiac ablation in the United States. [SEF Brown, San Francisco Business Times, Dec 7, 10]


A place of talent, money, and opportunity.  "If I'm in Minnesota, I probably could find a gynecologist," OuYang says, "but the gynecologist might not be a tech-savvy one or he might not be as savvy about the [Silicon] valley's can-do spirit."  ...  Endosee  (no SBIR), a company that is taking a technological approach to a mission that the 64-year-old [gynecologist] Indman has been on since he was a young physician. ....   a handheld device with a disposable scope that could be used for hysteroscopy. It would look a little like an iPhone with an attached tube that contains two bright but minuscule LED lights and a chip that acts as a video camera lens -->OmniVision [OuYang's previous company], the chip company, was also nearby.   [Mike Cassidy, San Jose Mercury News, Jun 6, 13]

EndoStim (St. Louis, MO)

EndoStim (St. Louis, MO;  SBIR) medical device maker that earlier this year canceled plans to go public, has closed on a $25 million Series D financing round led by Switzerland investor  [Brian Feldt, St. Louis Business Journal, May 12, 16]

EndoStim (St. Louis, MO; no SBIR) medical device maker that earlier this year canceled plans to go public, has raised more than $11 million from a group of undisclosed investors, according to [SEC] documents   [Brian Feldt, St Louis Business Journal, Apr 1, 16]

EndoStim (St. Louis, MO; no SBIR) medical device maker that earlier this year canceled plans to go public, has raised more than $11 million from a group of undisclosed investors, according to [SEC] documents  [Brian Feldt, St. Louis Business Journal, Mar 24, 16]

EndoStim (St. Louis, MO; no SBIR) medical device maker that had planned an initial public offering, has officially canceled its IPO  [Brian Feldt, St. Louis Business Journal, Jan 22, 16]

St. Louis-based Prolog Ventures participated in a $7.4 million financing deal for New Mexico-based IntelliCyt (Albuquerque, NM; no SBIR), a provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology.  ... According to CrunchBase, the IntelliCyt deal was Prolog’s fifth of 2015 — the company also participated in Veran Medical Technologies’ (no SBIR) $41.7 million round in September; Benson Hill Biosystems (no SBIR) $7.3 million deal in August; and EndoStim (no SBIR) $2.5 million funding in May.   [Brian Feldt, St. Louis Business Journal, Oct 23, 15]

EndoStim (St Louis, MO; no SBIR) raised half of a planned $5 million offering, according to [SEC] documents  ...   is commercializing a medical device called the Lower Esophageal Sphincter (LES) Stimulation System, which treats gastroesophageal reflux disease (GERD), commonly known as acid reflux, through electrical stimulation. ...  Including this most recent funding, EndoStim has raised nearly $45 million  [Brian Feldt, St. Louis Business Journal, May 11, 15]

EndoStim (St. Louis, MO; no SBIR) expects to raise $35.8 million [IPO] ... is commercializing a medical device called the Lower Esophageal Sphincter (LES) Stimulation System, which treats gastroesophageal reflux disease (GERD), commonly known as acid reflux, through electrical stimulation. ... has raised more than $42 million   [Brian Feldt, St. Louis Business Journal, Oct 3, 14]

medical device maker EndoStim (St. Louis, MO; no SBIR) filed a proposed [$40M IPO] ...  commercializing a medical device called the Lower Esophageal Sphincter (LES) Stimulation System, which treats gastroesophageal reflux disease (GERD), commonly known as acid reflux, through electrical stimulation. ... has its European offices in The Hague, Netherlands.  ...   raised$6.4 million in July.  [Brian Feldt, St. Louis Business Journal, Sep 8, 14]

medical device companyEndoStim (St Louis, MO; no SBIR, 12 employees) has raised $14.1 million in a fundraising round ... commercializing a medical device called the Lower Esophageal Sphincter (LES) Stimulation System which treats gastro-esophageal reflux disease (GERD), commonly known as acid reflux, through electrical stimulation. EndoStim’s device is already on the market in Germany and several other countries  [Amir Kurtovic, St Louis Business Journal, Jun 6, 13]

Medical device startup EndoStim (St Louis, MO; no SBIR) has raised $11.2 million of a planned $16.5 million fundraising round, according to [SEC] filing  .... makes medical devices to treat gastrointestinal disorders such as severe cases of gastroesophageal reflux disease (GERD), which affects about 30 million people in the U.S. and hundreds of millions worldwide. [Amir Kurtovich, St Louis Business Journal, Mar 26, 13]

EndoStim (St. Louis, MO; no SBIR) startup that makes medical devices to treat gastrointestinal and urological neuro-muscular disorders, said it raised $6 million in Series B equity financing.... to continue clinical trials and pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. .... In April, New York Times columnist Thomas Friedman hailed EndoStim as a new kind of venture-capitalist-backed company that relies on technology to operate worldwide. [Kelsey Volkmann, St Louis Business Journal, Jul 19, 10]


Stealthy startup Auris Surgical Robotics (San Carlos, CA; no SBIR) disclosed that it has raised $150 million ...  the fourth robotic surgery business co-founded by Dr. Frederic Moll. He previously co-founded Intuitive Surgical  ($2.5M SBIR) , Hansen Medical (no SBIR), Endotherapeutics (no SBIR), and Origin Medsystems (no SBIR) ....has now raised a total of $185 million.  [Cromwell Schubarth, Silicon Valley Business Journal, Sep 24, 15]

Ener1 (Ft Lauderdale, FL)

maker of rechargeable car batteries that was using a $118.5 million Energy Department grant to build a factory in Indiana filed for Chapter 11 bankruptcy protection Thursday, becoming the latest green-energy company backed by the Obama administration to run into trouble.  Ener1 Inc. said its prepackaged bankruptcy filing will enable the company to receive a new infusion of capital and keep its operations going. Ener1 reached a deal with lenders to cut its $91 million debt in half and said it would receive $81 million in new funds, mostly from Bzinfin S.A., a company backed by Russian businessman Boris Zingarevich.A subsidiary of Ener1 called EnerDel Inc. employs 275 workers outside Indianapolis and is going forward with building its battery plant, Ener1 said. The subsidiary isn't in bankruptcy.  [K Stech and J Palank, Wall Street Journal, Jan 27, 12]

A start-up battery company is launching a joint venture with one of China's largest auto suppliers to serve the anticipated growth in electric vehicles in China and beyond. Wanxiang Electric Vehicle Co., a division of the Chinese conglomerate Wanxiang Group Corp., signed a joint venture agreement Monday night with Ener1 [spun off from U.S. auto supplier Delphi about three years ago] to make lithium-ion battery cells and packs for vehicles in China. Company officials on both sides said the partnership eventually could be expanded to export batteries from China, but officials at Ener1 have concerns about protecting its U.S. battery production.  [Matthew Dolan, Wall Street Journal, Jan 18, 11]

Ener1, the New York owner of Indianapolis battery maker EnerDel, said quarterly losses mounted as it ramped up production in Indiana and Korea.  [Indianapolis Star, Aug 6, 10]

Rechargeable-battery maker Ener1 dropped 16% after ending discussions with Fisker Automotive about the feasibility of a business relationship concerning the Fisker Karma vehicle program. [Wall Street Journal, Jan 14, 10]

Battery maker Ener1 , with its EnerDel subsidiary in Indianapolis, today said it received a $20 million injection of capital from a Japanese commercial trading giant with ties to the automotive, utility and renewable energy industries. [Indianapolis Star, Dec 7, 09]

Think, a Norwegian maker of electric cars,...said that EnerDel of Florida would supply batteries for its upcoming City vehicle in a contract that could be worth $70M from 2008 to 2010. San Jose Mercury News, Nov 1]

EnerDel's owner said it expects to secure a major supply agreement with Europe's Think City electric car. Sales in 2009 and 2010 could total $70 million for lithium-ion batteries to be produced in Indianapolis, said Florida-based Ener1. [Indianapolis Star, Oct 16]

Ener1 (one SBIR)'s subsidiary, EnerDel (Indianapolis IN), next week will unveil a lithium-ion battery pack developed for the hybrid electric vehicle market. [Indianapolis Star, Oct 6, 07]

Lithium ion battery researcher EnerDel has received a $6.5 M contract to continue research for Detroit's automakers, owner Ener1 (Ft Lauderdale, FL; one SBIR) said Tuesday. EnerDel is trying to develop an affordable and powerful lithium ion battery for hybrid vehicles. The U.S. Advanced Battery Consortium awarded the 18-month contract. [Indianapolis Star, Sep 19, 07]

EnerG2 (Seattle, WA)

EnerG2 (Seattle, WA; $800K SBIR) got a $9.4M venture round.pursues commercial opportunities in energy storage created by advanced material processing techniques [, Dec 31, 12]

A plant to produce carbon material that would increase the storage capacity of electric car batteries has opened in Albany.

EnerG2 (Seattle, WA; $800K SBIR) got a $21 million federal stimulus grant in 2010 to help remodel a warehouse of one of its partners, Oregon Freeze Dry. Chief executive Rick Luebbe told the Albany Democrat-Herald that the plant would initially produce 20 metric tons of the pure carbon material each month and employ more than 30 people. [AP, Feb 14, 12]

EnerG2(Seattle,WA;oneSBIR) advanced-materials startup, broke ground Tuesday on a plant in Albany, Ore., where it will manufacture components to make electric car batteries last longer and work more efficiently.   The company got a $21.3 million stimulus grant from the Department of Energy to help build the facility. .... EnerG2 can make activated carbon with fewer impurities, making its ultracapacitors more efficient, at a lower cost than companies using natural sources of carbon.  [Jason Bacaj, Seattle Times, Aug 10, 10]


Energen up 10% [Dec 17, 14]

Energen up 10% [Aug 1, 13]

Energen down 12% [Mar 5, 09]

Energen down 12% [Jan 20, 09]

Energen up 13% [Dec 17, 08]

Energen  down 10% [Dec 1, 08]  On a stock bloodbath day

Energen up 18% [Nov 24, 08]

Energen up 16% [Nov 21, 08]

Energen down 12% [Nov 14, 08]

Energen up 23% [Nov 13, 08]

Energen down 20% [Nov 12, 08]<

Energen down 15% [Nov 11, 08]

Energen up 10% [Nov 7, 08]

Energen down 12% [Nov 6, 08]

Energen up 15% [Nov 3, 08]

Energen up 15% [Oct 30, 08]

Energen up 14% [Oct 28, 08]

Energen down 10% [Oct 27, 08]

Energen up 13% [Oct 20, 08]

Energen up 12% [Oct 16, 08]

Energen down 14% [Oct 15, 08]

Energen down 10% [Oct 10, 08]

Energen down 11% [Sep 29, 08]

Energetiq Technology (Woburn, MA)

Energetiq Technology (Woburn, MA; one SBIR), a maker of advanced light sources for nanoscale fabrication and analysis, has landed $3.8 million of a $5 million Series C round, according online reports.  [Mass High Tech, Dec 2, 08]

Energid Technologies (Cambridge,MA)

Energid Technologies(Cambridge, MA; $9M SBIR) said it has developed a next-generation robot prototype to inspect nuclear power plants as part of an agreement with Mitsubishi Heavy Industries of Japan. ... the new robot’s main mission would be to inspect a nuclear plant’s heat exchanger and steam tubing systems at a faster and more reliable rate than existing robots can perform today  [Chris Reidy, Boston Globe, Jul 15, 11]

Energid Technologies (Cambridge, MA; $7.8M SBIR) said it has been given funding by the US Department of Agriculture to develop a commercial robotic citrus harvesting system. [Boston Globe, Oct 22, 10]

Energesis Pharmaceuticals (Cambridge, MA)

Johnson & Johnson Innovation said it has formed alliances with six Massachusetts-based life science and research companies to further innovation in pharmaceuticals, medical devices and diagnostic and consumer healthcare. .... • Minerva Neurosciences (Cambridge, MA; no SBIR)– Partnering with Janssen Pharmaceutica N.V., Johnson & Johnson Innovation and the Janssen neuroscience therapeutic area, Minerva has begun a program that will focus on the treatment of patients with primary and secondary insomnia and potentially treating other related neuropsychiatric disorders.Rodin Therapeutics (Cambridge, MA; no SBIR)- With initial investment from Johnson & Johnson Development Corporation, Rodin’s will work in collaboration with Johnson & Johnson Innovation in studying the inheritable changes in gene activity for the treatment of cognitive disorders, including Alzheimer’s disease.Energesis Pharmaceuticals (Cambridge, MA; no SBIR) - Janssen Pharmaceuticals Inc. and Johnson & Johnson Innovation have established a collaboration with biotechnology company Energesis to identify biological compounds that stimulate the formation of brown fat for use in treating metabolic diseases. The company’s approach is a novel strategy, leveraging recent scientific insights in BAT biology to increase the body’s ability to burn stored fat and lower insulin resistance.Navitor Pharmaceuticals (Cambridge, MA; no SBIR) - Johnson & Johnson Development Corporation has made an equity investment in Navitor, which will work in collaboration with Johnson & Johnson Innovation to develop highly-specific modulators to regulate a cell’s response to nutrient availability, including cell growth and function.Ascelegen Therapeutics (Cambridge, MA; no SBIR)– With an equity investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Ascelegen is working on developing novel therapies for cardiovascular diseases, including heart failure. Ascelegen’s work builds on research conducted at the Harvard Stem Cell Institute and Brigham and Women's Hospital. Padlock Therapeutics (Cambridge, MA; no SBIR) – With an investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Padlock is developing new therapies targeting a protein that mediates how protein conversions lead to rheumatoid arthritis and how it drives inflammation and immune complex formation in active autoimmune disease.  [Boston Business Journal, Jun 19, 14]

Energous (San Jose, CA)

Energous down 24% [Feb 27, 19]

Energous down 31% [Feb 26, 19]

Energous up 19% [Jan 2, 19]

Energous down 17% [Dec 28, 18]

Energous (San Jose, CA; no SBIR) up 54% [Dec 27, 18] developer of WattUp, a revolutionary wireless charging 2.0 technology,  announced the first customer product to receive FCC approval. [company press release, Dec 27, 18]

Energous up 13% [Aug 3, 18]

Energous up 10% [Apr 16, 18]

Energous up 10% [Apr 10, 18]

Energous up 12% [Mar 26, 18]

Energous down 12% [Mar 20, 18]

Energous up 13% [Feb 23, 18]

Energous up 10% [Jan 30,18]

Energous up 15% [Jan 24,18]

Energous down 13% [Jan 12, 18]

Energous up 15% [Jan 2, 18]

Energous down 38% [Dec 29, 17]

Energous up 33% [Dec 28, 17]

Energous (San Jose, CA; no SBIR, founded 2013, 73 employees) up 168% [Dec 27, 17] a revolutionary wire-free, power-at-a-distance charging technology, today announced Federal Communications Commission (FCC) certification of its first-generation WattUp Mid Field transmitter, which sends focused, RF-based power to devices at a distance. As the first FCC certification for power-at-a-distance wireless charging [company press release, Dec 26, 17]

Ener-G-Rotors (Schenectady, NY)

The Eastern New York Angels will fund more companies, this time focusing on later stage companies instead of startups. 
The goal is to raise $2.5 million by the end of the year.  ...  recently has invested $1.5 million into six early-stage companies with a seventh pending .... Companies funded in the first round include Paper Battery (Troy, NY; no SBIR),  Ener-G-Rotors (Troy, NY; no SBIR), Vital Vio (Troy, NY; no SBIR),ThermoAura (Troy, NY; no SBIR) (a manufacturer of high performing thermo-electric material, will open a new production plant in suburban Albany this summer as it moves into commercialization), and Free Form Fibers (Saratoga Springs, NY; one SBIR).   [Keshia Clukey, Albany Business Review, Jun 30, 14]

Ener-G-Rotors (Rotterdam, NY;  no SBIR)  landed $1.5 million from Bright Capital Seed Fund, a division of a Russian venture capital firm, to accelerate the company’s commercialization efforts. ..  makes devices that convert waste heat to electricity. [Richard D'errico, Business Review (Albany) Nov 7, 12]

Ener-G-Rotors   (Rotterdam,  NY;  no SBIR)  landed $1.5 million from Bright Capital Seed Fund, a division of a Russian venture capital firm, to accelerate the company’s commercialization efforts.  ....  makes devices that convert waste heat to electricity.  .... founded in 2004, has attracted interest from large manufacturers and industrial companies   [Richard D'errico,The Business Review (Albany), Sep 13, 12]

Ener-G-Rotors (Rotterdam, NY; no SBIR) which is developing a machine that turns industrial waste heat into electricity, received a $150,000 investment from the Eastern New York Angels today.  The investment is the first by the angel fund, which has raised $800,000. [Larry Rulison, Albany Times Union, Nov 15, 11]

Ener-G-Rotors (Rotterdam, NY; no SBIR) was awarded $725,000 from the New York State Energy Research and Development Authority ... to fund field-test equipment that captures waste heat from two manufacturing plants and turns it into electricity. ... five-person company said it expects to add five to 12 jobs by the end of 2012 and add as many as 120 jobs by the end of 2015.  [The Business Review (Albany), Sep 6, 11]

Ener-G-Rotors (Schenectady, NY; no SBIR) got $200K from the state's Energy R&D Authority to expand marketing and outreach for generating systems that use low temperatures to convert waste heat for industrial use, or sell it to the electric grid. The company is preparing to raise money to build a new manufacturing facility [The Business Review (Albany), Dec 8, 09]

Ener-G-Rotors (Schenectady, NY; no SBIR) will receive a $800,0000 grant through the New York State Energy Research and Development Authority to develop a 50-kilowatt prototype system that will convert low-temperature heat to energy. ... made its first commercial sale in April ...  four-year-old company employs five people. It was started with $200,00 in angel funding and has continued operations with grants-in-lieu-of-services contracts with NYSERDA. [Pam Allen, Business Review (Albany), Jul 7, 09] Entropy forbids getting much more than scraps of work from low temperature heat.

Energy Control (Albuquerque , NM)

Energy Control (Albuquerque , NM; no SBIR) has a received one of two Stevie Awards for the Best Overall Company in the U.S. with under 100 employees. ... New Mexico's oldest energy technology company, recently celebrated its 32nd anniversary. It has 65 employees and annual revenues of approximately $14 million.  [New Mexico Business Journal, Jun 27, 08]

Energy Conversion Devices (Troy,MI)

Energy Conversion Devices down 80% to well under the buck after filing for bankruptcy.  [Feb 14, 12]

Energy Conversion Devices rose the most in more than three years after announcing plans to adapt its products for consumer and military applications. ... rose 13 cents, or 20% , to 79 cents at of 12:36 p.m. in Nasdaq Stock Market trading. Earlier it climbed 24 cents, the biggest intra-day gain since May 2008. The share have dropped 83% this year.  [Aug 25, 11]  Solar has lost a lot of power recently everywhere.

Energy Conversion Devices down 22% [Mar 11,11]

Meanwhile in solarsubsidyland,  Energy Conversion Devices this afternoon warned that it will have to reduce production of its thin-film solar products as a result of changes in the solar incentive regimes in France and Italy [Eric Savitz, Forbes, Mar 10,11]

Energy Conversion Devices up 13% [Aug 31, 10]  after its fiscal fourth-quarter loss widened on higher costs, but the Rochester Hills, Mich., company's earnings still beat analysts' expectations. Energy Conversion forecast revenue for the new year and the first quarter below analysts' average estimates. [Wall Street Journal, Sep 1]

Energy Conversion Devices down 11% [Aug 19, 10]

Energy Conversion Devices down 10% [Aug 11, 10]

Energy Conversion Devices  up 11% [Jul 7, 10]

Energy Conversion Devices up 11% [May 10, 10]

Energy Conversion Devices up 11% [Nov 3, 09]

Energy Conversion Devices up 10% [Oct 22, 09]

Energy Conversion Devices up 15% [Oct 12, 09] did just sign an agreement to supply 4.8 megawatts of its UNI-SOLAR photovoltaic laminates to a solar project in Spain, and industry bull davbeirney predicts it will slowly gain advantage in different markets as the conversion to solar takes hold... There is no way to slow down the solar industry. Solar is the future, but there are going to be different levels of clean energy before solar. [Energy Conversion Devices] has a foothold in the Chinese market, which is a favorable advantage to hold over competitors. [Rich Duprey,, Oct 12]

Energy Conversion Devices up 25% [Sep 8, 09]

Energy Conversion Devices up 13% [Jul 24, 09]

Energy Conversion Devices   down 20% [May 7, 09]

Energy Conversion Devices  up 12% [Apr 22, 09]

Energy Conversion Devices  down 10% [Apr 20, 09]

Energy Conversion Devices  up 11%% [Apr 2, 09]

Energy Conversion Devices  down 15% [Mar 30, 09]

Energy Conversion Devices  up 12% [Mar 26, 09]

Energy Conversion Devices down 23% [Mar 17, 09]  said it is slowing the pace of its expansion plan and pulled its guidance for the third quarter and fiscal year.  [Wall Street Journal, Mar 18]

Energy Conversion Devices up 13% [Mar 10, 09]

The financial crisis has wreaked havoc on the big-swinging solar stocks. Since September, solar energy stocks have lost 79% of their value, according to the Claymore/MAC Global Solar Energy Index exchange-traded fund. ....  First Solaris another hot company due to its unique manufacturing process. Unlike SunPower's conventional crystalline silicon-based solar products, First Solar uses thin-film technology, which is cheaper. As a result, the Tempe, Ariz.-based company saw earnings and revenue double in 2008. For the year, First Solar reported net income of $348 million on revenues of $1.25 billion. ....  Energy Conversion Devices also uses thin-film technology, but its product is different in interesting ways. Most solar panels are hard, flat planes, but ECD's product can be rolled onto roofs in strips, are lightweight, and can become part of the physical roof. ....   But the nascent market likely will benefit from a number of trends, including the reduction of carbon sources, resistance to nuclear energy and the potential for renewable mandates and carbon dioxide regulations.  Industry observers say those trends will lead to higher costs for conventional energy sources, while solar energy prices decrease. Says O'Rourke: "When that happens, it will be potentially explosive."  [Carl Gutierrez, Forbes, Mar 6, 09]

Energy Conversion Devices  up 12% [Feb 24, 09]

Energy Conversion Devices   down 10% [Feb 17, 09]

Energy Conversion Devices up 10% [Dec 3, 08]

Energy Conversion Devices  down 18% [Dec 1, 08]  On a stock bloodbath day

Energy Conversion Devices down 10% [Oct 23, 08]

Energy Conversion Devices down 15% [Oct 22, 08]

Energy Conversion Devices up 25% [Oct 13, 08]

The risk with Energy Conversion Devices has to do with the company's spending much of the 13 years since it went public fostering exaggerated expectations while delivering only meager results to the bottom line. But this time I am a believer. I expect ECD's fiscal 2009 revenues to almost double and its earnings per share to almost quadruple from the year before. The shares trade at 32 times my 2009 estimate of $1.80. [Jim Oberweis, Forbes, Oct 27, 08]

Energy Conversion Devices down 14% [Oct 8, 08]

Energy Conversion Devices down 19% [Oct 7, 08]

Energy Conversion Devices up 10% [Sep 30, 08]

Energy Conversion Devices down 12% [Sep 29, 08]

Energy Conversion Devices up 13% [Sep 24, 08] after a Senate energy bill extended investment tax credits for the solar power industry for eight years. [AP]

Energy Conversion Devices down 19% [Sep 23, 08]

Energy Conversion Devices up 17% [Sep 19, 08]

Energy Conversion Devices up 10% [Sep 16, 08]

Energy Conversion Devices up 15% [Jun 16, 08]

Energy Conversion Devices up another 16% [May 30, 08] after Germany, the largest market for sun-power supplies, cut its subsidies by less than expected. [Wall Street Journal, May 31]

Energy Conversion Devices up 43%  [May 8, 08] as increased demand for solar products helped the Rochester Hills, Mich., energy-products supplier post higher fiscal third-quarter results and peg the high end of its fiscal fourth-quarter sales outlook ahead of Wall Street estimates. [Wall Street Journal, May 9]

Energy Conversion Devices up 12% [Feb 7, 08] on talk of sustainable profitability.

Energy Conversion Devices up 10% [Dec 20, 07] presumably basking in handouts of the newest energy law.

Energy Conversion up 11% [Dec 12, 07]had its day in the sun after winning an important deal to supply solar panels to a major installer of rooftop energy-collecting devices. [Forbes]

Energy Conversion Devices up 12% on bigger loss and even bigger revenues. [Nov 8, 07]

Is something brewing at Energy Conversion Devices Inc., a developer of alternative energy products? ... Stock and options on the Rochester Hills, Mich., company traded briskly yesterday ... Options activity also was heavier than usual as investors got in position for a sharp uptick in the share price in coming weeks. [Yvonne Ball, Wall Street Journal, Oct 4]

Energy Conversion Devices up 11% on news of Chinese company getting a royalty-bearing right to make certain batteries using ECD's technology .  [Aug 8, 07]

Energy Conversion Devices took a 16% hit [Feb 9, 07] when it reported more losses. The company said that it doesn't expect to reach sustainable profitability during fiscal 2007. "This is in large part due to the fact that it is taking longer than we originally expected to secure additional funding opportunities for our emerging technologies,"  That sounds like send us more money to develop a product that might make money in the future.

Ovshinsky, 84 years old, finds himself running his factory at full capacity and overwhelmed with orders. His company, Energy Conversion Devices Inc., is the largest U.S.-owned maker of photovoltaic materials, which convert sunlight to electricity. The company is a pioneer in an exploding global industry selling $15 billion a year of what's called "PV." [Wall Street Journal. Nov 27]

Energy Conversion Devices says that its President and Chief Scientist and Technologist, Stanford Ovshinsky, discussed a fundamentally new device, called the Ovonic Quantum Control, which has the potential to open a whole new field of semiconducting control devices. The Ovonic Quantum Control, based on Stan Ovshinsky's invention of a unique proprietary all thin-film control device, is based on new physics and has multifunctionality beyond that of transistors. In response, the stock traders yawned the stock down 4%.  Last week, the fourth broker in the last year initiated coverage of the stock - with a BUY. Caveat emptor. The stock trades in the low 40s, and has ranged from 5 to 58 in the last six years.

Wall Street has grown increasingly enamored with alternative energy stocks. A prime example: Energy Conversion Devices, a 40-year-old company that sports a market cap of $1.4 billion and has never made any money. ... In 1968, the New York Times featured an invention from the company and its founding inventor, Stanford Ovshinsky, with the headline: "Glassy Electronic Device May Surpass Transistor." That didn't exactly happen. [Jesse Eisinger. Wall Street Journal, Feb 15    ]

Energy Conversion got a 12% cold bath when Herb Greenberg of Market Watch said it was selling a stale tale, part of which was that the company has a history of going through joint-venture partners the way sick people go through Kleenex.  Read Greenberg Energy Conversion Devicesled the NASDAQ percentage gainers with 20%. on news of  a long-term license agreement for Memory (OUM) thin-film semiconductor memory technology originally invented by ECD founder S. R. Ovshinsky [press release, Dec 28, 05]

One Economist annual innovation award to: Stanford Ovshinsky, president and chief scientist and technologist, Energy Conversion Devices, for developing the nickel-metal-hydride battery. This is the battery technology found in hybrid cars, laptop computers and many other devices, and is just one of the many innovations devised by Mr Ovshinsky, a self-taught inventor who pioneered the field of amorphous materials in the 1950s. He is now focusing on solar panels and hydrogen-powered cars.  [The Economist, Dec 10, 05]

What gets investors excited about Energy Conversion Devices are the patents it owns on nickel metal hydride batteries used in hybrid cars. ..Most of Energy Conversion Devices' revenue comes from solar-panel sales. In these days of high energy prices, solar has been an "if you build it, they will come" sort of business. Nevertheless, the company has failed to meet analysts' sales projections for four quarters.  [Justin Lahart, Wall Street Journal, Nov 8]  Meanwhile The Economist opines on ECD as  a pioneer in hydrogen storage and solar cells, has seen its shares soar by 50% this year and venture-capitalists are taking an increasing interest in the industry. ... and as High oil prices are spurring investments in alternative fuels for a False Dawn? The report of soggy profits (=$6M loss) sent the stock tumbling 8%

Energy Conversion Devices, another NiMH company, has seen its stock has double since last summer and got a recent plug from Gene Marcial's Business Week column (Jul 4).  Some big money is involved: GM has ordered batteries for its hybrid vehicles and Chevron has a join venture with ENER for production and marketing the batteries.

Energy Focus (Solon, OH)

Energy Focus up 25% [May 5, 17] (Solon OH; $3M SBIR, 130 employees)  [CEO] Tewksbury, commented, "As expected, we continued to experience headwinds due to excess inventory in the channel, lackluster Navy demand and delays in commercial projects, but we are beginning to see signs that our restructuring efforts and five-point strategy will return the Company to profitable growth.  [company press release, May 4, 17]

Energy Focus down 10% [Feb 28,17]

Energy Focus up 10% [Nov 8, 16]

Energy Focus up 11% [Sep 28, 16]

Energy Focus down 17% [Aug 11, 16]

Energy Focus up 10% [Jun 20, 16]

Energy Focus  up 16% [Mar 17,16]

Energy Focus down 10% [Mar 16,16]

Energy Focus (Solon, OH; $3M SBIR) down 40% [Mar 10,16]   reported profit and revenue for the fourth quarter that missed forecasts, sending shares lower as the LED lighting firm signaled its business would be challenged by diminished sales to the U.S. Navy well into 2016  [Dow Jones newswire]

Energy Focus up 12% [Feb 24, 16]

Energy Focus up 10% [Feb 23, 16]

Energy Focus up 12% [Feb 16, 16]

Energy Focus up 11% [Nov 13, 15]

Energy Focus down 22%  [Nov 5, 15]

Energy Focus up 37%  [Nov 4, 15]

Energy Focus up 13% [Oct 5,15]

Energy Focus down 11% [Sep 23, 15]

Energy Focus up 14% [Sep 16, 15]

Energy Focus down 29% [Sep 11, 15] announced the pricing of a registered underwritten follow-on offering of shares of its common stock at only $17 [Wall Street Journal, Sep 11, 15]

Energy Focus (Solon, OH; $3M SBIR)  down 15% [Aug 17, 15]

Energy Focus (Solon, OH; $3M SBIR)  up 40% [Aug 14, 15] designs, develops, manufactures, and markets LED lighting products

Energy Focus (Solon, OH; $3M SBIR)  up 13% [Jul 1, 15]  announced that it has shipped its first order for the Royal Australian Navy. The order consists of Energy Focus' military Intellitube(R) LED tubes and full fixture LED bunk lights for one of the Royal Navy's twelve frigate-class warships and totals approximately half a million dollars. ... remains the only U.S. Navy military-spec qualified tubular LED lamp provider    [company press release]

Energy Materials (Norcross, GA)

The Department of Energy will award $128M to support 75 research projects that seek to advance the development of solar technologies. Most money went to academic and large businessses. Several awards went to former SBIR winners: Energy Materials (Norcross GA, one SBIR) won a $4M Solar project award to create new methods to deposit layers of material to make the cell, develop a high-speed process ; Leading Edge Crystal Technologies (Gloucester, MA; one SBIR) won $2.5M to develop a floating-silicon method for producing high-quality single crystalline wafers ; Sunvapor (Livermore, CA ; one SBIR) won $2.5M to show how using enormous tanks that normally store liquefied petroleum gas can be used to accumulate and store solar-generated steam ; Brayton Energy (Hampton,NH; $3M SBIR) won $700K to partner w Oak Ridge Lab to examine examine creep behavior—the tendency to deform under mechanical stress—in thin-sheet nickel alloys; Ceramic Tubular Products (Lynchburg, VA; $3.2M SBIR) won $1.9M to develop silicon carbide composite receiver tubes for molten chloride salt and liquid sodium receivers; Echogen Power Systems, (Akron, OH; $300K SBIR) won $4.4M to develop a large-scale, low-cost, single-shaft compressor for supercritical carbon dioxide (sCO2) power cycles; Osazda Energy (Albuquerque, NM; one SBIR) won $1M to develop a cost-effective metal paste that strengthens the metal connections in solar cells; Scion Plasma (East Lansing, MI; $200K SBIR) won $1M to develop a tool that rapidly deposits transparent conductive oxide onto heterojunction silicon with intrinsic thin layer (HIT) solar cells; Swift Coat (Peoria, AZ; one SBIR) won $1M to make and scale multilayer, anti-reflective and anti-soiling coatings for solar glass [Jane Edwards, govconwire, Nov 7, 19]

Energy Recovery (San Leandro, CA)

A process that helps water-desalination plants recycle energy drew investors to the initial public offering of Energy Recovery (San Leandro, CA; no SBIR) creating some excitement in an otherwise barren new-stock market.  [Wall Street Journal, Jul 3]

Energy Solutions (Salt Lake City, UT)

no objections have been raised on health and safety grounds, not even from the state, on a scheme by Energy Solutions (Salt Lake City, no SBIR)  to import nucear waste from Italy, reprocess it in Tennessee, and dump the residue in Utah. But the enviro watchdog groups have weighed in with cards and letters to the politicians who are now awake and posturing. [Salt Lake Tribune, Jun 11]

Energy Storage Systems

Gov. Kate Brown says she wants small businesses to thrive in Oregon. As such, she's allocated $400,000 toward that end. The SBIR Grant Support Program will provide individual grants of $125,000 to four Oregon companies participating in a companion federal grant program ....  The Oregon Innovation Council [public-private partnership of  more than 40 leaders] that helps create new jobs and new companies will review applications and recommend award recipients.  [Elizabeth Hayes, Portland Business Journal, Feb 2, 16]  Unclear what that little money will do to advance true high tech innovation, especially if the company has already won SBIR money.  Oregon Inc claims More than $490M in federal grants on a $77M state investment (6-1 ROI); 90 companies formed; $130 million in private capital raised.  Its 2015 report claims 196 jobs and $77M new investments attracted from $1.4M "invested". It further claims that Energy Storage Solutions  (Portland, OR; no prior SBIR) startup earned a $75,000 matching grant to support its research into next generation energy storage for solar and wind power. Energy Storage Solutions also won grants through Oregon BEST and [SBIR] and raised $3.2 million in venture capital to start large-scale battery production. Energy Storage Solutions was among five companies that received SBIR matching grants in 2015 to support Oregon’s small business innovators.  If the returns are that rewarding, why only $400K? Politics likes to spread money as widely as possible.

Energy Storage Systems (Portland, OR; no SBIR, founded 2011) is ready to begin commercializing a storage battery for solar and wind power....  has raised $3.2 million to start larger-scale production of its battery, designed for long-duration energy storage. ... ESS’ All-Iron Flow Battery, with six to 12 hours of energy capacity, is meant to address the market need for long life, low cost-per-kilowatt-hour storage systems that would give wind and solar deeper penetration of renewables on electric grids.   [James Cronin, Portland Business Journal, Oct 7, 15]

(Oregon) Gov. Kate Brown announced that five companies would receive a combined $300,000 to fund innovation from Business Oregon, the state's economic development arm, and act as follow-on funding for awards from [SBIR]: DesignMedix (Portland, OR; $1.4M prior SBIR): makers of a drug to improve malaria treatment, $75,000;  Energy Storage Systems (Portland, OR; no SBIR): makers of a new kind of battery for utility-scale energy storage, $75,000;   SupraSensor  (Eugene, OR; no SBIR, founded 2012): makers of a testing device that helps farmers use fertilizer more efficiently, $61,875; NemaMetrix  (Eugene OR; $200K SBIR, founded 2011): makers of an advanced drug screen for cheaper, faster testing, $49,100HM3 Energy (Gresham, OR; one SBIR): developers of a technology that converts forest debris into briquettes that can replace coal in power plants, $40,171.  [Mason Walker, Portland Business Journal, Apr 17, 15]

Energy Storage Systems secured a $135,000 investment after winning the Seattle Angel Conference's sixth investment competition ... to develop a cost-effective energy management system through its patented flow cell design.  ... The Seattle Angel Conference has invested more than $1 million in seven Washington-based firms in less than three years.   [Wendy Culverwell, Portland Business Journal, Nov 14, 14]

EnerMat Technologies (Troy, NY)

The co-founders of EnerMat Technologies (Troy, NY; no SBIR) are building a prototype for their fast-charging, long-lasting battery that could have applications in the automotive and electronics industry. ... developed the technology as mechanical engineering graduate students at Rensselaer Polytechnic Institute [and licensed the technology from Rensselaer] ... . Now, they are using a $250,000 state grant to build a scalable prototype.  ...  working with private investors to raise $250,000 to serve as a match to the $250,000 grant  [Megan Rogers, Albany Business Review, Jun 16, 15]

EnerMed (Buffalo, NY)

EnerMed (Buffalo, NY; no SBIR) will locate in downtown Buffalo, pledging to create three new jobs and invest $360,000. The biotechnology research and development company owns and intends to license patent-pending technologies for wound and bone-healing devices.  ....  [one of] Three new companies accepted into the Start-Up NY tax breaks program through the University at Buffalo, pledging to create a total of 25 new jobs. The program wipes out all state and local taxes and fees for qualified companies, as long as they hit investment and job creation goals  [Dan Miner, Buffalo Business First, Sep 18, 15]

Enertech Environmental (Atlanta GA)

Enertech Environmental (Atlanta GA; $2M SBIR) (of 34 total awards) won a runner-up award  in the Environmental field for Technology Innovation 2007 by the Wall Street Journal.

EnerVault (Sunnyvale, CA)

EnerVault (Sunnyvale, CA; no SBIR, founded 2008)   has developed a new electrolyte pumping system to improve the efficiency of the charge and discharge cycle [a a flow battery]. ....  using an iron chromium chemistry, one sixth the cost of the vanadium used in some flow batteries. [Martin LaMionica, MIT, Mar 22, 13]   $4.7M grant from [DOE], to install a 250kW/1MWh system near Turlock CA [companywebsite]

Engage Therapeutics (Summit, NJ)

Engage Therapeutics (Summit, NJ;  no SBIR), a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds from the financing to fund a Phase 2b clinical trial of its lead candidate Staccato® alprazolam, an acute epileptic treatment designed to stop seizure activity.  [company press release, Sep 27, 17]

Engineered BioPharmaceuticals (Manchester, CT)

NIST TIP winners  $22 million in funding for nine research projects targeting innovative manufacturing technologies in fields ranging from biopharmaceuticals and electronics to renewable energy sources and energy storage:  Isogenis (Aurora, CO; $4.8M SBIR);  ActaCell,  (Austin, TX; no SBIR);  Engineered BioPharmaceuticals (Manchester, CT; no SBIR); Arsenal Medical  (Watertown, MA; no SBIR); Kent Displays (Kent, OH; $2.6M SBIR); Precision BioSciences (Research Triangle Park, NC; $340K SBIR); Ginkgo BioWorks (Boston, MA; one SBIR); Sinmat (Gainesville, FL; $4.4M SBIR); Polyera (Skokie, IL; no SBIR).   

Engineered Propulsion (New Richmond, WI)

Engineered Propulsion Systems (New Richmond, WI; no SBIR) raises $3.6 million from investors. ... brings to nearly $20 million the amount the  developer of a diesel engine for general aviation has raised since it formed in 2010. [Milwaukee Journal Sentinel, Feb 5, 16]

Engineered Propulsion Systems (New Richmond,WI; no SBIR) start-up that is developing a new type of diesel engine for general aviation, raised $1.4 million from three investors.  [Milwaukee Journal Sentinel, Dec 8, 15]

Engineered Propulsion (New Richmond, WI; no SBIR) start-up that is developing a new engine for general aviation, has raised $1.4 million of a proposed $14.5 million offering [Milwaukee Journal Sentinel, Sep 24, 15]  with our state-of-the-art lightweight diesel engine, the Graflight V-8, which runs in the 320 to 420 horsepower range. This engine is the first of its kind, designed from scratch to achieve the best fuel economy the business has ever seen  [company website]

Engineered Propulsion (New Richmond, WI; no SBIR) start-up company that is developing a new engine for general aviation, raised $1 million [a combination of equity and debt] from one investor, according to a [SEC] filing ... making a lightweight, high-performance, water-cooled, diesel engine  [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 13, 15]

Engineous Software (Cary,NC)

Engineous Software (Cary, NC; 3 Phase 1 SBIRs) agreed to be acquired by French software maker Dassault Systemes for $40M. [Raleigh News & Observer, Jun 20] 

Engrail Therapeutics (San Diego, CA)

Engrail Therapeutics (San Diego, CA; no SBIR) announced the close of a $32 million Series A financing round [to] support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator. [company press release, Jun 18, 20]


Enlibrium (San Diego, CA)

San Diego County companies that raised the largest amount of venture capital in the fourth quarter of 2015
Sapphire Energy ($200K SBIR) $91 million;  Effector Therapeutics: $40 million;  MD Revolution: $22.45 million;  AltheaDX: $20.1 million;  Elcelyx Therapeutics: $20 million;  Amplyx Pharmaceuticals: $20 million;  Astute Medical: $20 million;   Glysens  ($6.8M SBIR): $20 million;  Crinetics Pharmaceuticals  ($200K SBIR): $18 million;   Enlibrium: $15 million   Source: MoneyTree Survey by PricewaterhouseCoopers and the NVCA with data from Thomson Reuters  []

Enlibrium (San Diego, CA; no SBIR) raised $15 million in a Series A financing to advance the diabetes drug metformin as a potential new anti-cancer drug. ...  to advance Enlibrium’s lead compounds through Phase 1 clinical trials.  [Bruce Bigelow,, Dec 12, 15]

Enlight Bioscience (Boston, MA)

startup Enlight Biosciences LLC (Boston, MA; no SBIR) has partnered with Johnson & Johnson Co., bringing its available development funding up to $52 million. In July, Enlight made its formal launch announcement, with backing from drug giants Eli Lilly & Co., Pfizer Inc., and Merck & Co. Inc. At that time, it claimed it had $39 million on hand.  [Mass High Tech, Jan 22, 09]

Enlight Biosciences, a Boston life sciences startup, reports it has launched in collaboration with the support of three major pharmaceutical companies to advance technologies for drug discovery and development. The company said that will direct up to $39 million in funding, and its pharma partners include drug giants Eli Lilly, Pfizer, and Merck. ...  puretech ventures, boston venture founded enlight with academic bigwigs such as nobel laureate robert horvitz mit sam gambhir radiology stanford universit rakesh jain tumor biology raju kucherlapati a professor genetics at harvard medical school co-founder of cambridge-based biotech firm millennium pharmaceuticals , according to startup [mass high tech, jul 10] if have eventually marketable goods and the brains you don't need government subsidy.

EnSync Energy Systems (Menomonee Falls, WI)

EnSync Energy Systems (Menomonee Falls, WI), formerly ZBB Energy,  now has a four-year supply agreement with Solar Power, a Chinese solar project developer, that's expected to yield sales of $80 million to $120 million.   [Thomas Content, Milwaukee Journal Sentinel, Apr 6, 16]

Ensysce Biosciences (Houston, TX)

Ensysce Biosciences (Houston, TX; $300K SBIR) up 67% [Dec 9, 21]

Ensysce Biosciences (Houston, TX; no SBIR) Using carbon nanotubes to deliver treatments to individual cancer cells. ... Bob Gower founded the company in 2008 as spinoff of Carbon Nanotechnologies, ... Founder Gower has invested a little more than $1 million, Kirkpatrick said, and the state’s Emerging Technology Fund has committed $1.5 million if the company meets certain milestones. The company has already received $250,000 from the fund. [Purva Patel, Houston Chronicle, Aug 28, 10]

Entasis Therapeutics (Waltham, MA)

Entasis Therapeutics (Waltham, MA: no SBIR, founded 2015) an antibiotics developer, filed to go public, hoping to raise the cash needed to finance more clinical tests of  experimental drugs. [Frank Vinluan,, Aug 20, 18]  total funding $128M []

Entasis Therapeutics (Waltham, MA; no need for SBIR?), the AstraZeneca spinout developing novel antibiotics, has raised a $50 million Series B round to push forward the creation of a portfolio of treatments for drug-resistant bacterial infections.  AstraZeneca announced it was creating Entasis in July, having funded the company with a $40 million Series A.  [David Holly,, Apr 5, 16]

Entech (Dallas, TX)

Solar technology company Entech Solarhas moved its corporate headquarters from Ewing, N.J., to Fort Worth ... also said it has changed its name from WorldWater & Solar Technologies Corp. Entech ($5M SBIR), a company that WorldWater acquired, is now a subsidiary of Entech Solar.  Entech makes and sells a combined photovoltaic and thermal concentrating solar systems for commercial and industrial customers.  [Dallas Business Journal, Jan 13, 09]


Entegrion (Research Triangle Park, NC; no SBIR; 9 employees)  said it was awarded $7.8 million from the Department of Defense to develop freeze-dried platelets to be used for emergency treatment of wounded soldiers....    ...   Stasix, under development for 12 years, is not expected to be approved for use until about 2020. has received a total of $88 million from the Pentagon to develop blood products. In 2011 the company was awarded $43.7 million to develop dehydrated plasma, which is now in the first phase of clinical trials.   [John Murawski, Raleigh News & Observer, Oct 13, 14]

Entegrion (Research Triangle Park, NC; no SBIR) that is working on a replacement for fresh frozen blood plasma, will get an infusion of $43.7 million from [DOD] The product, Resusix, is dehydrated plasma and could be used more easily in combat situations, according to the company. ...  In August, won a $9.84 million contract with the Navy to study the potential of combining two of its products to develop a treatment for the hemorrhaging and shock that accompany traumatic combat injuries. ... eight employees and expects to hire more  [Mary Cornatzer, Raleigh News & Observer, Oct 6, 11]

Entegrion (Research Triangle Park, NC; no SBIR) that develops techniques to stop emergency bleeding has won an [DOD] $8.2 million grant to develop dried plasma for blood transfusions in battlefield and emergency situations. ... founded 2002, six employees [John Murawski, Raleigh News & Observer, Sep 10, 10]

Three Triangle technology firms raised $10.5M last month to hire workers, invest in research and market new products Medical-implants maker Sicel Technologies raised $7M; Biotech startup Entegrion raised $2M (first VC); Centice Corp. raised $1.5M. [Raleigh News and Observer, Nov 10] Sicel and Centice have had SBIRs.

Entellus Medical (Plymouth, MN)

Entellus Medical  (Plymouth, MN; no SBIR) up 29% [Jan 29, 15] after $80M IPO

Entellus Medical  (Plymouth, MN; no SBIR). has set [IPO] terms, which the med-tech company estimates could raise $63-72 million.  ... makes devices for treating chronic sinusitis   [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jan 20, 15]

Entellus Medical (Plymouth, MN; no SBIR, founded 2006) which makes devices for treating chronic sinusitis, has filed to raise up to $69 million [IPO]  ...  raised several rounds of venture capital [Katharine Grayson, Minneapolis / St. Paul Business Journal, Dec 23, 14] 

Entera Biotech

Entera Biotech down 16% [Sep 10, 18]

Entergem Ventures (Somerville, MA)

XL Hybrids (Somerville, MA; no SBIR; first founded as Entergem Ventures) has secured $300,000 in new investments, just a month after reporting capping a recent funding round at $1.5 million, according to a regulatory filing.  ... has said little about what it’s working on, but its website does state that XL Hybrids has a proprietary technology that will allow for the conversion of gas-powered or diesel-powered vehicles to become hybrids.  <[Kyle Alspach, Mass High Tech, Aug 16, 10]

Enterin (Philadelphia, PA)

Enterin (Philadelphia, PA; no SBIR, founded 2016) developing a drug that has the potential to provide a new way to treat Parkinson’s patients, raises $16.7M [John George, Philadelphia Business Journal, Feb 1, 19] prior funding $13M []

Enterin (Philadelphia, PA; no SBIR, founded 2016) biotechnology company developing novel compounds to treat Parkinson’s disease (PD),  announced the completion of a $12.7 million Series A financing round   [company press release, Jul 10, 17]  the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease.  []

EnteroMedics (Roseville,MN)

Weight loss device maker EnteroMedics wrapped its largest funding round to date, raising upwards of $61 million, according to an SEC filing  ... best known for its flagship vBloc System, a pacemaker-shaped device designed to curb hunger by manipulating nerve signals between the brain and body.   [Sam Schaust, Twin Cities Business, Oct 18, 17]

EnteroMedics (St Paul, MN), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, announced that it has acquired ReShape Medical (no SBIR) medical technology company that develops, manufactures and markets the ReShape Dual Weight Loss Balloon®, an FDA-approved, minimally invasive intragastric balloon designed to treat obesity patients with a body mass index (BMI) between 30 and 40, with one or more related comorbid conditions.     [company press release, Oct 2, 17]

EnteroMedics down 40% [Aug 11, 17] announced the pricing of an underwritten public offering of units for gross proceeds of $20 million  [company press release]

EnteroMedics (St Paul, MN; no SBIR), the developer of medical devices treating obesity, metabolic diseases and other gastrointestinal disorders, announced today that it has acquired the Gastric Vest System™ (the "Gastric Vest" or "Vest"), through its acquisition of BarioSurg (Lake Forest, CA; no SBIR, founded 2008) [for stock and $2M cash].   The Gastric Vest is an investigational, minimally-invasive, laparoscopically implanted medical device being studied for weight loss in morbidly obese patients. [Enteromedics press release, May 23, 17]

EntertMedics up 11% [May 23,17]

EnteroMedics up 11% [May 18, 17]

Enteromedics down 28% [May 16,17]

Enteromedics up 31% [May 15,17]

EnteroMedics down 10% [Apr 25, 17]

Enteromedics down 11% [Apr 21, 17]

EnteroMedics up 14% [Feb 9, 17]

EnteroMedics down 14% [Feb 2,17]

EnteroMedics up 33% [Feb 1, 17]

EnteroMedics, maker of obesity treatment devices, closed its latest public offering round after raising $19 million. [Sam Schaust, Twin Cities Business, Jan 25, 17]

EnteroMedics up 29% [Jan 20, 17]

EnteroMedics down 37% [Jan 18, 17]

EnteroMedics down 35% [Jan 17, 17]

EnteroMedics down 45% [Jan 11,17]

EnteroMedics up 57% [Jan 10,17]

Enteromedics up 93% [Jan 9,17]

Enteromedics up 131% [Jan 6,17] announced that the Company's vBloc(R) Neurometabolic Therapy has now been implanted at two additional vBloc Institutes -- MedStar Health in Maryland and Roper St. Francis in South Carolina.  [company press release, Jan 5, 17]

Enteromedics up 90% [Jan 5, 17] the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company's vBloc(R) Neurometabolic Therapy has now been implanted at two additional vBloc Institutes [company press release, Jan 5, 17]

Medical-device maker EnteroMedics (Roseville, MN; no SBIR) raised $16 million after canceling an earlier [IPO] that aimed to reel in $35 million. ... to ramp up sales and marketing of its obesity device, product development and general corporate purposes ... makes an implantable device that treats obesity using electrical pulses to regulate nerves. The Food and Drug Administration approved the product early this year. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jul 8, 15]

FDA approved EnteroMedics (Roseville, MN; no SBIR)  implantable device for treating obesity, the company announced   [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jan 14, 15]

[FDA] approved a surgically implanted device to treat obesity in some adults. Called the Maestro system, the implant is the first to generate an intermittent electrical pulse that blocks nerve signals from the brain to the stomach, reducing hunger pangs.  ... The manufacturer, EnteroMedics  (St. Paul, MN; no SBIR), hopes to offer the implant at roughly 20 centers nationwide by the end of 2015. The price has not been set, and insurers have not decided whether to cover it.   [CATHERINE SAINT LOUIS, New York Times, JAN. 14, 2015]

EnteroMedics (St Paul, MN; no SBIR, 32 employees) raised $13 million through a stock offering. ...developing a device to treat obesity,  [Katherine Grayson, Minneapolis / St Paul Business Journal, Mar 8, 13]     proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses.  [Yahoo Finance]

EnteroMedics (Roseville, MN; no SBIR) considered one of the most promising local med-tech start-ups in recent years, said it is laying off about 18 percent of its workforce.... developing a pacemaker-like device to treat obesity ... went public in November 2007, raising about $40 million....  Last month, closed on a $20 million loan to help fund a 300-patient clinical study testing its obesity-fighting device. [Janet Moore, Minneapolis Star Tribune, Dec 2, 08]

Entia Biosciences (Sherwood, OR)

Entia Biosciences (Sherwood, OR; no SBIR) which is developing high-end skin care products and a nutritional supplement from mushrooms, has raised $360,000 ...  previously raised $1.5 million in 2013. It has completed a Parkinson’s studies with Harvard Medical School  ...  to use targeted genetics and nutrition to treat iron-related disorders, rather than using just a pharmaceutical approach    [Elizabeth Hayes, Portland Business Journal, May 14, 15]

Entira Bio

Entira Bioup 13% [Sep 6, 18]

Entopica Therapeutics (Andover, MA)

Entopica Therapeutics (Andover, MA; no SBIR), a stealth-mode drug development company incubating in the offices of Ora Inc., has sold $1 million in option or warrant securities to an unidentified investor ...  focusing on therapies to address “ear, nose and throat” maladies  [Mass High Tech, Mar 4, 10]

Entrada Therapeutics (Boston, MA)

Entrada Therapeutics (Boston, MA; no SBIR, founded 2016), a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics [developed by Ohio State University professor and company co-founder Dehua Pei], announced it has raised $59 million in a Series A financing. [company press release, Dec 19, 18]

EntreMed (Rockville, MD)

EntreMed (Rockville, MD; $1.5M SBIR) has been through plenty of turbulence. In 1998, it was the subject of a breathless front page New York Times story suggesting the biotech was on the verge of curing cancer, based on promising mice studies. Those hopes (and EntreMed's share price) deflated in the coming years, when the company found itself shedding jobs and executives and struggling to survive.  ....  changing its name to CASI Pharmaceuticals   [Bill Flook, Washington Business Journal, Jun 13, 14]  

Pharmaceutical developer EntreMed  (Rockville, MD; $1.5M SBIR) said this week that its market value is too low to meet requirements to retain its Nasdaq listing. [Washington Post, Aug 21, 10]

Entra Pharmaceuticals (Waltham, MA)

drug delivery startup Entra Pharmaceuticals  (Waltham, MA: no SBIR) raised $4.23 million in a first tranche of a Series A round, which could be expanded to $12.5 million by November 30 [Mass High Tech, Dec 18, 08]

ENTrigue Surgical (San Antonio, TX)

ArthroCarecompleted its acquisition of  ENTrigue Surgical (San Antonio, TX; no SBIR) for $45 million in cash, the companies said ....   develops implants, disposables and instruments for sinus surgery. [Kirk Ladendorf, Austin American Statesman, Jul 2, 13]

Entrotech Life Sciences (San Francisco, CA)

The companies [Jim] McGuire has developed include ones that make polymers for hard disk drives, car paint protectants, a super-thin film that has replaced spray paint on racing cars, carbon fiber lacrosse sticks, and medical devices designed for use on the battlefield.  .... These days, McGuire is mostly running Entrotech Life Sciences  (San Francisco, CA; no SBIR), that has developed or helped a similarly broad array of products. There's a medical dressing McGuire says can reduce hospital-acquired infections, a bandage that compresses wounds, a chest dressing that prevents air from entering the thorax through injuries, a device that illuminates veins in the dark through night vision goggles and a clamp tourniquet for bleeding. .... in Columbus, Ohio, where it started, one EntroGroup division, called AERO, makes a paint-replacement film that is so thin and durable Boeing is testing it for airplanes.   [Patrick Hoge, San Francisco Business Times, May 8, 14] 

Entvantage Diagnostics (Austin, TX)

Entvantage Diagnostics (Austin, TX; no SBIR) has secured $1 million of a $1.4 million round of capital to fund the development of a test to diagnose bacterial sinus infections. ... to cover all expenses in the six-month development phase of the test, which is based on research from Ohio State University and Nationwide Children’s Hospital in Columbus, Ohio.   [Chad Swiatecki, Austin Business Journal, Apr 22, 15]

Envia Systems (Hayward, CA)

Thievery charged.    Envia Systems  (Newark, CA; no SBIR), a battery startup, made a big splash in early 2012 when it claimed it had achieved a milestone: a rechargeable lithium-ion battery with the highest "energy density" ever recorded. The company had been awarded a $4 million grant from ARPA-E, the innovation arm of the Department of Energy, and General Motors invested in the company with the hopes of licensing the technology.  Now, in an explosive and highly detailed lawsuit, three of Envia's top former executives allege that Sujeet Kumar, the company's co-founder and chief technology officer, created the company using intellectual property that he stole outright from NanoeXa  (Santa Clara, CA; no SBIR), his previous employer. [Dana Hall, San Jose Mercury News, Dec 4, 13]

ARPA-E winners in San Francisco Bay area: Envia Systems (Hayward); NanOasis Technologies (Richmond);Pax Streamline, (San Rafael); and Stanford University. None had SBIR. official list of winners

EnviroFlight ((Yellow Springs,OH)

EnviroFlight (Yellow Springs, OH; no SBIR)  was recently acquired by  [synthetic biology firm] Intrexon (West Palm Beach, FL; no SBIR) [Kaitlin Schroeder, Dayton Business Journal, Apr 15, 15]  develops sustainable animal and plant nutrients using regionally available, low-value materials. ... “We produce the insect proteins to feed the fish, to feed the people.”   [Enviro website]

Envisia Therapeutics (Research Triangle Park, NC)

Investors in Envisia Therapeutics (Research Triangle Park, NC; no SBIR) are pumping $16.5 million more into the eye drug developer to carry the company’s lead candidate, a potential glaucoma treatment, through mid-stage clinical trials.  Envisia’s new financing adds to the $25 million Series A round the company initially raised in 2013. At that time, Envisia was spun out of nanotechnology company Liquidia Technologies. .... Rather than developing a new drug, Envisia is trying to administer an old one more effectively.    [Danielle Kurtzleben, NPR, Mar 24, 16]

drug developer Envisia Therapeutics (Research Triangle Park, NC; no SBIR, 23 employees) reported positive results for a possible next-generation glaucoma treatment. ...  ENV515 showed comparable results to Travatan Z, a once-daily eye drop made by Alcon (no SBIR). Envisia reports these as positive because if its product can show the same results, but must be applied only once every six months, it could become a more desirable treatment.  Alcon was founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Alcon is now the second-largest division of Novartis with sales topping $10 billion.  ...  Envisia Therapeutics spun out of Liquidia Technologies (one SBIR) in late 2013. ... raised $25 million from Liquidia investors   [Jason deBruyn, Triangle Business Journal, Oct 6, 15]

GlaxoSmithKline exercised an option that gives the company the exclusive rights to nearly all inhaled uses of a particle manipulating technology developed by Liquidia Technologies  (Research Triangle Park, NC; one SBIR, founded 2004 as spun out of UNC-Chapel Hill, 50 employees).  ... More recently, [Liquida] spun out two separate companies: Envisia Therapeutics, to develop new drugs targeted at glaucoma and cataracts, and Lq3 Pharmaceuticals, to focus on advancing therapies for oral health conditions. Envisia has 23 employees and Lq3 has seven   [Jason deBruyn, Triangle Business Journal, Sep 30, 15]

Liquidia Technologies (Research Triangle Park, NC; no SBIR, founded 2004) drug-development company, has spun out its second new company in the past year. The latest spinoff, Lq3 Pharmaceuticals, will focus on developing therapies for oral health conditions using Liquidia’s technology. The company has raised $10 in venture capital ...  Liquidia's proprietary Particle Replication In Non-Wetting Templates, or PRINT, technology to develop therapies. PRINT enables precise engineering of the size and shape of microscopic particles, which can then be combined with drugs for delivery to targeted tissues within the body. ... Liquidia’s other recent spin off, Envisia Therapeutics, is also using the PRINT technology to focus on developing ophthalmology products. Envisia was launched in November and has raised $25 million from venture capital firms that have also invested in Liquidia.   [David Bracken, Raleigh News & Observer, Sep 10, 14]

The management team behind Liquidia Technologies (Research Triangle Park, NC; one SBIR) drug-development company, has created a new company to focus exclusively on using Liquidia’s technology to develop ophthalmology products. The new company, Envisia Therapeutics, announced it has raised $25 million from a group of venture capital firms [David Bracken, Raleigh News & Observer, Nov 12, 13]


Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]

EnVivo Pharma (Cambridge, MA)

EnVivo Pharmaceuticals (Redwood City, CA; one SBIR) and FoldRx Pharmaceuticals (no SBIR) will share with four other companies a $2.1 million grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). [Mass High Tech, Jan 26, 10]

EnVivo Pharmaceuticals (Watertown, MA; one Phase 1 SBIR) has announced positive results, including a reversal of behavior characteristic of Alzheimer’s disease in animal testing, for its drug candidate EVP-0962. .... last received funding in the amount of $65 million from a fourth-round venture capital financing [Mass High Tech, Jul 15, 09]

EnVivo Pharma (Cambridge, MA; one SBIR) got $65M in fourth round VC from Fidelity Biosciences which has already bought out other investors.   Total funding $125M.  [Mass High Tech, Nov 3, 08]

Enzium (Philadelphia, PA)

BioAdvance, the operator of a $50 million early stage life sciences fund that work with health-care entrepreneurs in the mid-Atlantic region, invested $2.9 million in companies and technologies targeting human health during fiscal 2016. Among the winners were:   

  • Genome Profiling (Newark, DE; no SBIR)  $100,000 to discover novel epigenetic biomarkers based on its proprietary, genome-wide methylation profiling platform to improve how to treat, diagnose, and predict chronic and life-threatening disease;
  • Mebias Discovery (Philadelphia, PA; no SBIR) $800,000 to launch its platform for identifying biased ligands for next generation GPCR drugs;
  • Enzium (Philadelphia,PA; no SBIR)  $140,000 to develop its proprietary protease assay technology for use in measuring drug levels of the new direct oral anticoagulants in patients;
  • Hsiri Therapeutics (King of Prussia, PA; no SBIR) $70,000 to develop novel siderophore-based antibiotics for hard-to-treat bacteria;
  • RiboNova (Wynnewood, PA;  no SBIR) $175,000 to develop small molecules against novel defective transfer RNA anti-cancer targets and to pursue a clinical trial in mitochondrial diseases.  
[John George, Philadelphia Business Journal, Aug 5, 2016]

The DOD spooks renewed their license subscription for Ezenia (Burlington, MA; $800K SBIR) InfoWorkSpace product, The DIA has used InfoWorkSpace the past nine years. [company statements] Note: the spooks needn't do SBIR.


BioAdvance, operator of the Biotechnology Greenhouse Corp. of Southeastern Pennsylvania, said it made commitments of $2.4 million to seven new life science companies:  RMH Sciences  (Philadelphia, PA; no SBIR) which is developing antibacterial agents for the treatment of resistant gram negative and gram positive infections; Ossianix  (no SBIR), which is developing single domain antibodies based on the shark VNAR structure to treat immunological, inflammatory, musculoskeletal, neurologic, and other disorders; Merganser Biotech (Newtown Square, PA; no SBIR) which is developing hepcidin peptides for the treatment of hemoglobinopathies such as sickle cell anemia and diseases of iron overload; Anakim Biologics (Exton, PA; no SBIR) which is developing efficiencies and improvements in biologics manufacturing; Enzium (Philadelphia, PA; no SBIR) which is developing highly sensitive biosensor methodologies for the testing of proteases and other enzymes; Imiplex (Newtown, PA; two SBIRs) which is developing the TriPol platform, engineered from proteins, designed to provide a flexible system for constructing diverse nanostructures; Cool-Bio (Wayne, PA; no SBIR) which is developing platelet-inhibiting technology geared specifically to activation during the cooling process of cardiac bypass.  [John George, Philadelphia Business Journal, Jun 20, 12]

Enzo Biochem

Enzo Biochem (New York, NY; $1.6M SBIR) up 50% [Mar 6, 20] announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. [company press release, Mar 6, 20]

Enzo Biochem (NYC, NY; $1.5M SBIR) up 13% [Jun 9,17]

Enzo Biochem ($1.4M SBIR) up 10%  [Nov 11, 15]

Enzo Biochem up 15% [Feb 24, 15]

Enzo Biochem up 12% [Dec 17, 14]

Enzo Biochem down 10% [Dec 15, 14]

Enzo Biochem (traded NYSE; $1.6M SBIR) up 10% [Aug 6, 14]

Enzo Biochem down 11% [Aug 19, 10]

Enzo Biochem down 10% [Aug 11, 10]

Enzo Biochem up 11% [Jul 23, 10]

Enzo Biochem  down 12% [Jan 21,10]

Enzo Biochem up 10% [Dec 1, 09]

Enzo Biochem up 11% [Sep 23, 09]

Enzo Biochem up 17% [Jul 15, 09]

Enzo Biochem  down 10% [Jul 2, 09]

Enzo Biochem down 12% [Jun 16, 09]

Enzo Biochem up 10% [Apr 2, 09]

Enzo Biochem  up 10% [Mar 23,09]

Enzo Biochem up 12% [Mar 11, 09]

Enzo Biochem  down 12% [Mar 5, 09]

Enzo Biochem down 11% [Jan 20, 09]

Enzo Biochem up 12% [Jan 13, 09]

Enzo Biochem down 10% [Jan 9, 09]

Enzo Biochem down 10% [Dec 11, 08]

Enzo Biochem  up 18% [Dec 2, 08]

Enzo Biochem down 18% [Dec 1, 08]  On a stock bloodbath day

Enzo Biochem up 17% [Nov 26, 08]

Enzo Biochem up 23% [Nov 21, 08]

Enzo Biochem up 14% [Nov 13, 08]

Enzo Biochem up 14% [Nov 4, 08]

Enzo Biochem down 11% [Oct 21, 08]

Enzo Biochem up 13% [Oct 20, 08]

Enzo Biochem down 11% [Oct 17, 08]

Enzo Biochem down 15% [Oct 15, 08]

Enzo Biochem down 12% [Oct 8, 08]

Enzo Biochem down 26% [Oct 9, 08]

Enzo Biochem up 10% [Jun 12, 08]

Enzo Biochem  up 11% [Mar 18, 08]

Enzo Biochem up 16% [Dec 6, 07]

Enzo Biochem up 13% on good financials. [Oct 16, 07]

Enzo Biochem up 11%  [Aug 8, 07]

Enzo Biochem Up 19% [Aug 7, 07]

Enzymatics(Beverly, MA)

Enzymatics (Beverly, MA; no SBIR, founded in 2006) that makes enzymes for use in DNA sequencing, has bought  ArcherDx (Boulder, CO; no SBIR) [which makes a test for a specific gene mutation common to several types of cancers] in what may be the first in a series of acquisitions of startups that make diagnostic tests that use those enzymes.  [Don Seiffert, Boston Business Journal, Sep 7, 13]

EnzyMed (Iowa City, IA)

Richard Gross founded SyntheZyme (Brooklyn, NY; $150K SBIR, founded 2008) to commercialize biocatalysis (with natural molecules). This year partnered with DSM (Netherlands).  From the same chemistry department , Prof Jonathan Dordick pursuing biocatalysis over 30 years, founded Solidus Biosciences (Troy, NY; $3.5M SBIR). Dordick also founded EnzyMed (Iowa City, IA; $200K SBIR) that was sold to Albany Molecular in 1999.  [Rensselaer magazine, Fall 2014]

Enzyvant (Cambridge, MA)

Enzyvant (Cambridge, MA; no SBIR) that licensed the [Duke University] rights to the [DiGeorge anomaly] therapy, is now preparing to file for FDA approval. [Frank Vinluan,, Mar 5, 18]

EO2 Concepts (San Antonio, TX)

EO2 Concepts (San Antonio, TX; no SBIR)  medical device company says its product could potentially be more effective on chronic wounds than other treatments and limit healthcare costs. EO2 Concepts has released results from a recently completed clinical trial of its device—a therapy that uses a constant stream of oxygen to treat chronic wounds like ulcers—that it says showed the device performed better than the standard of care.  [Angela Shah,, Feb 21,17]

EO2 Concepts (San Antonio, TX; no SBIR) focused on advanced wound care, has reached a key milestone en route to commercializing [ready to raise up to $12M] its initial product called the TransCu O2 System — completing a double-blind study of patients with chronic wounds treated using the technology.  [W. Scott Bailey,  San Antonio Business Journal, Jan 13, 17]

EOIR Technologies (Spottsylvania, VA)

EOIR Technologies (Spottsylvania, VA) (a subsidiary of Technest Holdings) got a $3.4M Army contract including night vision and advanced sensor applications, disposable sensors and other threat-detection systems. Since July , EOIR Technologies has brought another $29M under the overarching contract to add to its funded backlog of $55M.[story Mass High Tech, Dec 2]  EOIR had one Army Phase 2 in 2003 for chemical agent detection.

Eonix (Colonie,NY)

Two Albany area startups in the battery and energy storage industry have been awarded $250,000 in New York state funding for product development. Eonix (Colonie, NY; no SBIR) [startup developing technology to expand the capacity of ultracapacitors] and Combined Energies (Latham, NY;  SBIR) [developing distributed generation systems to extend the life of electrochemical batteries] were among the nine companies that received funding from the New York State Energy Research and Development Authority.  ... also gave $250,000 to Hollingsworth & Vose  (East Walpole, MA; no SBIR) an advanced materials manufacturing company with filtration, battery separator and industrial applications.   [Megan Rogers, Albany Business Review, Oct 27, 14]  Since 2012, the state agency has funded Paper Battery Co., BESS Technologies, Rensselaer Polytechnic Institute, and many other state entities. 

EpiBiome (Union City, CA)

Genomics startups are increasing in number and quality, so much so that three-year-old Illumina Accelerator has expanded with its latest class to accommodate five of them.  ... provides genomics-focused startups with capital, lab space at Illumina Accelerator’s offices in San Francisco, access to Illumina’s sequencing equipment and expertise, and advice on developing a business from legal experts, recruiting professionals, and Illumina executives and scientists, says Amanda Cashin, co-founder and head of the accelerator.  ..... takes an 8 percent equity stake ..   Checkerspot: designing advanced physical materials that can be used in industrial applications; Chimera Bioengineering:  aims to improve the efficacy and reduce the side effects of engineered cell therapies for oncology;  Encompass Bioscience:  wants to integrate genetic information into the healthcare system; Mantra Bio: studies exosomes, small lipid vesicles that are excreted from cells and deliver information, aiming to discover new drug targets and therapies;  Solarea Bio: The only company not from the Bay Area, Boston-based Solarea is developing probiotic treatments that are derived from natural sources   ....   Of the previous 13 startups that have completed the program since 2014, a few have already made some funding splashes.  Xcell Biosciences (San Francisco, CA; no SBIR) develops a type of cell culture that can be used in certain types of cell propagation and gene editing, raised a $12 million Series A round of funding in February.  EpiBiome (South San Francisco, Ca) raised a $6 million seed Series A round of funding for its process of engineering microbiomes that might be used against drug-resistant bacteria in early 2016.  Trace Genomics (New York) raised a $4 million seed round in mid-2016 for its work sequencing and analyzing the genomes of soil.     [David Holley,, Jul 26, 17]  

Illumina revealed the first three companies admitted to its six-month accelerator program in San Francisco for genomics-related startups. The three companiesEncoded Genomics  (San Francisco, CA; no SBIR), Xcell Biosciences (San Francisco, CA; no SBIR), and EpiBiome  (Union City, CA; no SBIR) —get full access to Illumina’s next-generation gene sequencing systems.  [Alex Lash,, Oct 17, 14]

EpiBone (New York, NY)

Wealthy investor Peter Thiel put money into three biotech startups through his Breakout Labs, a nonprofit fund aimed at scientific innovation.  Breakout Labs, led by Executive Director Lindy Fishburne, has now invested in 19 companies.  The three most recent investments are:   Cortexyme (San Francisco, CA;  no SBIR) seeking treatments for Alzheimer's and other aging disorders;      G-Tech Medical (Palo Alto, CA;  no SBIR) working on a wireless, wearable sensor that will track muscle activity in a person's gastrointestinal system;    EpiBone  (New York, NY; no SBIR) engineers a patient's own living bone to fit where there's a defect. Breakout Labs gives up to $350,000 to the startups it supports.  [Silicon Valley Business Journal, Jun 11, 14] 

Epicentre Biotechnologies (Madison, WI)

Epicentre Biotechnologies (Madison, WI, three SBIRs) has been acquired for an undisclosed price by Illumina. ...  founded in 1987, makes research tools used for gene sequencing and genetic tests.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 12, 11]

Epic Sciences(La Jolla, CA

Oncology diagnostics company Epic Sciences (San Diego, CA; $1.2M SBIR, founded 2008) announced that the company has completed a $52 million Series financing ... will advance a portfolio of predictive tests and decision support analytics that can guide clinicians and patients toward the ideal cancer drugs to prolong life and minimize spend on ineffective therapies. [company press release, Sep 12, 18] total funding $152M []

Epic Sciences (San Diego, CA; no SBIR) announced that the company has completed a $40 million Series D financing ....  is developing a portfolio of blood-based tests that predict drug response in cancer and recently partnered with Genomic Health to commercialize the OncotypeDx® AR-V7 Nucleus Detect™ test to leverage Genomic Health’s world-class commercial channel and enterprise systems.  [company press release, Apr 28, 17]

Epic Sciences (San Diego, CA;  no SBIR) said it had raised an additional $40 million that will be used in part to bring the first of these diagnostic tests to market under a partnership with Genomic Health (no SBIR).  .... has been rapidly developing a portfolio, a series of predictive tests for cancer that tell a doctor whether a specific drug will work,” Prahalad said in a phone interview  [Bruce Bigelow,, May 1, 17]

Epic Sciences  (San Diego, CA; $200K SBIR, 60 employees), a spinoff of The Scripps Research Institute developing cancer diagnostics, has raised $30 million from venture capital investors  ....  has developed a test to find and characterize tumor cells circulating in the blood, a less invasive way of diagnosing cancer than extracting solid tissue for biopsies. ....  Pharmaceutical partners include Genentech, Pfizer and Celgene, [CEO Murali Prahalad] said.   [Bradley Fikes,, Jul 30, 14]

Epic Sciences (La Jolla, CA; one SBIR) has raised $13 million from venture capital investors, the cancer diagnostics company said Tuesday.... bring to market cancer tests based on tumor cells found circulating in the blood, said [CEO] David Nelson  [Bradley Fikes, utsandiego, Nov 13, 12]

Epicypher (Woodlands,TX)

Epicypher(Woodlands, TX;  no SBIR, founded 2012) recently raised more than $90,000 in equity and plans to use the funds to pay employees and manufacture its products. ..... manufactures and sells products used to perform research of cell biology  [Bayan Raji, Houston Business Journal, Jun 6, 13]

Epic Systems (Verona, WI)

She made it; she'll give it. Judith Faulkner, founder and CEO of electronic health-records vendor Epic Systems  (Verona, WI; no SBIR, founded 1979), will leave much of her stake in the privately held company to a charitable foundation, Modern Healthcare reports.  The estate gift to the Epic Heritage Foundation will comprise nearly every share of stock that Faulkner owns. Exactly how much her share of Epic Systems, which has an estimated value of $12.5 billion, is worth is not publicly known, but Forbes ranks her 239th on its list of the four hundred wealthiest Americans with an estimated net worth of $2.8 billion. [, Jan 26, 16]

EpiCypher (Research Triangle Park, NC)

NCBiotech announced last week that it had awarded $1,060,352 through 17 grants and loans in the first quarter of its 2016-17 fiscal year. In total, four Triangle firms snagged funding.  InnAVasc Medical (Durham, NC; no SBIR), 410 Medical Innovation  (Durham, NC; no SBIR), UVision360 (Research Triangle Park, NC; no SBIR), and EpiCypher  (Research Triangle Park, NC; no SBIR) each received a $250,000 small business research loan for applied research, NCBiotech said.   [Jennifer Henderson, Triangle Business Journal, Oct 20, 16]

EpiEP (New Haven, CT)

EpiEP (New Haven,CT; no SBIR)  received its second $1 million investment from Connecticut Innovations in as many years....  makes a device that verifies the outside surface of the heart has been accessed in order to treat arrhythmia, is in clinical trials in Europe. It has successfully completed animal trials at the Mayo Clinic ... moved from Virginia in 2010 ... The state is borrowing $25 million this year to send more cash to CI for investments such as this one.  [Mara Lee, Hartford Courant, Jan 31, 12]

medical device startup EpiEP New Haven, CT; no SBIR). has boosted its latest funding round to take in $1.4 million of a planned $1.5 million financing, according to federal documents. ... Founded as a spinout from the University of Virginia, EpiEP moved to New Haven in June of 2010 upon receiving a $1 million commitment for the $1.5 million funding round from Connecticut Innovations ... The initial product for EpiEP is the EpiAccess system, a minimally invasive way to help control cardiac arrhythmia [Rodney Brown, Mass High Tech, Jul 8,11]

Epigen Bioscience (San Diego, CA)

Novo Nordisk (Denmark) has picked up the worldwide rights to a kidney disease drug in development at Epigen Bioscience(San Diego, CA; $5M SBIR) [which] gives Novo control of orally available LPA1 receptor antagonist EPGN696 in exchange for up to $200 million in upfront and milestone payments. [Nick Paul Taylor, Fierce Biotech, May 24, 18]

Epion (Billerica, MA)

Exogenesis (Billerica,MA; no SBIR), a gas cluster ion beam (GCIB) technology firm in Billerica, has raised $3.19 million in an equity and  securities offering ... Founded in 2005, Exogenesis uses the GCIB technology to process implantable medical devices, according to the Exogenesis website. The company has developed the ClusterCoat Processing System, used in surface coating medical devices by changing the physical and chemical properties of the atomic layers of a surface. Exogenesis’ core technology, GCIB, was first developed in the 1990s at Kyoto University’s Ion Beam Engineering Experimental Laboratory, with further development conducted at Epion (Billerica, MA; $4.8M SBIR) in the US  [Michelle Lang, Mass High Tech, Dec 1, 10]

Epiphany Solar Water Systems (New Castle, PA)

Epiphany Solar Water Systems (New Castle, PA; no SBIR) named Pittsburgh Innovator of the [2012] Year ...  began in 2005 when Tom Joseph and Henry Wandrie first conceived of a simple and inexpensive method of distilling water with concentrated solar energy.  ....    seed funding from Innovation Works (a PA Ben Franklin Technology Partner) in 2009 ....  a parabolic concentrating dish to focus sunlight on a proprietary, high-throughput distillation unit mounted at the dish’s focal point [company website, Feb 14, 13] Meanwhile,The Pennsylvania Sunshine program is on its last leg, with $7.25 million in new solar rebates expected to close out the $100 million program that started in 2009.  [Anya Litvak, Pittsburgh Business Times, Feb 1]

Epirus {Los Angeles, CA)

Toasting drones in battle. Epirus (Hawthorne, CA; $700K SBIR) announced they had won a $66 million prototyping contract from the Army’s Rapid Capabilities and Critical Technologies Office for its experimental Leonidas counterdrone microwave weapon ... Epirus privately funded the research, development and validation of its systems. [company press release, Jan 23, 2023]

Epirus {Los Angeles, CA; $250K SBIR, founded 2018) announced their solution to the problem [of drone swarms]: a microwave-emitting pod that can sit on the bottom of heavy-lift drones and quickly down sudden drone swarms. [DefOne, Feb 14, 22] a startup company that develops directed energy systems and is working with General Dynamics to add counter-unmanned aerial system capabilities to Strykers, has a technology platform that brings high power density and efficiency, according to the AAL release. [, Jan 30, 22]

Epitomics (Burlingame, CA)

Epitomics (Burlingame, CA; $1.2M SBIR) is spinning out an antibody development company aimed at cancer and immuno-disorder treatments for humans and animals....  the new company, Apexigen, was split off to Epitomics shareholders.  ...  Epitomics for years has sold to drug developers humanized rabbit monoclonal antibodies, which it calls RabMAbs, as a backup system to antibodies derived from mice.  [Ron Leuty, San Francisco Business Times, Aug 13, 10]

Epiva Biosciences

Flagship Ventures announced the merger of its portfolio companies Evelo Biosciences (Cambridge, MA; no SBIR, founded 2014) and Epiva Biosciences to create the leading immuno-microbiome company, developing therapeutics for cancer, autoimmune and inflammatory diseases. The new entity will keep the name Evelo Biosciences (40 employees).   ...  Flagship has financed the company with about $40 million to date and plans to make additional investments to support its rapid growth.  [Evelo press release, Jun 12, 16]

EpiVax (Providence, RI)

EpiVax (Providence, RI; $4.5M SBIR) developer of therapeutics for cancer and autoimmune diseases, has attracted a $458,000 grant from the National Institute of Allergy and Infectious Diseases, ...  to develop a universal influenza vaccine. [Michelle Lang, Mass High Tech, Jan 26, 11]

NIH gave EpiVax (Providence, RI; $3M SBIR, 16 employees) two more SBIRs totaling $1M for vaccine and diabetes work.  Which brings the company's grants to $2.5M for the year. [Mass High Tech, Dec 1, 08]

EpiVax (Providence, RI; $3.6 M SBIR) got a $600K NIH grant to develop a treatment for type 1 diabetes. [Mass High Tech, Jul 8, 08]

EpiVax (Providence, R.I) got a $358K Innovative Research Grant to re-engineer botulinum toxin (Botox). It already had about $3M in SBIR.

EpiWorks (Champaign, IL)

II‐VI (Saxonburg, PA; $4.3M SBIR) announced that it signed agreements to acquire two businesses that will expand its technology platforms and production capacity for semiconductor lasers with a scalable 6‐inch epitaxial growth and wafer fabrication platform.    These acquisitions will further position the company to serve fast‐growing markets addressed by Vertical Cavity Surface Emitting Lasers (VCSELs). ...  EpiWorks  (Champaign, IL; $2.4M SBIR), global leader in high volume epitaxial growth of compound semiconductor wafers ....   ANADIGICS (Warren, NJ; $600K SBIR)  a high volume foundry unmatched in the production of 6‐inch gallium arsenide (GaAs) wafers. [II-VI press release, Jan 19, 16]

Epix Pharmaceuticals

At least five Massachusetts biotechs — Dynogen Pharmaceuticals Inc., Epix Pharmaceuticals, Oscient Pharmaceuticals, Biopure Corp. and Altus — have more or less ceased operations since the stock market meltdown in September 2008.  [Julie Donnelly, Mass High Tech, Mar 5, 10]

Epix Pharmaceuticals (no SBIR) has became the second Massachusetts biotechnology company in the past week to fold, raising fresh concerns about the health of the sector.  [Boston Globe, Jul 22]

EPIX Pharmaceuticals said that the US Food and Drug Administration has approved a use for Vasovist, its blood pool magnetic resonance angiography agent. [Boston Globe, Dec 23, 08]

Epix Pharmaceuticals (no SBIR) shares have shed about half their value and are trading at all-time lows after the company stopped development of an experimental depression treatment. [Boston Globe, Mar 21]

Epizyme (Cambridge, MA)

Epizyme down 24% [Nov 6, 20] announced that the company has entered into an amended and restated agreement with funds managed by Pharmakon Advisors, LP, an affiliate of Royalty Pharma, to expand its loan facility and plans to draw down $150 million. [company press release, Nov 6, 20]

Epizyme (Cambridge, MA; no SBIR) a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the [FDA] has approved the supplemental New Drug Application (sNDA) for TAZVERIK™ (tazemetostat) for two distinct follicular lymphoma (FL) indications.    [company press release, Jun 18, 20]

Epizyme down 16% [Jan 24, 20] Epizyme won accelerated FDA approval for a drug developed to treat the rare cancer epithelioid sarcoma (ES). [Frank Vinluan,, Jan 23, 20]

Epizyme up 19% [Dec 6, 19]

Epizyme up 18% [Nov 5, 19]

Epizyme up 33% [Jan 4, 19]

Epizyme down 24% [Aug 2, 18] reported quarterly results

Epizyme down 15% [Apr 24, 18]

Epizyme up 10% [Apr 10, 18]

Epizyme down 10% [Nov 2, 17]

Epizyme up 14% [Aug 4, 17]

Epizyme up 17% [Jun 15,17]

Epizyme up 11% [Jun 14,17]

Epizyme up 17% [Apr 25, 17]

Epizyme up 12% [Sep 12, 16]

Epizyme down 10% [Sep 9, 16]

Epizyme up 11% [Sep 7, 16]

Epizyme down 12% [Aug 8, 16]

Epizyme down 24% [Jan 6, 16]

Epizyme up 13% [Nov 21, 13]

Epizyme down 37% [Nov 14, 13]

Epizyme down 14% [Aug 19, 13]

Epizyme down 11% [Jul 22, 13]

Epizyme (Cambridge, MA; no SBIR) armed with UNC-developed technology has announced terms for an [IPO]. ... develops enzyme-based treatments for genetic cancers, plans to raise $60 million [Lauren Ohnesorge, Triangle Business Journal, May 21, 13] 

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals (Cambridge, MA; no SBIR) Epizyme (Cambridge, MA; no SBIR) and Karyopharm Therapeutics (Natick, MA; no SBIR) Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.  [press release, Jan 6, 11]

Epizyme (Cambridge, MA; no SBIR) has entered into a cancer therapeutics development and commercialization alliance with GlaxoSmithKline worth potentially more than $630 million in milestone payments. ...  to conduct research into small molecule therapeutics that target a class of epigenetic enzymes, called histone methyltransferases (HMTs), in treating cancer. [Michelle Lang, Mass High Tech, Jan 10, 11]

Epizyme (Cambridge, MA; no SBIR) raised an additional $8 million dollars to close out a series B financing totalling $40 million. ... announced in September that it had raised $32 million [Mass High Tech, Dec 9, 09]

Epizyme (Cambridge, MA; no SBIR) closed a $32 million series B funding round ... focuses on therapeutics that inhibit those enzymes that are potentially responsible for certain cancers, inflammatory conditions, metabolic disorders and neurodegenerative diseases.  [Mass High Tech, Oct 8, 09]

Eppin Pharma (Chapel Hill, NC)

Real seed investment. On average, every dollar N.C. Biotech loans to young life science companies is met with $118 in additional funding to those firms from disease philanthropy and government grants, angel and venture investment and other financial support, according to the center. Every grant dollar is met with an average $28 in additional funding.  ...  loans and grant made by the Biotech Center in the second fiscal quarter:      $50,000 in a Company Inception Loan to Spyrix (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, developing a treatment for cystic fibrosis. The loan is intended to help position the company for outside investor and foundation funding and to help with preclinical development of its product.       $75,000 to Eppin Pharma (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, to help in its development of a reversible, oral, non-hormonal male contraceptive pill. This money will help support toxicology and other testing of the company's lead drug candidate and help position Eppin to seek additional funding from investors, federal grants and foundations.       $250,000 to Dignify Therapeutics (Research Triangle Park, NC; one SBIR, eight employees), developing a novel drug to help people with spinal injuries clear their bladders and bowels when they choose to do so. The loan will support studies of the drug's safety and help Dignify develop a final formulation of the remedy, for use in clinical trials.      $458,000 to Bioptigen  (Morrisville, NC; $2.9M SBIR), to support late-stage development and clinical testing needed for FDA approval of its intrasurgical optical coherence tomography device for real-time guidance of ophthalmic surgery.       $500,000 to Baebies (Durham, NC; no SBIR),  to help it develop its products to diagnose health risks in infants from a single dried blood spot, using a technology called digital microfluidics. This loan supports the company's newborn screening tests for three devastating disorders (Pompe, biotinidase deficiency and galactosemia).  [Jason deBruyn,Triangle Business Journal, Feb 4, 15]   SBIR has no chance of such rewarding results because about three-fourths of the money is spent by agencies that just want what they can use for their own purposes with no regard for whether there is any widespread economic payoff, nor any payoff to society. SBIR can hide these facts behind privacy of private business whihc is OK with Congress as long as the small biz get the prescribed handouts.

EQRx (Cambridge, MA)

EQRx (Cambridge, MA; no SBIR) announced it is launching [with $200 million in Series A financing] to create novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems. EQRx, a first of its kind biotechnology company, is focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. [company press release, Jan 12, 20]  total funding $200M []


last month EqualLogic , a New Hampshire data storage start-up, was just days away from its initial public offering when Dell, the Texas-based computer maker, floated a formal offer to buy the company.  The price tag was $1.4 B cash. ..great news for EqualLogic's employees and its venture capital investors  ... But every sale of a promising New England start-up to an out-of-state entity makes our region feel a bit more like we're running a farm team, rather than playing in the majors. ... we also need to build the next generation of "pillar companies" here - companies like EMC , Genzyme , Boston Scientific , Hologic , and Nuance Communications These companies employ hundreds or thousands of people. They're acquirers, not acquirees. They lead industries, set the agenda, and attract the attention of media and Wall Street analysts. Smaller companies cluster around them.  [Scott Kirsner, Boston Globe, Dec 16]  What might the federal role be in doing the same thing for the nation? Well, if SBIR is to be one of such engines, it has to focus on companies with a future, not just a scientifically competent present.

Equex (Houston,TX)

(Apr 8) Although Howard Schmidt still has an equity position (of declining value) in his foundee SI Diamond Technology, he has a new enterprise. A web-based supplies exchange, Equex. in Houston. Howard founded Schmidt Instruments after leaving nearby Ionwerks with "$275 and not enough sense to know better", got SBIR for diamond research, took a license on a gamma-ray spinoff technology to make nearly diamond, went public in 1993, and flopped when the display development outran its capital. If good entrepreneurs are told by their scars, Howard is ready for success. Maybe, as Randy Frey said at the SBIR Conference, "The harder you work, the luckier you get."

Equillium (La Jolla, CA)

Equillium (La Jolla, CA; no SBIR) down 47% [Jul 14, 20] announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19. Biocon has announced that the Drugs Controller General of India (DCGI), the regulatory agency that oversees drug approvals, has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome (CRS) in COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in India. [company press release, Jul 13, 20]

Equillium (La Jolla, CA; no SBIR, founded 2017) filed for an IPO to finance clinical testing of a drug to treat graft-versus-host disease. [Ben Fidler,, Sep 28, 18] leveraging deep understanding of immunobiology to develop products for autoimmune and inflammatory disorders. []

Equipment Concepts

Fifteen of the 18 machines that Equipment Concepts is exhibiting at Wisconsin Manufacturing and Machine Tool Expo are completely new models since the last show in 2005.  It's proof of how fast the machine-tool industry is evolving, said Mike McNamara, president of the Mukwonago-based company.

EraGen Biosciences (Madison, WI)

Luminex (Austin, TX; $800K SBIR) ) has agreed to acquire a Wisconsin diagnostic testing company for $34 million in cash. .... Luminex, which makes testing systems for biotechnology companies, said EraGen Biosciences (Madison, WI; $4.7M SBIR)  provides it with access to a highly complementary portfolio of molecular diagnostics. Founded in 1999, EraGen generated $8 million in product revenue in 2010. Luminex said it expects the acquisition to add between $5 million and $7 million to its 2011 revenue. EraGen has 70 employees. Luminex said operations are expected to remain in Wisconsin. [Austin American Statesman, Jun 22, 11]

Erallo Technologies (Littleton, MA)

Listen to the bridges. Erallo Technologies (LIttleton, MA;  $300K SBIR) won an Army $730K Phase II SBIR to develop a smart sensor system to monitor the safety of temporary bridges, the company announced. ... specializes in wireless sensor networks with remote monitoring capabilities to detect and report for defense and industry applications.....  has not sought venture capital funding yet because he believes the market for it isn’t there, but said that eventually he may seek investors. ....  Erallo was reconstituted from a telecom solutions and services company established in the early 1990’s.  [Mass High Tech, Feb 29, 12]

Erasca (San Diego, CA)

Erasca (San Diego, CA; no SBIR), whose mission is to erase cancer, announced the completion of a $200 million Series B financing [to] to support the clinical development of multiple promising oncology programs and further advance the company’s in-house drug discovery pipeline. [company press release, Apr 27, 20]

Erasca (San Diego, CA; no SBIR, founded 2018) dedicated to advancing exceptional scientific approaches to erase cancer, has closed an extension to its Series A financing round, bringing the total raised to $64 million [to] support the company's efforts to potentially in-license new investigational compounds in development, while also accelerating the buildout of Erasca's artificial intelligence (AI) platform that will drive discovery and development of a new generation of oncology drugs designed to not just treat, but actually cure, cancer. [company press release, Mar 5, 19] prior funding $42M []

Erasca (San Diego, CA; no SBIR) raised a $42 million series A round to work toward the lofty goal to “not just treat, but actually cure cancer.” [Amirah Al Idrus, Fierce Biotech, Dec 18, 2018]

Ercole Biotech (RTP,NC)

Ercole Biotech , (RTP, NC; one Phase 2 SBIR) a UNC-Chapel Hill spinoff that employs eight, will be bought by a Portland, Ore., drug development company [AVI BioPharma ($1.5M SBIR)] in a $9 million stock and cash deal. ...The drug is being tested in humans in Britain  [Raleigh News&Observer, Mar 15, 08]

ERT (Philadelphia, PA)

ERT (Philadelphia, PA), a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has acquired Biomedical Systems (Maryland Heights, MO; no SBIR), a well-recognized provider of reliable imaging as well as cardiac safety and respiratory data collection solutions. Coupled with its recent addition of imaging technology invented by the Cleveland Clinic, the acquisition of Biomedical Systems enables ERT to further expand its ability to reduce customer risk and uncertainty when imaging, cardiac safety and respiratory data collection are required. In particular, the acquisition positions ERT to better meet the significant demand for imaging in clinical trials, which is being driven from regulators’ increasing requests that imaging data be included in submissions.  [ERT press release, Sep 8, 17]

Escalier Biosciences BV (Encinitas, CA and the Netherlands))

Escalier Biosciences BV (Encinitas, CA and the Netherlands) announced the closing of a $19 million Series B financing. .... is developing both topical and oral RORγt drug candidates for psoriasis and expects to be in the clinic with its topical compound in mid 2018.  [company press release, Mar 15, 18]

Escalon Medical (Wayne, PA)

Escalon Medical (Wayne, PA; no SBIR) completed a $1.1 million private placement of common stock and common stock purchase warrants.  Founded in 1987, Escalon develops and markets ophthalmic diagnostic, surgical and pharmaceutical products along with vascular access devices.  [Philadelphia Business Journal, Nov 21, 08]

E-Scape Bio (South San Francisco, CA)

neurodegenerative disease upstart E-Scape Bio (South San Francisco, CA; no SBIR) closed an extension of its series A round, boosting its cash to $63 million.  ...   working on small-molecule drugs that target the inherited genetic drivers of neurodegenerative disorders and correct the dysfunctional proteins at the root of the disease.  [Ben Adams, Fierce Bioteh, Jul 12, 17]

neurodegenerative disease upstart E-Scape Bio (South San Francisco, CA; who needs SBIR?) closed an extension of its series A round, boosting its cash to $63 million.  ... some big backers, including VC OrbiMed, Novo Holding, Johnson & Johnson Innovation, Novartis Venture Fund and Osage University Partners, as well as Lilly Asia Ventures and Sutter Hill Ventures.  ... working on small-molecule drugs that target the inherited genetic drivers of neurodegenerative disorders and correct the dysfunctional proteins at the root of the disease.  [Ben Adams, Fierce Biotech, Jul 12, 17]

Escient Pharmaceuticals (San Diego, CA)

Escient Pharmaceuticals (San Diego, CA) launched with $40 million in series A funding to develop novel G protein-coupled receptor (GPCR)-targeted drugs for a wide range of indications. The startup's first focus will be neuro-immuno-inflammatory and autoreactive diseases. [Amirah Al Idrus, Fierce Biotech, May 7, 18]


Biogen Idec reports it has attracted the first biotechnology startup into its incubator intended to help fill the large biotech's drug pipeline. The Cambridge incubator's first occupant, Escoublac, is developing treatments based on scientific discoveries made at Columbia University Medical Center in New York. The firm's technology centers on a new link between bone biology and metabolism  [Mass High Tech, Dec 19, 07]

eScription (Needham, MA)

Speech recognition software maker Nuance Communications Inc. of Burlington said today it will buy privately held medical transcription company eScription (Needham, MA; one Phase 2 SBIR) for $363 M. [AP, Apr 9, 08]


Here’s e-mail from Bill Gross, who runs eSolar, a promising California solar-thermal start-up: On Saturday, in Beijing, said Gross, he announced “the biggest solar-thermal deal ever. It’s a 2 gigawatt, $5 billion deal to build plants in China using our California-based technology. China is being even more aggressive than the U.S. We applied for a [U.S. Department of Energy] loan for a 92 megawatt project in New Mexico, and in less time than it took them to do stage 1 of the application review, China signs, approves, and is ready to begin construction this year on a 20 times bigger project!”  [Tom Friedman, New York Times, Jan 10]

Eso-Technologies (Middleton,WI)

Eso-Technologies (Middleton, WI;  no SBIR) that is developing a patented esophageal probe, said it has raised $600,000 from Wisconsin-based angel investors in an oversubscribed offering. [Milwaukee Journal Sentinel, Sep 10, 13]

A company that won the Governor's Business Plan Contest earlier this year has raised $1 million from angel investors. Eso-Technologies (Middleton, WI; no SBIR) will use the money to develop a heart monitoring device that would replace the one being used now by surgeons, said Bonnie Reinke, the company's [CEO].  [Kathleen Gallagher, Milwaukee Journal Sentinel, Nov 6, 09]

Esperance Pharmaceuticals (Houston, TX)

Esperance Pharmaceuticals (Houston, TX; no SBIR, founded 2006 in Baton Rouge, LA), a biotech developing drugs for a variety of cancers. ....  based on research done at [LSU], but relocated to Houston earlier this month.  ....  developing a group of drugs meant to home in on cancer cells in a targeted fashion and spare healthy ones. ....  will look to raise as much as $40 million in Series C round this summer as it gears up for more trials of EP 100. ... had previously raised a $28 million Series B round in 2011   [Angela Shah,, Mar 30, 16]

Esperion Therapeutics (Plymouth, MI)

Esperion (Ann Arbor, MI; no SBIR) announced that they have entered into a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of NEXLETOL and NEXLIZET tablets in Japan. Both medicines were recently approved in both the US and EU. ... Otsuka will fund all Japan-specific development costs associated with the program. Esperion estimates this amount to total up to $100 million over the next few years. Esperion will receive an upfront cash payment of $60 million as well as up to an additional $450 million in total development and sales milestones. Esperion will also receive tiered royalties from 15 percent to 30 percent on net sales in Japan. [company press release, Apr 20, 20]

Esperion (Ann Arbor, MI; no SBIR, founded 2008) announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study (1002-058). This was a randomized, double-blind, parallel group study assessing the efficacy and safety of the bempedoic acid / ezetimibe combination tablet compared to ezetimibe and placebo in 179 patients with both hypercholesterolemia and type 2 diabetes. Patients enrolled were on stable background diabetes medications and washed out of lipid modifying therapies. [company press release, Aug 29, 19] total funding $245M []

Esperion Therapeutics (Ann Arbor, MI; no SBIR) announced that they have entered into a licensing agreement with Daiichi Sankyo Europe (DSE) providing DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland. The agreement combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, bempedoic acid, with Daiichi Sankyo’s European commercial capabilities which includes more than 1000 professionals dedicated to the commercialization of cardiovascular (CV) products, as well as synergies with their existing portfolio of novel oral anticoagulant and antiplatelet products ... Esperion to Receive $300 Million in Upfront and Near-term Milestones – – Up to $900 Million in Total Milestones [company press release, Jan 4, 19]

Esperion Therapeutics (Plymouth, MI; no SBIR) received the MichiganVCA’s Financing of the Year award for its June IPO, which raised approximately $70 million. ... co-founded by Roger Newton 1998 and was the company behind the blockbuster anti-cholesterol drug Lipitor. The company sold to Pfizer in 2004 for $1.3 billion, one of the most successful exits in Michigan startup history. Pfizer eventually shut the company down, and Newton went about licensing the name and some of the intellectual property to continue developing small-molecule, LDL cholesterol-lowering technology. .... Last week, Esperion announced that the Phase 2b clinical trial for ETC-1002 has officially begun.    [Sarah Schmid,, Nov 8, 13]

ESS (Wilsonville,OR)>

ESS (Wilsonville, OR; $3M SBIR) announced the commissioning of six of its Energy Warehouse units with a major electric utility in what could be the grid-scale battery company's biggest sign of progress since going public in 2021. [Pete Danko, Portland Inno, September 11, 2023]

Essential Biotechnology

Essential Biotechnology LLC (no SBIR), a spin-out from the Medical College of Wisconsin that is working on a new drug for pancreatic cancer, has won the top prize and $50,000 in the first-ever Southeast Wisconsin Healthcare Pitch event. [Milwaukee Journal Sentinel, Dec 7, 15]  discovered a molecule that serves as a nexus in regulating tumor cell survival- allowing the tumor cells to survive the stresses of their environment and chemotherapies. We have developed monoclonal antibodies that target this nexus and kill cancer cells by making them sensitive to stress once again. Preclinical work has shown that this approach works, even on traditionally “undruggable” Ras-driven cancers.  [company website]

Essential Medical (Malvern, PA)

Essential Medical (Malvern, PA; no SBIR, founded 2010) addressing the rapidly growing large bore vascular closure market, announced  that it has completed a Series B financing of $14.9M  ....  has developed two femoral artery closure devices intended to seal femoral punctures following vascular access medical procedures requiring a cardiac catheterization.  [company press release, Sep 14, 16]

Essentient (now Pronutria)

Pronutria, (formerly Essentient, Cambridge, MA; no SBIR) unveiled details about its funding from founder Flagship Ventures and its plans to offer novel nutrient products that can treat diseases. ....  disclosed that it raised $10.8 million in Series A funding during [past two years]  ....  company says its ProNutrein products are naturally occurring, orally consumed pure protein products that "trigger pharmacological effects through precise and reproducible delivery of specific amino acids."  [Kyle Alspach, Boston Business Journal, Oct 22, 13]

Essex Corp

Just the Government. Northrop Grumman Corp. has agreed to buy Essex Corp., a Columbia MD intelligence firm with strong ties to the national security agency, for $580million cash plus absorbed debt. ...  Essex is the star of a Cinderella story. It was expected to go out of business when chief executive Leonard E. Moodispaw, a former National Security Agency analyst, came on board in 1998. The company began building revenue from its optical processing technology, and after it landed significant contracts with NSA, the company's bottom line mushroomed. Essex went public, made five acquisitions and now employs nearly 1,000 people  [Baltimore Sun, Nov 9] Eight Phase 2 SBIRs from only nine Phase 1s, and NSA doesn't even do SBIR. Its $150M in US intelligence and defense contracts make up over 90% of company revenue for its 761 employees. From 1992 to 2003, Essex received nine SBIR awards from [DOD], totaling about $6.1 M, to develop the Raptor optoelectronic processor. ..The company since has sold more than $6 M worth of Raptor-based systems to [MDA].  [Washington Technology 2003] Clearly the company made its mark selling intel to NSA with the help of an entrepreneurial former NSA staffer; the MDA purchase of $6M hardware after $6M of R&D is something that keeps companies going only as long as the government contract lasts. Sounds like Essex will fit in nicely in NG's government empire.

ESS Tech (Wilsonville, OR)

ARPA-e reports ESS Tech (Wilsonville OR; $3M SBIR, market cap $2B) went public after SBIR funding for continued development of its iron flow batteries for commercial and energy storage applications. [company website]. The only serious question is whether the government was competing with private capital that would heave invsted the same aounts if the technical risk was within usual VC boundarie. The $2B market cap a month after IPO paints a low hanging fruit question. No great surprise that govt agency and th Congresscritter wants some good publicity.

ESS Tech (Wilsonville, OR; $2.8M SBIR] down 20% [Oct 13, 21] began trading ... ESS manufacturer of long-duration batteries for commercial and utility-scale energy storage applications, and ACON S2 Acquisition a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"), resulting in ESS becoming a publicly listed company. [joint companies press release, Oct 11, 21]

Eta Devices (Cambridge, MA)

Nokia bought Eta Devices (Cambridge, MA with an R&D office in Stockholm; no SBIR, founded 2010) for an undisclosed price. The 20-person startup’s technology helps extend smartphone battery life and reduces power consumption at the base stations that connect mobile phone calls to telephone networks. Nokia said it sees the latter capability as crucial as the telecommunications industry moves to 5G networks. [Jeff Engel,, Oct 12, 16]

EtaGen, (Mountain View,CA)

Innovator Shannon Miller is getting an internal combustion engine to work at extremely high compression and expansion ratios. ....  use 25 percent less fuel than conventional gas-powered generators.  ....  cofounded by CEO  EtaGen  (Mountain View, CA; no SBIR), aims to bring the engine to market. The company has built a prototype that runs for hours at target performance levels.  [Kevin Bullis, Technology Review, S/O12]

E-Tek Dynamics (San Jose, CA)

E-Tek Raises $140M (Aug 13) E-Tek Dynamics (San Jose, CA) sold 4M shares and some stockholders sold 2M at $38.50 in a secondary offering. The next day the stock rose another 7%. E-Tek sells high quality passive components and modules for fiber optic systems and got some of its early money from SBIR, although not enough from SBIR to claim any great paternity.

Opinions Do Matter. When the Wall Street house started coverage of E-Tek Dynamics (San Jose, CA) with a Neutral opinion, the stock price plummeted 14%. Sky-high P-Es can't stand a Neutral.

World trade recently ranked 7th among nation high-tech exporters. Inc. magazine's the fastest-growing companies in america placed E-Tek number 281 for 1998.

E-Tek Goes Public (Dec 3) E-Tek Dynamics (San Jose, CA), riding the Internet stock wave, went public yesterday raising $60M and leaving the founders with a personal value of $500+M after the price doubled on the first day's trading. E-Tek has seven SBIR Phase 2s when it was 5-7 employees in the mid-80s (five AF, one SDIO, one Army). If DOD would do some inventive accounting, it could calculate a healthy ROI from a hypothetical stock value and thus have some quantitative metric of its SBIR investment efficiency. Actually, vibes coming from DOD say that metrics are gaining favor with DOD upper management (that MAY trickle down to lower management where the decisions are made). It does no good for upper management to adopt an accounting scheme if it has no practical effect on management decision at lower levels. Ask Mr McNamara. E-Tek made $17M last year.

E-Tek Files IPO (Aug 24) E-Tek Dynamics (San Jose, CA) filed to raise $90M in an IPO. E-Tek plans to make $17M profit this year on $100M sales and its 650 employees. That's a long haul from its 1985 AF SBIR days of 5 employees for ELECTRO-OPTIC MODULATORS and 1987 BMDO for MULTIAPERTURE COMPOUND EYE CONFIGURATIONS. E-Tek had seven Phase 2 SBIRs 1985-1992. Hoover's description: E-Tek Dynamics is helping communication networks light up. The company makes passive components used in fiber-optic networks: optical isolators, filters, couplers, and wavelength division multiplexing. Alcatel, Pirelli, and Corning account for about 60% of E-Tek's sales. Silicon Valley VC firm Summit Partners owns 47%, and wife-and-husband 1983 founder team of Chinese immigrants Theresa and J. J. Pan own 35%. How did E-Tek go so far with so few SBIRs when other info-tech optics companies seem to never quite get past the starting gate? Ask Physical Optics to explain the gap. Better still, ask the government why it allows Physical Optics and its ilk to sustain life on SBIR. The answer is that government doesn't care whether companies live on SBIR. The politicians get the same pork-barrel votes no matter which companies get the money and the federal agencies prefer "competent" and compliant companies to do their R&D.

Etegent Technologies (Cincinnati, OH)

Etegent Technologies (Cincinnati, OH; no previous SBIR, 30 employees) is getting [$750K SBIR] from USAF to find ways to cope with a boom in data.  [Joe Cogliano, Dayton Business Journal, Apr 15, 13]  Innovation will be in the eye of the beholder. The company says it has commercial clients as well.

EternoGen Aesthetics (St. Louis, MO)

EternoGen Aesthetics  (Columbia, MO; no SBIR, founded 2009), a startup developing an alternative to Botox, has raised $5 million ...  has partnered with Biomedical Devices (Tonganoxie, KS; no SBIR) to manufacture the collagen for the European market. [Brian Feldt, St. Louis Business Journal, Nov 16, 15]

EternoGen Aesthetics (St. Louis, MO; no SBIR, founded  2009, moved from Columbia, MO after it received a $50,000 non-equity Arch Grant in 2013.) startup developing an alternative to Botox, has raised more than $700,000 from a group of investors, according to [SEC] filing  ... unlike Botox, which reduces muscle movement to relax and soften wrinkles, EnternoGen's nano-engineered collagen also boasts the ability to restore and repair skin.  [Brian Feldt,  St. Louis Business Journal, Mar 3, 15]

Eton Pharma {Deer Park, IL)

Eton Pharma {Deer Park, IL; no SBIR) down 16% [Jul 15, 19]

Euclid Labs (Solon, OH)

The rest of DOE,'s Phase II list also shows a preference for SBIR experience: Euclid Labs (Solon, OH; $18M SBIR since 2004, all DOE including one $10M award), four new Phase IIs;  Radiabeam Technologies (Santa Monica, CA, $10M SBIR since 2005  SBIR) three awards; Tech-x (Boulder, CO; something over $50M SBIR since 1994) three new awards; Muons (Batavia, IL;  $13M since 2002 SBIR, all DOE) three awards; Far-Tech (San Diego, CA;$9+M SBIR since 2003) two awards;Ridgetop Group (Tucson, AZ; $10M SBIR since 2002) two awards;  Calabazas Creek Research (San Mateo, CA; $26M since 1994) two awards; Niowave (Lansing, MI;  $5M since 2007 SBIR) two awards; Mesa Photonics  (Santa Fe, NM;  $0.8M since 2008 SBIR) two awards; Green Mountain Radio Research ( Colchester, VT;  $5.7M SBIR)  two awards.  Of 104 awards, 33 went to multiple winners who already had collected $378M SBIR from the federal government.  Is DOE over-emphasizing contractor competence at the expense of companies and technologies with brighter futures?  No one knows becasue Congress shows little interest in the question, and the agency has a bias toward making itself smarter.  

Euclises Pharmaceuticals (St Louis, MO)

Euclises Pharmaceuticals  (St Louis, MO; no SBIR) a biotech startup looking to develop treatments for cancer, has added approximately $700,000 to its Series A financing round, which has closed just shy of $2 million.  ...  developing selective cyclooxygenase-2 (“COX-2″) inhibitors to help treat cancer, reported raising $1.3 million of the round in September 2014  ...  has raised around $2.5 million.  [Brian Feldt,  St. Louis Business Journal, Apr 17, 15]

Cultivation Capital has invested just short of $11 million of the $20 million tech fund it created in 2012.   ...  started out as a tech fund, created its life sciences fund in 2013 with plans to invest some $30 million over five years.  ....  its portfolio: Immunophotonics (Columbia, MO; no SBIR) developed a cancer vaccineMolecular Sensing  (Nashville, TN; no SBIR) commercializing a label-free molecular interaction assay system based on Back-Scattering InterferometryAdarza BioSystems (WEST HENRIETTA, NY; $1.8M SBIR) early stage medical diagnosticsCardialen (Minneapolis, MN; no SBIR) developed a treatment to keep the heart in a normal rhythm for people suffering from atrial fibrillation (AF)Euclises Pharmaceuticals (St Louis, MO; no SBIR) developing pain and cancer medications; Mobius Therapeutics (St Louis, MO; no SBIR) commercial stage venture focused on ophthalmic surgery solutions; Pulse Therapeutics (St. Louis, MO; no SBIR) developed a new approach to accelerate the concentration and delivery of physician-selected agents within the vasculature; Galera Therapeutics (Malvern, PA; no SBIR) focused on the development of breakthrough drugs targeting the oxygen metabolic pathways.  [Brian Feldt, St. Louis Business Journal, Oct 27, 14]   

Eureka Therapeutics (Emeryville, CA)

Eureka Therapeutics (Emeryville, CA; no SBIR) a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatment of solid tumors, today announced the successful completion of a $60 million Series D financing round. Proceeds will be used to advance Eureka’s lead candidate, ET190L1-ARTEMIS™ T cells in relapsed and refractory CD19+ Non-Hodgkin Lymphoma, as well as to accelerate its pipeline of innovative immunotherapies against other hematological and solid tumors. [company press release, Jan 22, 18]

Euthymics Bioscience (Cambridge, MA)

Euthymics Bioscience (Cambridge, MA; no SBIR) has added $4 million to its July, 2010, Series A financing round of $24 million ...  lead product candidate is EB-1010, intended to treat depression. The compound is a triple reuptake inhibitor that acts on serotonin, norepinephrine and dopamine and is given as monotherapy. The company plans to initiate a large multicenter Phase 2b/3a clinical trial of EB-1010 in major depression in the first half of this year, according to officials.  [Rodney Brown, Mass High Tech, Mar 10, 11]

A merger and a $24 million Series A funding has landed life sciences startup Euthymics Bioscience (Cambridge, MA; no SBIR). ... to complete the purchase of New Jersey firm DOV Pharmaceutical which it announced at the beginning of July.  [Rodney Brown, Mass High Tech, Jul 22, 10]

Evapt (Austin, tx)

EVapt and 10 other Austin companies graduated Thursday from the incubator, which is affiliated with the University of Texas and the think tank IC2 Institute. Since its founding in 1989, ATI has graduated more than 200 companies, which have raised an estimated $750 million in funding.[Austin American-Statesman, Apr 24, 09]

Evelo Therapeutics (Cambridge, MA)

Evelo Biosciences down 24% [Aug 27, 20]

Evelo Biosciences up 23% [Apr 24, 20]

Evelo Biosci down 25% [Mar 20, 20]

Evelo BioSciences up 17% [Sep 12, 19]

Evelo Biosciences (Cambridge, MA; no SBIR, founded 2015) developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, entered into a loan and security agreement for up to $45M with K2 HealthVentures, a health care investment firm. [company press release, Jul 25, 19] prior funding $132M []

Evelo Biosciences up 10% [Oct 4, 18]

Evelo Biosciences up 11%  [Jun 20, 18]

Evelo Biosciences (Cambridge, MA; no SBIR) raised $85 million in an initial public offering to finance clinical trials of its microbiome drugs in inflammatory diseases and cancer. [Frank Vinluan,, May 11, 18]

Evelo Biosciences (Cambridge, MA; no SBIR, founded 2015) filed for a $100 million [IPO], as the Flagship Ventures’ startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans. ....developing oral formulations of specific microbial strains. Evelo selects the strains on the strength of their potential to interact with host immune cells in the gut, thereby up or down-regulating immune responses via multiple pathways.   [Nick Paul Taylor. Fierce Biotech, Apr 16, 18] total funding $132M []

Mayo Clinic is adding to a growing list of collaborations with cutting-edge startups focused on understanding what the teeming microorganisms essential to digestion can tell us about a broad range of health issues.....  announced it established a formal collaboration with Evelo Biosciences (Cambridge, MA; no SBIR), a new firm established last year after a $35 million investment  ...  Mayo’s other microbiome collaborators include:     Seres Therapeutics  (Cambridge, MA; no SBIR) focused on using micro-organisms as therapeutic agents for disease in clinical trials.   Enterome  (France) focuses on discovery and validation of gut microbiome-based diagnostics to predict responses to nutritional interventions in overweight and obese patients.  Second Genome (San Francisco, CA; no SBIR) collaborate in areas such as irritable bowel disease; obesity/metabolic disease; and surgery in obese patients with and without type 2 diabetes.     Whole Biome  (San Francisco, CA; no SBIR) collaborating to decrease rates of preterm birth and labor, the leading cause of infant mortality in the United States, through microbiome-based diagnostics and therapies. [Don Jacobson, Twin Cities Business, Aug 31, 16]

Flagship Ventures announced the merger of its portfolio companies Evelo Biosciences (Cambridge, MA; no SBIR, founded 2014) and Epiva Biosciences to create the leading immuno-microbiome company, developing therapeutics for cancer, autoimmune and inflammatory diseases. The new entity will keep the name Evelo Biosciences (40 employees).   ...  Flagship has financed the company with about $40 million to date and plans to make additional investments to support its rapid growth.  [Evelo press release, Jun 12, 16]

Evelo Therapeutics (Cambridge, MA) launched this past week with a $35 million round and a plan to use insights into the human microbiome—the trillions of bacteria that populate our bodies—to battle cancer. Evelo aims to create mixtures of naturally occurring, unmodified bacteria and use them as cancer therapies.  [Ben Fidler,, Nov 19, 15]

Biotech venture group Flagship Ventures is doubling down on the microbiome. The firm, which specializes in building new therapeutics companies in stealth mode, today launched Evelo Therapeutics  (Cambridge, MA) its second microbiome-based startup, with $35 million in funding to develop cancer treatments fashioned from mixes of bacteria found in nature. [Alex Lash,, Nov 4, 15]

Evena Medical (Roseville, CA)

Evena Medical (Roseville, CA; no SBIR) startup is about to start selling products that could change the practice of medicine around the world by helping health professionals locate veins under the skin.... has developed mobile devices to help health care workers place needles accurately in patients who need intravenous therapy. This could greatly help treat elderly patients and others whose veins are hard to find, company CEO Frank Ball says.  [Mark Anderson, Sacramento Business Journal, Jan 29, 16]

Ever Cat Fuels

Augsburg, a small liberal arts college in Minneapolis that, at least until now, was not particularly known for its energy acumen .. invented a cheaper process for making biofuel - a metal-oxide catalyst, instead of nasty NaOH reactions ... Ever Cat Fuels, a start-up co-founded by Augsburg alumnus Clayton McNeff, is building a $5 million plant in Isanti that eventually will produce 3 million gallons of biodiesel fuel a year.  [Thomas Lee, Minneapolis Star-Tribune, Mar 7]

Evergen Biotechnologies

Connecticut gave out $9.8 M in stem-cell research grants to scientists at Yale and UConn with $900K to start-up Evergen Biotechnologies establishing the Connecticut therapeutic cloning core facility. [Mass High Tech, Apr 3]

Evergreen Solar

Evergreen Solar filed for Chapter 11 bankruptcy protection yesterday, completing a stunning reversal of fortune for a high-flying alternative-energy company that once seemed to herald a new era for the Massachusetts economy.  [Chris Reidy, Boston Globe, Aug 15, 11]

Evergreen Solar, the once promising alternative energy company that received millions in state subsidies, warned late Monday that its shares will likely be worth little or nothing even if it is able to strike a deal with creditors to restructure its debt. ....  Three years ago, Evergreen opened a gleaming 450,000-square-foot manufacturing plant in Devens, a former military base in central Massachusetts, promising to create hundreds of new jobs. Governor Deval Patrick’s administration awarded the company $58 million in tax breaks and other aid, one of the largest state incentive packages in recent years....prices plummeted because of increased global competition and tepid demand in the wake of the economic slowdown.    [Todd Wallack, Boston Globe, Jul 12, 11]

Thanks for the money, we're outta here.   Evergreen Solar chief executive Michael El-Hillow rejected [Mark Montigny, chairman of the Senate Post Audit and Oversight Committee] demand that the Marlborough company return “every penny’’ of aid it received from the state to build a solar manufacturing plant in Devens that it has since closed. Evergreen eliminated more than 800 jobs as part of the plant closing, saying it couldn’t compete with cheaper manufacturing in China, where Evergreen recently opened a facility. Massachusetts offered Evergreen $58 million in grants, tax breaks, and other aid. But El-Hillow noted that only about $21 million of it was in cash. He said the company complied with nearly all of the terms with the state, creating far more jobs than it promised until shutting the plant earlier this month. Moreover, he said Massachusetts probably earned a profit of $20 million from a small investment it made in Evergreen years earlier that it sold off.  [Todd Wallack, Boston Globe, Mar 30, 11]

Evergreen Solar expects to sell its Devens factory and equipment for “well below” the $430 million the company spe.  [Bruce Bigelow,, Mar 10, 11]

Evergreen Solar China expects to sell its Devens factory and equipment for “well below” the $430 million the company spent to open the plant in 2008, the company said  ... had received at least $31 million in direct state support in connection with the opening of the plant, where the company has produced solar panels, cells and wafers. But Evergreen says it’s been unable to compete on cost with Chinese manufacturers ...  will continue producing wafers at its plant in Wuhan, China, which opened last year. [Kyle Alspach, Mass High Tech, Mar 10, 11] Nice subsidy, nice jobs, while they lasted. Globalization respects no subsidies. A warning that the government, including the politicians, should be extra wary about SBIR commercialization strategies that make illusionary assumptions.

Not even $58M.   Evergreen Solar will eliminate 800 jobs in Massachusetts and shut its new factory at the former military base in Devens, just two years after it opened the massive facility to great fanfare and with about $58 million in taxpayer subsidies. ... calling itself a victim of weak demand and competition from cheaper suppliers in China, where the government provides solar companies with generous subsidies. Evergreen itself has a factory in Wuhan, China  [Todd Wallack, Boston Globe, Jan 12, 11] Massachusetts says Evergreen must repay $4M. Be suspicious when your local politician wants to hand your money to a company to locate in your neighborhood. Companies have all kinds of optimistic plans and the proof won't come until after several election cycles. The same goes for subsidy programs like SBIR - input of money overrides ROI.

Evergreen Solar said it is unveiling its upcoming line of higher efficiency solar panels featuring its newly developed BOOST Cell Technology in Paris  [Boston Globe, Jun 16, 10]

Evergreen Solar announced a wafer factory and subcontractor relationship in China. [Boston Globe, May 1, 09]

Evergreen Solar down 12% as its second-quarter net loss widened, and it projected third-quarter revenue below analysts' expectations. [WSJ, Jul 19, 08]

Evergreen Solar signed a sales contract with Germany's IBC Solar AG worth $1.2 billion - the biggest deal in the company's history. [Boston Globe, Jul 15, 08]

Evergreen Solar jumped 20% .... signed two long-term sales contracts valued at $600 million with solar-product makers GroSolar and Wagner & Co. Solartechnik  [Wall Street Journal, Jun 20, 08]

Shares in Evergreen Solar were lit up by more than 33% at one point [May 22, 08] after the company announced $1 billion worth of new contracts. [, May 22]

Evergreen Solar won $44 million in state incentives to build its manufacturing plant at the former Fort Devens and is already going full-steam ahead on a privately funded expansion that will double the capacity of that facility.  [Boston Globe, May 16, 08]

Evergreen Solar is expected to announce today that it will double the size of its manufacturing facility at the former Fort Devens in Harvard and add about 350 new jobs as part of its ongoing expansion. [Boston Globe, Apr 8]

Just over a week after it was announced, Evergreen Solar  has scaled back its a public offering of common stock from 20 million shares to 16 million, due to market conditions,  [Mass High Tech, Feb 12,08]

Evergreen Solar up 10%, after it struck a silicon-supply agreement.

Everspin Technologies (Chandler, AZ)

Everspin Technologies (Chandler, AZ; $500K SBIR) up 40% [Aug 12, 22]

Everspin Technologies (Chandler AZ; $600K SBIR) up 63% [Nov 12, 21] Reports its Best Quarter in Company History [company press release, Nov 11, 21]

Everspin Technologies (Chandler AZ; $700K SBIR) up 18% Aug 26, 21] reported quarterly financial results

Everspin Technologies down 23% [Nov 6, 20] reported quarterly financial results

Everspin Technologies down 26% [Aug 6, 20] announced financial results for the second quarter [company prss release, Aug 6, 20]

Everspin Technologies up 18% [May 11, 20]

Everspin Tech (Chandler AZ; $600K SBIR) up 52% [May 8, 20] announced unexpectedly higher revenue

Everspin Tech up 18% [Feb 20, 19]

Everspin Tech (Chandler, AZ; $600K SBIR)up 16% [Feb 19, 19] develops and manufactures magnetic RAM or magnetoresistive random-access memory, including stand-alone and embedded MRAM products as well as spin-torque MRAM. [company website]... announces that it commencedshipment of pre-productioncustomer samplesofits 28nm 1-Gigabit(Gb)Spin Torque Transfer Magnetoresistive Random Access Memory (STT-MRAM)product in December 2018.[company press release, Jan 8, 19]

Everspin Tech up 14% [Jul 26, 17]

Everspin Tech (Chandler AZ, one SBIR)down 13% [Jul 24, 17]

Everspin Technologies (Chandler, AZ; one SBIR) up 18% [Jun 8,17]

Evestra (San Antonio, TX)

Evestra (San Antonio, TX; no SBIR)’s wholly-owned Polish subsidiary, Evestra Onkologia Sp., has received $4.6 million project, co-financed by the European Union Regional Development Fund, [to] support development of a drug – EC313 – designed to treat endometriosis.    [company press release, Jan 24, 17]

Evident Technologies (Troy, NY)

Evident Technologies (Troy, NY; $300K SBIR) once used semiconductor nanocrystals in biotechnology, for LEDs. Now is using nano-sized semiconductors for thermoelectric uses.  It's part of the company's push into the thermoelectric industry aided by an agreement to use NASA-developed technology to market a new line of commercial products, said CEO Clint Ballinger.  [Chelsea Diana, Albany Business Review, Apr 10, 15]

Evident Technologies (Troy, NY), one of the region's most promising nanotechnology companies, filed for Chapter 11 bankruptcy protection ...  a protracted legal battle with the California biotechnology company Invitrogen had sapped Evident financially [$1M for lawyers]...  Started in 2000, Evident employs 20 people and specializes in developing products out of a semiconductor material called quantum dots. [Albany Times Union, Jul 7, 09]

Shifting Incubators. . Evident Technologies (Troy, NY)  is moving into a new and different incubator. Having started life in an Albany incubator, and grown to 50 employees, it is now coming into the new incubator at Russell Sage college in downtown Troy for more research on quantum dots. It has had two DOD Phase 1 SBIRs.  [Eric Anderson, Albany Times-Union, Sep 28]

Evofem Biosciences (San Diego, CA)

Evofem Biosciences (San Diego, CA; no SBIR) struck a deal to raise up to $80 million in a private placement. ... closed the first $30 million, from PDL BioPharma with the firm paying a 26.4 percent premium, ... PDL also can invest up to $30 million more. [Sarah de Crescenzo,, Apr 12, 19]

Evoke Pharma (Solana Beach, CA)

Evoke Pharma (Solana Beach, CA; no SBIR) down 15% [Jul 19, 16] after announcing a Phase 3 trial on a gastroinetestinal drug for diabetes patients failed to meet its goals. ...  Others have had trouble developing a treatment for diabetic gastroparesis, too. In 2012, then-Research Triangle Park, NC-based Tranzyme Pharma (Research Triangle Park, NC;  no SBIR), which was acquired by Ocera Therapeutics in a reverse merger in 2013, stopped work on its experimental treatment for the condition after the company’s pill was outperformed by a placebo in a mid-stage clinical trial.  [David Holly,, Jul 18, 16]

Evolution Robotics (Pasadena, CA)

iRobot will buy robot maker Evolution Robotics (Pasadena, CA; no SBIR) for $74 million. ... adds a new line of floor-cleaning robots to iRobot’s suite of consumer and military robots. Evolution Robotics’ Mint, which is designed to ......


The next airport security scanner you have to walk through might just be using technology developed by inventors at Bellevue-based Intellectual Ventures. [which] announced it has spun out its third company, Evolv, from its "Metamaterials Commercialization Center," the same incubation team that spun out the nuclear power company TerraPower. .... Evolv will be based in Boston and is backed by $11.8 million in funding from Bill Gates [et al] .... Redmond antenna company Kymeta also recently spun out of IV [which was co-founded by Microsoft veteran Nathan Myhrvold] [Emily Parkhurst, Puget Sound Business Journal, Aug 29, 13]

Evolve BioSystems (Davis, CA)

Evolve BioSystems (Davis, CA; no SBIR, founded 2011) the leading infant gut microbiome company, announced that it has completed a $40 million Series C round of funding co-led by the Bill & Melinda Gates Foundation, ... joined by new investors Johnson & Johnson and Continental Grain [company press release, Jun 14, 18] total funding $69M []

Evolved By Nature (Boston, MA)

Chanel invested in biotech Evolved By Nature (Boston, MA; no SBIR) which has developed liquid silk. No financial terms were disclosed. [Sri Kalyanaraman, Boston Inno, Jun 11, 19]

Evozyne [Chicago, IL)

Evozyne [Chicago, IL; no SBIR) new startup led by a University of Chicago biochemistry researcher [Rama Ranganathan] is designing artificial proteins that could result in major innovations for agriculture, energy, therapeutics and other industries. The startup has created machine-learning models that review protein information from genome databases, and found a simple method for building artificial proteins that are important for life in bacteria, fungi and plants. [Jim Dallke, ChicagoInno, July 29, 20]


the Ohio Third Frontier Commission approved more than $84.9 million to support promising startups, new cutting-edge technologies and getting innovative ideas to the marketplace.  Two Cincinnati companies are to receive $100,000 grants:   Sense Diagnostics (Cincinnati, OH; no SBIR) will use the money to enable commercialization of a device named SENSE, a noninvasive radio frequency sensor that detects changes in the brain – including seizures, hemorrhage and increased swelling/edema.      Standard Bariatrics (no SBIR) will use the money to further develop and commercialize a stapler guide. It will improve surgical procedures that reduce the volume of the stomach to help morbidly obese patients lose weight. [Barrett J. Brunsman, Cincinnati Business Courier, Jun 18, 14]  Other Central Ohio entities receiving Third Frontier funds:     EWI:$4.9 million as part of its matching funds toward a federal award creating a $148 million high-tech manufacturing research institute near Detroit in collaboration with Ohio State and the University of MichiganCardiox (Columbus, OH; no SBIR) :$1.7 million loan toward commercializing its device that detects abnormal blood flow from the earInmobly (Columbus, OH; no SBIR):$1 million loan for scaling up the spread of its technology that helps stop broadband traffic logjams from video downloads. [Carrie Ghose, Columbus Business First, Jun 23, 14]  Third Frontier seems a standard subsidy program with metrics that don't really measure the impact against the investment.  But political programs usually work that way: fanfare for the handouts and no public ROI rerports and no control group for comparison.

Exact Sciences (Marlborough, MA)

Exact Sciences up 25% [Jan 9, 2023] reported surprise earnings

Cancer test maker Exact Sciences will invest $350 million to grow its Madison campus with a new research and development facility as well as an expansion of an existing laboratory and warehouse space. [Wisconsin Inno, Jan 13, 22]

Exact Sciences up 23% [Oct 27, 20]

Exact Sciences and Thrive Earlier Detection (Cambridge, MA; no SBIR), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. [joint companies press release, Oct 27, 20]

Exact Sciences up 27% [Sep 24, 20] after the company’s" CEO offered" favorable early-stage results of a blood-based screening test for some major cancers at an industry conference [Barron's, Sep 24 20]

Did it.  Cancer diagnostics company Exact Sciences has more than doubled the capital investment [$26M by 2020] and job creation numbers [750 jobs] it proposed under an [2015] agreement with the Wisconsin Economic Development Corp. So far, Exact Sciences made a capital investment of $95.85M and created 1,672 jobs in Wisconsin since 2015. [Nick Williams, WiscInno, Feb 4, 20]

Exact Sciences completes $2.8B acquisition of Genomic Health [Milwaukee Business Journal, Nov 8, 19]

Exact Sciences moved to acquire Genomic Health, and plans to bring their cancer diagnostics up through a single commercial organization. For $2.8B. [Conor Hale, Fierce Biotech, Jul 29, 19]

Exact Sciences, which makes the Cologuard take-home colon cancer test, reported revenue of $162M and test volume of about 334,000 for its first quarter of 2019. The numbers were a 79 percent increase from a year ago, according to the company’s quarterly report. [WisconsinInno, May 2. 19]

Exact Sciences up 15% [Jan 7, 19]

Exact Sciences (Madison, WI; no SBIR) announced the acquisition of Biomatrica (San Diego, CA; $1.4M SBIR) , a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. ... Exact Sciences intends to use Biomatrica's proprietary technology to support ongoing and future development of its own blood-based cancer detection tests.   [Exact press release,, Oct 18, 18]

Exact Sciences up 31% [Aug 22, 18] announced a collaboration deal with Pfizer to market its signature product, Cologuard, a stool DNA screening test for colorectal cancer. [Charley Grant, WSJ, Aug 22, 18] estimated $174M [Nick Williams, Milwaukee Business Journal, Aug 21, 18]

Exact Sciences down 13% [Aug 2, 18]

Exact Sciences said it plans to raise up to $190 million through the sale of notes that can be converted into cash or shares of the company’s stock, starting in 2025. [, Jun 8, 18]

Exact Sciences up 11%  [May 30, 18]

Exact Sciences up 12% [Apr 27, 18]

molecular diagnostics company Exact Sciences acquired Armune BioScience (Kalamazoo and Ann Arbor, MI; no SBIR, founded 2008), a cancer diagnostic startup. Terms not disclosed. “Armune is scaling down,” says [CEO] David Esposito. “Exact Sciences acquired all of our intellectual property and assets underlying our technology. For all intents and purposes, we have ceased marketing our products.” [, Jan 26, 18]

Exact Sciences down 10% [Jan 17, 18]

Exact Sciences said it plans to raise up to $600 million through the sale of notes that can be converted into cash or shares of the company’s common stock, starting in 2025. ... is developing several screening tests for cancer patients. Its flagship product is Cologuard, a non-invasive, stool-based DNA test for colorectal cancer.   [Jeff Buchanan,, Jan 12, 18]

Exact Sciences down 13% [Jan 8, 18]

Exact Sciences up 10% [Oct 31, 17]

Exact Sciences (Madison, WI; no SBIR) up 12% [May 31,17] on news that the health insurer UnitedHealthcare will cover Cologuard, Exact’s stool-based DNA test for colorectal cancer, starting July 1. [Jeff Buchanan,, May 31, 17]

Exact Sciences up 11% [May 5, 17]

Exact Sciences up 27% [Apr 27, 17] announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter  [company press release, Apr 27, 17]

A study from Exact Sciences (Madison, WI; no SBIR) and Mayo Clinic released by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages. [company press release, Mar 2, 17]

Exact Sciences up 13% [Feb 21,17]

Exact Sciences up 19% [Jan 9, 17]

Exact Sciences  up 11% [Jan 4, 17]

Exact Sciences down 18% [Nov 16, 16]

Exact Sciences up 30% [Jul 26, 16]

Exact Sciences up 19% [Nov 2, 15

Exact Sciences  up 17% [Oct 30, 15]

EXACT Sciences down 22% [Oct 8,15]

Exact Sciences (Madison WI; no SBIR)  down 46% [Oct 6,15]  after the U.S. Preventive Services Task Force issued a preliminary recommendation, saying it considers the company’s non-invasive colon cancer test as an “alternative test.”  [Milwaukee Journal Sentinel, Oct 6, 15]

Exact Sciences (no SBIR) said it has submitted an application to federal regulators for approval to market a DNA-based, non-invasive colon cancer test.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 10, 13] 

Exact Sciences has licensed technology from a Belgian company that it can use to strengthen the non-invasive DNA-based test for colon cancer it is developing. ...  from OncoMethylome Sciences S.A. an exclusive license for up to two DNA methylation biomarkers to use in stool-based detection of colon cancer.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 27, 10]

Exact Sciences (Madison, WI; no SBIR), developing a non-invasive DNA test for detecting colon cancer, said Wednesday that it has raised $17.6 million in a secondary stock offering. [Kathleen Gallagher, Milwaukee Journal Sentinel, Apr 15, 10]

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] ....  founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers.  ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

Armed with a $1 million loan from the Wisconsin Department of Commerce,Exact Sciences (no SBIR) said Thursday that it will move from the Boston area to Madison's University Research Park.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 19, 09]

cancer diagnostics company Exact Sciences (Marlborough, MA; no SBIR) has made biotech firm Genzyme a strategic partner in a deal worth $24.5 million. Under the terms of the deal Genzyme will acquire intellectual property rights to some of Exact’s prenatal and reproductive health technologies, and three million shares of Exact’s common stock. Exact will receive $24.5 million in cash.  [Mass High Tech. Jan 28, 09]

Genzyme offered to acquire Exact Sciences for $1.50 a share, valuing the Maynard, Mass., maker of DNA-screening technologies at $41 million.  [Wall Street Journal, Jan 13, 09]

Exact Sciences (Marlborough, MA; no SBIR) which is trying to use genomics to develop cancer screening technology, said late Wednesday night it has slashed its operations to preserve its cash, while pursuing a possible sale or other strategic alternatives. [Boston Globe, Jul 18]

Exagen Diagnostics (Vista, CA) formerly in Albuquerque,NM)

Exagen (Vista, CA, formerly in Albuquerue, NM; one SBIR) up 64% [Mar 17, 20] an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has entered into a strategic partnership with Sonora Quest, the nation's largest integrated laboratory system. [company press release, Mar 17, 20]

Exagen up 24% [Dec 23, 19]

Exagen (Vista, CA; one SBIR) which sells diagnostic blood tests for autoimmune diseases, raised $50 million in an IPO. [Alex Lash,, Sep 19,19]

Exagen Diagnostics (Albuquerque, NM; one SBIR)  filed with the SEC detailing $3 million in funds that it recently raised.  [Dan Mayfield, Albuquerque Business First, Jul 7, 15]   a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases/autoimmune connective tissue disease, or ARDs/CTD [company website]

After 10 years of developing its Autoimmune Rheumatic Disease tests, Exagen (Albuquerque, NM; one SBIR) first launched its Avise SLE Diagnostic tests in 2012. They’ve gained quick acceptance, the company said recently in a filing with the SEC for an initial public offering worth $69 million.  ...  using a technology licensed exclusively from the University of Pittsburgh and a proprietary algorithm to optimize its performance, Exagen's Avise tests can pinpoint an ARD with more accuracy than traditional tests   [Dan Mayfield, Albuquerque Business First, Sep 23, 14]

Exagen Diagnostics (Albuquerque, NM; no SBIR) which markets diagnostic tests for lupus and other autoimmune rheumatoid diseases has filed for [IPO]  ...  uses software to identify key genomic biomarkers to better diagnose and treat disease. It released its first lupus test in January 2012.  Launched in 2002, the company has raised about $40 million in venture capital [AP, Sep 24, 14]

Exagen Diagnostics (Albuquerque, NM; one Phase 1 SBIR) plans to expand its Austin operations while it awaits FDA approval for its breast cancer detection kit. [Lilly Rockwell, Austin Statesman-American, Apr 7]

Excelimmune (Woburn, MA)

Excelimmune (Woburn, MA; one SBIR, founded 2006) working on a treatment for methicillin-resistant Staphylococcus aureus (MRSA), has rounded up $12 million from an undisclosed private investor.  [Michelle Lang, Mass High Tech, Dec 20, 11]

Excelimmune (Woburn, MA; $300K SBIR) announced it has closed its Series B financing at $10.5 million – funding that will be used to advance the company’s drug candidate to treat methicillin-resistant Staphylococcus aureus (MRSA).  [Mass High Tech, May 31, 11]

Excelimmune(Woburn, MA; one SBIR) has taken in $4.5 million of a planned $8.9 million equity financing, according to [SEC] filing ... develops therapies using human recombinant polyclonal antibodies (HRPA). Its Staphguard drug candidate, used to treat methicillin-resistant Staphylococcus aureus (MRSA), has gone through preclinical studies on mice and awaits an investigational new drug filing.  [Michelle Lang, Mass High Tech, Jul 7, 10]

Excelimmune (Woburn, MA; one SBIR 2009) has pulled in $1 million in a Series B investment round that will support studies of the company’s drug candidate to treat methicillin-resistant Staphylococcus aureus (MRSA). ...  founded in 2006 [Mass High Tech, Feb 12, 10]

Excision BioTherapeutics (Philadelphia, PA)

Excision BioTherapeutics (Philadelphia, PA; no SBIR, founded 2015 out of Temple University’s Lewis Katz School of Medicine) a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, announced it has completed a $10 million seed round of financing [to] enter into human clinical trials with its HIV-1 targeted CRISPR platform, giving Excision BioTherapeutics the first effort to fully remove/excise the HIV-1 genome from all human cells and tissues. [company press release, Sep 6, 17]

Excivity (Birmingham, AL)

Applied Technology Associates (Albuquerque, NM; $39M SBIR) announced it's joining the formation of BlueHalo, a leading provider of advanced engineering solutions and technology to the national security community. BlueHalo was formed through the combination of AEgis Technologies (Albuquerque, NM; $22M SBIR), including its previously integrated acquisitions Excivity (Birmingham, AL; no SBIR) and EMRC Heli (no SBIR) , and its recently announced acquisition of Brilligent Solutions (Fairborn, OH; one SBIR). [ATA press release, Oct 29, 20]


With Exelixis (no SBIR)and Renovis (South San Francisco, CA; $500K SBIR) already under his belt, the longtime Bay Area biotech entrepreneur's newest venture, Labrys Biologics(no SBIR), has acquired a Phase II-ready experimental migraine treatment from Pfizer and snagged $31 million in a Series A financing round.   ... Labrys' new drug, called RN-307, was discovered and developed by South San Francisco's Rinat Pharmaceuticals  (South San Francisco, CA; no SBIR) which Pfizer bought in 2006   [Ron Leuty, San Francisco Business Times, Jan 3,13]

Excel Technology

GSI Group (Billerica,MA) says that it will purchase Bedford’s Excel Technology (Bedford, MA; $1M SBIR in the 1980s)  for $360 million cash. [Mass High Tech, Jul 10] A sister company Excel Superconductor also got $1M SBIR

Exelixis Plant Sciences (Portland, OR)

Exelixis (a public firm founded 1994; $200K SBIR to Exelixis Plant Sciences  (Portland, OR raised about $180 million on early data to support this idea back in March, and now more and more public data is rolling in to buttress the argument.  ...  has shown off results over the past several days from a trial that enrolled 490 patients with nine different tumor types, to see where cabozantinib (XL184) might work best. The latest batch of data for this drug, from 171 patients with prostate cancer, is being presented to doctors today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.  Exelixis formed Exelixis Plant Sciences in December 2000, after acquiring Agritope ($600K SBIR) in order to expand its access to plant model system technologies and product development. [Luke Timmerman, francisco, Jun 6, 11]

Exemplar Genetics (Sioux Center, IA )

Exemplar Genetics (Sioux Center, IA; $800K SBIR) has designed animals to study human disease. In the eight years since Exemplar’s founding, it has developed pig models of cardiovascular diseases, neurological disorders, cancer, and more. It’s also adding services to its portfolio: housing the human-size minipigs for urban researchers who don’t have space, for example, and running safety and efficacy trials of new therapeutics using its porcine subjects. Pigs might prove more reliable than rodents for the purpose, says Swart. For example, when Exemplar treated its cardiovascular pig model with Lipitor, it turned out that “they respond almost exactly like humans, and very unlike the mouse,” in which the drug had no effect, he notes.  [Jenny Rood,, Aug 1, 16]

Exicure (Cambridge, MA)

Exicure (Cambridge, MA; $1.5M SBIR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Exicure, Inc. have entered into a global collaboration agreement to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. [company press release, Nov 14, 19]

Exo (New York, NY)

Exo (New York, NY; no SBIR), the leading company developing insects as an alternative protein source, announced it closed a $4M round of Series A funding. ...  Previously, Exo raised $400,000 in pre-seed funding and $1.2M in seed funding in October 2014 [company press release, Mar 7, 16]  thanks to PrivCo for the alert

Exogenesis (Billerica, MA)

Exogenesis (Billerica, MA; no SBIR), a gas cluster ion beam (GCIB) technology firm in Billerica, has raised $3.19 million in an equity and  securities offering ... Founded in 2005, Exogenesis uses the GCIB technology to process implantable medical devices, according to the Exogenesis website. The company has developed the ClusterCoat Processing System, used in surface coating medical devices by changing the physical and chemical properties of the atomic layers of a surface. Exogenesis’ core technology, GCIB, was first developed in the 1990s at Kyoto University’s Ion Beam Engineering Experimental Laboratory, with further development conducted at Epion (Billerica, MA; $4.8M SBIR) in the US  [Michelle Lang, Mass High Tech, Dec 1, 10]

Exogenesis (Billerica,MA; no SBIR) a gas cluster ion beam (GCIB) technology firm in , has raised $4.5 million in an equity offering filed with the [SEC] ... founded in 2005, uses the GCIB technology to process implantable medical devices, according to the Exogenesis website.  [Michelle Lang, Mass High Tech, Aug 10, 10]

Exone (Pittsburgh, PA)

3-D printers can produce even junk food these days. Appropriate, as the firms making them have given investors a sharp case of indigestion. The share price of Stratasys (no SBIR) has collapsed 50% in the past 12 months, while close rival 3D Systems (no SBIR) is down more than 60% in that time. That has erased the huge gains those stocks enjoyed during a run-up in 2013. Smaller 3-D printer plays such as ExOne (no SBIR)and voxeljet (no SBIR) have charted a similar course. ExOne shares are actually 10% below their IPO price from February 2013.   [Dan Gallagher, Wall Street Journal, Feb 22, 15]

A number of Pittsburgh companies, including ExOne (no SBIR) and [Start-Up Entrepreneur Awards to] Cohera Medical (Pittsburgh, PA; $1.7M SBIR) and ThreeRivers 3D (no SBIR), were honored with 2013 Carnegie Science Awards. [Paul Gough, Pittsburgh Business Times, Jan 31, 13]

Exonics Therapeutics (Watertown, MA)

biotech giant Vertex Pharmaceuticalsplans to acquire preclinical gene editing startup Exonics Therapeutics (Cambridge, MA; no SBIR, founded 2017) for $245M.  [BostonInno, Jul 2, 19]  total funding about $45M []

Vertex Pharmaceuticals ($1M SBIR) is committing $420 million in a pair of deals that expand the company’s research scope to experimental genetic treatments for two forms of muscular dystrophy. Vertex announced that it reached an agreement to pay $245 million up front to acquire Exonics Therapeutics (Watertown, MA; no SBIR, prior funding $45M []), using gene editing techniques to develop a treatment for Duchenne muscular dystrophy and myotonic dystrophy type 1. Vertex also said it is paying CRISPR Therapeutics (Swiss) $175 M to expand an existing research collaboration to include Duchenne and myotonic dystrophy type 1. [Frank Vinluan,, Jun 7, 19]

Exosome Diagnostics (Cambridge, MA)

Exosome Diagnostics (Waltham, MA; no SBIR), that has developed technology to test for disease by analyzing blood and other bodily fluids, agreed to be acquired by Bio-Techne in a $250 million cash deal. ... develops and sells diagnostics that test for exosomes, which are nanoparticles found in biological fluids. [Frank Vinluan,, Jun 25, 18]

Exosome Diagnostics  (Cambridge, MA; no SBIR), developer of a revolutionary liquid biopsy platform that enables non-invasive detection of clinical biomarkers, potentially obviating the need for tissue biopsy, today announced the launch of ExoDx™ Lung(ALK), the world’s first liquid biopsy test designed to isolate and analyze exosomal RNA (exoRNA) from a blood sample. ExoDx Lung(ALK), which has been validated in Exosome Diagnostics’ CLIA certified laboratory, is a plasma-based diagnostic enabling sensitive, accurate and real-time detection of EML4-ALK mutations in patients with non-small cell lung cancer (NSCLC).   [company press release,January 21, 2016]

Exosome Diagnostics (Cambridge, MA; no SBIR) aims to raise $25 million, on top of the $27 million in Series B funding it raised last March. Exosome would use the cash to launch its first two products: a blood-based test for lung cancer, and a urine test for prostate cancer. At that point, the long commercial slog would begin, with Exosome leaning on the results of a battery of clinical tests it’s been running to try to make its technology a factor in cancer care.  [Ben Fidler,, Jan 28, 15]

Exovita Biosciences (Albuquerque, NM)

NIH awarded a five-year, $1.7 million grant to the University of New Mexico Health Sciences Center to advance the development of new, exosome-based technology that empowers the body’s own natural defenses to fight cancerExovita Biosciences  (Albuquerque, NM; no SBIR) formed by the New Mexico Startup Factory, holds the option to an exclusive, worldwide license for the patent-pending technology developed by Kristina Antonia Trujillo, PhD, a research assistant professor in UNM’s Department of Biochemistry and Molecular Biology. Exovita executed a Sponsored Research Agreement in February 2015 with UNM. The agreement will fund the development of the exosome-based technology as a therapeutic, while the NIH grant will fund the mechanistic investigation of how the exosomes exert their anti-cancer properties. The data generated through these awards will be the foundation for eventual cancer-fighting therapeutics. [company press rlease, Jun 9, 15]

Exploramednc4 (Mountain View, Ca)

ExploraMed NC4: The stealthy Mountain View company has raised $18.5 million of an expected $20 million first funding round, we're told. The medical-device start-up doesn't have a Web site, and doesn't even seem to have its own address yet.  Instead, ExploraMed NC4 - the name is a placeholder intended to obscure the start-up's strategy - is still housed at ExploraMed, a medical-device incubator backed by New Enterprise Associates,among others.  [Venture Beat: San Jose Mercury News, Apr 30]

Expression Analysis (Durham, NC)

Expression Analysis (Durham, NC; no SBIR) has partnered with HemoShear (Charlottesville, VA; one SBIR) to develop a database to evaluate the vascular pharmacology of new drug compounds.   The project will be funded by a $4.3 million [NIH SBIR]  ....  The goal is to profile how human vascular cells respond at the genomic level to existing drug compounds. Pharma companies can then use the information to establish risk profiles and better identify and investigate potential effects of drugs.  [Lorna Ohnesorga, Triangle Business Journal, Jul 11, 12]

Exquadrum (Adelanto, CA)

DARPA has awarded Exquadrum (Adelanto, CA; 48 SBIRs) and Dynetics (Huntsville, AL; 32 SBIRs) a contract to develop technology for hypersonic weapons. Called the Operational Fires (OpFires) Propulsion System program, "the program aims to develop and demonstrate a novel ground-launched system for hypersonic boost glide weapons to penetrate modern enemy air defenses and rapidly and precisely engage critical time sensitive targets," the companies said in a joint statement. [DefenseOne, Jan 17, 19]

DARPA, Army Select Three Firms to Build Propulsion Tech for Weapons Launcher Platform: Aerojet Rocketdyne, Exquadrum (Adelanto, CA; 48 SBIRs) and Sierra Nevada (Sparks, NV; 8 SBIRs)  [Peter Grahamon, GovConWire, November 12, 18]

Exsulin (Burnsville, MN)

Exsulin (Burnsville, MN; no SBIR), which is developing a drug to treat diabetes, is seeking $4 million in capital, according to a regulatory filing....   has created a protein technology that could allow patients to regenerate islet cells in the pancreas. Those cells detect patients’ glucose levels and generate insulin needed to control blood-sugar levels.  [Katharine Grayson, Minneapolis / St Paul Business Journal, Jun 8, 12]

Extreme Molding (Watervliet, NY)

The Arsenal Business & Technology Partnership has signed a new five-year agreement to continue its role as the on-site manager and developer of the Watervliet [NY] Arsenal.  ... will pay more than $15 million in rent and fees over the life of the contract. Tenants at the Arsenal include M+W Group, one of the largest builders of computer chip plants; Vistec Lithography, which manufactures electron beam lithography systems to etch computer chips; Extreme Molding LLC, a woman-owned silicones and plastics firm, and Solid Sealing Technology, which produces high-tech parts with air-tight seals for the semiconductor, nanotechnology, solar-energy and health care sectors.

Extremity Innovations

Competitive Meets Extremity. Intellectual property licensing firm Competitive Technologies Inc. (Fairfield, CT) reports it has signed a strategic alliance agreement with medical device company Extremity Innovations Inc (Memphis TN). [Mass High Tech, Oct 24]

EyeGate Pharmaceuticals (Waltham, MA)

EyeGate Pharma (Waltham, MA; no SBIR) acquired Jade Therapeutics  (Salt Lake City, UT; $900K SBIR) with hydrogel-based technology that can be used to help deliver drugs to the eye. Eyegate will repay $300,000 in Jade debt and issue its backers 765,728 shares of stock. If a Jade product wins FDA approval, EyeGate would also shell out about $2.2 million in cash. [Ben Fidler,, Mar 10, 16]

RXi Pharmaceuticals (Worcester, MA; no SBIR) is raising $8.1 million through a public stock offering ...  In September 2010, RXi teamed up with EyeGate Pharmaceuticals (Waltham, MA;  no SBIR) to collaborate on an effort to deliver RNAi therapeutics to the eye to treat retinal disorders. [Mass High Tech, Mar 1, 11]

Ocular Therapeutix (Bedford, MA; no SBIR), another eye therapy company launched by Amar Sawhney, has boosted its most recent funding round to $21 million, just days after Sawhney’s Eyegate Pharmaceuticals (Bedford, MA; no SBIR) itself announced a funding bump.  [Mass High Tech, Jan 12, 11]

EyeGate Pharmaceuticals (Waltham, MA; no SBIR) has secured $22.6 million in a Series D venture financing. Current Paris-based investors Ventech and Innoven Partners, and Icking, Germany-based Medicis Capital participated in the round. They were joined by two new investors, Paris-based Natixis Private Equity and Emerging Capital, of Washington D.C. ... to continue developing the company’s drug target for dry eye syndrome, which affects more than a million men and women in the United States. [Julie Donnelly, Mass High Tech, Jan 8, 10]  proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe.  [company website]

EyeGate Pharmaceuticals (Waltham, MA; no SBIR), a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye for treating serious ocular diseases, announced that the company has secured $15M million in a Series C venture financing round. ...  founded in 1999 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. [company website]

EyeNetra   (Centreville VA)

startup EyeNetra  (Somerville, MA; no SBIR) which has developed inexpensive eye-testing technology leveraging smartphones, has raised $2 million in new equity funding.  .... has developed a lens system which is snapped onto a smartphone, along with diagnostics software for taking the measurements.  [Kyle Alspach, Boston Business Journal, Jun 28, 13]

EyeTel  (Centreville VA)

EyeTel (Centreville, VA; one Phase 2 SBIR) going public this week to raise $12M.

helping small high-tech companies get from idea to market

Published by Carl Nelson Consulting, Inc,1325 18th St NW, Washington DC 20036  e-mail Carl Nelson     Last update Feb 20, 2024